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Abstract	
Enzymatic	 cleavage	 can	 modify	 the	 function	 of	 target	 proteins.	 In	 this	 thesis	 I	
investigate	the	enzymatic	cleavage	of	myoferlin	and	dysferlin,	two	members	of	the	
ferlin	 family.	 In	 response	to	membrane	 injury,	dysferlin	 is	cleaved	enzymatically	by	
calpains-1	and	-2,	releasing	a	C-terminal	mini-dysferlinC72	and	an	N-terminal	counter	
fragment.	My	thesis	provides	supporting	evidence	that	mini-dysferlinC72	functions	as	
a	specialised	module	in	the	emergency	response	of	membrane	repair.		
	 I	 investigate	the	calpain-dysferlin	membrane	repair	axis	in	different	types	of	
membrane	injury,	and	the	effect	of	calpain	knock-out	in	skeletal	muscle	in	a	murine	
model.	 Using	 CRISPR	 gene-edited	 single	 calpain-1	 or	 calpain-2	 knock-out	 cells,	 I	
reveal	 that	 calpains-1	 and	 -2	 can	 compensate	 for	 each	 other,	 leading	 to	 almost	
normal	membrane	repair	outcomes;	but	when	both	ubiquitous	calpains	are	missing,	
cells	lose	almost	all	of	their	Ca2+-dependent	membrane	repair	capacity.		
	 The	second	part	of	my	thesis	aims	to	compare	the	cleavage	of	myoferlin	to	
the	calpain	cleavage	of	dysferlin.	The	results	of	this	study	reveal	that	the	cleavage	of	
myoferlin	is	differently	regulated	to	the	calpain-cleavage	of	dysferlin.	I	show	that	the	
cleavage	of	myoferlin,	unlike	dysferlin	cleavage,	is	independent	of	calpains-1	and	-2,	
and	is	not	a	direct	response	of	the	Ca2+	flux	of	membrane	injury.	Mini-myoferlin	can	
be	detected	at	rest	in	different	cell	types,	including	breast	cancer	cell	lines,	as	well	as	
in	 human	 triple	 negative	 breast	 cancer	 tumour	 specimens.	 I	 investigate	 potential	
functional	 impact	 of	 enzymatic	 cleavage	 to	 release	mini-myoferlin,	 and	 discover	 a	
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link	between	myoferlin	cleavage	and	cancer	linked	to	upregulation	of	the	MAPK/ERK	
signaling	pathway.		
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Preface	
I	have	chosen	to	separate	this	thesis	into	two	parts:		
	
Part	1)	Modifiers	of	membrane	repair	and	
Part	2)	The	enzymatic	cleavage	of	myoferlin.	
	
Within	Part	1,	I	investigate	the	role	of	the	calpain-dysferlin	membrane	repair	axis	in	
response	 to	 scrape-,	 laser-	 and	 pore	 forming	 toxin	 injury.	 Chapters	 1-3	 form	 the	
introduction,	results	and	the	discussion	of	Part	1:	Modifiers	of	membrane	repair.	
	 The	 enzymatic	 cleavage	of	myoferlin	was	 initially	 a	 sub-aim	of	my	 research	
proposal.	My	 hypothesis	was	 that	 the	 enzymatic	 cleavage	 of	myoferlin	 is	 similarly	
regulated	 by	 Ca2+-signalling,	 as	 previously	 observed	 for	 the	 calpain	 cleavage	 of	
dysferlin.	However,	I	demonstrated	this	not	to	be	case,	and	the	enzymatic	cleavage	
of	myoferlin	turned	out	to	be	much	more	complicated	than	dysferlin	cleavage.		
	 I	 pursued	 the	 myoferlin	 project	 in	 greater	 depth	 to	 reveal	 a	 link	 between	
enzymatic	cleavage	of	myoferlin,	ERK	(extracellular	signal-regulated	kinase)	signalling	
and	cancer.	These	findings	were	published	in	Cellular	Signalling	in	early	2017	 (A.	K.	
Piper	 et	 al.,	 2017).	 As	 the	 myoferlin	 project	 diverged	 from	 that	 of	 dysferlin	 and	
membrane	 repair,	 I	 chose	 to	 separate	 this	 section	 into	 Part	 2:	 The	 enzymatic	
cleavage	of	myoferlin,	encompassing	an	 introduction,	 results	and	 the	discussion	as	
Chapters	4,	5	and	6,	respectively.		
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Thesis	aims	
Part	1)	Modifiers	of	membrane	repair		
Aim	 1:	 To	 establish	 whether	 the	 calpain-dysferlin	 membrane	 repair	 pathway	 is	
deployed	in	response	to	different	forms	of	membrane	injury:		
• Mechanical	scrape-injury,	
• Laser	ablation	membrane	injury,	
• Perforation	by	pore-forming	toxins,	
• Eccentric	contraction	injury	to	muscle	fibers.	
	
Aim	2:	To	establish	whether	calpain-1	or	calpain-2	is	more	important	for	membrane	
repair.		
• To	 use	 CRISPR/Cas9	 gene	 editing	 to	 separately	 knock-out	 calpain-1	 and	
calpain-2.	
• To	establish	if	calpain-1	or	calpain-2	is	more	important	for	membrane	repair.	
	
Aim	 3:	 To	 determine	 the	 importance	 of	 membrane	 repair	 in	 the	 pathology	 of	
muscular	dystrophy.		
• To	 develop	 a	murine	model	with	 targeted	 knock-out	 of	 both	 calpain-1	 and	
calpain-2	in	skeletal	muscle.	
• To	 establish	 whether	 loss	 of	 calpain-1	 and	 calpain-2	 results	 in	 a	 profound	
membrane	repair	defect	in	skeletal	muscle	fibres.	
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• To	 identify	whether	 loss	of	 calpain-1	and	 calpain-2	manifests	 in	 a	muscular	
dystrophy	phenotype,	in	comparison	to	a	dysferlinopathy	mouse	model.		
	
Part	2)	The	enzymatic	cleavage	of	myoferlin	
Aim	1:	The	 first	aim	of	 the	second	part	of	my	thesis	was	to	 identify	 the	enzymatic	
cleavage	 sites	 in	 myoferlin	 and	 to	 establish	 if	 myoferlin	 was	 also	 cleaved	 by	 the	
ubiquitous	calpains.		
	
Aim	2:	To	reveal	potential	function	of	cleaved	myoferlin.	
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 Chapter	1: Introduction	-	Modifiers	of	membrane	
repair	
1.1. Membrane	repair	
The	 plasma	 membrane	 of	 a	 cell	 is	 the	 barrier	 that	 keeps	 the	 inside	 of	 the	 cell	
separated	 from	 the	outside	milieu.	 The	plasma	membrane	 functions	as	 a	 selective	
barrier	 that	 allows	 for	 controlled	 exchange	 of	 ions	 and	 proteins	 between	 the	
cytoplasm	and	the	extracellular	milieu.		
	 The	integrity	of	the	plasma	membrane	is	essential	for	all	cells,	and	forms	the	
basis	 for	 essential	 cell	 processes	 like	 endo-	 and	 exocytosis,	 cell	 division	 and	
proliferation,	as	well	as	 cell	 adhesion	and	cell	 signalling	 (Elkin,	 Lakoduk,	&	Schmid,	
2016;	 Figard	 &	 Sokac,	 2014;	 P.	 L.	 McNeil	 &	 Steinhardt,	 1997;	 Piekny,	 Werner,	 &	
Glotzer,	2005).	Thus,	keeping	the	membrane	intact	is	essential	for	the	survival	of	the	
cell.	 Resealing	 of	 an	 injured	 plasma	membrane	 is	 a	 vital	 cell	 survival	 mechanism;	
particularly	 in	cells	that	are	mechanically	active,	such	as	skeletal	myofibers,	cardiac	
myocytes,	 gut	 epithelia	 (P.	 L.	 McNeil	 &	 Kirchhausen,	 2005;	 Paul	 L.	 McNeil	 &	
Steinhardt,	 2003),	 and	 milk-secreting	 epithelial	 cells	 (Aumuller,	 Wilhelm,	 &	 Seitz,	
1999).	Sustained	plasma	membrane	breaches	lead	to	necrotic,	apoptotic	or	lytic	cell	
death	due	to	cascades,	to	 loss	of	 intracellular	contents	and	Ca2+	 influx	 into	the	cell	
(Geeraerts,	 Ronveauxdupal,	 Lemasters,	 &	 Herman,	 1991;	 Sonnemann	 &	 Bement,	
2011).		
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	 In	my	 thesis	 I	 have	 studied	 the	 involvement	of	 the	ubiquitous	 calpains	 and	
dysferlin	 in	membrane	 repair	 following	different	 types	of	membrane	 injury.	 In	 the	
next	 section	 (1.2)	 I	will	 introduce	 the	different	 types	of	membrane	 repair	 that	 are	
employed	by	the	cell	after	different	types	of	membrane	injury.		
	
1.2. Different	types	of	membrane	repair	
Membrane	 repair	 has	 been	 studied	 over	 the	 last	 two	 decades	 (S.	 T.	 Cooper	 &	
McNeil,	 2015;	 P.	 L.	 McNeil	 &	 Ito,	 1989).	 Different	 hypotheses	 exist	 on	 how	
membrane	repair	is	facilitated.	The	most	widely	accepted	hypothesis	for	membrane	
lesions	>100	nm	is	the	patch-hypothesis	(Andrews,	Almeida,	&	Corrotte,	2014;	P.	L.	
McNeil,	Vogel,	Miyake,	&	Terasaki,	2000),	which	will	be	discussed	 in	greater	detail	
below.	 However,	 other	 repair	 models	 have	 also	 been	 proposed,	 for	 example,	 the	
self-sealing	 hypothesis	 for	 small	 lesions	 of	 a	 few	 nanometres	 (Lipowsky,	 1991).	
Further,	 there	 are	 the	 repair	 mechanisms	 involving	 the	 late	 endosomal	 pathway;	
namely	 caveolae-mediated	 and	 ESCRT	 (Endosomal	 Sorting	 Complex	 Required	 for	
Transport)-mediated	membrane	repair	 (Corrotte	et	al.,	2013;	 Jimenez	et	al.,	2014),	
reviewed	by	Andrews	et	al.	(Andrews	et	al.,	2014).	
	 I	 will	 introduce	 the	 different	 membrane	 repair	 hypotheses	 below,	 starting	
with	 the	 smallest	 lesions	 and	 finishing	 with	 the	 patch-hypothesis	 for	 large	
membrane	lesions.	
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1.2.1. Self-sealing	hypothesis	-	unassisted	membrane	repair	
It	 has	 been	 proposed	 that	 exocytic	 events,	 triggered	 by	 increasing	 [Ca2+]IC	 after	 a	
membrane	 disruption,	 can	 promote	 self-sealing	 of	 the	 plasma	 membrane	 by	
lowering	membrane	tension	(P.	L.	McNeil,	2002;	P.	L.	McNeil	&	Kirchhausen,	2005;	
Togo,	Krasieva,	&	Steinhardt,	2000;	Yang	et	al.,	2008).	Lowered	membrane	tension,	it	
is	 suggested,	 then	 helps	 the	 exposed	 phospholipids	 at	 the	 edge	 of	 the	 injured	
membrane	to	re-connect	(P.	L.	McNeil,	2002;	P.	L.	McNeil	&	Kirchhausen,	2005).		
This	 hypothesis	 is	 based	 on	 the	 amphipathic	 characteristics	 of	 the	 lipid	
bilayer	and	the	fact	that	local	lipid	disorder	is	an	energetically	unfavourable	state.	In	
the	case	of	a	membrane	disruption,	the	hydrophobic	domains	of	the	phospholipids	
become	 exposed	 to	 the	 aqueous	 environment;	 this	 leads	 to	 perturbed	 lipid	
arrangements	at	the	disruption	site	and,	following	thermodynamic	laws,	generates	a	
large	increase	in	free	energy.	The	lipid	disorder	now	present	at	the	edge	of	the	break	
results	 in	 a	 line	 tension	 that	 favours	 resealing	 (P.	 L.	McNeil	 &	 Kirchhausen,	 2005)	
(Figure	 1.1A).	 The	 adhesion	 of	 phospholipid	 head	 groups	 to	 the	 underlying	
cytoskeleton	however,	creates	a	membrane	tension	that	opposes	lipid	flow	over	the	
disruption	 site	 (Figure	 1.1B).	 Line	 tension	 then	 becomes	 sufficient	 to	 promote	
resealing	 (Paul	L.	McNeil	&	Steinhardt,	2003).	However,	 this	phenomenon	has	only	
been	observed	in	non-physiological	settings	with	very	low	levels	of	extracellular	Ca2+	
(S.	T.	Cooper	&	McNeil,	2015;	P.	L.	McNeil	&	Kirchhausen,	2005).	Figure	1.1,	below,	
depicts	the	self-sealing	hypothesis.	
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Figure	 1.1.	 Illustration	 of	 the	 self-sealing	 hypothesis	 for	 membrane	
repair.	 A1-4:	 Spontaneous	 resealing	 of	 a	 lipid-bilayer	 can	 occur	 in	 the	
non-physiological	 setting	 of	 the	 membrane	 not	 being	 attached	 to	 an	
underlying	 cytoskeleton.	 B1-4:	 The	 line-tension	 created	 by	 the	
cytoskeleton	attached	to	the	plasma	membrane	prevents	the	lipid	bilayer	
to	 spontaneous	 resealing.	 This	 image	 is	 reproduced	 from	 Cooper	 and	
McNeil,	2015	(S.	T.	Cooper	&	McNeil,	2015).	
	
The	next	section	will	introduce	the	membrane	repair	mechanisms	that	are	reliant	on	
endocytosis	and	exocytosis/exosomal	shedding.	
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1.2.2. ESCRT-mediated	membrane	repair	
The	endosomal	sorting	complex	required	for	transport	(ESCRT)	machinery	is	involved	
in	 numerous	 key	 processes	 of	 the	 cell	 that	 involve	 the	 scission	 of	 budding	
membranes	 (Wollert	 et	 al.,	 2009).	 For	 example,	 the	 formation	 of	 multivesicular	
bodies	(MVBs)	(Gruenberg	&	Stenmark,	2004;	Hurley,	2008;	R.	C.	Piper	&	Katzmann,	
2007),	cytokinesis	(Carlton	&	Martin-Serrano,	2007)	as	well	as	viral	budding	(Morita	
&	Sundquist,	2004).	Recently,	ESCRT	machinery	has	been	shown	to	play	an	essential	
role	in	the	exosomal	shedding	of	bacterial	pore	forming	proteins	integrated	into	the	
membrane,	enabling	 cellular	 repair	 from	 toxin	perforation	 (S.	 T.	Cooper	&	McNeil,	
2015;	Jimenez	et	al.,	2014)	as	portrayed	in	Figure	1.2,	below.	
	
	 							 	
Figure	1.2.	ESCRT-mediated	exosomal	shedding	as	a	form	of	membrane	
repair	 after	 pore	 forming	 toxin	 injury.	Green	channel:	pore	 integrated	
into	 the	 plasma	 membrane	 conducting	 Ca2+	 (blue	 dots).	 Pink	 spiral:	
assembled	 ESCRT-machinery,	 initiating	 budding	 of	 the	 pore	 and	
exosomal	 shedding	 of	 the	 vesicle	 containing	 the	 pore.	 This	 image	 is	
reproduced	 from	 Cooper	 and	 McNeil,	 2015	 (S.	 T.	 Cooper	 &	 McNeil,	
2015).	
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ESCRT	machinery	consists	of	five	sub-complexes:	ESCRT-0,	ESCRT-I,	ESCRT-II,	ESCRT-
III,	 and	 the	 VPS4	 (Vacuolar	 Sorting	 Protein)	 ATPase	 that	 sequentially	 assemble	 to	
create	a	scission-capable	ESCRT	complex.	For	a	comprehensive	review	on	the	ESCRT	
machinery	 see	 Schmidt	 and	 Teis	 2012	 Current	 Biology	 (Schmidt	 &	 Teis,	 2012)	 or	
Cooper	 and	McNeil,	 2015	 (S.	 T.	 Cooper	&	McNeil,	 2015)	 for	 a	 review	 of	 ESCRT	 in	
context	of	membrane	repair.	
	
1.2.3. Caveolae-mediated	membrane	repair	
Caveolae	 (latin	 for	 'little	 caves')	 are	 plasma	 membrane	 invaginations	 that	 form	 a	
special	type	of	lipid	raft	(Galbiati,	Razani,	&	Lisanti,	2001)	and	were	first	described	in	
the	1950s	 (Palage,	 1953;	 E.	 Yamada,	1955).	 Caveolae	are	not	only	 invaginations	 in	
the	membrane,	but	create	a	cholesterol-rich	microenvironment	that	'hosts'	a	variety	
of	 proteins	 such	 as	 caveolin	 (Rothberg	 et	 al.,	 1992),	 the	 dystrophin	 associated	
glycoprotein	 complex	 (Galbiati,	 Engelman,	 et	 al.,	 2001)	 and	 the	 epidermal	 growth	
factor	 receptor	 (EGFR)	 (Ringerike,	 Blystad,	 Levy,	 Madshus,	 &	 Stang,	 2002).	 Many	
transmembrane	 receptor	 complexes	 favour	 localisation	 to	 lipid	 rafts	 (Pike,	 2003;	
Pike,	Han,	Chung,	&	Gross,	2002).	Further,	caveolae	are	enriched	 in	signaling	 lipids	
such	as	arachidonic	acid	 (Pike	et	al.,	 2002)	and	cholesterol	 (Galbiati,	Razani,	et	al.,	
2001).		
	 The	 exact	 composition,	 as	 well	 as	 the	 appearance	 of	 caveolae,	 is	 cell-type	
specific	 (Stan,	 Ghitescu,	 Jacobson,	 &	 Palade,	 1999;	 Stan	 et	 al.,	 1997).	 Caveolae	
structures	can	vary	from	a	 linear	row	of	flask-shaped	units	to	clusters	of	grape-like	
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unconnected	clusters	in	muscle	cells	(Stan	et	al.,	1999;	Stan	et	al.,	1997).	In	epithelial	
cells	 the	 grape-like	 structures	 are,	 on	 average,	 a	 bit	 smaller	 than	 in	 muscle	 cells	
(Rothberg	et	al.,	1992).	
	 Caveolae	 have	 recently	 been	 implicated	 in	 different	 types	 of	 membrane	
repair.	Caveolin-mediated	endocytosis	has	been	shown	to	be	involved	in	the	removal	
of	 small	 injuries	 created	 by	 pore	 forming	 toxins	 (Corrotte	 et	 al.,	 2013).	 Larger	
injuries,	for	example	those	caused	by	mechanical	stress,	also	show	the	involvement	
of	 caveolae	 and	 the	 fusion	 of	 caveolin-vesicles	 in	 order	 to	 patch	 the	 membrane	
breach	(Corrotte	et	al.,	2013;	Sinha	et	al.,	2011).	
	 The	 next	 paragraph	 will	 introduce	 the	 patch	 hypothesis	 that	 is	 widely	
accepted	for	the	repair	of	larger	membrane	lesions	(P.	L.	McNeil	et	al.,	2000).	
	
1.2.4. The	patch	hypothesis	
The	patch	hypothesis	is	based	on	Ca2+-dependent	vesicle	fusion	as	a	consequence	of	
increased	 [Ca2+]IC	 after	 a	 membrane	 disruption	 (P.	 L.	 McNeil	 &	 Steinhardt,	 1997;	
Togo,	 Alderton,	 Bi,	 &	 Steinhardt,	 1999).	 Increasing	 cytosolic	 Ca2+	 concentration	 is	
hypothesized	 to	 rapidly	 trigger	 homotypic	membrane-fusion	 events,	which	 form	 a	
disruption	spanning	‘vesicle	patch’	(Figure	1.3B).	This	vesicle	patch	then	fuses	to	the	
plasma	membrane	via	heterotypic	membrane	fusion	and	restores	plasma	membrane	
continuity.		
	 The	patch-hypothesis	has	been	confirmed	using	the	sea	urchin	egg	model,	as	
well	as	mammalian	cells	(P.	L.	McNeil	&	Baker,	2001;	P.	L.	McNeil	et	al.,	2000;	Miyake	
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&	McNeil,	1995).	Most	recently,	Davenport	et	al.	were	able	to	visualize	the	process	
of	 vesicle	 fusion	 after	 membrane	 injury	 using	 Xenopus	 laevis	 oocytes	 in	 high	
spatiotemporal	resolution	(Davenport,	Sonnemann,	Eliceiri,	&	Bement,	2016).	
	 In	 the	 first	 step	 of	 this	 process,	 the	 vesicle	 population	 at	 sites	 of	 the	
membrane	 injury	 increases	greatly,	both	 in	echinoderm	eggs	and	mammalian	cells.	
These	 vesicles	 provide	 the	 membrane	 material	 needed	 to	 initially	 patch-up	 the	
lesion	 and	 are	 derived	 from	 internal	 sources	 (Davenport	 et	 al.,	 2016).	 In	 the	 sea	
urchin	egg	model,	the	organelles	employed	for	resealing	are	the	yolk	granules.	These	
yolk	 granules	 can	 undergo	 rapid	 Ca2+-triggered	 homotypic	 fusion	 in	 vitro	 (S.	 T.	
Cooper	&	McNeil,	2015;	P.	L.	McNeil	&	Kirchhausen,	2005).	Figure	1.3	illustrates	the	
patch	hypothesis	of	membrane	repair.	
	
		
	
37	
	
Figure	1.3.	 Illustration	of	 the	patch	hypothesis	of	membrane	repair	of	
large	membrane	lesions.	Upon	membrane	disruption,	[Ca2+]EC	flows	into	
the	 cell	 down	 a	 steep	 concentration	 gradient.	 The	 elevated	 [Ca2+]IC	
triggers	 a	 cascade	 of	 events	 including	 the	 recruitment	 and	 fusion	 of	
vesicles.	 The	 vesicles	 undergo	 homotypic	 fusion	 to	 form	 a	 membrane	
patch	that	then	fuses	to	the	plasma	membrane	and	seals	the	membrane	
breach.	 The	membrane	 patch	 needs	 to	 be	 remodelled	 and	 removed	 in	
order	 for	 normal	membrane	 integrity	 to	 be	 restored.	 This	 happens	 via	
exocytic	 and	 endocytic	 removal	 of	 the	 'repair-patch-membrane'.	 This	
image	 is	 reproduced	 from	 Cooper	 and	 McNeil,	 2015	 (S.	 T.	 Cooper	 &	
McNeil,	2015).	
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Paul	McNeil	and	Tom	Kirchhausen	demonstrated	that	Ca2+-dependent	vesicle	fusion	
is	 required	 for	 efficient	membrane	 repair	 in	 the	 sea	 urchin	 egg	model	 depicted	 in	
Figure	 1.4,	 below	 (P.	 L.	McNeil	&	 Kirchhausen,	 2005).	 The	 authors	 injured	 the	 sea	
urchin	 egg	 with	 a	 laser	 in	 the	 presence	 of	 extracellular	 Ca2+.	 The	 sea	 urchin	 eggs	
were	incubated	with	a	membrane	impermeable	dye,	FM1-43,	that	partitions	into	the	
inner	leaflet	of	the	plasma	membrane	and	becomes	fluorescent.	Using	confocal	and	
electron	microscopy,	the	recruitment	of	vesicles	to	the	injury	site	could	be	observed.		
	 The	 injury	site	(Figure	1.4A)	showed	enriched	membrane	staining	displaying	
the	membrane	patch	forming.	After	>300	seconds,	the	egg	was	repaired	sufficiently	
such	 that	no	more	membrane	dye	could	enter	 the	cell.	 If	 the	same	sea	urchin	egg	
was	 injured	 a	 second	 time,	 it	 repaired	 faster.	 But	 if	 re-injured	 in	 the	 absence	 of	
extracellular	Ca2+,	vesicle	recruitment	and	fusion	did	not	occur,	the	membrane	failed	
to	repair	and	the	cell	burst	apart	(P.	L.	McNeil	&	Kirchhausen,	2005)	(see	Figure	1.4B,	
below).		
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Figure	 1.4.	 Ca2+-dependent	 vesicle	 fusion	 and	membrane	 resealing	 in	
the	 sea	 urchin	 egg	 model.	 The	 sea	 urchin	 egg	 is	 incubated	 with	 the	
membrane	dye	FM1-43	that	cannot	pass	through	the	 intact	membrane.	
Then	 the	 sea	 urchin	 egg	 is	 injured	with	 a	 laser	 in	 the	 presence	A.	 and	
absence	B.	of	extracellular	Ca2+.	In	the	presence	of	extracellular	Ca2+	the	
egg	 can	 forms	 a	membranous	 patch	 and	 reseals	 the	membrane	 injury	
after	307	seconds.	 In	 the	absence	of	Ca2+,	 the	same	egg	cannot	 form	a	
membrane	 patch	 and	 fails	 to	 reseal	 the	 membrane	 disruption.	 This	
experiment	demonstrates	that	extracellular	Ca2+	 is	required	for	efficient	
membrane	 repair.	 This	 image	 is	 reproduced	 from	 McNeil	 and	
Kirchhausen,	2005	(P.	L.	McNeil	&	Kirchhausen,	2005).	
	
Vesicle	 fusion	 is	 an	 integral	 part	 of	 the	 membrane	 repair	 mechanism	 described	
above.	 Section	 1.3	 will	 further	 introduce	 the	mechanics	 of	 vesicle	 fusion	 and	 the	
proteins	involved	to	facilitate	it.	
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1.3. The	mechanics	of	vesicle	fusion	
Vesicle	fusion	is	a	fundamental	process	in	cell	membrane	repair;	however,	the	fusion	
of	vesicles/membranes	is	not	a	membrane	repair	specific	phenomena.	Vesicle	fusion	
is	 a	 central	 process	 involved	 in	 all	 transport	 between	 membrane-enclosed	
compartments	of	the	cell	e.g.	the	secretory	pathway	(G.	T.	Cooper,	2000).	Fusion	of	
vesicles	to	the	plasma	membrane	allows	for	inter-cell	communication	and	is	vital	for	
any	 multicellular	 system	 (Ahmed	 &	 Xiang,	 2011).	 Membrane	 fusion	 is	 generally	
understood	 to	 be	 an	 energy-dependent	mechanism.	 Electrostatic	 repulsion	mostly	
prevents	 unaided	 fusion	 of	 the	 negatively	 charged	 membranes.	 It	 has	 been	
demonstrated	 however,	 that	 spontaneous	 membrane	 fusion	 can	 happen	 if	 two	
membranes	are	in	critically	close	proximity	to	one	another	(Marrink	&	Mark,	2003).	
In	 a	 recent	 study,	 Francois-Martin	 et	 al.	 have	 measured	 the	 energy	 required	 for	
spontaneous	 vesicle	 fusion	 using	 an	 in	 vitro	 lipid	 vesicle	 model	 (Francois-Martin,	
Rothman,	&	Pincet,	2017).	In	vivo	spontaneous	fusion	of	miniature	vesicles	or	'minis'	
occurs	as	a	form	of	synaptic	exocytosis	and	was	first	described	by	Katz	and	Miledi	in	
1967	 (Katz	 &	 Miledi,	 1967).	 Spontaneous	 vesicle	 fusion	 only	 represents	 a	 minor	
proportion	 of	 the	 overall	 neurotransmitter	 release	 required	 for	 effective	
neurotransmission	 (Pang	 &	 Sudhof,	 2010).	 Protein-facilitated	 vesicles	 fusion	 is	
needed	to	meet	the	requirements	of	fast	and	reliable	neurotransmitter	release	and	
will	 be	 described	 in	 the	 following	 sections.	 The	most	 well	 studied	model	 of	 Ca2+-
triggered	 exocytosis	 for	 cellular	 communication	 is	 synaptic	 transmission	 and	 is	
discussed	below,	in	section	1.3.1.	
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1.3.1. Synaptic	vesicle	fusion	
The	release	of	neurotransmitter	is	mediated	by	exocytosis	of	synaptic	vesicles	at	the	
presynapse	 (Almers,	 1994;	 Fesce,	 Grohovaz,	 Valtorta,	 &	Meldolesi,	 1994;	 Hanson,	
Heuser,	 &	 Jahn,	 1997).	 Each	 presynaptic	 nerve	 terminal	 contains	 hundreds	 of	
synaptic	vesicles	of	∼40	nm	diameter	 that	are	 filled	with	neurotransmitters.	When	
an	 action	 potential	 depolarizes	 the	 presynaptic	 plasma	 membrane,	 Ca2+-channels	
open,	 and	 Ca2+	 flows	 into	 the	 nerve	 terminal	 to	 trigger	 the	 exocytosis	 of	 synaptic	
vesicles.	This	 leads	 to	 the	 release	of	 their	neurotransmitters	 into	 the	synaptic	cleft	
(Figure	1.5)	(Sudhof	&	Rizo,	2011)	as	portrayed	in	Figure	1.5,	below.		
	 Once	 released,	 synaptic	 vesicles	 undergo	 recycling	 to	 support	 rapid	 and	
repeated	 rounds	 of	 release.	 Ca2+-triggered	 exocytosis	 is	 the	 major	 process	 in	
neurotransmission	followed	by	endocytosis	and	recycling	(Sudhof,	1995).	
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Figure	 1.5.	 Synaptic	 vesicle	 cycling.	 Synaptic	 vesicles	 fuse	 with	 the	
plasma	membrane	to	release	neurotransmitters.	Membrane	and	protein	
components	 are	 recycled	 via	 endocytosis.	 The	 synaptic	 vesicle	 cycle	
consists	of	exocytosis	(red	arrows)	followed	by	endocytosis	and	recycling	
(yellow	 arrows).	 Synaptic	 vesicles	 (green	 circles)	 are	 filled	 with	
neurotransmitters	 (NT;	 red	 dots)	 by	 active	 transport	 (neurotransmitter	
uptake).	Synaptic	vesicles	are	docked	at	the	active	zone.	When	an	action	
potential	 depolarizes	 the	 presynaptic	 membrane,	 Ca2+-	 channels	 open,	
causing	 a	 local	 increase	 in	 [Ca2+]IC	 at	 the	 active	 zone	 that	 triggers	
completion	of	the	fusion	reaction.	Released	neurotransmitters	then	bind	
to	receptors	at	the	postsynaptic	density	(PSD).	After	fusion	pore	opening,	
synaptic	 vesicles	 recycle	 through	 an	 endosomal	 pathway.	 This	 image	 is	
reproduced	from	Südhof	and	Rizo,	2011	(Sudhof	&	Rizo,	2011).	
	
Vesicle	 fusion	 is	 generally	 understood	 to	 be	 an	 energy-dependent	 mechanism,	
however,	it	has	been	demonstrated	that	spontaneous	membrane	fusion	can	happen	
if	 two	membranes	are	 in	close	enough	proximity	 to	one	another	 (Marrink	&	Mark,	
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2003).	 	 The	minimum	 requirement	 for	 two	membranes	 to	 fuse	 spontaneously	 has	
recently	been	measured	by	Francois-Martin	et	al.	(Francois-Martin	et	al.,	2017).	
		The	 following	 sections	 will	 introduce	 the	 energy	 dependent,	 highly	 regulated	
process	of	SNARE-mediated	vesicle	fusion.	
	
1.3.2. The	SNARE	complex	
Fusion	of	synaptic	vesicles	is	a	tightly	regulated	cyclic	process	that	requires	precision	
machinery.	 SNARE	 (Soluble	 NSF	 (N-ethylmaleimide	 sensitive	 fusion	 protein)	
complexes	 form	 the	 core	 of	 the	 neurotransmitter	 release	machinery,	which	 is	 the	
best-characterized	vesicle	fusion	machinery.	The	SNARE	complex	attachment	protein	
receptors	facilitate	vesicle	docking	and	fusion	during	exocytosis	(Rothman	&	Warren,	
1994).		
Three	different	 proteins	 form	 the	quaternary	 alpha-helical	 SNARE	 complex:	
syntaxins,	 SNAPs	 (soluble	 N-ethylmaleamide	 attachment	 proteins)	 and	 VAMPs	
(vesicle	associated	membrane	proteins,	also	called	synaptobrevins)	(Blasi,	Chapman,	
Link,	et	al.,	1993;	Blasi,	Chapman,	Yamasaki,	et	al.,	1993;	Link	et	al.,	1992;	Schiavo	et	
al.,	1992;	Sutton,	Fasshauer,	 Jahn,	&	Brunger,	1998).	Syntaxin	 (Bennett,	Calakos,	&	
Scheller,	1992)	and	SNAP	(Oyler	et	al.,	1989)	are	located	at	the	target	membrane	(t-
SNARES),	and	VAMP	is	located	at	the	vesicle	membrane	(v-SNARE)	(Trimble,	Cowan,	
&	Scheller,	1988)	(see	Figure	1.6	below).		
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1.3.3. Synaptotagmin	
Synaptotagmin	 1	 (Syt1),	 a	 vesicular	 protein,	 is	 believed	 to	 be	 the	 key	 Ca2+-sensor	
regulating	the	temporal	control	of	SNARE-dependent	synaptic	vesicle	fusion	(Sudhof,	
2004).	 Syt1	 is	 the	 Ca2+-sensor	 that	 detects	 the	 transient	 increase	 in	 cytosolic	 Ca2+	
that	 accompanies	 an	 action	 potential	 and,	 in	 response,	 promotes	 exocytosis	 of	
synaptic	vesicles.	
The	synaptotagmin	family	consists	of	15	members	that	are	characterized	by	
an	N-terminal	transmembrane	domain,	a	variable	linker	region	and	two	cytoplasmic	
C-terminal	C2	domains	(C2A	and	C2B),	which	are	Ca2+-regulated	lipid-binding	domains	
(Clark	et	al.,	1991).	Syt1	is	a	major	Ca2+-sensor	and	facilitates	vesicle	fusion	with	the	
plasma	membrane	at	 the	presynapse	to	release	neurotransmitter	 into	the	synaptic	
cleft	(Y.	Lai,	X.	C.	Lou,	C.	Q.	Wang,	T.	Xia,	&	J.	S.	Tong,	2014).	During	SNARE	mediated	
vesicle	fusion,	in	the	stage	of	vesicle	docking,	Syt1	binds	to	the	t-SNARE	complex	and	
facilitates	synaptic	vesicle	docking	with	the	plasma	membrane	(de	Wit	et	al.,	2009).	
Figure	1.6,	below,	illustrates	the	Ca2+-triggered	zippering	of	the	SNARE	complex.	
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Figure	1.6.	The	model	of	the	zippering	of	the	SNARE	complex	after	Ca2+	
stimulus.	 In	 this	 model	 syntaxin-1A	 (red)	 and	 SNAP-25	 (green)	 pre-
assemble	 into	 the	 t-SNARE	 complex	 at	 the	 plasma	membrane.	 VAMP2	
(blue)	 and	 Synaptotogmin-1	 (Syt1)	 (pink)	 are	 anchored	 at	 the	 vesicle	
membrane.	In	the	stage	of	vesicle	docking,	Syt1	is	binding	to	the	t-SNARE	
complex	 and	 facilitates	 the	 synaptic	 vesicle	 docking	 with	 the	 plasma	
membrane.	The	N-terminus	of	the	t-SNARE	complex	then	starts	zippering	
with	 the	 N-terminus	 of	 VAMP2.	 This	 stage	 is	 called	 a	 trans	 SNARE	
complex.	 Syt1	 binds	 Ca2+	 and	 interacts	 with	 the	 partially	 zipped	 trans	
SNARE	 complex	 to	 facilitate	 the	 final	 stage	of	 the	docking	process	 that	
results	 in	the	vesicle	fusing	to	the	membrane.	This	 image	is	reproduced	
and	modified	 from	 Lai	et	 al.,	 2014	 (Y.	 Lai,	 X.	 Lou,	 C.	Wang,	 T.	 Xia,	&	 J.	
Tong,	2014).	
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1.4. C2	domain	containing	proteins	are	needed	for	membrane	fusion	
Like	synaptotagmin,	other	C2	domain-containing	proteins	have	been	shown	to	play	
important	 roles	 in	 Ca2+-triggered	 membrane	 binding	 and	 fusion	 events;	 including	
endo-	and	exocytosis,	multivesicular	body	formation	and	membrane	repair	(Martens	
&	McMahon,	2008;	Nalefski	&	Falke,	1996).	These	 include	proteins	 like	double	C2-
like-domain-containing	proteins	(DOCs)	(Mochida,	Orita,	Sakaguchi,	Sasaki,	&	Takai,	
1998),	 extended	 synaptotagmin-like	 proteins	 (Min,	 Chang,	 &	 Sudhof,	 2007)	 and	
synaptotagmin-like	proteins	 (SLPs)	 (Kuroda,	Fukuda,	Ariga,	&	Mikoshiba,	2002)	and	
the	ferlin	family	(Davis,	Doherty,	Delmonte,	&	McNally,	2002).	
	 Among	 the	 C2	 domain-containing	 proteins,	 the	 ferlin	 family	 stand	 out,	 as	
they	 contain	 more	 C2	 domains	 (between	 five	 to	 seven	 tandem	 cytoplasmic	 C2	
domains)	than	most	other	C2	domain-containing	proteins	(Lek,	Lek,	North,	&	Cooper,	
2010).	Figure	1.7	shows	a	schematic	of	the	domain	structure	of	several	C2	domain-
containing	proteins.	
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Figure	1.7.	Structure	schematic	of	C2	domain-containing	proteins.	This	
image	 is	 reproduced	 from	McMahon	 and	 Boucrot,	 2011	 (McMahon	 &	
Boucrot,	2011).	
	
Dysferlin	and	 the	 ferlin	 family	are	an	ancient	 family	of	proteins	 implicated	 in	Ca2+-
triggered	 vesicle	 fusion	 (Lek,	 Evesson,	 Sutton,	 North,	 &	 Cooper,	 2012),	 and	 are	
discussed	in	detail	below.	
	
1.5. The	ferlin	family	
In	 mammals,	 there	 are	 six	 ferlins:	 dysferlin	 (fer1L1),	 otoferlin	 (fer1L2),	 myoferlin	
(fer1L3),	fer1L4,	fer1L5	and	fer1L6	(Lek	et	al.,	2010).	Ferlins	are	named	after	the	first	
ferlin,	 fer-1,	 discovered	 in	 1978	 in	 the	 nematode	Caenorhabditis	 elegans	 (Ward	&	
Miwa,	 1978),	 leading	 to	 the	 naming	 of	 mammalian	 ferlins	 as	 Fer-1	 like	 proteins	
(Fer1L1-6).	
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	 Dr	Lek's	phylogenetic	studies	have	revealed	that	ferlins	have	ancient	origins	
in	eukaryotic	biology	(Lek	et	al.,	2010).	It	is	proposed	that	ferlins	are	a	family	of	Ca2+-
binding	 vesicle	 fusion	 proteins	 for	 regulated	 exocytosis.	 Ferlins	 are	 believed	 to	
evolutionarily	predate	 synaptotagmins	 (Lek	et	al.,	 2010),	 the	classical	 regulators	of	
vesicle	fusion	(Sudhof	&	Rizo,	2011).	This	is	important,	as	our	team	hypothesises	that	
dysferlin	might	be	 the	ancient	predecessor	of	 synaptotagmin	 for	 the	vesicle	 fusion	
required	for	membrane	repair.	This	will	be	further	discussed	in	section	1.5.4.2.	
	 Ferlins	are	divided	into	two	major	subgroups:	DysF	domain-containing,	type	I	
ferlins	 (dysferlin,	 myoferlin	 and	 Fer1L5)	 and	 non-DysF-containing	 type	 II	 ferlins	
(otoferlin,	 Fer1L4	 and	 Fer1L6)	 (Lek	 et	 al.,	 2010).	 Ferlin	 proteins	 have	 a	 distinctive	
structure,	with	 a	 C-terminal	 transmembrane	 anchor	 and	 five	 to	 seven	C2	domains	
(Clark	et	al.,	1991).	Figure	1.8	shows	the	schematic	domain	structure	of	the	ferlins.		
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Figure	1.8.	Domain	composition	and	layout	of	the	ferlin	protein	family.	
The	 ferlin	 family	of	proteins	 contain	 five	 to	 seven	 tandem	C2	domains,	
anchored	by	a	C-terminal	transmembrane	domain.	All	human	ferlins	are	
predicted	to	contain	FerI	and	FerB	domains.	The	type-I	ferlins,	dysferlin,	
myoferlin	 and	 Fer1L5	 also	 contain	 FerA	 and	 DysF	 domains,	 which	 the	
type-II	ferlins	(otoferlin,	Fer1L4	and	Fer1L6)	do	not	contain.	Otoferlin	also	
contains	 a	 unique	 lysine	 and	 aspartic	 acid-rich	 region	 of	 unknown	
function.	All	domain	predictions	are	sourced	from	SMART	and	UniPROT.	
This	 image	 is	 reproduced	 from	 Dr	 Gregory	 Redpath's	 PhD	 thesis,	 2016	
(Redpath,	2016).	
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1.5.1. 	Ferlin	function	in	vesicle	fusion	
It	is	known	that	dysferlin	is	involved	in	the	Ca2+-triggered	vesicle	fusion	required	for	
muscle	membrane	repair	(Dimple	Bansal	et	al.,	2003;	Lek	et	al.,	2013),	which	will	be	
discussed	in	detail	within	section	1.5.4.		
	 As	 mentioned	 before,	 ferlins	 also	 play	 roles	 in	 regulated	 exocytosis,	 in	
different	 membrane	 compartments	 within	 the	 cell	 (Lek	 et	 al.,	 2012;	 Redpath,	
Sophocleous,	 Turnbull,	Whitchurch,	&	Cooper,	2016).	Myoferlin	and	dysferlin	have	
been	 shown	 to	 be	 involved	 in	 the	 cellular	 trafficking	 of	 the	 insulin	 growth	 factor	
receptor	 (IGFR-1)	 (Demonbreun,	 Fahrenbach,	 et	 al.,	 2010;	 Demonbreun,	 Posey,	 et	
al.,	2010).	Dysferlin	has	also	been	shown	to	be	important	for	PECAM-1	trafficking,	an	
adhesion	 protein	 essential	 for	 immune	 cells,	 cell	 migration	 and	 angiogenesis	
(Sharma	et	al.,	2010).	Otoferlin	is	needed	for	the	recycling	of	auditory	vesicles	at	the	
ribbon	 synapse	 of	 the	 inner	 ear	 (Roux	 et	 al.,	 2006).	 Figure	 1.9	 illustrates	 the	
involvement	of	dysferlin,	myoferlin	and	otoferlin	in	different	vesicle	fusion	events.	
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Figure	1.9.	The	 ferlins	 in	different	vesicle	 fusion	events.	A.	Dysferlin	in	
membrane	 repair.	B.	 Dysferlin	 and	myoferlin	 in	 endocytosis	 of	 growth	
receptors	 and	 cellular	 trafficking.	 C.	 Otoferlin	 in	 vesicle	 fusion	 of	
neurotransmitter	 containing	 vesicles	 at	 the	 ribbon	 synapse.	 (Image	
adapted	from	(Lek	et	al.,	2010)).	
	
1.5.2. Ferlins	in	disease	
The	 importance	of	 ferlins	 in	vesicle	 fusion	 is	 further	highlighted	by	the	fact	that	all	
ferlin-mediated	pathologies	-	in	humans	as	well	as	in	C.elegans	and	D.	melanogaster	
-	show	the	unifying	feature	of	impaired	Ca2+-dependent	vesicle	fusion	as	part	of	the	
underlying	pathogenesis	(Lek	et	al.,	2012).	
	 Ward	et	al.	found	that	mutations	of	the	fer-1	gene	cause	a	fertilisation	defect	
in	C.elegans	 (Ward	&	Miwa,	1978).	 In	1997	Achanzar	et	al.	 further	discovered	that	
this	defect	was	due	to	inadequate	sperm	vesicle	fusion	(Achanzar	&	Ward,	1997).		
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Mutations	 in	 the	Drosophila	melanogaster	 ferlin	gene,	misfire,	 cause	 infertility	due	
to	defective	exocytosis	and	endocytosis	of	the	sperm	acrosome;	a	vital	step	allowing	
the	 male	 DNA	 to	 exit	 from	 the	 sperm	 into	 the	 fertilized	 egg	 (Ohsako,	 Hirai,	 &	
Yamamoto,	2003;	M.	K.	Smith	&	Wakimoto,	2007).	Mutations	 in	the	otoferlin	gene	
(OTOF)	 cause	 congenital	 deafness	 (Yasunaga	et	 al.,	 1999;	 Yasunaga	&	Petit,	 2000),	
due	to	defective	Ca2+-triggered	vesicle	fusion	at	the	ribbon	synapse	in	the	inner	ear	
(Roux	et	al.,	2006).	Mutations	in	the	dysferlin	gene	(DYSF)	cause	autosomal	recessive	
forms	of	muscular	dystrophy,	termed	dysferlinopathies	(Bashir	et	al.,	1998;	Liu	et	al.,	
1998)	and	will	be	discussed	 in	detail	 in	section	1.5.3.	There	are	no	known	disease-
causing	mutations	in	the	myoferlin	gene	to	date.	
	
1.5.3. Dysferlinopathies	
Mutations	in	the	human	dysferlin	gene	cause	dysferlin-muscular	dystrophy,	termed	
dysferlinopathy.	 Dysferlinopathy	 describes	 a	 heterogeneous	 group	 of	 late-onset	
muscular	 dystrophies	 with	 patients	 initially	 presenting	 symptoms	 in	 their	 late	
teenage	 years	 to	 early	 twenties	 (Ueyama	 et	 al.,	 2002).	 Two	 main	 initial	 clinical	
phenotypes	can	be	distinguished:	limb	girdle	muscular	dystrophy	type	2B	(LGMD2B)	
(Bashir	 et	 al.,	 1998)	 and	 Miyoshi	 myopathy	 (MM)	 (Liu	 et	 al.,	 1998).	 LGMD2B	
primarily	manifests	with	proximal	weakness	of	the	hip	and	shoulder	girdles,	whereas	
Miyoshi	myopathy	first	manifests	 in	the	distal	muscle	groups	 like	calf	muscles,	 feet	
and	 ankles,	 as	 well	 as	 forearm	 and	 hand	muscles.	 Figure	 1.10	 depicts	 the	muscle	
groups	first	affected	in	both	forms	of	dysferlinopathies.	
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Figure	 1.10.	 The	 two	 main	 initial	 manifestations	 of	 dysferlinopathy.	
Limb	 girdle	 muscular	 dystrophy	 type	 2B	 (LGMD2B)	 initially	 affects	 the	
hip-	 and	 shoulder	 girdle	 whereas	 Miyoshi	 myopathy	 (MM)	 initially	
presents	 with	 distal	 weakness	 in	 the	 hand/forearm	muscles	 as	 well	 as	
calves	 and	 foot	 muscles.	 Affected	 muscle	 groups	 shown	 in	 red.	 This	
image	is	reproduced	from	www.mda.org.	
	
With	 disease	 progression,	 symptoms	 of	 both	 clinical	 phenotypes	 become	 more	
severe	and	spread	over	several	muscle	groups,	resulting	in	an	overlapping	spectrum	
of	clinical	weakness	affecting	both	distal	and	proximal	muscles.	
	 It	 is	 believed	 that	 the	 membrane	 repair	 defect	 caused	 by	 the	 lack	 of	
functional	dysferlin	protein	contributes	to	the	disease	pathogenesis	 (Dimple	Bansal	
et	al.,	2003)	and	will	be	discussed	in	section	1.5.4,	below.		
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1.5.4. Dysferlin	in	membrane	repair	
The	dysferlin	 research	 field	has	gained	valuable	 insight	 into	 the	underlying	disease	
mechanism	of	dysferlinopathies	through	the	development	of	the	first	mouse	model	
in	2003	by	Bansal	et	al.	(Dimple	Bansal	et	al.,	2003).	This	mouse	model	revealed,	for	
the	first	time,	that	lack	of	dysferlin	led	to	a	membrane	repair	defect	(Dimple	Bansal	
et	al.,	2003).		
	 In	this	study	the	authors	used	laser	ablation	to	injure	the	plasma	membrane	
of	isolated	mouse	foot	muscle	fibers	and	used	the	fluorescent	membrane	dye,	FM1-
43,	 to	 quantify	 membrane	 injury.	 The	 authors	 injured	 fibers	 in	 the	 presence	 or	
absence	 of	 extracellular	 Ca2+,	 showing	 that	 DYSF-/-	 fibers	 lack	 Ca2+-dependent	
membrane	repair	and	were	unable	to	exclude	the	fluorescent	dye	FM1-43.	The	WT	
fibers	were	able	to	reseal	within	30	seconds	after	 injury	but	were	unable	to	repair	
and	exclude	the	dye	in	the	absence	of	extracellular	Ca2+	(Dimple	Bansal	et	al.,	2003).	
Figure	1.11	depicts	DYSF-/-	and	WT	mouse	muscle	fibers	injured	in	the	presence	and	
absence	of	extracellular	Ca2+.	
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Figure	 1.11.	 Membrane	 repair	 defect	 in	 dysferlin	 deficient	 mouse	
muscle	 fibers.	 A.	 Membrane	 repair	 assay	 performed	 on	 single	 mouse	
muscle	 fibres	 from	wild-type	 (WT)	 and	dysferlin-deficient	 (DYSF-null)	 in	
the	 presence	 and	 absence	 of	 extracellular	 Ca2+.	 Scale	 bar:	 50mm	 B.	
Quantification	of	 fluorescence	 intensity	over	 time	 comparing	WT	 (filled	
circles)	 and	 DYSF-null	 (open	 triangles)	 fibres	 in	 the	 presence	 of	
extracellular	 Ca2+.	C.	 Quantification	 of	 fluorescence	 intensity	 over	 time	
comparing	WT	(filled	circles)	and	DYSF-null	(open	triangles)	fibres	in	the	
		
	
56	
absence	of	extracellular	Ca2+.	This	image	is	reproduced	from	Bansal	et	al.,	
2003	(D.	Bansal	et	al.,	2003).		
	
1.5.4.1. What	is	the	role	of	dysferlin	in	membrane	repair?	
Since	the	initial	findings	that	connect	dysferlin	to	Ca2+-dependent	muscle	membrane	
repair	 (Dimple	 Bansal	 et	 al.,	 2003),	 the	 question	 of	 how	 dysferlin	 is	 involved	 in	
membrane	repair	has	motivated	the	dysferlin-research	field.	
	 A	 compelling	 study	 conducted	 by	 Roostalu	 and	 Strähle	 using	 zebrafish,	
showed	 recruitment	 of	 C-terminally	 tagged	dysferlin,	 as	well	 as	 a	 small	 C-terminal	
transmembrane	 fragment.	 However,	 N-terminal	 and	 cytoplasmic	 fragments	 of	
dysferlin	 were	 not	 recruited	 to	 injury	 sites	 following	 laser	 ablation	 of	 the	 muscle	
(Roostalu	&	Strähle,	2012).		
	 The	 results	 from	 Roostalu	 and	 Strähle	 resonate	with	 data	 from	 our	 group,	
which	showed	that	ballistic	injuries	('ballistic'	refers	to	the	shooting	action	of	a	flying	
object,	in	this	case	silica	bullets)	in	primary	human	myotubes	were	labeled	positively	
only	 by	 antibodies	 that	 recognize	 the	 C-terminus	 of	 dysferlin,	 and	 not	 by	 other	
antibodies	recognizing	the	N-terminus	or	the	mid-region	of	dysferlin	(Lek,	2012;	Lek	
et	 al.,	 2013).	 Figure	 1.12,	 below,	 shows	 that	 only	 the	 C-terminal	 anti-dysferlin	
antibody	recognizes	dysferlin	at	injury	sites.	
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Figure	 1.12:	 Ballistic	 injury	 of	 primary	 human	 myotubes.	 C1504	
myotubes	 were	 injured	 and	 labelled	 for	 dysferlin	 using	 the	 C-terminal	
anti-dysferlin	antibody,	Hamlet-1,	the	mid-region	anti-dysferlin	antibody,	
SAB2100636	 or	 the	 N-terminal	 anti-dysferlin	 antibody,	 Romeo.	 Only	
Hamlet-1	recognised	dysferlin	at	injury	sites	following	ballistic	injury	with	
silica	bullets.	This	image	is	reproduced	and	modified	from	Lek	et	al.,	2012	
(Lek,	2012).	
	
The	 reason	 why	 only	 the	 C-terminal	 dysferlin	 can	 be	 detected	 at	 injury	 sites	 is	
discussed	below,	in	section	1.5.4.2.	
	
1.5.4.2. Dysferlin	is	enzymatically	cleavage	following	membrane	injury	
Our	team	has	subsequently	established	that	dysferlin	undergoes	enzymatic	cleavage	
by	activated	calpains	in	response	to	elevated	[Ca2+]IC	after	membrane	injury	(Lek	et	
al.,	2013;	Redpath	et	al.,	2014).	Dysferlin	is	cleaved	into	two	pieces	-	an	N-terminal	
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fragment	 including	 the	 C2A,	 C2B,	 C2C,	 FerA,	 DysF,	 C2D	 and	 C2DE	 domains,	 and	 a	 C-
terminal	fragment	with	the	C2E,	C2F	and	the	transmembrane	domain	(Woolger	et	al.,	
2017).	 We	 have	 named	 the	 released	 C-terminal	 fragment	 'mini-dysferlinC72'	
according	to	its	size	of	~72	kDa	(see	Figure	1.13).	Our	collective	data	suggests	that	it	
is	mini-dysferlinC72	that	is	recruited	to	injury	sites,	and	may	play	a	specialised	role	in	
the	vesicle	fusion	of	membrane	repair;	we	have	not	yet	defined	a	repair-specific	role	
for	 the	 N-terminal	 remaining	 part	 of	 dysferlin.	 Further	 research	 has	 revealed	
subsequently	 that	 dysferlin	 is	 cleaved	 enzymatically	 by	 activated	 calpains	within	 a	
motif	encoded	by	an	alternately-spliced	exon,	exon	40a	(Redpath	et	al.,	2014).		
	 Figure	1.13	shows	the	schematic	of	dysferlin	 indicating	the	calpain	cleavage	
site	 in	exon	40a,	 in	the	 linker	region	between	the	C2DE	and	C2E	domains,	as	well	as	
the	resulting	C-terminal	mini-dysferlinC72.	
	 	
	
Figure	 1.13.	 Calpain	 cleaves	 dysferlin	 to	 release	 a	 C-terminal	 mini-
dysferlinC72.	Schematic	illustration	of	the	dysferlin	protein;	the	seven	C2	
domains	are	shown	as	smaller	grey	ellipses	as	A,	B,	C,	D,	DE,	E	and	F.	The	
DysF	domain	 is	 shown	as	a	 larger	grey	ellipse	and	 the	 trans-membrane	
domain	(TM)	as	a	vertical	cylinder.	The	calpain	cleavage	site	is	indicated	
with	an	arrow	between	the	C2DE	and	C2E	domain	and	calpain	is	shown	as	
scissors.	 The	 released	 mini-dysferlinC72	 is	 shown	 below	 the	 full-length	
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dysferlin.	 The	 N-terminal	 counter	 fragment	 is	 not	 shown	 in	 this	
illustration.	
	
Interestingly,	 mini-dysferlinC72,	 that	 we	 believe	 has	 a	 specialized	 function	 in	 the	
vesicle	fusion	required	for	efficient	membrane	repair,	bears	structural	resemblance	
to	 synaptotagmin	 (see	 section	 1.4).	 Both	 mini-dysferlinC72	 and	 synaptotagmin	
contain	 two	 cytoplasmic	 C2	 domains	 anchored	 by	 a	 transmembrane	 domain.	
Moreover,	previous	phylogenetic	studies	reveal	the	two	most	C-terminal	C2	domains	
are	the	most	evolutionarily	conserved	(Lek	et	al.,	2010).	These	results	suggest	 that	
the	dual	C2-domain	cleaved	mini-dysferlinC72	might	be	an	evolutionary	predecessor	
of	synaptotagmins.	
	
Is	mini-dysferlin	important	for	membrane	repair	but	not	for	muscular	dystrophy?	
In	2010	Krahn	et	al.	identified	a	dysferlinopathy	patient	with	a	mutation	in	the	DYSF	
gene	resulting	in	the	expression	of	a	C-terminal	mini-dysferlin	protein	(Krahn	et	al.,	
2010).	This	mini-dysferlin	is	almost	identical	in	size	to	mini-dysferlinC72	released	after	
dysferlin	cleavage	following	membrane	injury	(Lek	et	al.,	2013;	Redpath	et	al.,	2014).	
Using	 recombinant	 adeno-associated	 virus,	 Krahn	 et	 al.	 introduced	 an	 expression	
construct	 encoding	 for	 the	 patient's	 mini-dysferlin	 into	 dysferlin	 deficient	 (DYSF-/-)	
mouse	muscle	 (Krahn	 et	 al.,	 2010).	 The	 authors	 showed	 that	DYSF-/-	muscle	 fibers	
expressing	mini-dysferlin	 displayed	 near	 normal	muscle	membrane	 repair	 capacity	
following	laser	injury	(Krahn	et	al.,	2010).	The	expression	of	mini-dysferlin,	however,	
did	not	rescue	the	muscular	dystrophy	phenotype	of	the	mice	(Krahn	et	al.,	2010).	
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These	results	further	underpin	that	defective	membrane	repair	is	only	one	aspect	of	
the	underlying	pathology	in	dysferlinopathies.	
		
The	calpain-cleavage	of	dysferlin	has	introduced	a	new	aspect	to	the	mechanism	of	
dysferlin	 membrane	 repair.	 Below	 I	 will	 introduce	 calpains	 and	 their	 role	 in	
membrane	repair.	
	
1.6. Calpains	
Calpains	 are	 a	 family	 of	 Ca2+-dependent,	 non-lysosomal	 cysteine	 proteases	
expressed	 ubiquitously	 in	mammals	 and	many	 other	 organisms	 (first	 described	 in	
Guroff,	1964	(Guroff,	1964),	reviewed	in	Goll	et	al.,	2003	(Goll,	Thompson,	Li,	Wei,	&	
Cong,	2003)).		
	 Calpains	 are	 named	 after	 their	 papain-like	 core	 domains	 dI	 and	 dII	 (also	
referred	to	as	dIIa	and	dIIb)	that	bestow	their	catalytic	function.	Calpains	are	divided	
into	 'classical'	 and	 'non-classical'	 or	 'atypical'	 calpains.	 Classical	 calpains	 include	 a	
penta	EF	hand	motif	that	is	involved	in	Ca2+-binding.	The	EF	motif	consists	of	a	helix-
loop-helix	 topology	 and	 is	 the	most	 common	 Ca2+-binding	motif	 found	 in	 proteins	
(Lewit-Bentley	 &	 Rety,	 2000).	 The	 penta	 EF	 hand	 motif	 is	 lacking	 in	 the	 atypical	
calpains	 (Hosfield,	Elce,	Davies,	&	Jia,	1999).	The	 large	subunit	of	calpains-1	and	-2	
are	 homologous	 and	 comprised	 of	 four	 different	 domains,	 DI-IV	 (Hosfield	 et	 al.,	
1999;	Strobl	et	al.,	2000).	Figure	1.14	shows	a	schematic	structure	of	calpain-1.	
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Figure	 1.14.	 Schematic	 structure	 of	 μ‑calpain	 (calpain-1).	The	 image	 is	
reproduced	 from	 Storr	 et	 al.,	 2011	 (Storr,	 Carragher,	 Frame,	 Parr,	 &	
Martin,	2011).	
	
The	classical	calpains	include	the	ubiquitous	calpains,	calpain-1	(CAPN1)	and	calpain-
2	(CAPN2),	as	well	as	the	skeletal	muscle	specific	calpain-3	(CAPN3).	Calpain-1	and	-2	
are	also	known	as	µ-	and	m-calpains,	and	respectively	named	according	to	their	Ca2+-
activation	 concentration.	 Calpain-1	 shows	 half-maximal	 activation	 with	 Ca2+	
concentrations	of	around	~20	μM	whereas	calpain-2	shows	half-maximal	activation	
with	 Ca2+	 concentrations	 of	 ~200	 μM	 (Goll	 et	 al.,	 2003).	 Intracellular	 Ca2+	
concentrations	 of	 over	 100	 µM	 usually	 only	 occur	 if	 the	 cell	membrane	 has	 been	
breached,	as	in	the	case	of	membrane	injury.	
	 Calpain-1	and	-2	typically	exist	as	heterodimers,	with	a	large	catalytic	subunit	
of	 ~80	 kDa	 and	 a	 smaller	 regulatory	 subunit	 of	 28	 kDa,	 calpain	 small	 subunit	 1	
(CAPNS1)	 (for	 a	 comprehensive	 review,	 see	 Goll	 et	 al.,	 2003	 (Goll	 et	 al.,	 2003)).	
Without	CAPNS1,	calpain-1	and	calpain-2	are	rendered	inactive	and	unstable	(Arthur,	
Elce,	Hegadorn,	Williams,	&	Greer,	2000).	This	 is	an	 important	 fact,	as	 I	performed	
targeted	knock-out	of	CAPNS1	 in	order	to	study	the	effect	of	the	 lack	of	calpains-1	
and	-2	(described	within	Chapter	2.4.2).	
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1.6.1. Calpain	function	
Calpains	 are	 proteases	 that	 cleave	 their	 target	 substrates	 to	modify	 their	 function	
rather	 than	degrading	 them	 (Goll	 et	 al.,	 2003).	 Calpains-1	 and	 -2,	 target	 the	 same	
substrates;	 there	 is	 yet	 to	 be	 a	 substrate	 found	 that	 can	 uniquely	 be	 cleaved	 by	
either	 calpain-1	 or	 calpain-2.	 However,	 their	 function	 appears	 to	 be	 significantly	
different	 in	development	 (Arthur	et	al.,	2000;	Azam	et	al.,	2001;	Dutt	et	al.,	2006).	
Murine	knock-out	studies	suggest	non-overlapping	roles	for	calpain-1	and	calpain-2.	
Global	knock-out	of	calpain-2	results	in	embryonic	lethality	(Arthur	et	al.,	2000;	Dutt	
et	al.,	2006)	whereas	lack	of	calpain-1	is	compatible	with	mice	being	viable;	with	only	
minor	phenotypic	defects	linked	to	a	defect	in	platelet	function	(Azam	et	al.,	2001).	
This	 indicates	 that	 calpains-1	and	 -2	bestow	very	distinct	 functions	within	 the	 cell,	
even	though	they	can	cleave	the	same	substrates	in	vitro.		
	
1.6.2. Calpains	in	membrane	repair	and	disease	
Calpains	 are	 known	 to	 be	 essential	 for	 cellular	 processes	 that	 rely	 on	 dynamic	
remodelling	 of	 the	 cytoskeleton,	 including	 membrane	 repair	 (Miyake,	 McNeil,	
Suzuki,	 Tsunoda,	 &	 Sugai,	 2001),	 cell	 migration	 (Dourdin	 et	 al.,	 2001;	 Franco	 &	
Huttenlocher,	 2005)	 and	 the	 regulation	 of	 focal	 adhesions	 (K.	 T.	 Chan,	 Bennin,	 &	
Huttenlocher,	 2010;	 Franco	 et	 al.,	 2004).	 Here	 calpains	 catalyse	 the	 proteolysis	 of	
cytoskeletal	 proteins	 like	 talin	 (Franco	 et	 al.,	 2004),	 β3-integrin	 (Bialkowska	 et	 al.,	
2000;	Hayashi,	Suzuki,	Kawashima,	Saido,	&	Inomata,	1999)	and	the	focal	adhesion	
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kinase	(FAK)	(Carragher,	Fincham,	Riley,	&	Frame,	2001;	Carragher,	Levkau,	Ross,	&	
Raines,	1999)	to	allow	for	dynamic	remodelling	of	the	cytoskeleton.		
	 In	the	absence	of	the	ubiquitous	calpains,	these	processes	are	impaired	and	
reduced	 (Carragher	 et	 al.,	 2001;	 Carragher	 et	 al.,	 1999;	 K.	 T.	 Chan	 et	 al.,	 2010;	
Dourdin	 et	 al.,	 2001;	 Franco	 &	 Huttenlocher,	 2005;	 Franco	 et	 al.,	 2004).	 In	
membrane	repair	 for	 instance,	 the	cortical	cytoskeleton	needs	to	be	remodelled	 in	
order	for	vesicles	to	reach	the	injury	site	and	repair	the	membrane	breach	(Miyake	
et	al.,	2001).	The	ubiquitous	calpains	are	believed	to	be	essential	for	this	remodelling	
process	 to	 facilitate	 rapid	Ca2+	dependent	membrane	 repair	 (R.	 L.	Mellgren,	Zhang,	
Miyake,	&	McNeil,	2007).	
	 Calpain	 activity	 was	 first	 shown	 to	 be	 required	 for	 effective	 plasma	
membrane	repair	over	25	years	ago	(Xie	&	Barrett,	1991).	Xie	and	Barrett	revealed	
that	 treatment	 of	 transected	 squid	 axons	 with	 the	 specific	 calpain	 inhibitor	
calpeptin,	led	to	failed	resealing	of	the	severed	neurites	(Xie	&	Barrett,	1991).	Godell	
et	 al.	 confirmed	 these	 findings	 in	 1997	 and	 also	 demonstrated	 that	 addition	 of	
exogenous	calpain	enhanced	resealing	of	the	transected	axon,	even	in	the	absence	
of	extracellular	Ca2+	(Christopher	M.	Godell	et	al.,	1997).	Calpains	have	further	been	
shown	 to	 be	 required	 for	 Ca2+-mediated	 repair	 of	 damaged	 plasma	 membranes,	
following	mechanical	 scrape	 injury	 in	 cells	 (R.	 L.	Mellgren	&	Huang,	2007).	 In	 their	
study	Mellgren	et	 al.	 showed	 the	 requirement	 of	 calpains-1	 and	 -2	 for	membrane	
repair	 in	transformed	neonatal	 fibroblasts,	neonatal	primary	cardiac	myoblasts	and	
neurons	derived	from	CAPNS1-/-	mouse	embryos	(R.	L.	Mellgren	&	Huang,	2007).			
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1.6.2.1. Calpains	in	human	disease	
Despite	the	fact	that	activity	of	calpains-1	and	-2	is	needed	for	membrane	resealing	
and	 cytoskeletal	 remodelling,	 too	 much	 calpain	 activity	 has	 been	 proven	 to	 be	
detrimental	 in	 many	 human	 diseases.	 These	 include	 cardiovascular	 diseases	
(Letavernier	et	al.,	2008),	ischaemic	disorders	(Yokota	et	al.,	1999),	as	well	as	several	
neurodegenerative	disorders	(Amini	et	al.,	2013;	Diepenbroek	et	al.,	2014;	Hubener	
et	 al.,	 2013;	 Toba	 et	 al.,	 2013;	 M.	 Yamada	 et	 al.,	 2009;	 Yamashita	 et	 al.,	 2012),	
arterial	sclerosis	(Miyazaki	et	al.,	2011)	and	cancers	(Grieve,	Gao,	Hall,	Hu,	&	Greer,	
2016;	 Hoskin	 et	 al.,	 2015;	 Leloup	 &	 Wells,	 2011;	 Storr	 et	 al.,	 2011).	 Here	 the	
inhibition	of	calpains	has	been	shown	to	have	beneficial	effects	on	cell	survival	and	
the	 amount	 of	 tissue	 damage	 following	membrane-damaging	 insults	 (for	 example	
ischemia-reperfusion	injury)	(Amini	et	al.,	2013;	Diepenbroek	et	al.,	2014;	Grieve	et	
al.,	2016;	Hoskin	et	al.,	2015;	Hubener	et	al.,	2013;	Leloup	&	Wells,	2011;	Miyazaki	et	
al.,	2011;	Storr	et	al.,	2011;	Toba	et	al.,	2013;	M.	Yamada	et	al.,	2009;	Yamashita	et	
al.,	2012).	
	
Conclusion	 	
It	is	thus	not	all	'black	and	white'	when	it	comes	to	the	involvement	of	calpains	in	the	
cellular	 mechanisms	 of	 human	 diseases.	 Even	 though	 the	 ubiquitous	 calpains	 are	
essential	 for	 the	acute	phase	of	membrane	repair	 (Ronald	L.	Mellgren	et	al.,	2009;	
Xie	&	Barrett,	1991),	in	many	disease	situations,	hyperactivity	of	calpains	is	regarded	
to	be	a	major	problem.	
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	 In	 the	 following	 section,	 1.6.2.2,	 I	 am	 introducing	 calpain-3,	 the	 skeletal	
muscle	 specific	 calpain	 that,	when	mutated,	 causes	muscular	dystrophy	 in	humans	
(Richard	et	al.,	1995)	but	it	is	not	required	for	membrane	repair	(Ronald	L.	Mellgren	
et	al.,	2009).	
	
1.6.2.2. Calpain-3	is	not	required	for	membrane	repair	
When	 our	 team	 first	 discovered	 that	 dysferlin	 was	 cleaved	 by	 the	 ubiquitous	
calpains,	we	immediately	considered	the	possibility	that	the	skeletal	muscle	specific	
calpain,	calpain-3,	may	mediate	the	cleavage	of	dysferlin.	
	 Mutations	in	the	CAPN3	gene,	cause	a	rare	form	of	muscular	dystrophy:	limb-
girdle	muscular	dystrophy	type	2A	(LGMD2A)	(Richard	et	al.,	1995).	LGMD2A	shares	
overlapping	 clinical	 presentations	with	 the	 limb-girdle	muscular	 dystrophy	 type	2B	
(LGMD2B)	caused	by	mutations	 in	the	dysferlin	gene,	DYSF	 (Jia	et	al.,	2001).	Based	
on	similar	clinical	presentations	between	LGMD2B	and	LGMD2B,	it	was	feasible	that	
calpain-3	and	dysferlin	may	act	in	the	same	pathway	for	membrane	repair,	and	that	
calpain-3	may	be	responsible	for	dysferlin	cleavage.	Interestingly,	Mellgren	et	al.	had	
partially	 disproven	 this	 hypothesis.	 Mellgren	 et	 al.,	 had	 shown	 previously	 that	
murine	 myofibers	 deficient	 for	 CAPN3-/-	 showed	 normal	 membrane	 repair:	 thus	
mouse	calpain-3	is	not	required	for	plasma	membrane	repair	(Ronald	L.	Mellgren	et	
al.,	2009).		
	 With	this	in	mind	I	could	now	focus	my	research	finding	out	if	it	was	calpain-1	
or	calpain-2	that	was	more	important	for	membrane	repair.		
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Synopsis	
In	the	following	section,1.7,	 I	will	 introduce	pore-forming	toxins,	which	I	use	in	this	
PhD	 as	 a	 physiological	 model	 of	 membrane	 injury.	 In	 this	 study	 I	 investigate	 the	
involvement	of	calpains-1	and	-2	in	response	to	perforation	by	streptolysin-O.		
	
1.7. Pore-forming	toxins	(PFTs)	
Pore-forming	 toxins	 are	 cytotoxic	 proteins	 secreted	 by	 many	 of	 the	 well-known	
disease-causing	 bacteria	 including	 Escherichia	 coli,	 Staphylococcus	 aureus,	
Streptococcus	pneumoniae,	or	Mycobacterium	tuberculosis	as	well	as	Streptococcus	
A	 and	B,	 reviewed	 in	 Los,	 Randis,	 Aroian	 and	Ratner,	 2013	 (Los,	 Randis,	 Aroian,	&	
Ratner,	2013)	as	well	as	by	Dal	Peraro	and	van	der	Goot,	2016	(Dal	Peraro	&	van	der	
Goot,	 2016).	 PFTs	 are	 what	 equip	 bacteria	 with	 their	 virulence,	 making	 bacterial	
infections	 the	 leading	 cause	 of	 mortality	 and	 morbidity	 worldwide.	 Bacterial	
infections	 can	 affect	 all	 tissues	 of	 the	 human	 body,	 causing	 infections	 such	 as	
pneumonia,	urinary	tract	infections,	soft	tissue	and	skin	infections,	as	well	as	sepsis	
and	 surgical-wound	 infections	 (Fischbach	 &	Walsh,	 2009;	Woodford	 &	 Livermore,	
2009).	
	 	
1.7.1. Classification	of	pore	forming	toxins	
PFTs	 are	 generally	 divided	 into	 two	 main	 groups:	 α-PFTs	 and	 β-PFTs.	 This	
classification	 is	 based	 on	 the	 secondary	 structure	 assumed	 by	 the	 membrane	
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spanning	 component	 of	 the	 pores;	 this	 can	 either	 be	 composed	 of	 α-helices	 or	 β-
barrels	(Iacovache,	Bischofberger,	&	van	der	Goot,	2010),	reviewed	in	Lesieur	et	al.,	
1997	(Lesieur,	Vecsey-Semjen,	Abrami,	Fivaz,	&	Gisou	van	der	Goot,	1997)	as	well	as	
by	Gouaux,	1997	(Gouaux,	1997).	
	 To	date,	there	are	three	families	of	α-PFTs	identified	and	three	families	of	β-
PFTs.	The	α-PFTs	consist	of	the	colicin,	actinoporin	and	the	cytolysin-A	families,	and	
β-PFTs	 is	 subdivided	 into	 haemolysins,	 aerolysin	 and	 the	 cholesterol-dependent	
cytolysin	(CDC)	families	(Dal	Peraro	&	van	der	Goot,	2016).		
	
1.7.2. Mechanism	of	action	
PFTs	are	generally	secreted	as	water-soluble	monomers;	the	monomers	then	bind	to	
receptors	 on	 the	 host	 cell	 surface,	 which	 can	 be	 specific	 lipids,	 sugars	 or	 protein	
receptors.	Figure	1.15	illustrates	the	different	receptors	used	by	different	PFTs.	
			
68	
	
	
Figure	1.15:	Illustration	of	receptor	specificity	of	different	pore	form
ing	toxins.	Different	PFTs	target	their	host	cells	via	different	
receptor	binding	m
echanism
s.	PFTs	both	recognise	and	bind	to	different	sugars,	lipids	or	protein	receptors.	This	im
age	is	reproduced	
from
	Dal	Peraro	and	van	der	Goot,	2016	(Dal	Peraro	&
	van	der	Goot,	2016).	
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Once	bound	to	the	host	cell	surface	the	PFT	monomers	oligomerise	in	order	to	form	
pores.	 The	 assembled	 pore	 then	 integrates	 into	 the	 plasma	membrane	 (Parker	 &	
Feil,	 2005).	 Figure	 1.16,	 below,	 shows	 a	 schematic	 illustration	 of	 the	 general	
mechanism	 of	 pore-secretion	 and	 -assembly.	 The	 pore-assembly	 and	 membrane	
integration	can	vary	between	pore-types	and	is	reliant	on	specific	and	complex	inter-
molecule	interactions	reviewed	in	Dal	Peraro	and	van	der	Goot,	2016	(Dal	Peraro	&	
van	der	Goot,	2016).	
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Figure	 1.16:	 Pore	 forming	 toxins,	 general	 mechanism	 of	 action.	 This	
image	is	reproduced	based	on	Parker	and	Feil,	2005	(Parker	&	Feil,	2005).	
	
The	size	of	the	pore	formed	varies	widely.	Aerolysin,	for	instance,	creates	one	of	the	
smallest	pores	with	~1.5	-	2	nm	in	diameter	(Abrami,	Fivaz,	&	van	der	Goot,	2000).	
The	 family	 of	 cholesterol-dependent	 cytolysins	 (CDCs)	 generally	 generates	 the	
largest	pores	with	pore	diameters	of	~30	-	50	nm	(Gilbert,	2010).		
	 PFTs	 always	 increase	 the	 permeability	 of	 the	 target	membrane	 of	 the	 host	
cell.	 What	 kind	 of	 molecules	 the	 pores	 'allow'	 to	 pass	 through	 the	 membrane,	
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however,	is	specific	to	each	pore-type	(Dal	Peraro	&	van	der	Goot,	2016).	Some	PFTs	
create	pores	that	only	allow	K+	and/or	Ca2+	ions	to	pass	or	small	molecules	like	ATP.	
PFTs	 that	 form	 large	pores,	as,	 for	example	streptolysin-O	with	a	pore	diameter	of	
~30	nm,	allow	for	molecules	up	to	150	kDa	to	pass	through	the	membrane	(Bhakdi,	
Tranum-Jensen,	&	Sziegoleit,	1985;	Palmer	et	al.,	1998;	Walev	et	al.,	2001).		
	 The	 diameter	 of	 the	 pore	 is	 directly	 correlated	 to	 its	 conductance.	 A	 small	
pore,	 like	 that	 formed	 by	 aerolysin,	 might	 only	 conduct	 400	 pS	 (Iacovache	 et	 al.,	
2006)	 whereas	 the	 large	 pores	 formed	 by	 CDCs	 such	 as	 pneumolysin	 can	 reach	
conductance	of	>	1	nS	(Korchev	et	al.,	1998);	meaning,	that	larger	pores	will	let	more	
Ca2+	in	and	more	K+	out	than	smaller	pores.	Whether	a	pore	conducts	Ca2+	is	directly	
relevant	 to	whether	Ca2+-dependent	or	Ca2+-independent	 removal	mechanisms	are	
deployed	by	a	cell.		
	 The	severity	of	the	infection	caused	by	bacteria	pore-forming	toxins	depends	
on	 the	 PFT	 concentration	 that	 the	 body	 and	 the	 cells	 are	 subjected	 to.	 The	
intracellular	increase	in	Ca2+	causes	cellular	stress	triggering	pathways	that	can	cause	
cell	death.	Following	perforation,	the	cell	can	die	either	via	apoptosis,	necrosis	or	the	
highly	 inflammatory	 form	 of	 programmed	 cell	 death,	 pyroptosis	 (Bischofberger,	
Iacovache,	&	van	der	Goot,	2012).	
		 	
1.7.3. Repair	mechanisms	of	perforated	cell	membranes	
In	 order	 to	 prevent	 PFT-induced	 death	 the	 cell	 is	 equipped	 with	 different	
mechanisms	 to	 remove	 the	 pores	 from	 the	 plasma	membrane.	Membrane	 repair	
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after	pore-forming	toxins	has	briefly	been	introduced	in	section	1.2.	Here	I	provide	
further	 information	 about	 the	 different	 repair	 mechanisms	 deployed	 following	
perforation	of	different	types	of	pore-forming	toxins.	
	 It	 has	 been	 shown	 that	 pores	 can	 be	 removed	 via	 endocytosis,	 with	
subsequent	 degradation	 of	 the	 pores	 in	 the	 lysosomes	 (Idone,	 Tam,	 &	 Andrews,	
2008).	Corrotte	et	al.	have	 further	demonstrated	that	caveolae	may	be	 involved	 in	
the	 endocytic	 removal	 of	 pores	 created	 by	 streptolysin-O	 (Corrotte	 et	 al.,	 2013).	
Another	 proposed	mechanism	 of	 pore	 removal	 is	 exosomal	 shedding	 of	 the	 pore-
containing	 membrane	 into	 the	 extracellular	 space	 by	 using	 the	 ESCRT	 machinery	
(Jimenez	et	al.,	2014;	Keyel	et	al.,	2011).	
	 It	has	been	suggested	that	the	removal	of	CDC	pores,	such	as	those	formed	
by	 streptolysin-O,	 occurs	 rapidly,	 within	 a	 couple	 of	 minutes,	 by	 Ca2+-triggered	
endocytosis	(Corrotte,	Fernandes,	Tam,	&	Andrews,	2012;	V.	Idone	et	al.,	2008;	Tam	
et	 al.,	 2010).	 Interestingly,	 the	 removal	of	 the	 smallest	pores,	 formed	by	aerolysin	
(Gonzalez	et	al.,	2011)	and	α-haemolysin	 (also	known	as	α-toxin	Hla)	 (Husmann	et	
al.,	2009;	Husmann	et	al.,	2006)	 takes	much	 longer	 than	 the	 rapid	 removal	of	CDC	
pores.	Husmann	et	al.	 showed	 that	 it	 takes	 several	hours	 to	 remove	α-toxin	pores	
from	 human	 keratinocytes	 (Husmann	 et	 al.,	 2009).	 The	 reason	 for	 this	 delay	 in	
membrane	repair	response	may	be	due	to	whether	a	pore	sufficiently	conducts	Ca2+	
(Gonzalez	 et	 al.,	 2011;	 Husmann	 et	 al.,	 2006).	 Ca2+-triggered	 endocytosis	 or	
exosomal	 shedding	 may	 be	 faster-acting	 than	 Ca2+-independent	 removal	
mechanisms.	Other	pores	conduct	sufficient	Ca2+	through	their	channels	to	trigger	a	
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Ca2+-dependent	 membrane	 repair	 response,	 and	 this	 involves	 the	 activation	 of	
calpains.	
	
1.7.4. Calpain	activation	through	PFT	infection	
Recent	 studies	 have	 shown	 that	 calpains	 are	 activated	 as	 a	 consequence	 of	 PFT-
induced	 membrane	 injury	 (Bumba,	 Masin,	 Fiser,	 &	 Sebo,	 2010;	 Kennedy,	 Smith,	
Lyras,	Chakravorty,	&	Rood,	2009;	 Soong,	Chun,	Parker,	&	Prince,	2012).	PFTs	 that	
have	been	 shown	 to	 cause	 calpain	 activation	 include:	α‑haemolysin	 secreted	by	S.	
aureus	(Soong	et	al.,	2012),	cytoslysin	A	(ClyA)	secreted	by	B.	pertussis	(Bumba	et	al.,	
2010)	and	the	α‑toxin	secreted	by	C.	septicum	(Kennedy	et	al.,	2009).	
		 The	 only	 downstream	 target	 of	 calpains	 following	 PFT-induced	 membrane	
injury,	identified	to	date	is	the	cytoskeletal	protein,	talin	(Bumba	et	al.,	2010).	
	 In	my	thesis	I	am	the	first	to	investigate	the	role	of	calpain-1	and	calpain-2	in	
the	repair	of	pore-forming	toxin	injury	caused	by	streptolysin-O.	
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 Chapter	2: Results	 -	 Modifiers	 of	 membrane	
repair	
This	chapter	contains	large	amounts	of	data	so	I	sub-divide	my	results	into	four	parts	
-	part	A,	B,	C	and	D,	and	briefly	explain	my	rationale	for	doing	so	below:		
Ø Part	A	describes	data	generated	from	when	I	first	started	my	PhD.	My	former	
colleague,	Dr	Lek,	had	just	finished	her	PhD,	and	together	we	were	tidying	up	
'loose	 ends'	 stemming	 from	 her	 work,	 which	 formed	 the	 basis	 of	 the	 first	
ideas	of	my	PhD.	Dr	Gregory	Redpath,	who	was	in	the	middle	of	his	PhD,	and	
I,	subsequently	pursued	separate	(but	inter-related)	investigations	stemming	
from	 Dr	 Lek's	 discovery	 that	 dysferlin	 was	 cleaved	 enzymatically	 into	 two	
pieces.		
Ø Part	 B	 describes	 the	 search	 to	 establish	 which	 ubiquitous	 calpain	 is	 more	
important	 for	membrane	 repair,	 via	 the	 generation	of	 single	 knock-out	 cell	
lines	 deficient	 for	 calpain-1,	 calpain-2,	 or	 both,	 using	 CRISPR/Cas9	
technology.		
Ø Part	 C	 investigates	 different	 types	 and	 sizes	 of	 membrane	 injury	 and	 the	
involvement	of	dysferlin	and	the	ubiquitous	calpains.	
Ø Part	 D	 describes	 the	 generation	 of	 a	 mouse	 model	 with	 skeletal	 muscle-
specific	knock-out	of	CAPNS1.	
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Part	A		
2.1. Is	dysferlin	cleaved	in	response	to	ballistic	injury	in	human	skeletal	
muscle	cells?	
When	 I	 first	 started	my	PhD,	our	 team	had	 just	discovered	 that	dysferlin	 could	be	
cleaved	enzymatically	into	two	pieces,	releasing	a	C-terminal	mini-dysferlinC72	and	an	
N-terminal	 counter	 fragment	 (Lek,	2012;	 Lek	et	al.,	2013).	Dr	 Lek	had	developed	a	
ballistic	 injury	assay	 to	visualise	dysferlin	 recruitment	 to	 sites	of	membrane	 injury,	
using	 confocal	 and	 super-resolution	 microscopy.	 To	 study	 dysferlin	 cleavage	 by	
western	 blot,	 the	 team	 used	 a	 cell	 scrape	 assay	 injuring	 a	 larger	 quantity	 of	 cells	
simultaneously.	With	membrane	injury,	Dr	Lek	observed	a	rapid	(within	10	seconds),	
Ca2+-dependent	 formation	 of	 dysferlin	 cleavage	 products.	 She	 also	 observed	 that	
dysferlin	recruited	to	injury	sites	was	detected	only	with	antibodies	recognising	a	C-
terminal	dysferlin	epitope.	But	our	team	could	only	infer	that	the	dysferlin	we	saw	at	
injury	 sites,	 using	 the	ballistic	 assay,	was	 the	C-terminal	mini-dysferlinC72	 fragment	
we	saw	by	western	blot.	
	 To	tie	the	two	results	together	and	collect	more	evidence	that	it	is	in	
fact	mini-dysferlinC72	 that	 gets	 recruited	 to	 sites	 of	 injury,	 the	 first	 aim	of	my	PhD	
became	to	use	the	ballistic	assay	to	shoot	cells	and	run	those	samples	on	a	western	
blot.	This	made	a	small	but	important	contribution	to	Dr	Lek's	work	as	published	in	
The	Journal	of	Neuroscience	in	2013	(see	Lek	et	al.,	2013,	figure	5a,	page	5090	(Lek	et	
al.,	2013).	
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	 Figure	2.1,	below,	shows	the	western	blot	analysis	of	differentiated	primary	
human	 muscle	 cells	 (c1504s)	 shot	 in	 the	 presence	 and	 absence	 of	 900	 µM	
extracellular	Ca2+,	compared	to	an	unshot	control.	When	probed	with	the	C-terminal	
anti-dysferlin	 antibody,	 Hamlet-1,	 I	 could	 detect	 mini-dysferlinC72	 only	 when	 cells	
were	shot	in	the	presence	of	Ca2+,	but	not	without	extracellular	Ca2+	(arrow	indicates	
mini-dysferlinC72).	 In	 the	unshot	 sample	 a	 faint	mini-dysferlinC72	 band	 can	be	 seen,	
potentially	due	to	a	degree	of	enzymatic	cleavage	during	cell	harvesting	for	western	
blot	as	the	unshot	sample	was	harvested	in	the	presence	of	extracellular	Ca2+.	
	
	
Figure	2.1:	Ballistic	injury	causes	mini-dysferlinC72	formation	in	primary	
human	myotubes	(c1504).	Western	blot	analysis	of	myotubes	shot	with	
silica	bullets.	Cells	were	shot	in	the	presence	or	absence	of	extracellular	
Ca2+	 and	 compared	 to	 an	 unshot	 control.	 The	 C-terminal	 anti-dysferlin	
antibody	 (Hamlet-1)	 picks	 up	 full-length	 dysferlin	 and	 the	 C-terminal	
mini-dysferlinC72	(arrow).	GAPDH	serves	as	a	loading	control.	
	
My	 experiment	 served	 as	 an	 important	 link	 between	 the	 two	 different	 modes	 of	
membrane	injury:	mechanical	scrape	and	ballistic	injury.		
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Second	aim	
Next	 I	 wanted	 to	 establish	 how	 much	 extracellular	 Ca2+	 was	 needed	 to	 cleave	
dysferlin,	 and	 to	 correlate	 this	 with	 the	 amount	 of	 Ca2+	 required	 for	 effective	
membrane	 repair.	 This	 study	 aimed	 to	 establish	 if	 dysferlin	 cleavage	 occurs	
specifically	 under	 the	 extreme	 circumstances	 of	 a	 membrane	 injury,	 where	 local	
intracellular	Ca2+	 concentrations	 ([Ca2+]IC)	are	unusually	high,	or	 if	 less	Ca2+	 (e.g.	as	
during	a	muscle	contraction),	could	be	enough	to	trigger	dysferlin	cleavage.	
	 I	undertook	membrane	repair	assays	to	establish	the	half	maximal	activation	
concentration,	 the	 EC50,	 of	 extracellular	 Ca2+	 required	 for	 membrane	 repair.	 Dr	
Redpath	conducted	complementary	western	blot	analyses	to	address	the	question	of	
how	much	extracellular	Ca2+	was	required	to	cleave	dysferlin.	As	these	two	aims	are	
inter-related	 I	 am	 going	 to,	 with	 Dr	 Redpath's	 consent,	 reproduce	 his	 results	 in	
section	2.1.1,	below,	to	put	my	own	data	into	context.	
	
2.1.1. How	much	Ca2+	is	needed	for	dysferlin	cleavage?	
Figure	2.2	shows	the	result	of	Dr	Redpath's	western	blot	analysis	of	primary	human	
myotubes	 (c1504s)	 scraped	 in	 the	 presence	 of	 increasing	 amounts	 of	 extracellular	
Ca2+.	 The	 result	 shows	 that	 mini-dysferlinC72	 formation	 (detected	 using	 the	 C-
terminal	 anti-dysferlin	 antibody	 Hamlet-1)	 becomes	 detectable	 at	 ~50	 µM	
extracellular	Ca2+	concentration	([Ca2+]EC)	with	the	signal	intensity	increasing	at	~200	
µM.	
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Figure	 2.2:	 Ca2+-requirements	 for	mini-dysferlinC72	formation.	Western	
blot	analysis	of	c1504s	scraped	in	the	presence	of	increasing	amounts	of	
extracellular	 Ca2+.	 Mini-dysferlinC72	 formation	 (arrow)	 can	 be	 detected	
from	~50	µM	[Ca2+]EC	and	increases	in	intensity	at	~200	µM	(using	the	is	
C-terminal	 anti-dysferlin	 antibody	 Hamlet-1).	 Actin	 serves	 as	 a	 loading	
control.	This	image	is	reproduced	from	Lek	et	al.,	2013	(Lek	et	al.,	2013).	
	
2.2. The	Ca2+-	dependence	of	membrane	repair	
Membrane	 repair	 has	 been	 extensively	 studied	 over	 the	 last	 decades	 (Togo	 et	 al.,	
1999).	However,	to	date,	the	exact	[Ca2+]EC	needed	for	efficient	membrane	resealing	
had	not	been	determined	in	human	cellular	models.		
	 My	study	focused	on	the	Ca2+	dependence	of	cell	membrane	repair	in	human	
primary	muscle	cells	compared	to	non-muscle	cells.	Skeletal	muscle	cells,	 like	other	
excitable	 cells,	 experience	 Ca2+-transients	 up	 to	 100	 fold	 than	 the	 typical	 resting	
[Ca2+]IC	 of	 ~50	 nM	 (Berchtold,	 Brinkmeier,	 &	 Muntener,	 2000).	 I	 therefore	
hypothesized	 that	 primary	 human	 muscle	 cells	 (c1504s)	 may	 have	 a	 different	
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requirement	 for	 Ca2+	 in	 membrane	 repair,	 compared	 to	 a	 non-excitable	 cell	 line	
(human	oligodendroglial	cell	line,	MO3.13).	 	
	 To	analyse	 the	membrane	 repair	 capacity	of	 the	 cells	 in	different	 [Ca2+]EC,	 I	
performed	 mechanical	 scrape	 injury	 experiments.	 I	 subjected	 the	 cells	 to	 large	
mechanical	 plasma	 membrane	 injuries	 by	 scraping	 them	 off	 the	 substrate	 in	
different	 [Ca2+]EC.	 Afterward	 the	 cells	were	 left	 to	 recover	 and	 reseal	 their	 plasma	
membranes	 for	 five	minutes	 at	 room	 temperature	 (RT).	 Cells	 that	were	 unable	 to	
repair	were	then	labelled	with	the	cell	 impermeable	dye,	propidium	iodide	(PI)	and	
analysed	 at	 the	 flow	 cytometer.	 PI	 is	 well	 established	 as	 a	 reliable	 readout	 for	
membrane	 fidelity/permeability	 (Corrotte,	 Castro-Gomes,	 Koushik,	 &	 Andrews,	
2015;	V.	Idone	et	al.,	2008;	Tam	et	al.,	2010).		
	 Figure	 2.3,	 below,	 shows	 the	 gating	 strategy	 I	 used	 for	 this	 assay;	wherein	
cells	 positive	 for	 PI	 reflect	 cells	 that	 suffered	 a	 lethal	 scrape	 injury	 and	 could	 not	
repair	their	plasma	membrane.		
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Figure	2.3:	Gating	strategy	for	PI	membrane	repair	assay.	A.	All	cell	gate	
chosen	of	size	 (FSC-A)	and	granularity	 (SSC-A)	of	 the	cells	excluding	cell	
debris	 (e.g.	nuclei).	B.	Gating	for	PI	positive	cells.	The	peak	on	the	right	
represents	 PI	 positive	 cells	 that	we	 are	 calling	 'damaged/dead'	 as	 they	
have	 failed	 to	 repair	and	exclude	PI.	The	 left	peak	 represents	cells	 that	
were	PI	negative.	C.	i)	PI-gate	setting	on	unstained	control.	ii)	Example	of	
a	c1504	cells	 scraped	 in	 the	presence	of	0	µM	and	 iii)	900	µM	[Ca2+]EC.	
Without	extracellular	Ca2+	more	cells	are	PI	positive	(65	%)	compared	to	
900	µM	[Ca2+]EC	(43	%).		
	
I	observed	that	primary	human	muscle	cells	(c1504s)	as	well	as	the	oligodendroglial	
cell	line,	MO3.13,	needed	between	~150-200	μM	[Ca2+]EC	to	reseal	and	subsequently	
survive	a	membrane	injury	caused	by	scraping	as	portrayed	in	Figure	2.4.		
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Figure	 2.4.	 Effect	 of	 extracellular	 Ca2+	 on	membrane	 repair	 in	muscle	
and	 non-muscle	 cells.	 A.	 Primary	 human	myoblasts	 (differentiated	 for	
three	 days	 only)	 and	 B.	 human	 oligodendroglial	 cells	 (MO3.13).	 Cells	
were	scraped	 in	 the	presence	of	different	 [Ca2+]EC	 (PBS	0,	50,	100,	150,	
200,	 400	 and	 900	 µM	 Ca2+)	 and	 left	 to	 reseal	 for	 10	minutes	 at	 room	
temperature.	 Cells	 were	 pelleted	 at	 300	 g	 for	 one	 minute	 and	
resuspended	in	propidium	iodide	(PI)	(1:200	from	1	mg/mL).	N=3	c1504s,	
N=2	 MO3.13s.	 As	 this	 is	 not	 a	 typical	 dose-response	 curve	 no	 line	 fit	
would	match.	 The	 data	 points	 have	 been	 connected	 via	 a	 line	 and	 the	
EC50	is	only	estimated.	
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This	 result	 suggested	 that,	 even	 though	 muscle	 cells	 are	 used	 to	 handling	 higher	
[Ca2+]IC	for	contraction,	the	[Ca2+]EC	needed	for	effective	plasma	membrane	repair	is	
not	different	to	that	needed	for	the	non-excitable	MO3.13	cells.	
	 Next	 I	 wanted	 to	 establish	 if	 a	 threshold	 of	 ~150-200	 µM	 [Ca2+]EC	 for	
membrane	repair	was	a	common	requirement	for	other	cell	lines.		
	
2.2.1. Do	all	cell	lines	have	the	same	Ca2+-	threshold	for	membrane	repair?	
I	 used	 COS-7	 cells	 (monkey	 kidney	 fibroblast-like	 cells)	 and	 HEK293	 cells	 (human	
embryonic	kidney	cells)	and	subjected	them	to	mechanical	scrape-injury	in	different	
[Ca2+]EC.		
	 For	these	studies	I	optimised	the	scrape	membrane	repair	assay	to	now	label	
the	population	of	repaired	cells	and	distinguish	them	from	the	cells	that	were	unable	
to	 repair,	based	on	 the	 saponin	membrane	 repair	assay	developed	by	Dr	 Lek	 (Lek,	
2012).	For	this	assay	two	cell	impermeable	dyes	were	successively	added	to	the	cells:	
the	first	dye,	TO-PRO-3,	was	added	during	the	scrape	injury,	labelling	all	injured	cells.	
The	second	dye,	PI,	was	added	after	a	recovery	period	of	five	minutes	to	now	label	
all	cells	that	were	unable	to	repair	their	plasma	membrane.	The	population	of	cells	
that	was	positive	for	TO-PRO-3	but	negative	for	PI	 labelled	the	repaired	population	
of	 cells.	 Figure	 2.5	 shows	 the	 workflow	 of	 the	 two-dye	 flow	 cytometric	 scrape	
membrane	repair	assay.	A	detailed	description	of	this	assay	can	be	found	in	Material	
&	Methods	7.2.1.	
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Figure	 2.5:	 Two-dye	 membrane	 repair	 assay.	 Cells	 are	 injured	 via	
scraping	 in	 the	 presence	 of	 the	 first	 membrane	 impermeable	 dye	 TO-
PRO-3	(1:2500	from	1	mM	stock).	All	injured	cells	will	be	positive	for	TO-
PRO-3.	Cells	are	collected	in	a	5	mL	round	bottom	FACS	tube	and	left	to	
recover	for	five	minutes	at	room	temperature.	Cells	are	pelleted	at	300	g	
for	one	minute	and	 resuspended	 in	 ice	 cold	PBS	 containing	 the	 second	
membrane	 impermeable	 dye,	 PI	 (1:200	 from	1	mg/mL	 stock).	 Cells	 are	
kept	on	 ice	from	now	on	to	avoid	pinocytosis	of	the	dye.	Repaired	cells	
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will	exclude	PI	and	be	only	positive	 for	TO-PRO-3.	Cells	 that	are	double	
positive	are	referred	to	as	'damaged/dead'.	
	
Figure	 2.6	 shows	 the	 gating	 strategy	 I	 used	 to	 extract	 the	 percentage	 of	 repaired	
cells	relative	to	all	injured	cells.	
	
	 								 	
Figure	 2.6:	 Gating	 strategy	 for	 membrane	 repair	 assays	 analysing	
repaired	cells.	A)	Controls	captured	for	each	experiment.	A	blank	sample	
without	 any	 dye,	 a	 PI	 only	 sample	 and	 a	 TO-PRO-3	 only	 sample.	Gates	
were	set	as	quadrangles	 (Q1-4)	based	on	 these	controls.	B)	 Example	of	
scrape-injured	 cells	 in	 the	 presence	 of	 Ca2+.	Q1	 represents	 all	 repaired	
cells;	 these	 cells	 are	 positive	 for	 TO-PRO-3	 but	 are	 negative	 for	 PI.	Q2	
shows	 the	 'damaged/dead'	 cells	 that	 are	 positive	 for	 TO-PRO-3	 and	 PI	
thus	 were	 unable	 to	 repair	 their	 membranes.	 Q3	 are	 'dead	 but	 not	
injured	cells'	and	does	therefore	not	apply.	Q4	represents	the	uninjured	
cells.	 To	 extract	 the	 data	 I	 have	 analysed	 the	 amount	 of	 repaired	 cells	
relative	to	all	injured	cells.	See	equation	above.	
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The	 results	 showed	 that	COS-7	 cells	 behaved	 similarly	 to	 c1504	and	MO3.13	 cells,	
with	 the	 maximum	 membrane	 repair	 capacity	 reached	 at	 ~150-200	 µM	 [Ca2+]EC	
(Figure	2.7A).	HEK293	cells	appeared	 to	be	 the	exception,	with	more	 than	200	µM	
Ca2+	needed	to	maximise	membrane	repair	capacity.	The	membrane	repair	capacity	
of	HEK293	cells	did	not	saturate,	even	at	Ca2+	concentrations	of	900	µM.	In	order	to	
further	 increase	 the	 [Ca2+]EC,	 I	 changed	 to	 HEPES	 buffer	 instead	 of	 PBS	 as	 Ca2PO4	
precipitates	in	PBS	when	Ca2+	levels	are	increased	with	CaCl2.	Using	up	to	1100	µM	
[Ca2+]EC,	the	membrane	repair	capacity	of	HEK293	cells	did	not	plateau	(Figure	2.7B).	
After	 increasing	 the	 [Ca2+]EC	 even	 further,	 cell	 death	 increased,	 potentially	 due	 to	
Ca2+	toxicity.	Even	though	I	could	not	measure	the	exact	[Ca2+]IC,	my	results	could	still	
be	used	 to	 infer	 the	general	 requirement	 for	Ca2+	 for	membrane	 repair	 in	HEK293	
cells.		
	 Figure	 2.7,	 below,	 shows	 the	 increased	 percentage	 of	 repaired	 cells	 with	
increasing	 [Ca2+]EC.	 The	 percentage	 of	 repaired	 cells	 (TO-PRO-3	 positive	 but	 PI	
negative)	 relative	 to	all	 cells	 that	have	been	 initially	 injured	 (TO-POR-3	positive,	PI	
positive),	normalised	to	900	µM	[Ca2+]EC	was	measured.	
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Figure	2.7:	Ca2+	titration	of	membrane	repair	in	COS-7	and	HEK293	cells.	
In	these	experiments	the	percentage	of	cells	that	repaired,	relative	to	all	
injured	 cells	was	 analysed.	 A.	 In	 COS-7	 cells	 the	 graph	 shows	 a	 similar	
trend	 to	MO3.13	 and	 c1504	 cells	with	 the	maximum	membrane	 repair	
capacity	 reached	 at	 ~150-200	 µM	 [Ca2+]EC	 .	 B.	 The	 membrane	 repair	
capacity	of	the	HEK293	cells	however,	did	not	peak	at	~150-200	µM	and	
did	not	reach	saturation	when	using	a	maximum	of	900	µM	[Ca2+]EC.	To	
achieve	 higher	 Ca2+	 concentration,	 the	 buffer	 was	 changed	 to	 HEPES	
buffer	 instead	 of	 PBS,	 using	 up	 to	 1100	 µM	 [Ca2+]EC.	 This	 graph	 shows	
that	 we	 could	 not	 reach	 saturating	 [Ca2+]EC	 for	 maximum	 membrane	
repair	capacity	 in	HEK293	cells	even	when	using	up	to	1100	µM	[Ca2+]EC	
we	did	not	reach	saturation.	When	we	used	more	than	1100	µM	[Ca2+]EC,	
the	membrane	repair	capacity	deteriorated	drastically	due	to	cell	death	
from	Ca2+	 toxicity	 (data	not	 shown).	 The	 curves	 represent	 a	 hyperbola,	
non-linear	line	fit.	N	=	2.	 	
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Synthesis	
In	 these	 studies	 I	 have	 shown	 that	 ~150-200	 µM	 [Ca2+]EC	 was	 a	 reproducible	
threshold	of	'maximum	membrane	repair'	capacity	in	primary	human	muscle	cells	as	
well	 as	 the	 non-muscle	 cell	 lines	 MO3.13	 and	 COS-7	 cells	 with	 the	 exception	 of	
HEK293	cells.		 Dr	Redpath	has	also	shown	that	dysferlin	needed	~50	µM	[Ca2+]EC	to	
be	 cleaved	 and	 release	 mini-dysferlinC72,	 with	 enhanced	 cleavage	 in	 Ca2+	
concentrations	of	~200	µM.	
	 To	 better	 understand	 the	 link	 between	 the	 Ca2+-dependence	 of	membrane	
repair	and	the	amount	of	[Ca2+]EC	required	to	cleave	dysferlin,	it	is	important	to	know	
the	 activating	 Ca2+	 concentrations	 for	 calpain-1	 and	 calpain-2.	 The	 half	 maximal	
activation	concentration	(EC50)	of	Ca2+	to	activate	calpain-1	 is	~20	µM	and	the	EC50	
for	calpain-2	is	~200	µM	(Goll	et	al.,	2003).	Based	on	this,	my	results	implied	that	it	
might	be	calpain-2	(EC50	~200	µM),	rather	than	calpain-1	(EC50	~20	µM),	that	is	most	
important	 for	membrane	repair.	But	given	 that	dysferlin	was	cleaved	with	~50	µM	
[Ca2+]EC,	 it	was	not	clear	 from	Dr	Redpath's	experiments	whether	calpain-1,	and/or	
calpain-2,	was/were	responsible	for	the	enzymatic	cleavage	of	dysferlin	in	response	
to	mechanical	scrape	membrane	injury.		
	 Not	all	cell	lines	used	in	this	study	show	detectable	levels	of	dysferlin	protein.	
COS-7	cells,	 like	c1504	and	MO3.13	cells	express	dysferlin	protein	but	HEK293	cells	
do	 not	 express	 detectable	 levels	 of	 dysferlin	 protein.	 All	 four	 cell	 lines	 express	
calpain-1	and	calpain-2	protein.	The	expression	of	other	membrane	repair	relevant	
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proteins	like	annexins	or	ESCRT	complex	proteins	have	not	been	tested	as	part	of	my	
studies.		
	 The	 effect	 of	 calpain	 inhibition,	 as	 well	 as	 addition	 of	 extracellular	
recombinant	 calpain-1	 and	 calpain-2	 on	 membrane	 repair	 outcomes	 following	
scrape	injury	is	described	in	section	2.3,	below.	
	
2.3. Calpains	in	membrane	repair	
2.3.1. Inhibition	of	calpains	is	detrimental	for	cell	survival	after	scrape	injury	
In	 this	 study	 I	 investigated	 the	 role	 of	 calpains	 in	 membrane	 repair	 by	 inhibiting	
calpain-1	and	-2	with	the	specific	calpain	inhibitor	calpeptin.	This	study	was	aimed	to	
further	 establish	 the	 link	 between	 activated	 calpains	 and	 dysferlin	 cleavage	 in	
membrane	repair.	
	 Dr	Lek	showed	that	calpain	inhibition	by	calpeptin	also	inhibits	the	formation	
of	mini-dysferlinC72	after	 scrape	 injury	 (Lek	et	al.,	 2013).	 In	 this	 regard	 I	wanted	 to	
establish	the	half	maximal	inhibitory	concentration	(IC50)	of	calpeptin	for	cell	survival	
after	 membrane	 injury.	 As	 calpeptin	 is	 known	 to	 inhibit	 other	 classes	 of	 cysteine	
proteases	 (i.e.	 cathepsins),	 information	 regarding	 IC50	 helped	 to	 indicate	 a	
requirement	for	activated	calpains	for	the	cleavage	of	dysferlin	in	membrane	repair.	
Also,	 the	 team	 had	 only	 ever	 used	 calpeptin	 at	 saturating	 levels	 and	 needed	 to	
establish	a	dose-response	curve	to	inform	the	most	appropriate	inhibitory	treatment	
conditions.		
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	 My	results	showed	that	addition	of	calpeptin	led	to	increased	cell	death	after	
scrape	 injury	 in	 primary	 human	 muscle	 cells	 (c1504s).	 I	 determined	 the	 half	
maximum	 inhibitory	 concentration	 of	 calpeptin	 to	 be	 11.81	 ±	 5.83	 µM	 in	 primary	
human	 muscle	 cells.	 Figure	 2.8,	 below,	 portrays	 the	 dose-response	 curves	 I	
generated	from	four	separate	experiments.	 	
	 	
Figure	2.8.	Calpeptin	inhibits	cell	survival	after	scrape	injury	in	primary	
human	muscle	 cells	 (c1504).	The	four	separate	experiments	are	shown	
on	this	graph.	Cells	were	incubated	with	calpeptin	(5,	10,	20,	40,	80,	160	
and	320	µM)	one	hour	prior	to	the	experiment.	Cells	were	then	scraped	
in	the	presence	of	calpeptin	in	900	µM	Ca2+	PBS	and	left	to	reseal	for	10	
minutes	at	RT.	Cell	death	increases	in	a	dose	dependent	manner.	The	IC50	
for	calpeptin	for	cell	survival	after	scrape	injury	is	11.81	±	5.83	µM.	(four	
separate	experiments).	N=4.	
	
Dr	Redpath	performed	complementary	studies	of	calpeptin	treatment	on	the	injury-
induced	 cleavage	 of	 dysferlin.	 Figure	 2.9	 shows	 his	 western	 blot	 analysis	 of	 the	
calpeptin	 treatment	 of	 differentiated	 primary	 human	 myotubes	 (c1504s).	 Mini-
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dysferlinC72	 formation	was	 strongly	 reduced	 after	 treatment	with	 ~5	 µM	 calpeptin	
and	almost	undetectable	after	treatment	with	~40	µM	calpeptin.		
	 											 	
Figure	 2.9:	 Calpeptin	 blocks	 mini-dysferlin	 formation.	 Western	 blot	
analysis	 of	 c1504s	 scraped	 in	 the	 presence	 of	 increasing	 amounts	 of	
calpeptin.	 Cells	 have	 been	 pre-treated	 for	 three	 hours	 and	 again	 30	
minutes	 prior	 to	 the	 scrape	 injury.	 Mini-dysferlin	 formation	 (arrow)	 is	
strongly	 reduced	at	 5	µM	calpeptin	 and	almost	undetectable	 at	 40	µM	
calpeptin	 (detected	with	Hamlet-1).	GAPDH	serves	as	a	 loading	control.	
This	 image	 is	 reproduced	 from	 Redpath	 et	 al.,	 2014	 (Redpath	 et	 al.,	
2014).		
	
Summary	
Dr	 Redpath's	 data	 and	 my	 data	 provided	 the	 team	 with	 compelling	 evidence	 to	
suggest	that	the	cleavage	of	dysferlin	is	linked	directly	to	activated	calpains	and	may	
be	 a	 requirement	 for	 successful	 membrane	 repair	 outcomes.	 When	 calpains	 are	
blocked	by	calpeptin,	dysferlin	did	not	get	cleaved	and	cells	could	no	 longer	repair	
their	membrane	after	scrape	injury.	
	 The	Ca2+	titrations	(c1504	and	MO3.13	cells),	as	well	as	the	calpain	inhibition	
experiments,	are	part	of	Dr	Redpath's	publication	in	Molecular	Biology	of	the	Cell	in	
2014,	where	I	am	a	co-author	((Redpath	et	al.,	2014)	figure	6A	and	B,	page	3043).	In	
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his	 work	 Dr	 Redpath	 showed	 that	 dysferlin	 was	 unable	 to	 be	 cleaved	 in	 mouse	
embryonic	 fibroblasts	 (MEFs)	 where	 calpains-1	 and	 -2	 were	 rendered	 functionally	
inactive	due	to	genetic	knock-out	of	their	small	regulatory	subunit	CAPNS1	(Redpath	
et	al.,	2014).		
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Part	B	
Part	B	of	 this	chapter	describes	 the	search	to	 identify	which	of	 the	two	ubiquitous	
calpains	 is	 responsible	 for	 membrane	 repair.	 For	 this	 study	 I	 treated	 cells	 with	
recombinant	calpains-1	and	-2	as	well	as	generated	single	calpain	knock-out	cell	lines	
using	CRISPR/Cas9	technology	to	answer	this	question.	
	
2.4. Is	calpain-1	or	calpain-2	more	important	for	membrane	repair?	
The	team's	collective	research	indicated	that	 it	 is	the	ubiquitous	calpains,	calpain-1	
and/or	 calpain-2	 that	 cleave	 dysferlin	 (Lek	 et	 al.,	 2013;	 Redpath	 et	 al.,	 2014),	 in	
keeping	 with	 results	 published	 by	 Mellgren	 et	 al.,	 showing	 that	 the	 ubiquitous	
calpains	are	indispensable	for	membrane	repair	(Ronald	L.	Mellgren	et	al.,	2009;	R.	L.	
Mellgren	et	al.,	2007).	What	remained	unclear,	however,	was	whether	it	is	calpain-1	
or	calpain-2,	or	both,	that	mediate	the	acute	membrane	repair	response	in	vivo.	
	 To	 date	 there	 are	 no	 commercially	 available	 specific	 calpain	 inhibitors	 that	
only	 inhibit	 calpain-1	 or	 calpain-2.	 I	 therefore	 used	 several	 different	 experimental	
approaches	 to	address	 the	question	which	calpain	mediates	membrane	 repair.	My	
fellow	PhD	student	Natalie	Woolger,	who	refined	the	calpain-cleavage	motif	within	
dysferlin	to	residues	encoded	by	exon	40a	(Redpath	et	al.,	2014),	examined,	as	part	
of	her	PhD	thesis,	the	question	of	which	calpain	cleaves	dysferlin.		
	 The	 first	 experiment	 I	 conducted	was	 the	 treatment	 of	 scrape-injured	 cells	
with	extracellular	recombinant	calpain	-1	or	calpain-2.	
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2.4.1. Recombinant	calpain-1	and	calpain-2	aid	membrane	repair	
I	wanted	to	establish,	using	the	flow	cytometric	membrane	repair	assay,	if	treatment	
with	 extracellular	 recombinant	 calpain-1	 or	 calpain-2	 would	 assist	 recovery	 from	
scrape	injury.	Although	previous	work	had	shown	that	administration	of	exogenous	
calpain	 could	 promote	 membrane	 repair	 (C.	 M.	 Godell	 et	 al.,	 1997),	 it	 was	 not	
established	whether	 it	was	calpain-1	or	calpain-2	that	was	performing	the	majority	
of	the	task.		
	 Godell	 et	 al.	 showed	 that	 the	 resealing	 of	 a	 transected	 crayfish	 axon	 was	
improved	when	 extracellular	 calpain	was	 administered	 (C.	M.	Godell	 et	 al.,	 1997).	
Later	 studies	 in	 calpain-deficient	 mouse	 embryonic	 fibroblasts	 (CAPNS1-/-	 MEFs)	
showed	that	the	membrane	repair	defect	of	the	CAPNS1-/-	MEFs	can	be	rescued	by	
re-expressing	 CAPNS1	protein	 (that	 thus	 restores	 the	 activity	 of	 calpains-1	 and	 -2)	
using	lentiviral	transduction	(Ronald	L.	Mellgren	et	al.,	2009).		
	 I	 used	 CAPNS1-/-	 MEFs	 as	 well	 as	 wild	 type	 primary	 human	 muscle	 cells	
(c1504s)	 to	establish	which	calpain	might	be	more	beneficial	 for	membrane	repair,	
and,	 if	adding	calpain	could	 improve	recovery	from	scrape	 injury	 in	healthy	muscle	
cells.	I	used	our	established	scrape	membrane	injury	assay,	adding	the	recombinant	
calpains	during	the	five-minute	cell	recovery	period,	and	analysed	the	cell	survival	at	
the	flow	cytometer.	
	 The	results	showed	that	cell	survival	after	scrape	injury	improved	in	a	dose-
dependent	manner	following	treatment	with	either	calpain	for	both	CAPNS1-/-	MEFs	
as	 well	 as	 human	 myoblasts	 (c1504s).	 Figure	 2.10,	 below,	 shows	 the	 percentage	
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increase	 in	 cell	 survival	 associated	 with	 the	 increase	 in	 amounts	 of	 extracellular	
calpains	 used.	 Calpain-1	 is	 depicted	 as	 open	 triangles	 and	 calpain-2	 as	 grey	 filled	
squares.		
	 											 	
Figure	 2.10:	 Calpain	 treatment	 increases	 cell	 survival	 after	 scrape	
injury.	 A.	 Primary	 human	 myoblasts	 (c1504s)	 and	 B.	 CAPNS1-/-	 MEFs	
show	 dose	 dependent	 improvement	 in	 cell	 survival	 with	 calpain	
administration.	Cells	were	injured	via	scraping	in	PBS	containing	900	µM	
Ca2+	 then	 transferred	 into	 a	 test	 tube	 containing	 the	 recombinant	
calpains.	 Cells	 were	 left	 to	 recover	 for	 five	 minutes	 at	 RT	 and	 then	
pelleted	 at	 300	 g	 for	 one	 minute	 and	 resuspended	 in	 PBS	 containing	
propidium	iodide	(PI)	as	a	death	marker.	Both	calpain-1	and	-2	increased	
cell	survival	after	scrape	injury	in	a	dose-dependent	manner	up	to	~25	%.		
N	=	1.	
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Addition	of	either	calpain-1	or	calpain-2,	with	the	highest	calpain	dose,	improved	cell	
survival	 by	 over	 25	 %,	 compared	 to	 untreated	 cells.	 I	 noted	 that	 in	 c1504s	 less	
calpain	was	 required	 to	achieve	a	 similar	 increase	 in	 cell	 survival	 compared	 to	 the	
CAPNS1-/-	MEFs.	In	c1504	cells	calpain-1	increased	cell	survival	by	~10	%	more	than	
calpain-2.	To	verify	this	difference	further	experiments	would	be	required.	
	 As	both	calpains	showed	capacity	to	improve	cell	survival	after	scrape	injury,	
and	only	one	experiment	has	been	conducted,	I	could	not	conclude	that	calpain-1	or	
calpain-2	 is	 more	 beneficial	 for	 membrane	 repair	 from	 these	 experiments.	 I	 thus	
decided	to	generate	single	calpain	knock-out	cell	lines	to	answer	this	question.	
	
2.4.2. Single	calpain	knock-out	using	CRISPR/Cas9	technology	
The	 second	approach	 to	 get	 to	 the	bottom	of	which	 calpain	 is	more	beneficial	 for	
membrane	repair,	I	decided	to	utilise	the	latest	gene	technology	tools	to	selectively	
knock-out	calpain-1	or	calpain-2	(or	both).			
	 Using	 CRISPR/Cas9	 technology	 (CRISPR	 stands	 for	 'Clustered	 regularly	
interspaced	short	palindromic	repeats'	and	Cas	9	for	'CRISPR	associated	protein	9'),	I	
successfully	generated	several	knock-out	cell	lines	in	HEK293	cells	as	well	as	in	COS-7	
cells.	 Our	 research	 assistant,	 Samuel	 Ross,	 helped	 me	 with	 the	 generation	 and	
analysis	of	these	cell	lines.		
	 Figure	2.11	shows	the	schematics	of	the	CRISPR/Cas9	targeting	strategies	for	
the	 human	CAPN1,	CAPN2	 and	CAPNS1	 genes	 (used	 for	 HEK293	 and	 COS-7	 cells).	
Each	exon	is	represented	as	a	black	line,	the	5'	UTR	as	white	boxes	and	the	3'	UTR	as	
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a	white	arrow.	The	 sequences	of	 the	 targeted	exons	are	displayed	with	 the	 target	
sequence	underlined	and	bolded.	I	aimed	to	target	an	area	relatively	close	after	the	
start	codon	(ATG)	and	exon	2	was	the	best	target	exon	for	all	three	genes.		
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Figure	 2.11:	 CRISPR-targeting	 of	 human	CAPN1,	CAPN2	 and	CAPNS1.	The	5'	
and	the	3'	UTR	are	shown	as	white	boxes/arrows	respectively	and	the	exons	as	
black	boxes.	All	 three	calpains	were	 targeted	 in	exon	2.	The	sequence	of	 the	
exon	 is	 shown	 in	 the	 box	 'Exon	 2'	 above	 the	 exon/intron	 schematic	 and	 the	
CRISPR	targeting	sequence	 is	shown	 in	bold	and	underlined.	Exon	schematics	
were	generated	using	wormweb.org)	
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2.4.2.1. Generating	CRISPR	knock-out	cell	lines	
The	 generation	 of	 knock-out	 cell	 lines	 using	 CRISPR/Cas9	 gene	 editing	 has	 been	
proven	very	successful	in	our	laboratory.	It	took	a	substantial	amount	of	work	from	
the	start	of	designing	the	CRISPR	guides	to	the	fully	characterised	knock-out	cell	line.	
Figure	2.12	shows	a	schematic	of	the	workflow	that	I	have	followed	to	generate	my	
knock-out	cell	lines.	
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Figure	 2.12:	 Schematic	 of	 workflow	 generating	 CRISPR	 knock-out	 cell	
lines.	 Cells	were	 plated	 into	 3.5	 cm	dishes	 the	 day	 before	 transfection	
with	 the	 pSpCas9(BB)-2A-Puro	 (px459)	 vector	 containing	 our	 CRISPR	
guides.	~24	hours	post	transfection	cells	were	split	into	2	x	10	cm	dishes	
followed	by	puromycin	selection.	After	two	days	in	selection,	media	was	
replaced	by	growth	media.	Dependent	on	the	cell	line	it	takes	~3-10	days	
for	 colonies	 to	grow.	Under	a	dissection	microscope	~30	 colonies	were	
picked	 off	 the	 plate	 with	 a	 200-µL	 pipette	 using	 sterile	 tips.	 Colonies	
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were	 transferred	 into	 96-well	 plated	 containing	 ~200	 µL	 of	 growth	
media.	 Single	 clones	were	 grown	 and	 transferred	 into	 bigger	 dishes	 as	
required.	 The	 rest	 of	 the	 colonies	 from	 the	 dish	 were	 pulled	 for	
polyclonal	 analyses.	 Once	 we	 established	 that	 the	 correct	 locus	 was	
targeted	 single	 clones	were	 harvested	when	 at	 least	 3	 x	 3.5	 cm	dishes	
were	 almost	 confluent.	 One	 dish	 was	 harvested	 for	 gDNA,	 one	 for	
western	blot	and	at	 least	one	dish	of	cells	was	archived.	Three	positive	
clones	were	then	PCR	amplified	and	the	amplicon	cloned	into	pTOPO	2.1.	
At	least	12	clones	were	sequenced	and	once	we	have	established	that	all	
four	alleles	were	targeted	the	cell	lines	were	expanded	and	archived.	
	
All	 knock-out	 cell	 lines	 that	 have	 been	 fully	 analysed	 by	 Sam	Ross	 and	myself	 are	
listed	 below.	 For	 this	 thesis,	 I	 developed	 CAPN1,	 CAPN2	 and	 CAPNS1	 knock-out	
HEK293	 cell	 lines	 as	 well	 as	 CAPNS1	 knock-out	 COS-7	 cell	 lines.	 Within	 the	 time	
constrains	of	my	PhD	I	was	unable	to	establish	the	single	calpain	knock-out	cell	lines	
in	COS-7	cells.		
	 HEK293		
CAPNS1-/-	(clone	#10,	#13)	
CAPN1-/-	(clone	#4,	#14)	
CAPN2-/-	(clone	#7,	#26)		
	 	
	 COS-7	
CAPNS1-/-	(clone	#11,	#16)	
	
2.4.2.2. Analysing	the	CRISPR	cell	lines	
The	 successfully	 'CRISPRed'	 cell	 lines	were	 analysed	 and	 the	 best	 two	 clones	 from	
each	 knock-out,	 together	 with	 wild-type	 controls,	 were	 run	 on	 a	 western	 blot	
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confirming	 the	 absence	 of	 the	 corresponding	 calpain	 protein(s)	 (see	 Figure	 2.13,	
below).		
	
	 	
Figure	 2.13.	Western	 blot	 analysis	 of	 calpain	 knock-out	 HEK293	 cells.	
Two	 clones	 for	 each	 knock-out	 were	 chosen.	 Successful	 CRISPR	 gene	
targeting	 and	 subsequent	 knock-out	 resulted	 in	 the	 elimination	 of	
protein.	CAPN1	and	CAPN2	knock-out	only	led	to	the	target	protein	being	
missing.	CAPNS1	knock-out	led	to	subsequent	loss	of	CAPNS1	as	well	as	
CAPN1	and	CAPN2	protein.	GAPDH	serves	as	a	loading	control	
	
The	 western	 blot	 analysis	 showed	 that	 CAPNS1-/-	 led	 not	 only	 to	 the	 absence	 of	
CAPNS1	but	also	CAPN1	and	CAPN2	protein.	In	the	single	calpain	knock-out	cell	lines	
the	CAPNS1	protein	as	well	as	the	protein	levels	of	the	calpain	that	was	not	targeted	
for	knock-out,	were	detected	at	WT	levels.		
	
2.4.3. Calpains-1	and	-2	compensate	for	each	other's	loss	
With	 the	 help	 of	 Sam	Ross,	 I	 then	performed	membrane	 repair	 assays	 on	 the	 cell	
lines	in	which	we	had	confirmed	functional	ablation	of	both	calpain-1	and	calpain-2	
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(via	genetic	knock-out	of	CAPNS1),	or,	single	knock-out	of	either	calpain-1	 (CAPN1)	
or	calpain-2	(CAPN2)	to	finally	directly	address	the	question:	
	 Which	calpain	is	more	important	for	membrane	repair?		
	
The	 result	 showed	 that	 if	 only	 calpain-1	 or	 calpain-2	 was	 absent,	 the	 membrane	
repair	capacity	appeared	almost	normal.	 In	the	CAPNS1-/-	cells,	when	both	calpains	
are	rendered	inactive,	a	severe	membrane	repair	defect	could	be	observed.		
	 Figure	 2.14	 shows	 the	 results	 of	 the	 flow	 cytometric	 analysis	 of	 the	 scrape	
assay	using	WT,	CAPN1-/-,	CAPN2-/-	and	CAPNS1-/-	HEK293	cells.	
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Figure	2.14:	Flow	cytometric	analysis	of	 single	knock-out	HEK293	cells	
after	 scrape	 injury.	 A.	 Representative	 dot	 plot	 diagrams	 showing	 the	
florescence	intensity	of	the	death	marker	PI	on	the	x-axis	and	the	injury	
marker	 TO-PRO-3	 on	 the	 y-axis.	 The	 quadrant	 divides	 cells	 into:	
injured/repaired	 (red	 frame,	 top	 left),	 injured/dead	 (top	 right),	
uninjured	 (bottom	 left)	 and	 dead/uninjured	 (not	 applicable,	 bottom	
right).	 Experiments	were	performed	 in	 the	presence	or	 absence	of	 900	
µM	[Ca2+]EC	PBS.	B.	Graph	represents	the	percentages	of	repaired	cells	of	
all	 injured	 cells	 relative	 to	 WT	 +Ca2+	 (+Ca2+	 conditions	 only).	 For	 the	
knock-out	cell	lines	the	two	different	clones	were	used	are	shown	in	red	
and	 black	 respectively.	 The	 average	was	 calculated	 from	eight	 samples	
for	 WT	 and	 10	 samples	 for	 all	 knock-out	 lines	 from	 two	 separate	
experiments.	WT:	100	%	±	6.5,	CAPN1-/-:	112.5	%	±	31.3,	CAPN2-/-:	89.3	%	
±	 28.1	 and	CAPNS1-/-:	 21.9	%	 ±	 4.4.	 A	 one-way	ANOVA	was	 performed	
that	showed	significant	differences	between	WT	and	CAPNS1-/-	 samples	
(p	 <0.001)	 but	 not	 between	 WT	 and	 CAPN1-/-	 or	 WT	 and	 CAPN2-/-	
samples.	N	=	2.	
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From	 these	experiments	 it	 appeared	 that	 if	 the	 cell	 still	 expressed	one	of	 the	 two	
ubiquitous	 calpains	 it	 did	 not	 affect	 the	 membrane	 repair	 potential	 of	 the	 cell;	
implying	that	one	calpain	can	compensate	for	the	other.	
	 Interestingly,	all	cell	lines	-	even	in	the	CAPNS1-/-	cells	-	showed	residual	Ca2+	
dependent	 membrane	 repair,	 even	 when	 the	 membrane	 repair	 was	 significantly	
reduced	in	the	CAPNS1-/-	cells.	This	was	an	interesting	observation	that	might	point	
to	a	calpain-independent,	Ca2+-dependent	membrane	repair	pathway.	
	
2.4.4. What	is	the	Ca2+	dependence	of	membrane	repair	in	CAPNS1-/-	cells?	
I	 decided	 to	 analyse	 the	 residual	 Ca2+-dependent,	 calpain-independent	membrane	
repair	 pathway	 to	 determine	 how	 much	 extracellular	 Ca2+	 was	 needed	 for	 this	
membrane	repair	to	occur.	I	performed	scrape	membrane	repair	assays,	titrating	the	
[Ca2+]EC	comparing	WT	and	CAPNS1-/-	HEK293	cells.		
	 Figure	 2.15	 shows	 that	 CAPNS1-/-	 cells	 have	 almost	 no	 membrane	 repair	
capacity	compared	to	WT	HEK293	cells.		
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Figure	 2.15:	 HEK293	 cell	 Ca2+	 titration	 of	 membrane	 repair.	 A)	 Dot	 plots	 of	 flow	
cytometric	 analysis	 of	 Ca2+	 titration	 in	HEK293	 cells	 after	 scrape	 injury.	WT	 and	 two	
CAPNS1-/-	cell	 lines	(clone	#10	and	#13).	The	quadrangle	that	represents	the	repaired	
population	is	framed	in	red.	B)	Graphical	analysis	of	amount	of	repaired	cells	relative	
to	 all	 injured	 cells.	 Both	 CAPNS1-/-	 clones	 cells	 show	 reduced	 membrane	 repair	
capacity.	Note:	900	µM	 [Ca2+]EC	does	not	 saturate	 the	membrane	 repair	 capacity	 for	
HEK293	cells.	The	curves	represent	a	hyperbola,	non-linear	fit.	N	=	2.		
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The	 residual	 calpain-independent	membrane	 repair	 shows	 the	 same	 requirements	
for	 [Ca2+]EC	 than	calpain-dependent	membrane	repair,	~200	µM.	This	might	be	due	
to	expression	or	 activity	of	 other	 calpain	 isoforms	or	 another	possible	 explanation	
could	be	 the	existence	of	 residual	 low	 levels	of	 functional	 calpains-1	and	 -2	 in	 the	
CAPNS1-/-	 cells.	 CAPNS1	 protein	 is	 deemed	 to	 be	 essential	 for	 the	 stability	 and	
activity	of	calpains-1	and	2	but	this	was	determined	by	casein	zymogram	that	might	
not	be	sufficiently	 sensitive	 in	 this	 instance	 to	detect	 low	 levels	of	 residual	activity	
(Arthur	et	al.,	2000).		
	
Verifying	results	in	a	second	cell	line	
I	used	the	CAPNS1-/-	COS-7	cell	lines	that	I	have	generated	to	validate	my	findings	in	
a	second	cell	line.	Figure	2.16	shows	the	western	blot	analysis	of	the	two	CAPNS1-/-	
clones,	confirming	the	absence	of	CAPNS1,	CAPN1	and	CAPN2	protein.	
	
	 	 	 	
Figure	2.16:	COS-7	CAPNS1-/-	 cell	 line	analysis.	Western	blot	analysis	of	
CAPNS1-/-	clones	#11	and	#16	compared	to	two	WT	control	samples.	The	
knock-out	cell	lines	are	deficient	in	CAPNS1,	CAPN1	and	CAPN2	proteins.	
GAPDH	serves	as	a	loading	control.	
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I	mirrored	 the	 scrape	 injury	 experiment	 as	 performed	 for	 the	 previously,	 titrating	
[Ca2+]EC	and	analysing	the	population	of	repaired	cells.	The	flow	cytometric	analysis	
using	COS-7	WT	cells	and	the	two	CAPNS1-/-	clones	 (#11	and	#16)	showed	that	the	
membrane	 repair	 capacity	 in	 the	CAPNS1-/-	 clones	was	 reduced	 (Figure	 2.17).	 The	
residual	membrane	repair	 in	CAPNS1-/-	cells	appeared	to	be	following	a	similar	Ca2+	
requirement	to	the	WT	cells	peaking	at	~200	µM	[Ca2+]EC.		
	 I	noted	that	COS-7	cells	were	generally	more	adherent	than	HEK293	cells	and	
thus	prone	 to	more	 severe	 injuries	 following	 scraping.	 It	was	 therefore	difficult	 to	
obtain	a	population	of	cells	that	were	injured	but	still	able	to	repair	and	not	die.	This	
caveat	made	COS-7	 cells	 a	 suboptimal	model	 system	 for	 this	particular	membrane	
repair	 assay.	 They	 do,	 however,	 mirror	 my	 results	 obtained	 from	 HEK293	 cells,	
showing	maximum	membrane	 repair	 capacity	 at	 ~150-200	 µM	 [Ca2+]EC	 and	 severe	
membrane	repair	deficiency	in	both	COS-7	CAPNS1-/-	cell	lines.	
	 Figure	 2.17,	 below	 shows	 a	 representative	 dot	 plot	 analysis,	 as	well	 as	 the	
graphical	 illustrations	 of	 the	 percentages	 of	 repaired	 cells,	 of	 the	 two	 separate	
experiments	using	COS-7	WT	and	CAPNS1-/-	cells.	
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Figure	 2.17:	 Ca2+	 titration	 of	 WT	 and	 CAPNS1-/-	 COS-7	 cells.	 A.	
Representative	dot	plots	of	cells	after	scrape	injury.	PI	is	shown	on	the	x-
axis	 indicating	 dead	 cells	 and	 TO-PRO-3	 on	 the	 y-axis	 is	 staining	 the	
injured	 cells.	 The	 quadrant	 divides	 cells	 into	Q1:	 injured	 and	 repaired	
(framed	in	red),	Q2:	injured	and	dead,	Q3:	dead	and	uninjured	cells	(not	
applicable)	 and	 Q4:	 uninjured	 cells.	 B.	 and	 C.	 shows	 the	 graphical	
illustrations	of	the	percentage	of	repaired	cells	of	all	injured	cells	relative	
to	 WT	 900	 µM	 Ca2+	 from	 two	 separate	 experiments.	 The	 curves	
represent	a	hyperbola,	non-linear	fit.		N	=	2.	
	
Conclusion	
Taken	together,	data	from	the	HEK293	cells	and	COS-7	cells	 independently	showed	
that	genetic	ablation	of	CAPNS1	knocks	out	most	Ca2+-dependent	membrane	repair.	
The	observed	residual	membrane	repair	capacity	in	CAPNS1-/-	cells	might	point	to	an	
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additional	 membrane	 repair	 pathway	 that	 is	 still	 Ca2+-dependent	 but	 does	 not	
require	calpains-1	and	2.		
	
2.4.5. Are	calpain	deficient	cells	still	susceptible	to	calpeptin?	
To	investigate	if	the	residual	membrane	repair	capacity	of	the	CAPNS1-/-	clones	was	
due	 to	 residual	 calpain	 activity,	 I	 treated	CAPNS1-/-	 HEK293	 cells	with	 the	 specific	
calpain	 inhibitor	calpeptin	and	performed	scrape-injury	membrane	repair	assays	as	
described	before.	
	 Using	 the	 two	CAPNS1-/-	 HEK293	 cell	 lines	 (#10	 and	 #13),	 compared	 to	WT	
HEK293	 cells,	 I	 showed	 that	 calpeptin	 had	 no	 significant	 effect	 on	 the	membrane	
repair	outcomes	of	the	CAPNS1-/-	cells	but	reduced	the	number	of	repaired	cells	 in	
the	 WT	 samples.	 Figure	 2.18	 shows	 the	 outcome	 of	 this	 study	 displaying	
representative	 dot	 plots	 form	 the	 flow	 cytometer	 as	 well	 as	 the	 graphical	
quantification	of	the	percentage	of	repaired	cells.	
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Figure	 2.18:	 Calpeptin	 treatment	 of	 CAPNS1-/-	 HEK293	 cells.	 A.	
Representative	 dot	 plot	 diagrams	 showing	 the	 florescence	 intensity	 of	
the	death	marker	PI	on	the	x-axis	and	the	injury	marker	TO-PRO-3	on	the	
y-axis.	The	quadrant	divides	cells	 into	Q1:	 injured	and	repaired	(framed	
in	 red),	 Q2:	 injured	 and	 dead,	 Q3:	 dead	 and	 uninjured	 cells	 (not	
applicable)	 and	Q4:	 uninjured	 cells.	 Experiment	 was	 performed	 in	 the	
presence	 or	 absence	 of	 900	 µM	 Ca2+.	 Cells	 were	 treated	 with	 50	 µM	
calpeptin	three	hours	and	30	minutes	prior	as	well	as	during	the	scrape	
experiment.	B.	Graph	representing	the	percentage	of	repaired	cells	of	all	
injured	cells	that	repaired	relative	to	+Ca2+	for	each	genotype.	Error	bars	
represent	 standard	 deviation.	 Two	 experiments	 were	 performed	 in	
duplicate	repeats.		N	=	2.	
	
From	these	results	 I	could	conclude	that	 if	 the	observed	residual	membrane	repair	
capacity	 of	 the	 CAPNS1-/-	 cells	 was	 due	 to	 an	 incomplete	 functional	 knock-out	 of	
calpains-1	and	 -2	 (via	genetic	ablation	of	CAPNS1),	 calpeptin	 should	have	 inhibited	
the	residual	membrane	repair.	The	 fact	 that	calpeptin	treatment	had	 limited	or	no	
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effect	on	the	membrane	repair	outcome	of	the	CAPNS1-/-	cells	further	supports	the	
hypothesis	 that	 there	 is	 a	 calpain-independent,	 Ca2+-dependent	 membrane	 repair	
pathway.	
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Part	C	
In	Part	C	of	this	chapter	I	analyse	different	modes	of	membrane	injury	as	alternatives	
to	the	mechanical	scrape	wound	injury	I	have	used	thus	far.	Different	types	of	injury	
are	 known	 to	 trigger	 different	 cellular	 repair	 mechanisms	 (Andrews	 et	 al.,	 2014;	
Corrotte	et	al.,	2015).		
My	main	hypothesis	for	this	part	of	my	thesis	is:		
H1:	 Calpain-1	and	calpain-2	are	essential	 for	membrane	 repair	of	 injuries,	not	only	
caused	by	mechanical	scrape	but	also	from	laser	ablation	injury	and	perforation	by	
pore-forming	toxins.		
With	a	sub-hypothesis	regarding	the	pore-forming	toxins	being:		
H2:	Perforation	by	SLO-pore	forming	toxin	triggers	calpain-cleavage	of	dysferlin.		
	
2.5. 	Laser	ablation	injury	
To	 test	 if	 recovery	 from	 other	 forms	 of	 membrane	 damage	 depends	 on	 calpain	
activity	 for	 membrane	 repair,	 I	 went	 to	 the	 'gold	 standard',	 the	 benchmark	 of	
membrane	injury	assays:	the	laser	ablation	injury	(D.	Bansal	et	al.,	2003;	Steinhardt,	
Bi,	&	Alderton,	1994).		
	 For	 these	 experiments	 Dr	 Frances	 Evesson	 and	 I	 used	 the	 Zeiss	 LSM	 880	
inverted	 laser	 scanning	 confocal	 microscope	 located	 at	 the	 Biomedical	 Imaging	
Facility	 (BMIF)	at	 the	University	of	New	South	Wales	 (UNSW).	Here	 I	would	 like	 to	
thank	Dr	Evesson	for	her	support	and	expertise	helping	me	to	use	the	microscopes	
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and	to	perform	these	experiments.	Dr	Evesson	had	previous	expertise	in	using	laser	
ablation	to	 injure	cells,	and	provided	vital	 technical	support	 in	our	 tweaking	of	 the	
settings	 to	 generate	 the	 correct	 amount	 of	 injury	 and	 use	 of	 the	 microscope	
software.	We	performed	most	experiments	together,	and	each	did	equal	amounts	of	
cell	culture	and	preparation.		
	 Using	WT	 and	 CAPNS1-/-	 HEK293	 cells,	 we	 set	 the	 damage	 area	 to	 be	 4x4	
pixels,	corresponding	to	a	membrane	injury	of	~0.31	µm2.	In	comparison	to	the	large	
mechanical	scrape	injuries	I	have	studied	before,	these	membrane	lesions	caused	by	
the	laser	were	small.		
	 We	damaged	the	cells	for	10	milliseconds	(65.5	µsec	'pixel	dwell'	for	4x4	=	16	
pixels	=	10.5	ms)	using	a	2-photon	 laser	with	850	nm	wavelength.	To	visualise	 the	
membrane	damage	we	used	 the	membrane-impermeable	dye	FM1-43	 (2	µM)	 that	
increases	 in	 fluorescence	 intensity	 when	 it	 partitions	 into	 the	 membrane.	 I	 then	
analysed	the	mean	fluorescence	intensity	at	the	injury	site	and	captured	fluorescent	
data	from	the	same-sized	regions-of-interest	(ROIs)	on	the	opposite	membrane	and	
a	cytoplasmic	window	(see	Figure	2.19A)	over	two	minutes.	Two	minutes	was	chosen	
based	on	optimization	experiments	 showing	 this	 time	 to	be	 sufficient	 to	allow	 the	
cell	 to	 repair.	 These	 regions	 provided	 a	 control	 for	 FM1-43	 dye	 uptake	 in	 regions	
distal	 to	 the	 primary	 injury	 site	 by	 diffusion	 or	 due	 to	 a	 burst	 of	 endocytosis	 or	
exocytosis	 triggered	 by	 membrane	 injury	 and	 Ca2+	 flux.	 Figure	 2.19A	 shows	 an	
example	 of	 the	 measurements	 taken	 from	 one	 cell.	 The	 cells	 were	 injured	 at	 10	
seconds	after	the	measurement	started	(at	2	sec/frame).	Figure	2.19A	shows	the	cell	
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before	injury	(at	frame	1)	and	then	at	frame	10	(≙	20	sec),	20	(≙	40	sec),	30	(≙	60	
sec),	40	(≙	80	sec)	and	60	(≙	120	sec).	
	 To	allow	for	membrane	movement	and	blebbing	at	 the	 injury	site,	 I	 set	 the	
ROIs	to	be	larger	than	the	injury	site	(25	x	25	pixel).	Figure	2.19B-D	show	the	traces	
of	mean	fluorescence	intensity	(MFI)	of	the	three	different	ROIs	over	time.	Wildtype	
cells	 are	 depicted	 as	 black	 circles	 and	 CAPNS1-/-	 cells	 as	 open	 triangles;	 the	 black	
arrow	indicates	the	injury	at	10	seconds/5	frames.		
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Figure	2.19:	Laser	ablation	injury	in	HEK293	cells.	A.	Images	showing	six	
time	frames	(white	numbers	in	the	left	upper	corner)	of	one	HEK293	cell	
before	and	after	laser	injury	(injury	occurred	at	time	frame	5).	Cells	were	
incubated	 with	 100	 nM	 FM1-43	 (green)	 during	 imaging.	 Yellow	 boxes:	
regions	of	interest	(ROIs)	(three	small	boxes)	in	which	mean	fluorescence	
intensity	 (MFI)	 was	 measured.	 ROI	 #1	 is	 the	 injury	 site.	 ROI	 #2	 is	 a	
cytoplasmic	 ROI	 of	 the	 same	 dimensions,	 and	 ROI	 #3	 is	 the	 opposite	
membrane	 to	 the	 injury	 site.	B.	 Graph	 showing	 the	mean	 fluorescence	
intensity	 (MFI)	 at	 the	 injury	 site	 of	 WT	 (closed	 circles)	 and	 CAPNS1-/-	
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(open	 triangles)	HEK293	 cells.	 Arrow	denotes	 time	of	 injury.	 Error	 bars	
represent	 standard	 error	 of	 the	 mean	 (SEM).	 The	 slope	 at	 each	 time	
point	 was	 calculated	 and	 compared	 between	 WT	 and	 CAPNS1-/-	 cells	
followed	by	a	2-way	ANOVA	and	a	post-hoc	test.	The	result	showed	no	
significant	difference	in	dye	uptake	kinetics	between	the	two	cell	lines.	C.	
Graph	showing	the	analysis	of	ROI	#2,	the	cytoplasmic	region.	CAPNS1-/-	
cells	 showed	 a	 higher	MFI,	 compared	 to	 the	WT	 cells,	 at	 all	 points.	 D.	
Graph	 showing	 the	 analysis	 of	 ROI	 #3,	 the	 opposite	membrane	 to	 the	
injury	site.	WT	and	CAPNS1-/-	 cells	 showed	significant	differences	 in	 the	
MFI	 of	 the	 opposite	 membrane.	 N=10	 cells,	 over	 three	 experimental	
replications.	CAPNS1-/-	clone	#13	was	used	for	these	experiments.	N	=	3.	
	
Figure	 2.19B	 shows	 that	 following	 laser	 injury	 the	 dye	 uptake	 at	 the	 injury	 site	
increases	rapidly	in	both,	WT	and	CAPNS1-/-	cells.	The	increase	in	MFI	at	injury	sites	
did	not	appear	to	be	different	between	WT	and	CAPNS1-/-	cells	for	the	first	30	frames	
(Figure	2.19B).	I	observed	that	after	~35	frames	(1	minute	and	10	seconds),	WT	cells	
showed	a	trend	of	more	rapidly	decreasing	MFI	compared	to	the	MFI	of	the	CAPNS1-
/-	cells	that	seem	to	plateau	(Figure	2.19B).	
	 The	capacity	of	WT	cells	to	better	remove	or	redistribute	the	FM1-43	signal	
after	 injury,	 compared	 to	 CAPNS1-/-	 cells,	 became	 more	 pronounced	 over	 time	
(Figure	2.19B).	In	the	future,	capturing	the	experiment	for	longer	than	two	minutes	
might	aid	 to	 reveal	 true	differences	 in	 the	dye	extrusion	kinetics	between	WT	and	
CAPNS1-/-	cells.	
	 Analysing	the	MFI	of	the	internal	controls:	the	cytoplasmic	ROI	and	the	ROI	of	
the	opposing	membrane	 to	 the	 injury	 site,	 I	noticed	 that	 the	CAPNS1-/-	 cells	had	a	
higher	MFI	from	the	start	of	the	experiment	and	that	the	MFI	remained	significantly	
higher	compared	to	WT	cells	throughout	the	experiment	(Figure	2.19C).		
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	 This	 result	 suggested	 that	 the	membrane	of	 the	CAPNS1-/-	 cells	 allowed	 for	
more	FM1-43	dye	entry	prior	to	the	laser	injury.	I	also	noted	that	the	measurement	
of	the	injury	sites	showed	that	CAPNS1-/-	cells	had	an	increased	MFI,	however,	the	y-
axis	in	Figure	2.19B	is	adjusted	to	fit	the	large	increase	in	MFI	after	injury.		
	
Conclusion		
The	laser	ablation	experiments	did	not	show	a	clear	membrane	repair	deficiency	in	
repair	 of	 small	 laser	 injuries	 in	CAPNS1-/-	 cells,	 compared	 to	 the	WT	HEK293	 cells.	
This	 could	 suggest	 that	 although	 calpain-1	 and	 calpain-2	 are	 vital	 for	 the	 repair	 of	
large	injuries,	such	as	caused	by	mechanical	scrape,	their	role	in	membrane	repair	of	
smaller	lesions,	such	as	caused	by	this	laser	ablation	injury,	is	less	pronounced.	There	
are	however	caveats	with	the	laser	assay	that	cannot	be	discounted.	
	 The	diverse	cell	morphology	and	 resulting	variability	 in	 laser	 injury	 size	and	
location	 made	 it	 difficult	 to	 measure	 subtle	 differences	 in	 membrane	 injury	 and	
repair.	The	laser	ablation	injury	assay	measures	only	one	cell	at	a	time,	whereas	our	
scrape	membrane	repair	assay	can	analyse	more	than	500,000	cells	simultaneously.	
Hence,	 subtle	 differences	 are	 easier	 to	 detect	 using	 the	 high	 throughput	 flow	
cytometric	membrane	repair	assay	rather	than	the	laser	injury	assay.	
	 Despite	 this	 caveat,	 I	 was	 able	 to	 show	 that	 CAPNS1-/-	 cells	 displayed	
significant	differences	in	MFI	in	the	cytosolic	region	and	in	the	membrane	opposite	
to	the	injury	site	that	I	analysed	as	internal	controls.	The	overall	increased	intensity	
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of	FM1-43	signal	 in	CAPNS1-/-	cells	might	be	a	result	of	one	or	more	of	these	three	
factors:		
1) Differences	in	membrane	dynamics	or	membrane	composition	caused	by		the	
lack	of	CAPNS1.	
2) The	potential	'leakiness'	of	the	plasma	membrane	in	CAPNS1-/-	cells.	
3) A	 change	 in	 the	 dynamic	 balance	 between	 endocytosis	 and	 exocytosis.	 For	
example,	 increased	 pinocytosis	 of	 FM1-43	 in	 the	 absence	 of	 CAPNS1,	 or	
alternately,	decreased	exocytosis/exosomal	shedding.	Either	would	result	 in	
increased	basal	 levels	of	FM1-43	partitioned	 into	membrane	compartments	
in	uninjured	CAPNS1-/-	cells,	relative	to	WT	cells.		
	 	
To	be	confident	about	 the	 results	obtained	 from	the	one	CAPNS1-/-	 cell	 line	 (clone	
#13),	 it	would	be	desirable	to	repeat	these	experiments	with	the	second	CAPNS1-/-	
cell	 line	 (clone	 #10).	 I	 had	 used	 HEK293	 cells	 in	 order	 to	 establish,	 optimise	 and	
validate	the	laser	 injury	assay.	The	final	goal	was	to	repeat	these	experiments	with	
primary	mouse	muscle	cells	deficient	in	CAPNS1	(see	2.8).	However,	at	this	stage	my	
baby	 was	 due	 and	 time	 constrains	 prevented	 me	 from	 completing	 these	 final	
studies.	
	 In	 the	 next	 section	 below,	 section	 2.6,	 I	 studied	 the	 membrane	 repair	
response	of	WT	and	CAPNS1-/-	cells	following	perforation	by	the	pore-forming	toxin	
by	streptolysin-O.		
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2.6. Pore	forming	toxin	injury		
As	 neither	 scrape-	 nor	 laser	 injury	 represent	 physiologically	 relevant	 membrane	
injuries	I	decided	to	study	the	membrane	repair	response	after	perforation	by	pore-
forming	 toxins.	 I	 used	 the	 toxin	 streptolysin-O	 (SLO)	 secreted	 by	 Streptococcus	
pyogenes	that	can	cause	life-threatening	infections	(Stevens	&	Bryant,	2016).	
	 SLO	creates	pores	of	~30	nm	in	diameter	(Palmer	et	al.,	1998);	large	enough	
to	 conduct	 Ca2+,	 as	 well	 as	membrane	 impermeable	 dyes,	 into	 the	 cell.	With	 this	
study,	I	wanted	to	establish	if	the	calpain-dysferlin	membrane	repair	axis	is	involved	
in	 the	 repair	of	membrane	 injuries	 caused	by	SLO,	using	 the	high	 throughput	 flow	
cytometer	2-dye	assay,	as	well	as	Fura-2	Ca2+-imaging.	My	hypothesis	was	that	the	
repair	of	the	small	 injuries	caused	by	SLO	requires	calpain-1	and	calpain-2	and	that	
dysferlin	will	be	cleaved	by	activated	calpains	in	response	to	perforation	by	SLO.	
	
2.6.1. Is	dysferlin	cleaved	in	response	to	pore-forming	toxin	injury?	
First	 I	wanted	to	determine	 if	perforation	by	SLO	allowed	for	enough	Ca2+-influx	to	
trigger	 calpain	 activation	 and	 subsequent	 dysferlin	 cleavage.	 Figure	 2.20,	 below,	
portrays	the	western	blot	analysis	of	SLO	treatment	of	human	myoblasts	(c1504)	and	
transfected	HEK293	expressing	the	cleavable	dysferlin40a.	The	result	shows	that	with	
increasing	 amounts	 of	 SLO,	 low	 levels	 of	 cleaved	 mini-dysferlinC72	 (mDf.,	 arrow)	
could	be	detected,	using	the	C-terminal	anti-dysferlin	antibody	Hamlet-1.		
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Figure	2.20:	Membrane	perforation	by	streptolysin-o	(SLO)	causes	mini-
dysferlinC72	 formation.	Western	blot	analysis	of	endogenous	dysferlin	in	
c1504s	 and	 dysferlin40a	 expressed	 in	 HEK293	 cells	 shows	 a	 dose-
dependent	generation	of	mini-dysferlinC72	when	subjected	to	SLO.	
	
I	 could	 conclude,	 that	 perforation	 by	 SLO	 allows	 entry	 of	 enough	 Ca2+	 to	 trigger	
calpain	activation	and	subsequent	dysferlin-cleavage.	In	the	next	part	of	my	study	I	
wanted	 to	 establish	 if	 calpain-1	 and	 calpain-2	 were	 needed	 for	 the	 repair	 of	 the	
membrane	damage	caused	by	pore	forming	toxins.	
	
2.6.2. Is	calpain	needed	for	recovery	form	SLO	pore-forming	toxin	injury?	
With	 the	 help	 of	 our	 research	 assistant	 Sam	 Ross,	 who	 cultured	 the	 cells	 and	
performed	some	of	the	experiments,	 I	modified	our	scrape	membrane	repair	assay	
to	perform	perforation	by	SLO	on	cells	in	solution.		
	 Cells	were	trypsinized,	pelleted	and	resuspended	in	HEPES	buffer	containing	
1	mM	Ca2+.	They	were	divided	into	500,000	cells	per	FACS	tube	and	left	to	recover	
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from	trypsinisation	for	30	-	60	minutes	at	37°C.	Cells	were	thereafter	again	pelleted	
and	then	washed	in	-Ca2+	HEPES	buffer	followed	by	SLO	treatment	for	10	minutes	at	
37°C	 in	 the	 presence	 of	 the	 first	 dye,	 TO-PRO-3.	 SLO	 treatment	 was	 performed	
without	Ca2+	 in	 the	HEPES	buffer,	 as	 the	pore-removal	was	 instant	when	Ca2+	was	
present.	Afterward	SLO	perforation,	1	mM	Ca2+-	containing	HEPES	buffer	was	added	
for	 five	 minutes	 at	 37°C,	 to	 activate	 the	 Ca2+-dependent	 membrane	 repair	
mechanism.	 For	 the	 -Ca2+	 controls,	 HEPES	 buffer	 without	 Ca2+	 was	 added.	 The	
reaction	was	then	quenched	with	foetal	bovine	serum	(FBS).	As	SLO	is	a	cholesterol-
dependent	cytolysins,	the	cholesterol	in	the	FBS	will	quench	its	activity.		
	 The	cells	were	then	pelleted	and	resuspended	in	cold	HEPES	+Ca2+	(or	-Ca2+)	
containing	 the	 second	 dye,	 PI,	 to	 mark	 all	 cells	 that	 failed	 to	 repair.	 Cells	 were	
subsequently	analysed	at	the	flow	cytometer	(see	7.2.2	for	a	detailed	description	of	
this	assay).	
	 Figure	2.20	shows	the	results	of	WT	and	CAPNS1-/-	HEK293	cells	subjected	to	
50	U	SLO	with	or	without	extracellular	Ca2+.	
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Figure	 2.21:	 Calpain	 is	 not	 required	 for	 membrane	 repair	 from	 SLO	
perforation	 in	 HEK293	 cells.	 A.	 Representative	 dot	 plots	 for	 WT	 and	
CAPNS1-/-	 cells	 treated	with	50	U	SLO	with	or	without	Ca2+.	Experiment	
was	performed	in	triplicate	and	the	average	numbers	are	shown	on	dot	
plot	 diagram.	 The	 quadrants	 show:	 top	 left:	 injured	 and	 repaired	 (red	
frame),	 top	 right:	 injured	 and	 dead,	bottom	 right:	 dead	 and	 uninjured	
cells	(not	applicable)	and	bottom	left:	uninjured	cells.	B.	Graph	showing	
the	percentage	of	repaired	cells	of	all	injured	cells	(all	TO-PRO-3	positive	
cells)	 and	 the	 standard	 deviation	 (SD).	 In	 the	 absence	 of	 extracellular	
Ca2+,	cells	do	not	repair	the	perforation	injury	whereas	in	the	presence	of	
900	µM	extracellular	Ca2+	both,	WT	and	CAPNS1-/-	cells,	show	membrane	
repair	 to	 a	 similar	 extent.	 Paired	 t-test	 analysis	 shows	 no	 significant	
difference	 in	 the	membrane	repair	capacity	between	WT	and	CAPNS1-/-	
HEK293	 cells	 (p=0.48).	 Both	 CAPNS1-/-	 clones	 were	 used	 in	 these	
experiments.	 Shown	 is	 a	 representative	 image	 of	 CAPNS1/-	 clone	 #13.	
N=3.	
	
The	results	show	that	a	 large	percentage	of	cells	 (~65-75	%)	were	unable	to	repair	
the	 injury	 created	 by	 SLO	 and	were	 labelled	 positive	 for	 both,	 TO-PRO-3	 and	 PI.	 I	
noted,	 however,	 that	 when	 using	 SLO	 in	 this	 adapted	 two-dye	 membrane	 repair	
assay,	that	the	repaired	population	(Figure	2.21,	red	outlined	quadrant)	was	not	as	
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clearly	distinguished	as	I	had	seen	before	using	the	scrape	injury	assay.	This	could	be	
possibly	due	 to	 the	more	 transient	nature	of	 the	SLO	 'open	pores',	or	perhaps	 the	
relatively	 low	 permeability	 of	 pores	 to	 TO-PRO-3,	 using	 SLO	 instead	 of	 scraping.	
	 Despite	this	caveat,	 this	assay	was	able	to	detect	clear	differences	between	
+Ca2+	 and	 -Ca2+	 conditions.	 In	 the	 presence	 of	 1	mM	 extracellular	 Ca2+,	 two	 clear	
populations	could	be	distinguished:	undamaged	(bottom	left	quadrangle)	and	dead	
(top	 right	 panel).	 The	 dot	 plot	 heat	 map	 showed	 that	 most	 cells	 were	 either	
undamaged	(TO-PRO-3	negative)	or	dead	(TO-PRO-3	positive	and	PI	positive).	A	small	
population	of	 repaired	 cells,	 <	 4	%,	 could	be	 seen	on	 the	dot	plots	 as	 a	 TO-PRO-3	
positive,	PI	negative	'shoulder'	(see	Figure	2.21A,	top	two	panels,	red	squares).		
	 This	shoulder	was	not	present	when	the	cells	were	perforated	in	the	absence	
of	extracellular	Ca2+;	here	the	relationship	of	TO-PRO-3	positive	and	PI	positive	cells	
became	 linear	 and	 continuous,	 reflecting	 equal	 permeability	 to	 TO-PRO-3	 and	 PI.	
This	suggests	that	the	cells	were	unable	to	repair	their	membranes	in	the	absence	of	
extracellular	Ca2+	but	the	SLO	pores	were	still	able	to	perforate	the	cells.		
	 In	both,	the	presence	and	absence	of	extracellular	Ca2+,	the	dot	plots	of	the	
WT	and	CAPNS1-/-	cells	were	indistinguishable.	This	could	either	mean	that	calpains-
1	and	-2	are	not	required	for	the	removal	and	subsequent	repair	of	SLO	perforated	
membranes,	or	that	this	assay	might	not	be	sufficiently	calibrated	for	measuring	the	
fast	kinetics	of	pore	formation	and	pore	removal.	
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	 	To	establish	if	the	latter	was	the	case,	I	decided	to	instead	examine	Ca2+	flux	
after	 membrane	 perforation,	 as	 it	 promised	 to	 be	 a	 more	 dynamic	 and	 sensitive	
measure	of	membrane	perforation	and	repair	of	pores.	
	
2.7. Ca2+	flux	assay	for	pore	forming	toxins	injury	analysis	
In	collaboration	with	Reece	Sophocleus	from	the	University	of	Wollongong	(UOW),	I	
developed	a	Ca2+	 flux	assay	using	 the	 'FLexStation	3	microplate	 reader'	 (Molecular	
Devices,	Sunnyvale	California).	At	UOW	I	optimised	the	experiment	alongside	Reece	
who	 had	 previous	 expertise	with	 the	 FlexStation.	 After	 the	 assay	was	 established,	
Reece	performed	 two	experiments	on	my	behalf.	 Reece	and	 I	 together	performed	
the	analyses	of	the	results.	
	 In	this	assay	we	used	Fura-2-AM,	a	sensitive,	ratiometric	dye,	for	measuring	
[Ca2+]IC,	 to	 investigate	 the	 fast	 kinetics	 of	 membrane	 perforation.	 For	 these	
experiments	 cells	 were	 plated	 onto	 black,	 clear-bottom	 96	 well	 plates	 for	 18-24	
hours	 then	 pre-loaded	 with	 5	 µM	 Fura-2,	 30	 minutes	 prior	 to	 commencing	 the	
experiment.	 Fluorescence	 emission	 at	 510	 nm	 was	 acquired	 every	 60	 seconds	
following	excitation	at	340	and	380	nm.	Baseline	Fura-2	ratiometric	measurements	
were	 acquired	 for	 five	 minutes	 then	 diluted	 SLO	 was	 added	 to	 the	 cells.	 For	 the	
detailed	description	of	this	assay	see	Material	&	Methods	section	7.2.3.	
	 Figure	 2.22,	 below,	 shows	 the	 results	 of	 two	 separate	 experiments	
performed	 in	 duplicate,	 using	 one	 clone	 of	 CAPNS1-/-	 HEK293	 cells	 (clone	 #13),	
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compared	to	WT	HEK293	cells.	Figure	2.22A	shows	representative	Ca2+-traces	for	all	
SLO	concentrations	 (each	 in	a	different	 colour)	 for	WT	and	CAPNS1-/-	 cells	over	30	
minutes.	Figure	2.22B-D	shows	the	analyses	of	the	peak	SLO-induced	Ca2+	flux	at	1,	
10	and	20	minutes	after	SLO	administration.		
	
	
Figure	2.22:	Ca2+	flux	analysis	after	SLO	treatment	of	WT	and	CAPNS1-/-	
HEK293	cells.	A.	Representative	Ca2+	traces	of	WT	and	CAPNS1-/-	HEK293	
cells	 showing	 the	 mean	 value	 of	 the	 duplicate	 samples	 relative	 to	
baseline.	The	y-axis	shows	the	relative	Ca2+	flux	as	a	ratio	of	340/380	nm	
fluorescence	 intensity	 emitted	 by	 the	 Ca2+	 dye	 Fura-2	 at	 510	 nm.	 SLO	
addition	 occurred	 five	 minutes	 into	 the	 analysis	 (red	 arrow)	 and	 the	
fluorescence	was	measured	once	every	minute.	B.	-	D.	Peak	SLO-induced	
Ca2+	flux	(peak	fluorescence	minus	fluorescence	in	the	absence	of	SLO)	at	
individual	 times	 was	 plotted	 and	 the	 EC50	 (half	 maximal	 effective	
concentration)	 of	 SLO	 calculated	 (red	 dotted	 line,	 red	 numbers).	WT	 is	
shown	in	orange	and	CAPNS1-/-	in	blue.	Each	point	represents	the	mean	±	
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standard	deviation	of	two	individual	experiments.	B.	At	one	minute	after	
SLO	administration,	SLO-induced	Ca2+	flux	was	relatively	similar	between	
WT	 and	CAPNS1-/-	 cells.	C)	 10	minutes	 after	 SLO	 treatment	 the	 EC50	 of	
SLO	for	CAPNS1-/-	cells	was	increased	five-fold	in	comparison	to	WT	cells;	
which	remains	the	same	20	minutes	after	SLO	treatment	(D.	N	=	2.	
	
Figure	 2.22A	 shows	 that	 at	 3,000	 and	 1,000	U/SLO	 the	 Ca2+-traces	 of	 the	WT	 and	
CAPNS1-/-	 cells	 looked	 similar,	 suggesting	 these	 concentrations	 of	 SLO	 were	
saturating.	At	sub-saturating	SLO-levels	of	30,	100	and	300	U/SLO,	the	Ca2+-traces	of	
WT	and	CAPNS1-/-	cells	showed	differences	in	the	Ca2+-flux	kinetics.		
	 Unexpectedly,	CAPNS1-/-	cells	appeared	more	resistant	to	perforation	by	SLO,	
resulting	 in	a	decrease	of	Ca2+-kinetics	 (see	Figure	2.22A,	 compare	yellow	 (300	U),	
blue	(100	U)	and	orange-dashed	(30	U)	traces).		
	 Analysing	the	peak	Ca2+-flux	induced	by	SLO	at	different	time	points,	allowed	
me	to	calculate	the	EC50	of	SLO	for	WT	and	CAPNS1-/-	cells	(Figure	2.22B-D).	At	one	
minute	after	SLO	administration	there	was	only	a	negligible	shift	 in	the	EC50	of	SLO	
between	WT	and	CAPNS1-/-	cells	(Figure	2.22B).	In	contrast,	at	both	10	(Figure	2.22C)	
and	20	minutes	 (Figure	2.22D)	after	SLO	administration,	a	 five-fold	 increase	of	 the	
EC50	for	SLO	was	observed	in	the	CAPNS1-/-	cells	compared	to	WT	cells.		
	
Conclusion	
The	 results	 implicate,	 that	 in	CAPNS1-/-	cells,	 in	 the	absence	of	 functional	 calpain-1	
and	calpain-2,	the	cells	need	five	times	as	much	SLO	to	achieve	the	same	amount	of	
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intracellular	Ca2+-flux	as	WT	cells.	In	other	words,	CAPNS1-/-	cells	are	more	resistant	
to	perforation	by	SLO.		
	 These	 results	 can	be	 interpreted	 in	different	ways:	 either	 calpains-1	 and	 -2	
are	 involved	in	the	assembly	of	SLO	pores,	and/or	aiding	the	binding/incorporation	
of	 the	 SLO	 pores	 into	 the	 membrane,	 or	 CAPNS1-/-	 cells	 could	 have	 altered	
membrane	lipid	composition	that	lead	to	less	pore	integration	in	CAPNS1-/-	cells.	As	
SLO	is	a	cholesterol	binding	cytolysin,	altered	lipid-composition,	potentially	resulting	
in	less	cholesterol	at	the	plasma	membrane,	could	explain	the	decreased	sensitivity	
to	SLO	perforation	in	CAPNS1-/-	cells.		
	 To	 exclude	 clonal	 differences	 as	 a	 source	 for	 the	 observed	 differences,	 it	
would	 be	 desirable	 to	 repeat	 the	 experiments	 with	 both	 CAPNS1-/-	 clones	 to	
eliminate	 clonal	 effects.	 These	 experiments,	 together	 with	 studies	 of	 two	 clonal	
CAPNS1-/-	 COS-7	 lines	 that	 I	 also	 derived	 during	 my	 PhD,	 will	 be	 performed	
prospectively	 in	the	Cooper	 lab	to	confirm	a	role	for	calpain	activity	for	membrane	
perforation	by	pore	forming	toxins.	
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Part	D	
Part	D	will	describe	the	process	of	making	a	skeletal	muscle	specific	CAPNS1	knock-
out	mouse	model.		 	
	 Our	 postdoctoral	 research	 fellow	 Dr	 Frances	 Lemckert	 is	 the	 expert	 in	 all	
mouse-related	 concerns	 in	 our	 team	 and	 assisted	 me	 with	 the	 paperwork	 for	
importing	the	mouse	line,	as	well	as	with	the	writing	of	Ethics	applications	and	the	
planning	and	execution	of	the	experiments.		
	 During	 the	 generation	 of	 this	 mouse	 model,	 we	 encountered	 unexpected	
complications	with	a	leaky	MyoD-Cre	promoter,	which	led	to	the	loss	of	Mendelian	
genetics	(as	calpain	activity	is	required	for	embryonic	development).	These	data	will	
be	explained	and	discussed	in	detail	in	section	2.8.4,	below	(leakiness	describes	the	
ectopic	 expression	 of	 a	 transgene	 (Haruyama,	 Cho,	 &	 Kulkarni,	 2009)).	
	 Unfortunately,	 this	 meant	 that	 I	 could	 not	 perform	 the	 full	 scope	 of	
experiments	I	had	planned.		 Despite	this	caveat,	 this	study	produced	valuable	data	
that	 provided	 new	 insight	 into	 the	 role	 of	 calpains-1	 and	 -2	 in	muscle,	 and	 in	 the	
pathogenesis	 of	muscular	 dystrophy.	 Further,	 I	 gained	 experience	 in	 planning	 and	
executing	research	studies	that	involve	mice.		
	 The	following	paragraphs	explain	the	rational	of	making	this	mouse	model,	as	
a	 well	 as	 illustrate	 the	 experimental	 plan	 that	 was	 proposed	 initially	 for	 the	
comprehensive	analysis	of	this	mouse	model.		
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2.8. CAPNS1	Sk.mscl.-/-	mouse	model	
In	order	to	validate	the	data	obtained	using	CAPNS1-/-	cell	lines	and	to	study	the	role	
of	 the	 ubiquitous	 calpains	 in	 muscular	 dystrophy	 and	 muscle	 membrane	 repair,	 I	
decided	 to	 derive	 a	 CAPNS1-/-	 mouse	 model.	 As	 global	 knock-out	 of	 CAPNS1	 is	
embryonically	lethal	(Arthur	et	al.,	2000),	I	decided,	with	the	help	of	Dr	Lemckert,	to	
generate	a	skeletal	muscle	specific	CAPNS1-/-mouse	model	(CAPNS1	Sk.mscl.-/-).	
	
Hypotheses		 	
I	proposed	three	major	hypotheses	using	the	CAPNS1Sk.mscl-/-	mouse	model:		
H1:	The	ubiquitous	calpains	are	vital	for	membrane	repair	of	injured	skeletal	muscle	
fibers.	
H2:	 Defective	membrane	 repair	 is	 a	 core	 pathway	 underpinning	 development	 of	 a	
muscular	dystrophy,	and	thus,	loss	of	calpain-1	and	calpain-2	activity	will	result	in	a	
muscular	dystrophy.	
H3:	 Calpain-1	and	calpain-2	are	essential	 for	membrane	 repair	of	 injuries,	not	only	
caused	by	mechanical	scrape,	but	also	from	laser	ablation	injury	and	perforation	by	
pore-forming	toxins.	
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2.8.1. Experimental	plan	
1)	 Determine	 the	 effect	 of	 acute	 muscle	 damage	 through	 eccentric	 contraction	
injury	
This	study	is	addressing	my	first	hypothesis,	asking	if	the	ubiquitous	calpains	are	vital	
for	membrane	repair	of	injured	skeletal	muscle	fibers.	
	 To	 assess	 the	 severity	 of	 muscle	 damage	 following	 eccentric	 contraction	
injury,	CAPNS1	Sk.mscl.-/-	mice	perform	downhill	running	on	a	treadmill,	alongside	DYSF-
/-	 mice	 and	 WT	 control	 mice.	 This	 assay	 is	 used	 to	 induce	 physiological	 muscle	
damage	through	eccentric	contraction	injury	(Allen,	2001),	allowing	me	to	study	the	
degree	of	muscle	damage	caused	and	the	physiological	repair	process	in	vivo.		
	 To	quantify	 the	amount	of	muscle	damage	 caused,	 I	 choose	blood	 creatine	
kinase	(CK)	as	well	as	Evans	blue	dye	uptake	into	the	muscle	fibers,	as	experimental	
readouts.	
	 1)	Blood	creatine	kinase	 (CK)	 levels.	CK	 is	a	muscle	specific	enzyme	and	 its	
appearance	 in	blood	 is	generally	considered	to	be	a	marker	of	muscle	damage	and	
inflammatory	breakdown	of	the	muscle	(Newham,	Jones,	&	Edwards,	1986).	The	CK	
levels	are	measured	at	base	line,	acutely	after	completion	of	the	exercise	protocol,	
as	well	as	several	days	later	in	order	to	assess	muscle	recovery.	
	 2)	Evans	blue	dye	 is	a	cell	 impermeable	dye	that	serves	as	a	visual	readout	
for	muscle	damage.	The	dye	is	injected	30	minutes	prior	to	commencing	the	exercise	
protocol	as	described	in	(Rooney	et	al.,	2006)	and	the	muscle	sections	are	analysed	
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after	 the	 mice	 are	 sacrificed.	 I	 established	 a	 detailed	 timeline	 of	 the	 eccentric	
contraction	injury	experiments,	which	is	portrayed	in	Figure	2.23.	
	
Figure	2.23:	Detailed	experimental	plan	of	eccentric	contraction	 injury	
protocol.	 ~8-week	 old	 mice	 were	 going	 to	 be	 acclimatized	 on	 the	
treadmill	 for	one	week	prior	to	the	start	of	the	experiment.	On	day	7	a	
baseline	CK	are	taken.	Day	8:	Evans	blue	dye	injection	and	downhill	run	
followed	 by	 acute	 CK	measurement	 shortly	 after	 the	 run	 has	 finished.	
The	next	day	(day	9)	one	group	of	mice	are	sacrificed	via	terminal	cardiac	
puncture.	The	second	group	are	sacrificed	7	days	post	exercise	to	assess	
muscle	recovery	over	time.	
	
2)	 Disease	 progression	 CAPNS1Sk.mscl.-/-	 mice	 compared	 to	 DYSF-/-	 mice	 and	 WT	
controls	
The	 goal	 of	 this	 study	 was	 to	 address	 my	 second	 hypothesis	 that	 defective	
membrane	 repair	 is	 a	 core	 pathway	 underpinning	 development	 of	 a	 muscular	
dystrophy	 and	 that	 loss	 of	 calpain-1	 and	 calpain-2	 activity	 results	 in	 a	 muscular	
dystrophy.	
	 To	assess	 the	effect	of	 the	 lack	of	CAPNS1	 in	skeletal	muscle	on	the	overall	
health	of	the	mice,	and	to	see	if	the	mice	display	features	of	a	manifesting	muscular	
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dystrophy,	 I	 designed	 an	 ageing	 experiment.	 Here	 I	 leave	 the	 mice	 with	 no	
experimental	 interruptions,	 just	 observing	 and	 recording	 their	 overall	 health	 and	
behaviour.	I	divide	the	mice	into	four	groups,	aged	till	2,	4,	6	or	a	max.	18	months.	
The	6-months	group	is	further	divided	into	two	separate	sub-groups;	one	sub-group	
has	 a	 running	 wheel	 in	 the	 cage	 to	 study	 the	 effect	 of	 voluntary	 exercise	 on	 the	
muscle	 compared	 to	mice	without	 a	 running	wheel.	 Figure	 2.24	 shows	 a	 detailed	
outline	of	this	ageing	experiment.	
	
	
Figure	 2.24:	 Ageing	 protocol	 to	 assess	 disease	 progression	 of	
CAPNS1Sk.mscl.-/-	mice.	
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At	 the	marked	time	points	mice	are	sacrificed	using	 terminal	cardiac	puncture	and	
the	 serum	CK	 levels	are	analysed.	Muscle	histopathology	 is	performed,	 looking	 for	
dystrophic	 features	 and	 western	 blot	 analyses	 evaluate	 potential	 differences	 in	
protein	 levels	 as	well	 as	 confirming	 genotypes	 through	 visualisation	 of	 the	 lack	 of	
calpain	proteins	in	the	CAPNS1Sk.mscl.-/-	mice.	
	 	
3)	Using	primary	mouse	muscle	cells	and	single	muscle	fibers	to	study	membrane	
repair	
This	study	aims	to	address	my	hypotheses	H3:	Calpain-1	and	calpain-2	are	essential	
for	membrane	repair	of	injuries	not	only	caused	by	mechanical	scrape	but	also	from	
laser	ablation	injury	and	perforation	by	pore-forming	toxins.	
	 When	using	cell	 lines,	 it	 is	always	a	possibility	that	observed	differences	are	
due	to	clonal	differences	between	the	individual	clones.	The	use	of	primary	cell	lines	
eliminates	 this	 caveat.	 This	 is	 why	 primary	 mouse	 muscle	 cells	 from	 the	
CAPNS1Sk.mscl.-/-	 mice,	 as	 well	 as	 DYSF-/-	 and	 WT	 mice,	 are	 used	 to	 mirror	 the	
membrane	repair	experiments	I	had	performed	earlier	using	HEK293	and	COS-7	cells	
and	were	expected	to	validate	our	findings.		
	 With	Ethics	approval	for	this	project	 I	started	by	 importing	a	 floxed	(flanking	
loxP	sites)	CAPNS1	mouse	line	from	Canada.	
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2.8.2. Generating	the	CAPNS1Sk.mscl.-/-	mouse	line	
We	imported	the	floxed	CAPNS1	mouse	model	form	Prof.	Peter	Greer	from	Queen's	
University	 in	 Canada.	 I	 would	 like	 to	 thank	 Prof.	 Greer	 for	 his	 contribution	 and	
productive	collaboration.		
	
Nomenclature	for	the	CAPNS1-/-	mouse	
At	 this	 point	 I	would	 like	 to	 clarify	 the	 nomenclature	 used	 to	 describe	 this	mouse	
line.	Tan	et	al.	have	published	this	conditional	knock-out	mouse	model	in	2006	(Tan	
et	 al.,	 2006)	 using	 the	 nomenclature	 'capn4'	 instead	 of	 'CAPNS1'	 to	 describe	 the	
calpain	small	subunit	1	gene	whereas	throughout	my	thesis	I	am	using	'CAPNS1'.		
	 The	CAPNS1	gene	of	this	mouse	line	is	 'floxed',	meaning	that	loxP	sites	have	
been	 inserted	 into	 this	 target	 gene.	 LoxP	 sites	 are	 recognition	 sites	 for	 the	 Cre	
recombinase	 enzyme.	 The	 'Cre-loxP	 system'	 is	 a	well-establish	 system	 to	 generate	
conditional	knock-out	mouse	models,	first	been	discovered	by	Dr	Brian	Sauer	(Sauer,	
1987;	 Sauer	 &	 Henderson,	 1988).	 With	 the	 Cre-loxP	 system,	 site-specific	
recombination	can	be	triggered	when	Cre	recombinase	is	expressed,	 leading	to	the	
excision	of	parts	of	the	CAPNS1	gene	and	subsequent	knock-out.		
	 Tan	 et	 al.	 also	 included	 the	 LacZ	 reporter	 gene	 into	 the	 CAPNS1	 locus,	 as	
visual/biochemical	readout	for	successful	Cre-recombination.	The	LacZ	gene	encodes	
for	the	enzyme	β-galactosidase	that	will	result	in	blue	staining	when	it	is	expressed.	
Upon	Cre-recombination,	 the	LacZ	gene	will	be	excised	 resulting	 in	 the	absence	of	
blue	staining.	
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	 The	mouse	 line	 that	 is	 homozygous	 for	 the	 floxed	 CAPNS1	 gene,	 and	 also	
includes	a	LacZ	reporter	gene	is	called	CAPNS1PZ/PZ.	The	'PZ'	stands	for	Peter	Greer	
and	 LacZ;	 (Peter	 Greer	 generated	 this	 transgenic	mouse	 line).	 CAPNS1PZ/PZ	 can	 be	
considered	as	'wild	type	mice',	as	it	normally	expressed	calpain-S1	with	a	bicistronic	
LacZ	reporter	(see	Figure	2.26).	
	 After	Cre-recombination,	CAPNS1	is	knocked-out	and	the	LacZ	reporter	gene	
will	be	excised,	 thus	 the	mice	will	be	called	CAPNS1P/P,	 indicating	 that	LacZ	 is	now	
missing	-	and	the	basis	for	excluding	the	'Z'	from	the	name.	
	
The	Cre-expressing	mouse	line	
To	achieve	Cre-driven	recombination	resulting	 in	CAPNS1	knock-out,	we	needed	to	
cross	our	CAPNS1PZ/PZ	mice	with	a	mouse	line	expressing	Cre	recombinase.	We	chose	
the	 MyoD/Cre	 mouse	 line,	 expressing	 Cre-recombinase	 under	 the	 control	 of	 the	
muscle	 specific	 promoter	MyoD.	MyoD	 is	 a	 transcription	 factor	 regulating	 skeletal	
muscle	 development,	 switched	 on	 at	 mid-gestation	 in	 mice	 (Maroto	 et	 al.,	 1997;	
Tajbakhsh,	Rocancourt,	Cossu,	&	Buckingham,	1997).	
	 These	 mice	 are	 heterozygous	 for	 the	 MyoD	 gene	 that	 is	 inserted	 as	 a	
transgene.	I	will	refer	to	these	mice	as	'MDC',	for	MyoD/Cre	and	their	heterozygous	
state	 will	 be	 indicated	 as	 'MDCTg/WT';	 meaning	 that	 one	 allele	 is	 expressing	 the	
transgene	(Tg)	and	the	other	allele	is	wild	type	(WT),	not	expressing	the	transgene.	
	 After	 the	 imported	 CAPNS1PZ/PZ	 mice	 were	 cleared	 from	 quarantine	 in	 our	
animal	 house,	 we	 started	 breeding	 them	with	 the	MDC	mouse	 line.	 The	 resulting	
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mouse	 line	will	 be	 called	CAPNS1Sk.mscl.-/-	 .	 The	 breeding	 strategy	 used	 to	 generate	
these	mice	is	described	below	in	section	2.8.3.	
	
2.8.3. CAPNS1Sk.mscl.-/-	breeding	strategy	
Figure	2.25,	below,	shows	the	breeding	strategy	Dr	Lemckert	and	I	used	to	generate	
the	CAPNS1Sk.mscl.-/-	mouse	line.		
	 	
			 	
Figure	2.25:	Schematic	of	breeding	strategies	to	generate	CAPNS1-/-Sk.mscl..	
Homozygous	 BL6	 mice	 carrying	 the	 floxed	 CAPNS1	 gene	 (CAPNS1PZ/PZ,	
MDCWT/WT;	 green	mouse)	were	 crossed	with	 BL6	mice,	 heterozygous	 for	
MyoD/Cre	(CAPNS1PZ/PZ,	MDCTg/WT)	(black	mouse	with	red	skeletal	muscle).	
This	is	the	parental	(P)	generation.	The	offspring	of	this	cross,	F1,	yielded	
50	%	of	mice	 being	CAPNS1PZ/WT	and	MDCWT/WT.	 The	 other	 50	%	of	mice	
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were	CAPNS1PZ/WT	again	and	heterozygous	for	MDC,	MDCTg/WT.	These	mice	
were	 then	 used	 to	 backcross	 onto	 the	 parental	 CAPNS1PZ/PZ	 line	 to	
generate	our	 experimental	mice.	 This	 cross	 should	have	 yielded	25	%	of	
CAPNS1PZ/PZ,	 MDCWT/WT,	 25	 %	 of	 CAPNS1PZ/PZ,	 MDCTg/WT	 (experimental	
mice),	25	%	CAPNS1PZ/WT,	MDCTg/WT	and	25	%	of	CAPNS1PZ/WT,	MDCWT/WT.		
	
First	 we	 crossed	 the	 homozygous	 floxed	 CAPNS1PZ/PZ	mice	 with	 the	 heterozygous	
MyoD-Cre	line,	MDCTg/WT	(this	is	the	parental	cross	(P),	Figure	2.25).	The	offspring	of	
this	 breeding	 cross,	 the	 F1	 generation,	 resulted	 in	 all	mice	being	heterozygous	 for	
the	 floxed	 CAPNS1	 allele	 (CAPNS1PZ/WT).	 50	 %	 of	 the	 F1	 generation	 mice	 were	
heterozygous	 for	 MyoD-Cre	 transgene	 (MDCTg/WT),	 resulting	 in	 mice	 with	 the	
CAPNS1PZ/WT,	MDCTg/WT	genotype.	
	 For	 the	 generation	 of	 our	 experimental	 mice,	 the	 CAPNS1PZ/WT,	MDCTg/WT	
mice	from	the	F1	generation	were	crossed	back	onto	the	parental	CAPNS1PZ/PZ	mice.	
This	cross	should	have	resulted	in	25	%	of	mice	carrying	the	correct	genotype.	
	 We	bred	53	animals	of	the	F2	generation	and	expected	~13	animals	(25	%)	to	
have	 the	 CAPNS1PZ/PZ,	 MDCTg/WT	 genotype.	 But	 this	 was	 not	 the	 outcome	 we	
obtained.	We	lost	Mendelian	genetics,	and	were	able	to	only	generate	two	mice	of	
the	desired	genotype	(of	the	13/53	expected).	Table	2.1,	below,	shows	the	expected	
versus	the	generated	numbers	of	mice	for	each	genotype.	
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Table	2.1:	Expected	versus	generated	mouse	genotypes.	The	genotype	
of	the	experimental	mice	is	indicated	in	green.	
Genotype	 Expected	number	of	mice	
Generated	number	
of	mice	
CAPNSPZ/PZ,	MDCWT/WT	 ~13.25	(25	%)	 3	(~5.6	%)	
CAPNS1PZ/PZ,	MDCTg/WT	 ~13.25	(25	%)	 2	(3.8	%)	
CAPNS1PZ/WT,	MDC	Tg/WT	 ~13.25	(25	%)	 24	(45.3	%)	
CAPNS1PZ/WT,	MDCWT/WT	 ~13.25	(25	%)	 24	(45.3	%)	
	
After	 undertaking	 thorough	 PCR-screening	 of	 ear	 clips	 from	 all	 our	 mice,	 we	
observed	clear	evidence	for	recombination	at	the	PZ	CAPNS1	 locus.	As	MyoD	is	not	
expressed	 in	 skin	 or	 cartilage,	we	 concluded	 that	 the	MyoD	 promoter	might	 have	
been	 'leaky',	 meaning	 ectopic	 expression	 of	MyoD	 in	 non-muscle	 cells	 must	 have	
occurred.		
	 	Using	 two	 different	 breeding	 strategies,	 one	 with	 the	 female	 carrying	 Cre	
and	 the	 other	 with	 the	 male	 being	 the	 Cre-carrying	 mouse,	 we	 discovered	 that	
ectopic	 expression	 of	MyoD-Cre	 occurred	 through	 the	 germline	 of	 both	male	 and	
female	mice.	How	we	 came	 to	 this	 conclusion	will	 be	 further	 explained	 in	 section	
2.8.4,	below.	
	
2.8.4. Screening	of	CAPNS1Sk.mscl.-/-	mice	
To	understand	the	PCR-screening	strategy	of	the	CAPNS1Sk.mscl-/-	mice,	it	is	important	
to	understand	how	the	mice	were	generated	in	the	first	place.	Figure	2.26	shows	a	
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schematic	 of	 the	of	 the	 conditional	murine	CAPNS1	 knock-out	 strategy	 (the	 image	
has	been	modified	from	Tan	et	al.	(Tan	et	al.,	2006)).		
	 Figure	 2.26A	 shows	 the	 floxed	murine	CAPNS1	 gene	 (PZ),	 and	 Figure	 2.26B	
the	 recombined	 gene	 product	 causing	 the	 CAPNS1	 knock-out	 (P).	 The	 screening	
primers	 are	 indicated	 as	 horizontal	 arrows	 in	 red,	 green	 and	 purple.	 Upon	 Cre	
recombination,	the	banding	pattern	of	the	resulting	PCR	products	of	these	primers	
changed.		
	 In	the	PZ	animals	the	primer	pair	8F	and	9R	resulted	in	a	PCR	product	of	335	
bp	 in	 size.	 Primer	 11R	 was	 too	 far	 upstream	 of	 the	 8F	 primer	 to	 generate	 a	
detectable	PCR	product.	After	Cre-driven	excision	of	exon	9	and	10,	and	substitution	
of	exon	11,	the	primer	pair	8F	and	11R,	now	resulted	in	a	PCR	product	of	435	bp	in	
size,	 and	 primer	 9R	 could	 no	 longer	 bind,	 since	 exon	 9	 had	 been	 excised.	 The	 PZ	
allele	showed	a	335	bp	PCR	product,	and	the	recombined	P	allele	resulted	in	a	435	
bp	PCR	product	when	using	the	three	primers	at	the	same	time.	Figure	2.26	shows	
the	schematic	of	the	strategy	used	to	generate	conditional	CAPNS1	knock-out	mice.	
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Figure	 2.26:	 Schematic	 presentation	 of	 conditional	 murine	 CAPNS1	
knock-out	 strategy.	 A.	 Floxed	 CAPNS1	 gene	 'PZ/PZ'	 (blue	 boxes	
indicating	exons)	with	the	targeting	vector	incorporated	that	encodes	for	
loxP	 sites,	 CAPNS1	 exon	 9,	 10	 and	 11	 and	 the	 IRES/lacZ/Neo	 cassette	
(black	 lined	 boxes).	 The	 loxP	 sites	 are	 depicted	 as	 flags	 and	 are	 were	
located	 in	 CAPNS1	 intron	 8	 and	 3'	 of	 the	 end	 of	 the	 Neo	 sequence.	
Sequencing	primers	(8F,	9R	and	11R)	are	 indicated	as	horizontal	arrows	
in	red,	green	and	purple.	The	resulting	PCR	product	of	the	8F	+	9R	primer	
pair	was	335	bp.	The	8F	and	11R	primer	pair	generated	a	product	too	big	
to	be	seen	with	this	PCR	screen.	B.	Schematic	of	resulting	gene	product,	
'P',	after	Cre	mediated	excision	(i.e.	crossing	the	CAPNS1PZ/PZ	mouse	with	
the	MDCTg/WT	mouse).	Now	the	primer	pair	8F	and	11R	resulted	in	a	435	
bp	PCR	product	whereas	primer	9R	could	no	longer	bind.	This	was	used	
as	a	screening	tool	for	successful	Cre	mediated	excision.	(IRES	=	internal	
ribosomal	 entry	 site,	 LacZ	 =	 β-galactosidase	 reporter	 gene,	 Neo	 =	
neomycin).	The	schematic	has	been	modified	based	on	Tan	et	al.	(Tan	et	
al.,	2006).	
	
Figure	2.27,	below,	shows	the	results	of	a	representative	PCR	screen	from	ear	clips	
from	eight	parental	mice	as	well	as	ten	mice	from	the	F2	generation.		
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Figure	 2.27:	 PCR	 analysis	 showing	 leakiness	 of	 MyoD	 promoter.	 A.	 PCR	
analysis	 of	 ear	 clips	 from	 the	 parental	 CAPNS1PZ/PZ	 line	 as	 well	 as	 the	 F1	
generation	 screening	 for	 mice	 that	 had	 the	 MyoD-Cre	 as	 well	 as	 the	
recombined	P	allele,	here	shortened	to	'PZMDC'.	Primer	8F,	9R	and	11R	were	
used	together	in	this	PCR.	The	parental	mice	all	showed	a	strong	band	of	335	
bp	 correctly	 showing	 the	 presence	 of	 the	 PZ	 allele	 (not	 recombined).	 The	
numbers	at	the	top	correspond	to	the	individual	mouse	number.	The	screen	of	
the	 F1	 generation	 showed	 different	 banding	 patterns.	 Some	 mice	 were	
showing	the	PZ	allele	as	well	as	the	WT	band	at	301	bp;	mouse	#63,	64	and	66	
showed	an	additional	band	at	435	bp	that	resembled	the	recombined	P	allele.	
Ai.	Screening	for	the	recombined	P	allele	using	only	primers	8F	and	11R	in	the	
same	mice	as	before.	When	the	primers	were	not	competing	it	was	clear	that	
all,	but	two	mice	(#61	and	62)	showed	the	recombined	P	allele	in	DNA	derived	
from	 ear	 clips.	 Aii.	 Cre-PCR	 screen	 showing	 the	 presence	 of	 the	MyoD/Cre	
transgene,	 #62	 showed	 a	weaker	 band	whereas	mouse	 #61	 and	 #63	 almost	
showed	no	positive	band	for	Cre.	B.	PCR	screen	of	isolated	muscle	fibers	and	a	
cell	mix	control	from	the	two	CAPNS1Sk.mscl.-/-	mice	using	all	three	primers.	The	
result	 showed	 that	 recombination	occurred	 in	 fiber	D;	and	 in	 the	mixed	cells	
both	alleles	(PZ	and	P)	could	be	detected.	
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Figure	2.27A,	above,	shows	the	screening	results	for	the	PZ	and	P	alleles	from	eight	
animals	of	the	parental	CAPNS1PZ/PZ	line	(#74-76	and	78-82)	on	the	left,	as	well	as	ten	
animals	of	the	F1	generation,	CAPNS1PZ/PZ,	MDCTg/WT,	shortened	to	'PZMDC',	on	the	
right	(#60-69).	All	three	screening	primers	were	used	(8F,	9R	and	11R).		
	 The	 result	 showed	 a	 strong	 positive	 band	 of	 335	 bp,	 corresponding	 to	 the	
floxed	 CAPNS1	 allele,	 the	 'PZ	 allele'	 in	 the	 parental	 animals	 (Figure	 2.27A,	 left,	
above).	The	F1	generation	of	mice	carrying	CAPNS1PZ/PZ,	MDCTg/WT	showed	bands	at	
different	sizes:	animal	#60-#63,	#65	and	#67-#69	showed	two	main	bands	at	335	and	
301	bp.	These	bands	corresponded	to	the	floxed	CAPNS1	allele	(PZ,	335	bp)	as	well	
as	the	WT	allele	(301	bp).	Mice	#63,	#64	and	#66	show	bands	at	435	and	335	bp.	The	
436	 bp	 band	 corresponded	 to	 the	 recombined	 P	 allele.	 This	 result	 suggested	 that	
there	has	been	Cre	activity	in	the	ear	of	these	mice	leading	to	recombination	of	the	
floxed	CAPNS1	PZ	allele	to	the	P	allele.	
	 To	 investigate,	 Dr	 Lemckert	 and	 I	 performed	 a	 PCR	 screen	 only	 using	 the	
primer	 set	 specific	 for	 the	 P	 allele	 (8F	 and	 11R)	 to	 reduce	 loss-of-signal	 through	
competing	primers.	Figure	2.27Ai.,	above,	demonstrates	that	all	mice,	except	for	#61	
and	#62,	showed	a	PCR	product	of	435	bp,	corresponding	to	the	excised	CAPNS1	P	
allele.	 Figure	 2.27Aii.,	 above,	 shows	 the	 PCR	 screen	 for	 the	 Cre	 transgene	 in	 the	
same	mice.	It	transpired	that	mouse	#61	and	#63	showed	low	or	no	significant	bands	
when	screening	for	Cre.	In	case	of	mouse	#63	however,	Cre	mediated	recombination	
resulted	in	the	positive	P	allele	screen.		
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	 One	 explanation	 for	 this	 peculiar	 result	 could	 be	 that	 Cre	 expression	 has	
occurred	during	gametogenesis,	where	the	oocyte	and	the	spermatids	are	syncytial,	
prior	 to	 the	 second	 meiotic	 division	 (Handel	 &	 Schimenti,	 2010).	 A	 Cre	 positive	
spermatid	 could	 have	 'leaked'	 Cre-enzyme	 into	 the	 adjacent	 spermatid	 that	might	
have	been	Cre	negative.	The	oocyte	also	 stays	connected	with	 its	polar	body	after	
division,	and	arrests	 in	 the	prophase	until	 fertilisation	 (Handel	&	Schimenti,	2010).	
These	possibilities	will	be	further	explored	in	the	discussion	in	section	3.2.		
	 Dr	Lemckert	also	 isolated	single	muscle	fibers	from	our	CAPNS1Sk.mscl.-/-	mice	
and	performed	PCR	analysis	using	all	three	screening	primers	(see		
Figure	2.27B,	above).	The	result	showed	that	at	 least	 in	 fiber	"D"	the	PZ	allele	was	
recombined	to	the	P	allele	whereas	in	the	control	(mixed	cells	of	non-muscle	origin)	
both	 alleles	 were	 amplified.	 This	 demonstrated	 that	 in	 muscle	 fibres,	 there	 was	
complete	recombination	between	loxP	sites	within	the	CAPNS1	locus.		
	 These	results	were	not	what	we	expected	since	there	should	not	have	been	
any	 Cre-recombination	 occurring	 in	 the	 ears	 of	 our	 mice.	 Cre-expression	 was	
supposed	 to	 be	 tightly	 regulated	 under	 the	 control	 of	 the	 MyoD	 promoter,	 and	
MyoD	 should	 only	 be	 turned	 on	 in	 developing	 skeletal	 muscle	 (Tajbakhsh	 et	 al.,	
1997).	We	concluded	that	the	MyoD	promoter	was	leaky,	causing	ectopic	expression	
of	 Cre-recombinase,	 leading	 to	CAPNS1	 knock-out	 in	 non-muscle	 cells	 and	 tissues.	
We	were	thus	not	able	to	generate	the	mice	with	the	desired	genotype,	using	this	
strategy.	Some	ectopic	expression	of	MyoD	has	been	described	in	the	original	study	
establishing	this	mouse	line	(Chen,	Mortimer,	Marley,	&	Goldhamer,	2005)	and	will	
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be	discussed	in	section	3.2.	The	two	'miracle	mice'	that	we	did	generate	could	still	be	
fully	 analysed.	 To	 ensure	 that	 we	 would	 detect	 a	 mild	 muscular	 dystrophy	
phenotype,	 if	one	manifested,	we	elected	to	age	the	mice	9-12	months.	This	was	a	
difficult	 decision,	 as	 analysis	 of	 these	mice	would	 occur	 once	 I	 had	 already	 taken	
maternity	leave.	However,	it	was	in	the	best	interest	of	reduction	and	refinement	of	
animal	numbers	to	determine	if	our	primary	hypothesis	was	correct	and	to	provide	
rationale	 for	 potentially	 repeating	 this	 breeding	 strategy,	 despite	 the	 loss	 of	
Mendelian	genetics.	
	
2.8.5. The	two	CAPNS1Sk.mscl.-/-	mice	show	a	severe	dystrophic	muscle	phenotype	
The	two	mice	with	the	desired	genotype	were	kept	 in	our	transgenic	 facility	under	
close	monitoring.	 Toward	 the	 12-month	mark	 the	 animal	 house	 staff	 informed	 us	
that	the	mice	were	deteriorating	in	health	and	we	decided	to	sacrifice	them	at	~12	
month.	The	two	CAPNS1Sk.mscl.-/-	mice	were	smaller	compared	to	their	littermates	and	
were	in	overall	worse	health	condition	than	their	littermates.		
	 As	I	was	already	on	maternity	leave,	Dr	Lemckert	and	our	research	assistant	
Samuel	Ross	conducted	the	tissue	harvest	and	subsequent	handling	of	the	samples.	
Under	the	supervision	of	Dr	Lemckert,	an	honours	student,	Omar	Saleh,	cut	sections	
on	the	cryostat	and	performed	haematoxylin	and	eosin	(H&E)	staining	to	analyse	the	
muscle	morphology	as	part	of	his	honours	project.		
	 We	 wanted	 to	 assess	 the	 potential	 effect	 of	 CAPNS1	 deficiency	 on	 the	
morphology	of	the	mouse	muscle,	 in	comparison	to	DYSF	deficient	muscle	and	WT	
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control	muscle.	 Psoas,	quadriceps	 (Quad),	 tibialis	 anterior	 (TA)	 and	 spinalis	muscle	
were	harvested	and	assessed	for	dystrophic	features	like	endomysial	fibrosis	(fibrotic	
infiltration,	seen	as	 increased	number	of	nuclei	 (purple)	around	the	muscle	 fibers),	
centralised	nuclei	and	atrophied	fibers.	
	 Despite	 the	 fact	 that	we	 only	 had	 two	mice,	 the	 results	were	 striking.	 The	
muscle	samples	from	the	CAPNS1Sk.mscl-/-	mouse	displayed	dystrophic	features	more	
severe	than	those	of	the	DYSF-/-	muscle.	Figure	2.28,	below,	shows	the	results	of	the	
H&E	 staining	 of	 several	 different	 muscle	 groups	 (the	 images	 for	 this	 figure	 were	
taken	by	Omar	and	I	composed	the	figure).		
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Figure	 2.28:	 H&E	 staining	 of	 WT,	 DYSF-/-	 and	 CAPNS1Sk.mscl.-/-	mouse	
muscle	 cross	 sections.	 Psoas,	 quadriceps	 (Quad),	 tibialis	 anterior	 (TA)	
and	spinalis	muscles	were	harvested	from	WT,	DYSF-/-	and	CAPNS1Sk.mscl.-/-	
mice	at	12	months	of	age.	8	µm	cross-sections	of	the	muscles	were	cut	
and	 stained	 using	 Haemotoxylin	 (purple)	 and	 Eosin	 (pink)	 (H&E)	 to	
visualize	 the	 nuclei	 (purple)	 and	 the	 general	 tissue	 (pink).	 DYSF-/-	 and	
CAPNS1Sk.mscl.-/-	 showed	 dystrophic	 features	 like	 fibrotic	 infiltration	 and	
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centralised	 nuclei	 in	 psoas,	 quadriceps,	 tibialis	 anterior	 whereas	 the	
spinalis	muscle	 seemed	 to	 be	 largely	 spared	 and	 looked	 comparatively	
healthy.	The	CAPNS1Sk.mscl.-/-	generally	showed	a	more	severe	phenotype	
than	the	DYSF-/-	muscle.	The	sample	size	of	n	=	2	was	too	small	to	make	
further	deductions.	The	scale	bar	=	100	µm.		
	
Psoas	 	
The	psoas	muscle	 showed	normal	morphology	 in	 the	WT	mouse	with	 peripherally	
located	nuclei	and	tightly	arranged	muscle	fibers	with	no	signs	of	fibrosis.	The	DYSF-/-	
psoas	showed	centralised	nuclei	and	signs	of	fibrotic	infiltration	(bottom	right	hand	
corner);	 some	 fibers	 were	 atrophied.	 The	 CAPNS1Sk.mscl-/-	 psoas	 showed	 severe	
symptoms	of	endomysial	fibrosis,	hypertrophied	fibers	(larger	than	normal),	as	well	
as	 atrophied	 fibers	 (much	 smaller)	 and	 some	 centralised	 nuclei.	 Further	
CAPNS1Sk.mscl-/-	 psoas	 appeared	 to	 have	 fat	 infiltration,	 shown	 as	 white	 areas	
between	the	fibers	as	well	as	within	the	fibers.	
	
Quadriceps	 	
The	 next	 muscle	 group	 I	 analysed	 was	 the	 quadriceps.	 The	 DYSF-/-	 muscle	 again,	
showed	 centralised	nuclei	 in	 several	 fibers,	 as	well	 as	 signs	of	 endomysial	 fibrosis.	
The	CAPNS1Sk.mscl-/-	quadriceps	displayed	a	large	amount	of	fibrotic	infiltration	as	well	
as	 atrophy	 in	 the	 majority	 of	 fibers.	 Fat	 depositions	 were	 also	 visible	 as	 well	 as	
centralised	nuclei	in	several	fibers.	
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Tibialis	anterior	(TA)	
The	TA	muscle	seemed	to	be	less	affected	in	DYSF-/-	and	CAPNS1Sk.mscl-/-.	The	DYSF-/-	
TA	 muscle	 appeared	 almost	 normal	 in	 morphology	 apart	 from	 some	 centralised	
nuclei	 and	 some	 fibrotic	 infiltration.	 The	CAPNS1Sk.mscl-/-	TA	 displayed	 signs	 of	mild	
atrophy	as	well	as	a	couple	of	centralised	nuclei	and	mild	fibrotic	infiltration.		
	
Spinalis	
The	spinalis	muscle	was	the	muscle	group	least	affected	by	the	absence	of	DYSF	and	
CAPNS1.	This	is	the	only	muscle	that	is	not	vertically	loaded,	as	it	is	located	along	the	
spine	 of	 the	mouse.	 The	 different	 force	 distribution	 the	 lesser	 amount	 of	 vertical	
force	 might	 have	 been	 sparing	 this	 muscle	 group	 from	 developing	 features	 of	
muscular	dystrophy.	
	
Conclusion	
It	was	disappointing	that	the	MyoD-Cre	promoter	was	leaky,	as	the	lack	of	CAPNS1	in	
our	 two	 'miracle	 mice'	 resulted	 in	 a	 significant	 dystrophic	 phenotype.	 We	
subsequently	 changed	 our	 strategy	 used	 the	 Prx/Cre	 ('paired-related	 homeobox	
gene-1',	 formerly	 known	 as	 'MHox1')	 instead	 of	 the	MyoD/Cre	mouse	 line.	 Prx	 is	
expressed	in	the	early	limb	bud	mesenchyme	from	mid-gestation	in	mice	(Cserjesi	et	
al.,	1992)	and	hence,	crossing	this	line	with	our	floxed	CAPNS1	mouse	line	will	result	
in	 a	 limb-specific	CAPNS1	 knock-out.	 This	mouse	 line	 had	been	used	previously	 to	
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successfully	 generate	 limb-specific	 knock-out	 of	 floxed	 target	 genes	 (Logan	 et	 al.,	
2002).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
		
	
150	
 Chapter	3: Discussion	 -	 Modifiers	 of	 membrane	
repair	
3.1. Calpains	are	important	for	the	repair	of	large	membrane	injuries	
In	this	study	I	have	investigated	the	specific	roles	of	the	ubiquitous	calpains-1	and	-2	
in	membrane	repair	after	different	types	of	membrane	injury.	I	was	the	first	to	show	
that	 even	 though	 calpains-1	 and	 -2	 are	 essential	 for	 the	 repair	 of	 large	 scrape	
injuries,	they	do	not	appear	to	play	a	major	role	 in	recovery	from	small	membrane	
lesions,	such	as	those	caused	by	perforation	by	SLO	or	laser	ablation	injury.		
	 After	 suffering	 a	 large	 scrape	 injury,	 the	 cell	 has	 to	 undergo	 significant	
cytoskeletal	remodelling	in	order	to	facilitate	membrane	repair.	During	scrape	injury,	
focal	adhesions	are	ripped	off,	membrane	edges	are	exposed	and	the	cytoskeleton	is	
disrupted.	Calpains-1	and	-2	are	known	to	be	involved	in	the	clearing	of	remnants	of	
the	 cortical	 cytoskeleton,	 helping	 repair-vesicles	 to	 access	 the	 injury	 site	 (R.	 L.	
Mellgren	 et	 al.,	 2007)	 as	 well	 as	 the	 remodelling	 of	 focal	 adhesions	 (Lebart	 &	
Benyamin,	2006;	Potter	et	al.,	1998).		
	 The	 repair	of	 smaller	 injuries	may	 require	 less	 cytoskeletal	 remodelling	and	
thus	the	involvement	of	calpains-1	and	-2	is	less	important.	
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3.1.1. Calpains-1	and	-2	can	compensate	for	each	others	loss	 	
My	 study	 also	 revealed	 the	 mutual	 compensation	 of	 calpain-1	 and	 calpain-2	 in	
membrane	 repair	 following	 scrape	 injury.	 This	 result	 suggests	 redundant	 roles	 of	
calpains-1	and	-2	in	membrane	repair.	I	have	thus	disproven	my	own	hypothesis	that	
calpain-2	would	be	more	important	for	membrane	repair,	at	least	in	cultured	cells.	It	
would	be	desirable	 to	 confirm	 this	 in	 vivo,	 via	muscle-specific	 knock-out	of	CAPN1	
and	CAPN2.	
	 This	 hypothesis	 was	 based	 on	 our	 teams	 collective	 data,	 showing	 that	
membrane	 repair	 has	 the	 same	 requirements	 for	 extracellular	 Ca2+	 as	 calpain-2	
activation	 (~150	 -200	 µM	 [Ca2+]EC),	 and,	 that	 injury-activated	 cleavage	 of	 dysferlin	
also	 requires	 150	 -	 200	µM	 [Ca2+]EC.	A	 requirement	 for	 150	 -	 200	µM	 [Ca2+]EC	may	
thus	not	relate	to	the	activation	of	calpain,	but	another	Ca2+-dependent	element	of	
the	membrane	repair	program.	
	
3.1.2. Calpains-1	 and	 -2	 are	 not	 involved	 in	 the	 recovery	 from	 small	
membrane	lesions	
In	 my	 studies	 I	 have	 used	 laser	 ablation	 and	 streptolysin-O	 (SLO)	 perforation	 to	
create	small	membrane	lesions	of	~30	nm	diameter	and	~0.31	µm2,	respectively.	My	
hypothesis	 was	 that	 calpains-1	 and	 -2	 would	 be	 essential	 for	 the	 removal	 of	 SLO	
pores	and	the	repair	of	the	small	injuries	caused	by	laser	ablation.	
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	 Interestingly,	 when	 using	 SLO	 in	 the	 adapted	 two-dye	 high	 throughput	
membrane	 repair	 assay,	 showed	 no	 significant	 differences	 in	 membrane	 repair	
capacity	and	cell	survival	between	WT	and	CAPNS1-/-	HEK293.		
	
3.1.2.1. Caveats	 of	 using	 SLO	 in	 the	 high	 throughput	 two-dye	 membrane	 repair	
assay	
These	 results	 suggested	 that	 either	 the	 removal	 of	 the	 pores	 happened	
independently	of	calpains-1	and	-2,	or	that	our	assay	might	not	be	able	to	pick	up	the	
differences.		
	 Idone	et	al.	have	shown	that	SLO-pores	are	removed	from	HeLa	cells	in	<	30	
sec	 (V.	 Idone	 et	 al.,	 2008).	 It	 is	 thus	 feasible	 that	 I	 am	 missing	 the	 crucial	 time	
window	of	pore-removal.	Concordant	with	 results	 from	 Iodine	et	al.,	 in	my	study	 I	
could	 not	 have	 Ca2+	 present	 during	 the	 pore	 perforation	 phase,	 as	 pores	 were	
effectively	removed	and	very	 little	dye	entered	the	cells.	Thus,	my	study	examined	
repair	after	severe	perforation	by	PFTs	in	no-Ca2+	conditions	-	a	condition	that	never	
occurs	in	vivo.	
	 It	is	known	that	the	ESCRT	machinery	is	involved	in	the	process	of	membrane	
repair	after	pore	forming	toxin	injury	(reviewed	in	Andrews	et	al.,	2014	(Andrews	et	
al.,	2014)).	The	ESCRT	machinery	gets	rid	of	the	membrane	pores	by	budding	them	
off	and	shedding	them	into	exosomes	(Jimenez	et	al.,	2014).	The	exosomal	shedding	
induced	 by	 the	 ESCRT	 machinery	 does	 not	 appear	 to	 be	 the	 mechanism	 solely	
responsible	for	recovery	from	pore-forming	toxin	 injury.	Walev	et	al.	were	the	first	
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to	 notice	 in	 1995,	 that	 in	 the	 case	 of	 SLO	 infection,	 shedding	 alone	 could	 not	 be	
responsible	 for	 membrane	 repair.	 When	 studying	 cells	 treated	 with	 low	 doses	 of	
SLO,	 the	 authors	 had	 noticed,	 that	 a	 fraction	 of	 the	 SLO	 would	 be	 shed	 into	 the	
supernatant,	 but	 ~50	 %	 of	 the	 toxin	 would	 remain	 cell-bound	 (Walev,	 Palmer,	
Valeva,	Weller,	 &	 Bhakdi,	 1995).	 The	 authors	 concluded	 from	 those	 experiments,	
that	 shedding	 alone	 could	 not	 explain	 the	 recovery	 from	 SLO-infection.	 A	 more	
recent	study	looking	at	SLO	infection	in	muscle	fibers	has	proposed	the	involvement	
of	 caveolae-induced	 internalisation	 of	 the	 pores	 as	 part	 of	 the	 repair	 mechanism	
(Corrotte	et	al.,	2013).		
	 Together	 these	 findings	 support	 a	 two-component	 repair	 mechanism	 for	
recovery	 from	 SLO-pores:	 1)	 exosomal	 shedding	 and	 2)	 caveolae-mediated	
endocytosis	with	subsequent	lysosomal	degradation.	
	 To	 improve	my	assay	 I	 could	perform	 the	experiment	at	~20°C;	 it	 is	 known	
that	endo-	and	exocytosis	are	significantly	slowed	when	the	temperature	 is	<	37°C	
(Tomoda,	 Kishimoto,	 &	 Lee,	 1989).	 This	 would	 potentially	 give	 us	 enough	 time	 to	
properly	measure	the	dye	uptake	prior	to	pore	removal.	
	
3.1.3. Altered	SLO-induced	Ca2+	flux	kinetics	in	CAPNS1-/-	cells		
I	 also	 investigated	 Ca2+	 flux	 into	 the	 cell	 after	 SLO-treatment	 in	WT	 and	CAPNS1-/-	
HEK293	 cells	 and	 showed	 significant	 differences	 the	 Ca2+	 entry	 kinetics	 after	 SLO	
treatment	 between	 WT	 and	 CAPNS1-/-	 HEK293	 cells	 using	 the	 sensitive	 Ca2+	 dye,	
Fura-2.	
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	 I	 propose	 two	 ways	 that	 my	 data	 may	 be	 interpreted:	 1)	 As	 SLO	 pore	
assembly	 requires	 initial	 binding	 of	 monomers	 to	 cholesterol	 in	 the	 plasma	
membrane	(Dal	Peraro	&	van	der	Goot,	2016),	it	could	be	possible	that	the	lipid	(and	
specifically	 cholesterol)	 composition	 of	 the	 plasma	membrane	 in	CAPNS1-/-	 cells	 is	
different	to	WT	cells.	2)	As	SLO	pores	conduct	Ca2+,	 it	 is	conceivable	that	activated	
calpains	 contribute	 to	 cytoskeletal	 remodelling	 required	 for	 pore	
formation/insertion	into	the	bilayer.	Both	possibilities	are	discussed	below.	
	 	Cholesterol	 hypothesis:	 Calpains-1	and	 -2,	 as	well	 as	 calpain-6	 (Miyazaki	&	
Miyazaki,	 2017),	 and	 calpain-5	 and	 calpain-10	 (Nicholson	 &	 Ferreira,	 2009)	 have	
been	 linked	 to	cholesterol	 regulation	and	metabolism.	Miyazaki	et	al.	 showed	 that	
the	ubiquitous	calpains	are	 involved	 in	the	regulation	of	receptor-mediated	uptake	
of	 low-density	 lipoprotein	 (LDL,	 that	 facilitates	 cholesterol	 uptake)	 and	 cholesterol	
efflux	(Miyazaki	&	Miyazaki,	2017).	It	is	therefore	plausible	that	the	lack	of	calpains-1	
and	 -2	 could	 lead	 to	 less	 cholesterol	 in	 the	 plasma	membrane.	 This	 subsequently	
could	lead	to	reduced	pore-formation,	as	it	is	also	known	that	less	cholesterol	in	the	
membrane	 equates	 to	 reduce	 cholesterol-dependent	 cytolysins	 (CDCs)	 pore	
formation	(Farrand	et	al.,	2015;	Mozola,	Magassa,	&	Caparon,	2014).		
	 To	 test	 this	 theory,	 my	 study	 should	 be	 repeated	 with	 PFTs	 that	 are	 not	
dependent	 on	 cholesterol	 like	 fragaceatoxin	 C	 (FraC)	 or	 α-haemolysin;	 both	 form	
pores	 independently	 of	 cholesterol.	 FraC	 is	 part	 of	 the	 actinoporin	 family	 of	 pore	
forming	 toxins	 and	 preferably	 forms	 pores	 in	 sphingomyelin-rich	 membranes.	 α-
Haemolysin	 uses	 phosphatidylcholine	 to	 initiate	 pore	 formation	 (reviewed	 in	 Dal	
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Peraro	 and	 van	 der	 Goot,	 2016	 (Dal	 Peraro	 &	 van	 der	 Goot,	 2016).	 The	 pore-
formation	and	Ca2+	flux	caused	by	FraC	and	α-Haemolysin	should	therefore	show	no	
significant	differences	between	WT	and	CAPNS1-/-	cells	 if	calpains-1	and	-2	are	only	
influencing	the	cholesterol	content	of	the	membrane.	
	 Cytoskeletal	 remodelling	 for	 pore	 formation	 hypothesis:	 Calpains-1	 and	 -2	
could	 also	 be	 playing	 a	 role	 in	 the	 assembly	 of	 the	 pore.	 If	 this	 is	 the	 case,	 the	
reduced	Ca2+	flux	in	CAPNS1-/-	cells	I	observed	could	be	due	to	a	reduced	number	of	
assembled	 pores	 and	 not	 due	 to	 less	 cholesterol	 in	 the	 membrane.	 To	 test	 this	
hypothesis,	we	could	perform	fractionation	experiments	using	sucrose	gradients	to	
separate	the	proteins	by	size	and	density.	The	fully	assembled	SLO	pores	should	be	
larger	than	SLO	monomers	or	intermediate	pores.	
	 The	overall	findings	of	my	study	to	define	a	possible	role	for	calpains	in	repair	
of	 pores	 paradoxically	 revealed	 that	 lack	 of	 calpains-1	 and	 -2	 render	 the	 cells	 less	
prone	to	perforation	by	SLO.	The	most	likely	explanation	appears	due	to	an	inability	
of	pores	to	form.		
	 If	 the	ubiquitous	calpains	are	 truly	 required	 for	pore	 formation/integration,	
this	 could	 lead	 to	 new	 treatment	 options	 for	 bacterial	 infections,	 and	 calpain	
inhibitors	 are	 already	 in	 clinical	 development	 (Ono,	 Saido,	 &	 Sorimachi,	 2016).	 As	
antibiotics	 are	 the	 treatment	 of	 choice	 for	 most	 bacterial	 infections	 (Huttner,	
Goossens,	Verheij,	Harbarth,	&	consortium,	2010),	more	and	more	bacteria	acquire	
resistance	 to	 commonly	 used	 antibiotics	 (Fischbach	 &	 Walsh,	 2009;	 Woodford	 &	
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Livermore,	 2009).	 Finding	 antibiotic-independent	 treatment	 options	 for	 bacterial	
infections	is	thus	a	goal	for	future	research.		
	 	
3.1.3.1. Calpains-1	 and	 -2	 are	 not	 essential	 for	 the	 recovery	 from	 laser	 ablation	
injury	
To	compare	the	results	obtained	using	scrape	injury	and	PFT	membrane	injury	to	the	
'gold	standard'	of	the	membrane	repair	field,	I	used	the	laser	ablation	injury.	I	used	
FM1-43	 as	 a	 fluorescent	membrane	 probe	 that	 increases	 in	 fluorescence	 intensity	
when	 partitioned	 into	 the	 inner	 lipid	 bilayer.	 We	 then	 measured	 the	 increase	 in	
mean	fluorescence	intensity	(MFI)	at	the	injury	site.	
	 When	 I	 subjected	 HEK293	WT	 and	CAPNS1-/-	 cells	 to	 laser	 injury,	 I	 did	 not	
observe	 significant	 differences	 in	MFI	 after	membrane	 injury	 over	 two	minutes	 of	
measurement.	Looking	at	 the	trend	of	the	graph	however,	 it	appeared	that	maybe	
over	 a	 longer	 time	 frame	 there	 could	 have	 been	 a	 difference	 between	 WT	 and	
CAPNS1-/-	cells.	A	more	rapid	decrease	in	MFI	could	be	observed	in	WT	cells	compare	
to	CAPNS1-/-	cells,	however	this	difference	did	not	show	statistical	significance.		
	 The	 more	 rapid	 decrease	 in	 MFI	 in	 the	 WT	 cells	 could	 have	 been	 due	 to	
differences	 in	 the	 membrane	 distribution	 dynamics	 of	 the	 dye.	 Once	 FM1-43	 is	
membrane-bound,	 cellular	 processes	 like	 endocytosis,	 exocytosis	 and	 exosomal	
shedding	contribute	 to	 its	diminishing	 fluorescent	signal	over	 time.	Calpain	activity	
has	 been	 previously	 linked	 to	 these	 key	 cellular	 processes	 (endocytosis:	 (Jeong,	
Martchenko,	 &	 Cohen,	 2013;	 Rudinskiy	 et	 al.,	 2009),	 exocytosis:	 (Evans	 &	 Turner,	
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2007),	exosomal	shedding:	(Almers,	1994;	Valimaki	et	al.,	2016)).	 It	 is	thus	feasible,	
that	 in	 the	 absence	 of	 calapins-1	 and	 -2,	 the	 removal	 of	 FM1-43	 from	 the	 plasma	
membrane,	and	therefore	the	reduction	of	its	fluorescent	signal,	is	slowed.	
	 For	future	experiments	I	would	extend	the	time	frame	to	10	minutes,	in	the	
hope	to	dissect	potential	differences.	
	
Caveats	of	the	laser	membrane	repair	assay		
The	laser	injury	assay	does	not	come	without	caveats:	Using	the	mean	fluorescence	
intensity	 of	 FM1-43	 as	 an	 outcome	 measure	 does	 not	 really	 measure	 membrane	
repair	directly,	but	rather	receives	information	about	the	amount	of	dye	partitioning	
into	 the	 lipid	 bilayer.	 This	 can	 be	 correlated	with	membrane	 injury,	 as	membrane	
breaches	 that	 fail	 to	 repair,	will	 subsequently	 allow	 for	more	 FM1-43	 to	enter	 the	
cell,	and	be	reflected	in	an	increased	MFI.	However,	it	would	be	desirable	to	have	a	
second	measure	of	membrane	injury,	like	a	Ca2+-indicator	for	example.		
	 Another	 potential	 problem	 with	 the	 laser	 was,	 that	 I	 was	 subjecting	 the	
membrane	to	high	temperatures	at	the	injury	site,	which	often	leads	to	blebbing	of	
the	 plasma	membrane.	 The	moving	 plasma	membrane	made	 it	 difficult	 to	 extract	
data	from	the	injury	site	alone,	as	the	membrane	moved	out	of	the	region	of	interest	
where	the	MFI	is	measured.	Also,	the	cell	morphology	is	important	to	create	a	'right	
amount'	of	injury.	When	plated	onto	normal	dishes	the	cells	are	all	slightly	different	
in	 size	 and	 shape,	making	 it	 difficult	 to	 standardise	 the	 injury	 and	 the	 subsequent	
measurements.	I	tried	to	overcome	this	caveat	by	trypsinizing	and	re-plating	the	cells	
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~1	hour	prior	to	the	experiment,	hoping	the	cells	would	adhere	in	a	similar	fashion	
and	thus	be	similarly	shaped.	This	was	not	always	the	case.	
	 To	overcome	these	caveats	 I	 suggest	 the	use	of	micropattern	 tissue	culture	
dishes	 (e.g.	 from	CYTOO	platesTM)	 for	 future	 experiments.	Micropattern	plates	 are	
prepared	 with	 an	 adhesive	 standardised	 micropattern	 (e.g.	 extracellular	 matrix	
proteins,	PDL	or	others),	forcing	each	cell	to	obtain	the	same	shape.	This	way	I	could	
normalise	 the	 cell	 shape	 and	 standardise	 the	 injury	 site	 to	 generate	 more	
reproducible	membrane	injuries	and	more	quantifiable	data.	 	
	 Table	 3.1	 compares	 the	 three	 different	membrane	 injury	methods	 used	 in	
this	thesis.	
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Table	3.1:	Comparison	of	the	different	membrane	injury	methods	used	
in	this	thesis	
Injury	type	 Mechanical	
scrape	
Laser	 SLO-pore	
forming	toxin	
Size	of	injury	 ~30	-	100	µm	 ~0.3	µm	 30	-	50	nm	
Measurement	 TO-PRO-3	and	PI	
using	the	two-dye	
flow	cytometry	
assay	
FM1-43	
membrane	dye	
and	confocal	
microscopy	
Fura-2	Ca2+-
imaging	using	the	
Flex	station	
Quantification	 High	throughput,	
100,000	-	500,000	
cells	at	a	time.	
Single	cell	
imaging,	
averaging	10	
cells.	
High	throughput,	
~35,000	-	40,000	
cells	per	well	in	a	
96-well	plate.	
Physiological	injury	 No	 No	 Yes	
Caveats	 Relatively	crude	
injury	method	
creating	large	
lesions.	
Heat	from	the	
laser	could	alter	
membrane	
fluidity.	Variable	
cell	shapes	
influence	
reproducibility.	
The	Ca2+-imaging	
measures	the	
pore	forming	
kinetics	rather	
than	the	
membrane	repair	
capacity	of	the	
cells.	
	
3.1.3.2. Differences	in	membrane	dynamics	between	WT	and	CAPNS1-/-	cells	
Despite	 the	 caveats,	 I	 was	 still	 able	 to	 generate	 data	 that	 showed	 significant	
differences	 between	 WT	 and	 CAPNS1-/-	 cells.	 The	 fluorescence	 of	 FM1-43	 in	 the	
cytoplasm	as	well	as	the	opposing	membrane	to	the	injury	site,	displayed	higher	MFI	
readings	from	the	outset	of	the	experiment.		
	 I	propose	several	possibilities	that	could	explain	this	observation:	1)	CAPNS1-
/-	membranes	could	be	leaky;	2)	the	balance	of	endo-	and	exocytosis	could	be	altered	
in	CAPNS1-/-	cells.	I	will	elaborate	on	both	possibilities	below.	
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	 Leakiness	 hypothesis:	 The	 leakiness	 could	 stem	 form	 altered	 membrane	
composition	 and	 would	 be	 in	 concordance	 to	 the	 prior	 discussed	 possibility	 of	
calpains	being	 involved	 in	 the	cholesterol	 regulation	of	 the	membrane.	 It	 is	known	
that	lack	of	cholesterol	leads	to	increased	fluidity	of	the	membrane	that	can	result	in	
leakiness	(Raffy	&	Teissie,	1999).	To	test	this	hypothesis	we	could	use	a	cholesterol	
stain	 like	the	'Amplex®	Red	Cholesterol	Assay	Kit	(A12216,	Thermo	Fisher)	or	filipin	
(Maxfield	 &	 Wustner,	 2012)	 to	 assess	 the	 amount	 of	 cholesterol	 present	 in	 the	
membrane	of	WT	and	CAPNS1-/-	cells.		
	 Balance	of	endo-	and	exocytosis	hypothesis:	As	discussed	above,	calpains	are	
known	to	play	a	role	in	endo-	and	exocytosis	as	well	as	exosomal	shedding	(Almers,	
1994;	Evans	&	Turner,	2007;	Jeong	et	al.,	2013;	Rudinskiy	et	al.,	2009;	Valimaki	et	al.,	
2016)).	 In	 the	 absence	 of	 calpains	 these	 processes	might	 be	 slowed,	 leading	 to	 a	
decrease	in	outward	transport	of	the	dye	and	thus	an	observed	increase	in	MFI.	As	
described	above	for	the	delayed	decrease	in	MFI	over	time	the	elevated	MFI	at	the	
start	 of	 the	 experiment	 could	 be	 explained	 by	 the	 same	 mechanism:	 reduced	
efficiency	of	endosomal	and	exosomal	transport	within	the	cell.		
	
3.2. Ectopic	MyoD-Cre	expression	complicated	our	mouse	studies		
As	global	loss	of	CAPNS1	is	lethal,	I	was	aiming	to	generate	a	skeletal	muscle	specific	
knock-out	 mouse	 model	 to	 study	 the	 effects	 of	 calpains-1	 and	 -2	 on	 muscle	
membrane	 repair	 and	 muscle	 function.	 Unfortunately,	 due	 to	 loss	 of	 Mendelian	
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genetics,	 I	was	 only	 able	 to	 generate	 two	 individual	mice	with	 the	 right	 genotype	
(2/53	CAPNS1PZ/PZ,	MDCTg/WT,	compared	to	13/53).	
	 One	explanation	for	loss	of	Mendelian	genetics	is	the	possibility	of	Cre	being	
present	 during	 gametogenesis.	 During	 murine	 gametogenesis,	 oocytes	 and	
spermatids	are	 syncytial	before	 their	 final	division.	The	oocyte	 remains	arrested	 in	
the	meiotic	prophase	before	its	final	meiotic	division	which	is	triggered	by	hormones	
only	 upon	 fertilisation	 (Handel	 &	 Schimenti,	 2010).	 The	 arrested,	 so-called,	
'secondary	 oocyte'	 is	 connected	 to	 its	 polar	 body.	 As	 the	 cells	 are	 haploid	 at	 this	
stage	 and	 our	 MyoD/Cre	 mouse	 line	 is	 heterozygous,	 the	 polar	 body	 can	 have	 a	
different	genetic	makeup	to	the	oocyte;	in	our	case	it	is	feasible	that	the	polar	body	
carries	MyoD/Cre	and	the	oocyte	carries	the	WT	allele	at	the	MyoD/Cre	locus.		
	 It	 is	known	that	during	gametogenesis	the	regulation	of	gene	expression	via	
methylation	 is	 altered	 (Marchal,	 Chicheportiche,	 Dutrillaux,	 &	 Bernardino-Sgherri,	
2004).	 A	 potential	 burst	 of	 MyoD	 expression	 during	 that	 stage	 of	 gametogenesis	
could	 have	 led	 to	 Cre	 recombinase	 being	 present	 in	 the	 polar	 body.	 As	 the	 polar	
body	is	connected	to	the	secondary	oocyte	it	is	possible	that	Cre	enzyme	has	leaked	
into	the	cytoplasm	of	the	oocyte;	this	could	have	caused	the	recombination	of	the	PZ	
allele.	
	 Similarly,	spermatids	are	connected	via	plasma	bridges	before	they	undergo	
their	 final	 division:	 called	 a	 spermatogenic	 syncytium.	 This	 connection	 allows	 the	
each	developing	spermatid	to	share	cytoplasmic	contents	with	its	neighbouring	cells.	
Thus	 the	 same	phenomena	 could	have	occurred:	 if	 one	 spermatid	 is	 Cre+	 and	 the	
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next	one	is	Cre-,	Cre	enzyme	could	have	leaked	into	the	Cre-	spermatid	causing	Cre	
mediated	recombination	and	subsequent	CAPNS1-excission.	This	would	explain	why	
we	see	PZ	to	P	recombination	in	mice	that	are	Cre	negative.	
	 	Figure	3.1	shows	a	schematic	explanation	of	the	described	possibility.	
				 	
Figure	 3.1:	 MyoD/Cre	 burst	 during	 gametogenesis	 as	 possible	
explanation	 for	 Cre-mediated	 recombination	 in	 Cre-negative	 animals.	
During	mouse	 gametogenesis	 the	 secondary	oocyte	 remains	 connected	
to	the	polar	body	until	fertilisation	occurs.	During	this	syncytial	stage	it	is	
possible	for	the	oocyte	and	the	polar	body	to	share	cytoplasmic	content.	
During	 spermatogenesis	 the	 spermatids	 stay	 connected	 until	 the	 final	
differentiation.	The	cytoplasmic	bridges	connecting	the	spermatids	allow	
for	cytoplasmic	contents	to	be	shared	between	the	spermatids.	The	cells	
are	haploid	at	 this	 stage	and	 the	MyoD/Cre	mouse	 line	we	are	using	 is	
heterozygous.	 Thus	 every	 second	 cell	 would	 be	 MyoD/Cre	 negative,	
carrying	 the	WT	allele	at	 the	MyoD	 locus.	The	MyoD/Cre	negative	cells	
could	 have	 been	 exposed	 to	 Cre	 leaking	 into	 the	 cytoplasm	 from	 their	
neighbouring	cell.	MyoD	should	not	be	expressed	at	this	stage,	but	 it	 is	
known	 that	 during	 gametogenesis	 gene	 regulation	 via	 methylation	 is	
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differently	regulated;	a	burst	of	MyoD	expression	during	gametogenesis	
would	explain	the	PZ	to	P	recombination	we	can	see	in	mice	that	are	Cre	
negative.	
	
The	 Cre	 expression	 during	 gametogenesis	 could	 have	 caused	 lethality	 for	 the	
majority	of	mice	that	were	homozygous	for	the	floxed	CAPNS1	(PZ)	allele.	
	
MyoD	promoter	is	known	to	be	leaky	 	
Another	 problem	with	 using	 the	MyoD	 promoter	was	 that	 it	was	 known	 to	 cause	
ectopic	MyoD	expression	in	vital	tissues	and	organs.	When	Chen	et	al.	developed	the	
MyoD-Cre	mouse	 line,	 the	authors	have	checked	 for	 the	accuracy	of	 the	promoter	
using	 the	 reporter	 gene	 LacZ	 that	 encodes	 for	 the	 enzyme	 β-galactosidase.	 β-
galactosidase	can	be	stained	for	using	X-gal.	Their	results	showed	ectopic	staining	in	
the	developing	mice	at	~E12.5	(embryonic	day)	that	was	restricted	to	a	band	of	cells	
extending	 from	 the	 developing	 ear	 to	 the	 mandible.	 Further	 the	 authors	 have	
observed	ectopic	staining	in	the	liver	as	well	as	on	rare	occasion	in	chondrocytes	and	
osteocytes	at	~E17.5.	In	the	adult	mouse,	the	authors	could	see	single	cells	and	some	
cell-clusters	 positively	 labelled	 for	 Xgal	 in	 the	 heart,	 lung	 and	 in	 the	 blood	 vessels	
(Chen	et	 al.,	 2005).	 It	 is	 known	 that	 in	 rare	 cases	MyoD	 can	be	 expressed	 in	 non-
skeletal	 muscle	 tissues	 and	 this	 mouse	 model	 seems	 to	 be	 consistent	 with	 that	
(Gerhart	et	al.,	2001).		
	 We	had	used	 this	mouse	 line	with	 insight	 from	our	 colleague	A/Prof	Aaron	
Schindeler,	 whose	 team	 in	 the	 adjacent	 laboratory	 had	 successfully	 generated	
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skeletal	muscle	specific	knock-out	mouse	 line	for	neurofibromin1	(NF1)	 (Sullivan	et	
al.,	2014).	As	global	knock-out	of	NF1	 is	also	 lethal	 (Gutmann	&	Giovannini,	2002),	
we	 were	 optimistic	 that	 the	 ectopic	 expression	 of	 the	 Cre	 recombinase	might	 be	
contained	enough	in	order	for	us	to	generate	our	desired	CAPNS1Sk.mscl.-/-	transgenic	
line.	
	
3.2.1. CAPNS1-/-	leads	to	severe	muscular	dystrophy	
At	the	time	we	demonstrated	ectopic	expression	of	the	MyoD-Cre	promoter	limited	
generation	 of	 our	CAPNS1Sk.mscl-/-	 line,	 I	 was	 about	 to	 take	maternity	 leave.	 At	 the	
time	 of	 my	 maternity	 leave,	 we	 had	 generated	 two	 individual	 mice	 that	 were	
CAPNS1Sk.mscl-/-.	Thus,	we	elected	to	age	the	two	CAPNS1Sk.mscl-/-	mice	I	had	derived	to	
~12	months;	 ensuring,	 that	 if	 they	 had	 a	 dystrophy,	 it	 would	 be	 apparent	 at	 this	
older	age.		
	 The	two	CAPNS1Sk.mscl-/-	mice	showed	clear	signs	of	ill	health	and	weight	loss	
from	~six	months,	 and	were	humanely	 sacrificed	at	 ~12	months.	Histopathological	
analyses	 (performed	 by	 Honours	 student	 Omar	 Saleh)	 confirmed	 both	 mice	
displayed	a	 severe	muscular	dystrophy,	with	marked	variation	 in	 fiber	 size,	 central	
nucleation	of	~40-50	%	of	fibers	and	severe	fibrotic	and	fatty	infiltrate	(Figure	2.28).	
The	dystrophy	was	so	striking	that	the	team	decided	to	 further	pursue	this	project	
via	derivation	of	an	alternate	conditional	limb-specific	CAPNS1-/-	transgenic	line.	The	
change	 in	 breeding	 strategy	 has	 been	 successfully	 planned	 and	 executed	 by	 Dr	
Lemckert.		
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	 The	 team	 choose	 the	 Prx-Cre	 transgenic	mouse	 line	 (Logan	 et	 al.,	 2002)	 to	
cross	with	our	floxed	CAPNS1	'PZ	line'	in	order	to	achieve	limb	specific	knock-out	of	
CAPNS1.	 Prx	 stands	 for	 'paired-related	 homeobox	 gene-1'	 (formerly	 known	 as	
'MHox1')	and	is	expressed	in	the	early	limb	bud	mesenchyme	from	mid-gestation	in	
mice	(Cserjesi	et	al.,	1992).	The	tissues	that	the	 limb	bud	mesenchyme	will	mature	
into	 include:	 skeletal	 muscle,	 bone	 and	 cartilage.	 After	 successful	 breeding,	 all	 of	
these	tissues	will	be	CAPNS1-/-.	
	 To	 date	 the	 team	 has	 been	 able	 to	 generate	 offspring	 with	 the	 correct	
genotype	that	are	CAPNS1-/-	in	the	limbs.	This	mouse	model	will	now	be	analysed	by	
the	next	PhD	student.	
	 	
	
	
	
	
	
	
		
	
166	
	
	
	
	
The	enzymatic	cleavage	of	myoferlin	
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 Chapter	4: 	Introduction	-	The	enzymatic	cleavage	
of	myoferlin		
	
Following	 the	 discovery	 that	 dysferlin	 is	 cleaved	 by	 calpains,	 in	 response	 to	
membrane	 injury,	 I	 decided	 to	 ascertain	 if	 the	 cleavage	 of	 myoferlin	 was	 also	
dependent	 on	 calpains-1	 and	 -2.	 Our	 team	 already	 knew	 that	myoferlin	 could	 be	
cleaved	by	calpains	in	vitro	(Redpath	et	al.,	2014),	but	I	wanted	to	know	if	myoferlin	
cleavage	actually	happens	in	response	to	Ca2+-signalling	in	the	cell.		
	 My	 initial	hypothesis	was	that	myoferlin	would	be	cleaved	 in	the	same	way	
dysferlin	is	cleaved,	and,	that	mini-myoferlin	might	function	as	a	C-terminal	effector	
module,	 similar	 to	 mini-dysferlin.	 But	 the	 cleavage	 of	 myoferlin	 turned	 out	 to	 be	
much	 more	 complex	 than	 the	 cleavage	 of	 dysferlin,	 and	 therefore	 this	 project	
developed	from	a	sub-aim	into	a	main	thesis	chapter.		
	
4.1. Myoferlin	
Myoferlin	has	briefly	been	introduced	before	as	part	of	the	ferlin	family	in	Chapter1,	
section	1.5.	Herein	 I	will	discuss	myoferlin	 in	more	detail	 in	 the	 context	of	 cancer,	
endocytosis	and	cell	signaling.	
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4.1.1. Myoferlin	gene	and	transcripts	
Myoferlin	 is	 the	 third	member	 of	 the	 ferlin	 family	 and	 is	 also	 known	 as	 Fer1	 like	
protein	 3	 (Fer1L3).	 The	 myoferlin	 gene	 (MYOF)	 (Gene	 identifier	
ENSG00000138119.12)	 is	 located	on	 chromosome	10	 (10q23.33,	 chr10:	 95066186-
95242074)	(ensembel.org)	(see	Figure	4.1	below).	
	
 
Figure	 4.1:	Myoferlin	 gene	 on	 human	 chromosome	 10.	The	 red	arrow	
indicates	the	location	of	myoferlin	at	10q23.33	(wikimedia.org/2017).	
	
Myoferlin	isoform	1	contains	59	exons	(gtexportal.org)	and	has	a	transcription	length	
of	 6719	 base	 pairs	 and	 a	 translation	 length	 of	 2061	 amino	 acids	 (ensemble.org).	
Figure	 4.2,	 below,	 shows	 the	 expression	 of	 the	 myoferlin	 gene	 in	 a	 selection	 of	
human	 tissues	 in	 'Reads	Per	Kilobase	Million'	 (RPKM)	 (gtexportal.org).	 The	bladder	
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has	the	highest	myoferlin	gene	expression	and	the	brain,	testes	and	skeletal	muscle	
show	 only	 a	 relatively	 low	 expression	 of	 the	 myoferlin	 gene.	 The	 myoferlin	 gene	
encodes	for	11	isoforms	according	to	the	GTEx	database.		
	
	
Figure	 4.2:	 Myoferlin	 gene	 expression	 in	 human	 tissues.	 Box	 and	
whisker	plots	of	myoferlin	gene	expression	in	different	human	tissues	in	
ascending	 order	 in	 RPKM	 ('Reads	 Per	 Kilobase	Million').	 The	median	 is	
indicated	 as	 a	 black	 line.	 The	 sample	 number	 varies	 from	 five	 to	 ~285	
individuals	(gtexportal.org).	
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4.1.2. Myoferlin	protein	structure	
The	 general	 structure	 of	 the	 ferlins	 has	 been	 previously	 discussed	 in	 Chapter1,	
section	 1.5.	 Hereunder	 I	 would	 like	 to	 revisit	 the	 myoferlin	 protein	 structure,	
indicating	 the	 antibody-binding	 sites	 of	 the	 two	 main	 anti-myoferlin	 antibodies	 I	
have	used	in	my	thesis.	Figure	4.3	shows	myoferlin	isoform	1	(Q9NZM1)	(generated	
using	DOG	1.0	 (Ren	 et	 al.,	 2009)).	 The	N-terminal	 (7D2)	 and	 the	 C-terminal	 (K-16)	
anti-myoferlin	antibodies	are	indicated	as	black	lines.		
	
	
Figure	 4.3:	 Myoferlin	 domain	 structure.	 Based	 on	 predicted	 domains	
from	B.	Sutton	(DOG	1.0	(Ren	et	al.,	2009))	based	on	myoferlin	isoform	1,	
Q9NZM1,	ENST00000359263.	Purple	are	 the	C2	domains,	 turquoise	 the	
FerA	and	DysF	domains	and	TM	is	the	trans-membrane	domain.	The	two	
main	 antibodies	 against	 myoferlin	 used	 in	 this	 study	 are	 indicated	 as	
black	 lines	 (7D2	 from	 abcam,	 aa300-400	 and	 K-16	 from	 Santa	 Cruz,	
aa1550-1600).	
	
Myoferlin	 encodes	 for	 seven	 C2	 domains	 (Ca2+-regulated	 lipid	 binding	 domains),	 a	
FerA	and	a	DysF	domain	and	a	C-terminally	anchored	transmembrane	domain	(TM).	
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4.1.3. Myoferlin	function	
C2	domain-containing	proteins	often	play	roles	in	membrane	fusion	events	and	the	
ferlins	 are	 generally	 implicated	 in	 a	 variety	 of	 vesicle	 fusion	 events	 (as	 discussed	
above	 in	 section	 1.4).	Myoferlin	 is	 involved	 in	 a	 variety	 of	 cellular	 processes	 that	
require	 vesicle/membrane	 fusion	 e.g.	 endocytosis,	 myoblast	 fusion,	 growth	 factor	
receptor	 recycling	 and	 endothelial	 cell	 membrane	 repair	 (Bernatchez	 et	 al.,	 2007;	
Bernatchez,	Sharma,	Kodaman,	&	Sessa,	2009;	Cipta	&	Patel,	2009;	Davis,	Delmonte,	
Ly,	 &	 McNally,	 2000;	 Demonbreun,	 Posey,	 et	 al.,	 2010;	 Doherty	 et	 al.,	 2005).	
Myoferlin	has	been	 found	 to	be	upregulated	 in	 regenerating	myofibers	where	 it	 is	
suspected	 to	 play	 a	 role	 in	 the	 fusion	 of	 activated	 satellite	 cells	 to	 the	 injured	
myofibers	(Doherty	&	McNally,	2003).		
	
4.1.3.1. Myoferlin	in	endocytosis	
Several	 studies	 show	 myoferlin	 regulates	 growth	 factor	 receptor	 recycling	 and	
endocytosis	(Bernatchez	et	al.,	2007;	Bernatchez	et	al.,	2009;	Demonbreun,	Lapidos,	
et	al.,	2010;	Fahmy	et	al.,	2016;	Turtoi	et	al.,	2013).		
	 Myoferlin	was	first	linked	to	endocytosis	by	Doherty	et	al.	in	2008.	Here	the	
authors	showed	that	myoferlin	 interacts	with	the	endocytic	recycling	protein	EDH2	
that	 is	 specifically	 involved	 in	 the	 clathrin-independent	 endocytosis	 pathways	
(Moren	 et	 al.,	 2012).	 Doherty	 et	 al.	 demonstrated,	 using	 a	 myoferlin	 knock-out	
mouse	model	that	the	absence	of	myoferlin	slows	down	endocytosis	(Doherty	et	al.,	
2008).	 Bernatchez	 et	 al.	 proposed	 a	 role	 for	 myoferlin	 in	 caveolin-dependent	
endocytosis	 in	 endothelial	 cells	 (Bernatchez	 et	 al.,	 2009).	 Demonbreun	 et	 al.	
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subsequently	 showed	 that	 if	myoferlin	 is	 present	 at	 the	plasma	membrane,	 ligand	
bound	 growth	 receptors	 are	 more	 likely	 to	 be	 recycled	 back	 to	 the	 plasma	
membrane	after	internalisation.	When	myoferlin	is	not	present,	receptors	are	more	
likely	to	travel	down	the	lysosomal	degradation	pathway	(Demonbreun,	Lapidos,	et	
al.,	2010).	Figure	4.4,	below,	shows	a	model	of	the	role	of	myoferlin	in	growth	factor	
receptor	recycling	that	Demonbreun	et	al.	developed.	
	
	
Figure	 4.4:	Model	 for	 the	 role	 of	myoferlin	 in	 growth	 factor	 receptor	
recycling	 and	 endocytosis.	 A.	 Upon	 ligand	 binding,	 growth	 factor	
receptors	are	internalized,	trafficked	down	the	recycling	endosome.	With	
myoferlin	the	receptor	containing	vesicles	are	more	likely	to	be	shuttled	
back	 to	 the	 plasma	membrane	 where	 they	 undergo	 further	 rounds	 of	
ligand	 binding	 and	 thereby	 initiate	 subsequent	 signaling	 cascades.	 This	
	 173	
can	lead	to	potential	signal	amplification.	B.	In	the	absence	of	myoferlin	
at	 the	 surface,	 the	 receptors	 are	 more	 likely	 to	 be	 trafficked	 to	 the	
lysosome	 where	 they	 are	 degraded	 and	 thus	 not	 able	 to	 undertake	
further	rounds	of	signaling	(Demonbreun,	Posey,	et	al.,	2010).	
	
The	different	types	of	endocytosis	
Myoferlin	 seems	 to	 be	 involved	 in	 the	 clathrin-independent,	 caveolin-dependent	
form	of	endocytosis.	Below	will	briefly	introduce	the	different	forms	of	endocytosis.	
	 Generally	 endocytosis	 is	 a	 form	 of	 transport	 into	 the	 cell,	 by	 actively	
engulfing	 substances	 and/or	 particles	 from	 the	 outside	 of	 the	 cell	 and	 actively	
transporting	 them	 to	 the	 inside	 of	 the	 cell.	 There	 are	 multiple	 pathways	 of	
endocytosis	 into	 cells,	 with	 three	 sub-classifications	 being:	 clathrin-dependent,	
caveolin-dependent	and	clathrin-	and	caveolin-	independent	endocytosis.	These	are	
further	described	below	in	see	Figure	4.5	(McMahon	&	Boucrot,	2011).	
	
1)	 Clathrin-dependent	 endocytosis	 (CME)	 is	 the	 best-characterized	 form	 of	
endocytosis	and	was	 first	described	 in	detail	over	50	years	ago	by	Roth	and	Porter	
(Roth	&	Porter,	1964).	CME	happens	via	the	formation	of	clathrin-coated	pits	(CCPs)	
and	clathrin-coated	vesicles	(CCVs).	The	GTPase	dynamin	is	essential	for	this	form	of	
endocytosis	(Mettlen,	Pucadyil,	Ramachandran,	&	Schmid,	2009).	
	
2)	Caveolin-dependent	endocytosis	(CavME)	was	first	described	in	1955	by	Yamada	
(E.	Yamada,	1955)	and	has	been	studied	in	great	detail.	CavME	has	been	found	to	be	
an	 essential	 process	 for	 mechanosensing,	 transcytotic	 trafficking	 as	 well	 as	 lipid	
regulation	 (Parton	 &	 Simons,	 2007).	 Dynamin	 is	 also	 required	 for	 this	 form	 of	
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endocytosis.	This	 is	 the	type	of	endocytosis	 that	myoferlin	seems	to	be	 involved	 in	
(Bernatchez	et	al.,	2007;	Bernatchez	et	al.,	2009;	Demonbreun,	Lapidos,	et	al.,	2010;	
Fahmy	et	al.,	2016;	Turtoi	et	al.,	2013).		
	
3)	Clathrin-	and	caveolin-independent	endocytosis	(CIE).		
There	are	several	pathways	included	in	the	term	CIE.	These	include	the	endophilin-,	
dynamin-	 and	 the	RhoA-dependent	 (Lamaze	et	 al.,	 2001),	 and	 the	Arf6-dependent	
pathways.	The	latter	was	first	described	as	mediating	the	uptake	and	recycling	of	the	
major	histocompatibility	antigen	1	(Donaldson	&	Jackson,	2011).	Another	of	the	CIE	
pathways,	 one	more	 recently	 discovered	CIE	 pathways	 is	 the	 'CLIC/GEEC	 pathway'	
which	 leads	 to	 the	 actin-dependent	 formation	 of	 'Clathrin-Independent	 Carriers'	
(CLICs)	 (Soldati	 &	 Schliwa,	 2006).	 The	 CLICs	 then	 fuse	 to	 form	 a	 specialized	 early	
endosomal	 compartment	 called	 'GPI-Enriched	 Endocytic	 Compartments'	 (GEECs)	
(Kirkham	et	al.,	2005).	
	 For	all	 forms	of	endocytosis	 the	cargo	gets	 internalized	and	shuttled	 to	 the	
endosomes.	 Here	 the	 cargo	 gets	 sorted	 and	 directed	 to	 different	 subcellular	
destinations,	 is	 recycled	 back	 to	 the	 plasma	 membrane,	 or	 directed	 to	 late	
endosomal	 compartments	 like	 the	 multivesicular	 bodies	 (MVBs)	 or	 lysosomes	
(McMahon	&	Boucrot,	2011).		
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Figure	4.5:	Different	 forms	of	endocytosis.	Schematic	showing	clathrin-
dependent	 endocytosis,	 clathrin-independent	 endocytosis	 (CIE)	 and	
caveolin-dependent	 endocytosis.	 This	 image	 is	 reproduced	 from	
Johannes	et	al.,	2015	(Johannes,	Parton,	Bassereau,	&	Mayor,	2015).	
	
4.2. Myoferlin	in	cancer	 	
Variants	in	the	myoferlin	gene	(MYOF)	are	not	linked	to	inherited	disease,	however,	
there	 is	growing	evidence	that	 links	the	expression	of	myoferlin	mRNA	and	protein	
to	 the	metastatic	 potential	 of	 cancer	 cells.	 In	 breast	 cancer	 and	 renal	 cell	 cancer,	
myoferlin	mRNA	expression	 is	upregulated	by	at	 least	 two-fold	 (in	at	 least	20	%	of	
the	tumour)	compared	to	the	highest	expression	levels	in	control	tissue	(Amatschek	
et	al.,	2004).		
	
Myoferlin	as	a	marker	for	aggressive	pancreatic	adenocarcinoma	
Myoferlin	 protein	 levels	 are	 significantly	 upregulated	 in	 high-grade	 pancreatic	
adenocarcinoma	 compared	 to	 low-grade	 pancreatic	 adenocarcinoma	 or	 adjacent	
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non-tumorous	 tissue,	 making	 it	 a	 potential	 prognostic	 readout	 for	 pancreatic	
adenocarcinoma	(see	Figure	4.6,	(W.-S.	Wang	et	al.,	2013)).		
	
	
Figure	4.6:	Myoferlin	in	pancreatic	cancer.	Western	blot	analysis	shows	
increased	myoferlin	expression	in	high-grade	pancreatic	adenocarcinoma	
compared	 to	 low-grade	pancreatic	 adenocarcinoma	or	 adjacent	 control	
tissue.	This	figure	 is	reproduced	from	Wang	et	al.,	2013	(W.-S.	Wang	et	
al.,	2013).	
	
	
Myoferlin	is	upregulated	in	breast	cancer	
In	 tissues	 from	 patients	 with	 breast	 ductal	 adenocarcinoma	 and	 breast	 lobular	
carcinoma,	myoferlin	 levels	 are	also	elevated	 compared	 to	adjacent	 control	breast	
tissue	 (see	 Figure	 4.7,	 below)	 further	 establishing	 that	myoferlin	 expression	might	
correlate	with	 the	 transition	 from	healthy	 tissue	 to	malignant,	 proliferative	 cancer	
tissue.	 Figure	 4.7,	 below,	 shows	 the	 western	 blot	 from	 the	 study	 undertaken	 by	
Turtoi	 et	 al.	 (Turtoi	 et	 al.,	 2013),	 showing	 the	 upregulation	 of	myoferlin	 in	 breast	
cancer	samples.		
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Figure	 4.7:	 Myoferlin	 protein	 in	 breast	 cancer	 samples.	Western	 blot	
analysis	 shows	 increased	 myoferlin	 protein	 expression	 in	 breast	
adenocarcinoma	 and	 breast	 lobular	 carcinoma	 compared	 to	 adjacent	
control	tissue.	This	image	is	reproduced	from	Turtoi	et	al.,	2013	(Turtoi	et	
al.,	2013).	
	
	
Myoferlin	knockdown	leads	to	reduced	tumour	burden	in	mice		
The	 role	 of	 myoferlin	 in	 cancer	 is	 further	 highlighted	 by	 studies	 that	 use	 siRNA	
against	 myoferlin	 injected	 into	 murine	 tumours	 grown	 from	 Lewis	 lung	 cells	
implanted	 into	 the	 backs	 of	 C57BL/6	 mice.	 The	 tumours	 with	 lowered	 myoferlin	
protein	 levels	 reduced	 in	 size	 by	 almost	 50	%	 compared	 to	 tumours	 injected	with	
control	 siRNA	 (Leung,	 Yu,	 Lin,	 Tognon,	 &	 Bernatchez,	 2013).	 Further,	 lowering	
myoferlin	protein	 levels	by	shRNA	knock	down	 in	MDA-MB-231	breast	cancer	cells	
reduces	 cell	migration	 velocity,	 increases	 substrate	 adhesion,	 and	when	 implanted	
into	 mice	 to	 form	 tumours,	 reduced	 myoferlin	 expression	 in	 MDA-MB-231	 cells	
correlates	with	a	 reduced	 risk	of	 cells	 escaping	 the	primary	 tumour	 (Volakis	 et	 al.,	
2014).		
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	 Thus,	 collective	 links	 myoferlin	 to	 cancer	 cell	 progression	 and	 metastasis	
formation,	with	the	underlying	mechanism	still	to	be	fully	understood.		
	
4.3. 	The	enzymatic	cleavage	of	myoferlin		
My	interest	in	myoferlin	was	piqued	by	reports	showing	myoferlin	as	a	doublet	band	
when	detected	with	N-terminal	antibodies	by	western	blot	(Balasubramanian	et	al.,	
2014;	Fahmy	et	al.,	2016;	Leung	et	al.,	2013;	Li	et	al.,	2012).	This	is	reminiscent	of	the	
N-terminal	 calpain-cleavage	 fragment	 we	 observe	 for	 dysferlin	 (Lek	 et	 al.,	 2013;	
Redpath	et	al.,	2014).		
	 A	 former	 colleague	 Dr	 Redpath,	 conducted	 calpain	 in	 vitro	 cleavage	 assays	
using	 HEK293	 cells	 overexpressing	 myoferlin,	 dysferlin	 and	 otoferlin.	 The	 results	
showed	that	all	three	ferlins	could	be	cleaved	by	calpains-1	and	-2	in	vitro	to	release	
a	 C-terminal	 'mini-ferlin'	 fragment	 of	 ~70-80	 kDa	 and	 an	 N-terminal	 'counter	
fragment'	(Redpath	et	al.,	2014).	Figure	4.8,	below,	shows	Dr	Redpath's	western	blot	
analysis	of	the	in	vitro	calpain	cleavage	assay	performed	on	dysferlin,	myoferlin	and	
otoferlin	(Redpath	et	al.,	2014).	
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Figure	 4.8:	 In	 vitro	 calpain	 cleavage	 of	 dysferlin,	 otoferlin	 and	
myoferlin.	 Western	 blot	 analysis	 of	 HEK293	 cells	 overexpressing	
dysferlin,	otoferlin	and	myoferlin	subjected	to	in	vitro	calpain	cleavage.	A	
C-terminal	 'mini-ferlin'	 as	 well	 as	 an	 N-terminal	 counter	 fragment	 is	
released	 as	 a	 result	 of	 calpain	 cleavage.	 The	 top	 panel	 shows	 the	 C-
terminal	 mini-ferlin	 fragment	 as	 well	 as	 the	 full-length	 protein.	 The	
molecular	weight	of	mini-dysferlinC72	is	 ~72	kDa,	mini-otoferlin	~85	kDa	
and	mini-myoferlin	~80	kDa.	The	bottom	panel	shows	the	corresponding	
N-terminal	cleavage	products	as	well	as	 the	 full-length	proteins.	The	N-
terminal	 cleavage	 product	 of	 dysferlin	 has	 a	molecular	weight	 of	 ~165	
kDa.	The	N-terminal	cleavage	product	of	otoferlin	appears	to	be	cleaved	
further,	 releasing	more	N-terminal	 protein	 fragments	 running	 at	 ~	 150	
and	120	kDa.	The	mini-myoferlin	counter	fragment	runs	at	~155	kDa.	This	
image	is	reproduced	from	Redpath	et	al.,	2014	(Redpath	et	al.,	2014).	
	
For	dysferlin,	our	team	knows	that	calpains	are	the	enzymes	responsible	for	cleaving	
dysferlin	 in	 situ,	 in	 response	 to	membrane	 injury	 (Lek	 et	 al.,	 2013;	 Redpath	 et	 al.,	
2014).	 I	 therefore	 also	 investigated	 calpains	 as	 possible	 candidates	 for	 myoferlin	
cleavage	as	well.		
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4.3.1. Calpains		
I	have	previously	introduced	calpains	and	their	role	in	membrane	repair	in	Chapter	1,	
section	1.6.	In	the	following	paragraphs	I	am	going	to	give	a	detailed	overview	of	the	
role	 of	 the	 ubiquitous	 calpains	 in	 cancer.	 The	 involvement	 of	 calpains-1	 and	 -2	 in	
cancer	was	the	reason	for	me	to	pursue	them	as	candidates	for	myoferlin	cleavage.	
	
Calpains	in	cancer	
Calpains	 were	 first	 investigated	 in	 the	 context	 of	 cancer	 by	 Shiba	 et	 al.	 in	 breast	
cancer	tissue	(Shiba	et	al.,	1996).	Since	then	numerous	studies	have	been	conducted	
investigating	 the	 roles	 of	 calpains	 in	 cancer.	 It	 has,	 for	 example,	 been	 shown	 that	
calpain	activity	is	altered	to	facilitate	tumorigenesis	(Storr	et	al.,	2011).	High	levels	of	
calpain-1	and	-2	were	observed	in	triple	negative	invasive	breast	cancers	(Storr	et	al.,	
2012).	 Further	 the	 expression	 of	 calpain-1,	 -2	 and	 -9	 was	 associated	 with	 poor	
clinical	 outcomes	 in	 patients	 suffering	 from	 gastro-oesophageal	 adenocarcinoma	
(Storr	et	al.,	2013).	Calpain-1	protein	was	shown	to	be	upregulated	in	schwannomas	
and	meningiomas	 (Kimura	et	 al.,	 1998),	 and	 increased	expression	of	 calpain-2	was	
observed	in	colorectal	adenocarcinomas	(Lakshmikuttyamma,	Selvakumar,	Kanthan,	
Kanthan,	&	Sharma,	2004).	Further	calpain-1	mRNA	was	found	to	be	upregulated	in	
renal	 cell	 carcinoma	 (Braun	 et	 al.,	 1999).	 For	 an	 in-depth	 review	 on	 the	 role	 of	
calpain	 in	 cancer	 see	 the	Nature	Review	 'The	 calpain	 system	and	 cancer'	 by	 Sarah	
Storr	et	al.,	2011	(Storr	et	al.,	2011).	
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Synopsis	
In	 cancer	 a	 lot	 of	 the	 normal	 cellular	 processes	 are	 hyperactive	 and	 escape	 the	
normal	control	mechanisms	leading	to	uncontrolled	cell	divisions,	cell	migration	and	
tumour	growth.	One	major	signalling	pathway	shown	to	be	in	overdrive	in	cancer	is	
the	 MAPK	 (Mitogen-activated	 protein	 kinase)/ERK	 (extracellular	 signal-regulated	
kinase)	 pathway	which	 is	 important	 for	 cell	 division,	 growth,	 proliferation	 and	 cell	
survival	(Dhillon,	Hagan,	Rath,	&	Kolch,	2007).		
	 During	 my	 studies	 I	 found	 a	 link	 between	 myoferlin	 cleavage	 and	 the	
MAPK/ERK	pathway.	When	myoferlin	 is	cleaved,	 it	appears	that	phosphorylation	of	
the	 downstream	 target	 ERK	 is	 increased,	 suggesting	 increased	 signaling	 activity	 of	
the	 MAPK/ERK	 pathway.	 This	 is	 a	 potential	 new	 role	 for	 myoferlin	 and	 links	 the	
cleavage	of	myoferlin	to	one	of	the	major	signalling	pathways	in	the	cell.	The	MAPK	
pathway	will	now	be	considered	in	more	detail.	
	
4.3.2. The	Mitogen-activated	kinase	(MAPK)	pathway	
The	MAPK	pathway	is	a	fundamental	signaling	pathway	within	the	cell	that	facilitates	
signal	 transduction	 from	 the	 cytoplasm	 or	 cell	 surface	 to	 the	 nucleus	 to	 regulate	
gene	expression	 (Dhillon	et	 al.,	 2007).	 The	MAPK	pathway	 is	 a	 complex	 regulatory	
network	 that	 directs	 important	 processes	 such	 as	 cell	 proliferation,	 cell	 death,	
adhesion	and	differentiation	(Wang	et	al.,	2007).		
	 The	MAPK	pathway	is	a	three-tier	protein	kinase	pathway	that	is	activated	via	
phosphorylation	and	regulates	a	variety	of	 substrates	 like	 transcription	 factors	and	
other	 protein	 kinases	 (D.	 Wang,	 Boerner,	 Winkler,	 &	 LoRusso,	 2007).	 Figure	 4.9,	
below,	illustrates	the	general	three-tired	outline	of	the	MAPK/ERK	pathway.	
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Figure	4.9:	General	outline	of	the	MAPK	pathway.	Upon	ligand	binding,	
the	 growth	 factor	 receptor	 gets	 autophosphorylated	 and	 starts	 the	
signaling	cascade	 through	 the	GRB2/SOS	complex	 that	causes	GDP/GTP	
exchange	 of	 Ras.	 Ras	 then	 phosphorylates	 Raf	 (MAPKKK),	 Raf	
phosphorylates	 MEK	 (MAPKK)	 and	 finally	 ERK	 (MAPK)	 gets	
phosphorylated	by	MEK	and	 is	able	to	activate	a	nuclear	response.	This	
image	is	reproduced	from	Kim	and	Bar-Sagi,	2004	(Kim	&	Bar-Sagi,	2004).	
	
4.3.2.1. Signal	transduction	of	the	MAPK	pathway	
Upon	 ligand	binding	 to	growth	 factor	 receptor	 tyrosine	kinases,	 the	kinase	domain	
becomes	 activated,	 leading	 to	 autophosphorylation	 on	multiple	 tyrosine	 residues.	
Signal	 proteins	 containing	 SH2	 domains	 (such	 as	 GRB2)	 bind	 the	 phosphorylated	
receptor	and	 initiate	multiple	 signaling	cascades.	SOS	 (son	of	 sevenless)	 complexes	
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with	GRB2	and	catalyzes	the	GDP/GTP	exchange	of	Ras.	Ras	then	phosphorylates	the	
MAP	 kinase	 kinase	 kinase	 (MAPKKK,	 Raf),	 which	 phosphorylates	 the	 MAP	 kinase	
kinase	 (MAPKK,	 MEK).	 This	 subsequently	 phosphorylates	 the	 MAP	 kinase	 (MAPK,	
ERK)	 ('three-tier	 process').	 Activated	 ERK	 can	 then	 activate	 transcription	 factors	 to	
generate	 a	 nuclear	 response	 by	 activating	 particular	 gene	 transcription	 or	 other	
kinases	(Figure	4.9).		
	
4.3.2.2. The	MAPK	pathway	in	cancer	
Maintaining	 balanced	 levels	 of	 activating	 and	 inhibiting	 signals	 within	 the	 MAPK	
pathway	 is	 essential	 for	 normal	 cell	 function.	 Constitutive	 activation	 of	 the	MAPK	
pathway,	 for	 example,	 by	 mutations	 or	 over	 amplification	 of	 genes	 encoding	
proteins	 involved	 in	 the	MAPK	pathway,	 can	 lead	 to	uncontrolled	cell	proliferation	
and	resistance	to	apoptotic	cell	death.	This	can	lead	to	malignant	transformation	and	
tumorigenesis	(Roberts	&	Der,	2007).		
	 Inappropriate	 activation	 of	 the	 MAPK	 pathway	 has	 been	 associated	 with	
different	types	of	cancers	(Sebolt-Leopold	&	Herrera,	2004).	The	abnormal	activation	
of	 the	 epidermal	 growth	 factor	 receptor	 (EGFR),	 via	 EGFR	 protein	 overexpression,	
EGFR	gene	amplification,	or	acquisition	of	activating	mutations	and	overexpression	
of	 EGFR	 ligands,	 commonly	 occurs	 in	 different	 cancer	 types	 (e.g.	 colorectal-,	
pancreatic-,	 lung-	and	non-small	 cell	 lung	cancer,	breast	cancer,	gastric	cancer	and	
others)	(Baselga	&	Arteaga,	2005)	(Roberts	&	Der,	2007).		
	 Figure	 4.10,	 below,	 shows	 an	 illustration	 of	 the	 different	mutations	 in	 genes	
encoding	for	proteins	that	are	functioning	in	the	MAPK	pathway	and	that	have	been	
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linked	to	particular	cancer	subtypes.		
	 	
	
Figure	 4.10:	Activation	of	 the	MAPK/ERK	 cascade	by	oncogenes.	Here	
using	the	epidermal	growth	factor	receptor	(EGFR)	as	an	example.	Upon	
ligand	 (e.g.	 TGFα	 or	 EGF)	 binding	 the	 EGF	 receptor	 tyrosine	 kinase	 is	
activated	 leading	 to	 receptor	 autophosphorylation	 on	multiple	 tyrosine	
residues.	Signal	proteins	containing	SH2	domains	(such	as	Grb2)	bind	the	
phosphorylated	 receptor	 and	 initiate	 multiple	 signaling	 cascades.	 SOS	
(son	 of	 sevenless)	 complexes	 with	 Grb2	 and	 catalyses	 the	 GDP/GTP	
exchange	 of	 Ras.	 Ras	 then	 phosphorylates	 MAP	 kinase	 kinase	 kinase	
(MEKKK	 or	 Raf),	 which	 phosphorylates	 the	 MAP	 kinase	 kinase	 (MEK)	
which	then	phosphorylates	the	MAP	kinase	(ERK).	Activated	ERK	can	then	
activate	transcription	factors.	Mutations/overexpression	of	genes	in	this	
cascade	 are	 involved	 in	 a	 variety	 of	 cancers	 and	 are	 indicated	 at	 each	
step.	 This	 image	 is	 reproduced	 from	Roberts	 and	Der,	 2007	 (Roberts	&	
Der,	2007).		
	
4.3.2.3. The	MAPK	pathway	as	a	target	for	anti-cancer	drug	development	
The	hyperactive	MAPK	pathway	has	been	shown	to	be	an	effective	drug	target	 for	
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treatment	 of	 a	 variety	 of	 different	 cancers	 (M.	 P.	 Smith	 &	 Wellbrock,	 2016).	
Promising	clinical	trials	have	been	conducted	that	target	the	MAPK	pathway	and	aim	
to	suppress	tumour	growth	and	induce	apoptosis	of	cancerous	cells	(D.	Wang	et	al.,	
2007).		
	 For	 instance,	 MEK1	 and	 MEK2	 have	 been	 successfully	 targeted	 using	 small	
compounds	 like	 'PD184352'	 that	 resulted	 in	 growth	 inhibition	 in	 colorectal	
carcinoma	tumour	xenografts	in	vivo	(Baselga	&	Arteaga,	2005;	Sebolt-Leopold	et	al.,	
1999).	 (For	 a	 comprehensive	 review	 on	MEK	 inhibitors	 see	 Smith	 and	Wellbrock,	
2016	(M.	P.	Smith	&	Wellbrock,	2016).	
	
Rationale	
Dysferlin	 gets	 cleaved	 by	 calpains	 in	 response	 to	 elevated	 [Ca2+]IC	 levels.	 The	
cleavage	is	regulated	by	the	alternately	spliced	exon	40a	(Lek	et	al.,	2013;	Redpath	et	
al.,	 2014).	 We,	 as	 a	 team,	 believe	 that	 the	 released	 mini-dysferlinC72	 bestows	
specialised	functions	in	vesicle	fusion	required	for	membrane	repair.	We	knew	that	
myoferlin	can	also	be	cleaved,	but	how	and	why	was	unknown.	Subsequently,	in	this	
thesis	I	seek	to	answer	the	following	questions:	
1) Does	myoferlin	also	have	an	alternate	exon	that	regulates	its	enzymatic	
cleavage?		
2) What	enzyme	is	cleaving	myoferlin?	
3) What	is	the	possible	function	of	the	released	mini-myoferlin?	
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 Chapter	5: Results	 -	 The	 enzymatic	 cleavage	 of	
myoferlin		
	
Chapter	2	of	this	thesis	is	published	as	(A.	K.	Piper	et	al.,	2017).	I	designed	the	study,	
analysed	the	data	and	wrote	the	drafts	of	the	manuscript.	
 The	key	 findings	of	my	work	on	 the	 'enzymatic	cleavage	of	myoferlin'	were	
published	 in	 Piper	 et	 al.,	 2017	 in	 'Cellular	 Signalling'	 (A.	 K.	 Piper	 et	 al.,	 2017)	
identifying	 the	 cleavage	 of	 myoferlin,	 that	 yields	 a	 membrane-associated	 dual	 C2	
domain	‘mini-myoferlin’.	In	the	next	sections	I	will	recapitulate	the	main	findings	of	
that	paper.	
	
5.1. Piper	et	al.,	2017	-	the	key	findings	
5.1.1. Does	myoferlin	also	have	an	alternate	exon?	 	
The	short	answer	to	this	question	is	yes.	Myoferlin	has	an	alternately	spliced	exon	in	
the	 same	 sequence	 position	 as	 exon	 40a	 in	 dysferlin:	 in	myoferlin	 this	 alternately	
spliced	exon	is	called	exon	38a.	However,	myoferlin	exon	38a	does	not	appear	to	be	
the	preferred	cleavage	site.	Unlike	dysferlin,	myoferlin	bears	two	enzymatic	cleavage	
sites:	a	canonical	cleavage	site	encoded	by	exon	38	at	the	end	of	the	C2DE	domain;	
and	a	 second	 cleavage	 site	 in	 the	 linker	 region	adjacent	 to	C2DE,	 encoded	by	exon	
38a	(see	figure	2,	in	Piper	et	al.,	2017).	
	
	 187	
5.1.2. Both	myoferlin	cleavage	sites	can	function	as	calpain	cleavage	sites	
I	 investigated	 if	 it	was	also	 calpains	 that	 cleave	myoferlin.	 I	 genetically	engineered	
each	 cleavage	 site	of	myoferlin	 into	 the	dysferlin	backbone	and	 shown	 that	 either	
can	functionally	substitute	for	exon	40a	(see	figure	3	and	4	in	Piper	et	al.,	2017).	
	
5.1.3. Is	it	calpains	that	cleave	myoferlin?	
Even	 though	 I	 showed	 that	 both	 myoferlin	 cleavage	 sites	 could	 be	 cleaved	 by	
calpains	 in	vitro,	the	enzymatic	cleavage	of	myoferlin	 in	situ	within	cultured	cells	 is	
not	dependent	on	calpains-1	or	-2.	Using	CRISPR	engineered	CAPNS1	knock-out	cell	
lines	 I	 demonstrated	 that,	unlike	 the	 cleavage	of	dysferlin,	myoferlin	 cleavage	was	
independent	of	calpains-1	and	-2	(see	figure	6,	in	Piper	et	al.,	2017).	Other	candidate	
enzymes	 that	 may	 be	 responsible	 for	 myoferlin	 cleavage	 are	 discussed	 below	 in	
section	6.1.1.	
	
5.1.4. What	is	the	function	of	mini-myoferlin?	
The	 functional	 impact	 of	 myoferlin	 cleavage	 was	 explored	 using	 phospho-protein	
arrays.	I	ectopically	expressed	the	'cleavable'	myoferlin	isoform	1	and	myoferlin38a	in	
HEK293	 cells.	 My	 study	 revealed	 that	 when	 myoferlin	 is	 cleaved,	 the	 signalling	
proteins	 ERK1	 and	 ERK2	 are	 activated,	 detectable	 through	 the	 increased	
phosphorylation	signal	by	western	blot.	This	was	not	the	case	when	myoferlin38a	was	
expressed	 and	 no	 myoferlin	 cleavage	 occurred.	 These	 results	 indicate	 a	 potential	
function	 of	 cleaved	 myoferlin	 in	 cell	 signaling	 that	 results	 in	 increased	 ERK1/2	
phosphorylation	(see	figure	7	in	Piper	et	al.,	2017).	
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1. Introduction
Myoferlin is a member of the ferlin family of Ca2+-regulated vesicle
fusion proteins [1]. In mammals, there are six ferlins: dysferlin (fer1L1),
otoferlin (fer1L2), myoferlin (fer1L3), fer1L4, fer1L5 and fer1L6 [2].
Ferlin proteins have a distinctive structure, with a C-terminal trans-
membrane anchor and 5–7 tandem cytoplasmic C2 domains [2],
which are Ca2+-regulated lipid and protein binding domains [3]. Pro-
teins that bear C2 domains have varied roles, often involving Ca2+-trig-
gered membrane binding events [4]. The ferlins, synaptotagmins,
double C2-like-domain-containing proteins (DOCs), extended synapto-
tagmin-like proteins and synaptotagmin-like proteins (SLPs) are C2 do-
main-containing proteins that have been functionally associated with
vesicle fusion [5]. Mutations in the dysferlin (DYSF) and otoferlin
genes (OTOF) cause inherited disorders in humans linked to defective
vesicle fusion. Mutations in the dysferlin gene cause an inherited late-
onset form of muscular dystrophy [6,7], believed to be partially due to
defective vesicle fusion required formusclemembrane repair [8]. Muta-
tions in otoferlin cause congenital deafness [9,10], due to defective syn-
aptic exocytosis [11] and vesicle replenishment [12] at the ribbon
synapse of the inner ear.
Variants in the myoferlin gene (MYOF) have not been implicated in
inherited disease, however, emerging evidence links the expression of
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myoferlin mRNA and protein to the metastatic potential of cancer cells.
In breast cancer and renal cell cancer, myoferlinmRNA expression is up-
regulated in tumours compared to control tissues [13]. Myoferlin pro-
tein levels are upregulated in high-grade pancreatic adenocarcinoma
compared to low-grade pancreatic adenocarcinoma or adjacent tissue
[14], and myoferlin levels were also elevated in breast ductal adenocar-
cinoma and breast lobular carcinoma, compared to adjacent control
breast tissue [15]. Targeted myoferlin knockdown using siRNA injected
intomurine tumours grown from Lewis lung cells engrafted into C57BL/
6 mice reduced tumour size by almost 50% [16]. Furthermore, shRNA-
mediated myoferlin knock down in MDA-MB-231 breast cancer cells
was associated with reduced cell migration velocity, and increased
cell-matrix and cell-cell interactions in vitro, and reduced proliferation
and localized invasive behaviour in mouse xenografts [17,18].
Thus, emerging evidence implicates myoferlin in cancer progression
and metastasis, with the underlying mechanism still to be elucidated.
Several studies show myoferlin regulates growth factor receptor
recycling and endocytosis [15,19–22]. Altered growth factor signalling
is linked to the progression and pathogenesis of different carcinoma
types [23,24], and tumours often secrete autocrine acting growth factors
[25]. Given the established roles of ferlin proteins in dynamic mem-
brane remodelling, including endocytosis and secretion, it is plausible
that myoferlin regulates signalling events in cancer cells that contribute
to proliferation and metastasis.
Our previous studies demonstrate that dysferlin is cleaved by
calpains-1 and -2 in response to the Ca2+ inﬂux caused by membrane
injury. Calpain cleavage of dysferlin releases a C-terminal fragment of
~72 kDa, mini-dysferlinC72, bearing two C2 domains anchored by the
transmembrane domain, with broad structural homology to the synap-
totagmin family of vesicle fusion proteins [26,27]. As antibodies directed
against N-terminal epitopes are unable to detect dysferlin at injuries
sites, data suggest the C-terminal mini-dysferlinC72 is the species re-
cruited to sites of membrane injury, where it may function as a special-
ized membrane repair module [26,27]. Our previous studies also
demonstrated other ferlin paralogues could be cleaved by calpains in
vitro [27].
Our interest in myoferlin was piqued by reports showing myoferlin
as a doublet band in western blots when detected with N-terminal epi-
tope speciﬁc antibodies [16,28–30]. This was reminiscent of the N-ter-
minal calpain-cleavage fragment we reported for dysferlin [26,27].
Herein, we provide evidence that myoferlin is also proteolytically
cleaved in breast cancer tumours and cell lines, releasing a C-terminal
‘mini-myoferlin’ fragment. We molecularly characterize two myoferlin
cleavage sites in close proximity at the ﬁfth C2 domain, C2DE (between
C2D and C2E, and not annotated by PFAM and/or SMART for all ferlin
paralogues). Further we show that ectopic expression of the cleav-
able canonical myoferlin isoform, but not an uncleavable isoform,
leads to increased ERK1/2 phosphorylation (extracellular signal–
regulated kinase), providing a potential connection between
myoferlin cleavage and the MAPK/ERK pathway linked to cancer
cell progression.
2. Material and methods
2.1. Cell culture
HEK293 and MO3.13 cells were cultured in DMEM (Life Technolo-
gies) containing 10% FBS (Life Technologies). COS-7 and MEF cells
were cultured in 1:1 DMEM:F12 (Life Technologies) containing 10%
FBS. EVSA-T cells were cultured in MEM + 1xNEAA (non-essential
amino acids) containing 10% FBS, MCF-7, BT-474 and MDA-MB-231
cells were cultured in RPMI 1640 (Life Technologies) containing 10%
FBS. All media contained 50 μg/mL gentamicin (Life Technologies).
Cells were harvested by scrape injury as described in Lek et al., 2013
[26].
2.2. SDS-PAGE and western blotting
Procedures were performed as described in [27].
2.3. Transfection
HEK293 cells were transfected using PEI (polyethylenimine Max,
Polysciences) and COS-7 with Lipofectamine® LTX (LifeTechnologies)
as described in [27].
2.4. Immunoprecipitation
Epitope-tagged ferlin constructs were immunoprecipitated from
transfected HEK293 cells using anti-Myc antibody following the proto-
col described in [27].
2.5. In vitro calpain cleavage
Puriﬁed calpain-1 (porcine) and -2 (human) were purchased from
Millipore. In vitro cleavage of the ferlin proteins was performed using
a modiﬁed protocol from Mandic et al. [31]. Protein G–Sepharose–
bound ferlin proteins were washed three times in 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (Sigma-Aldrich;
pH 7.5), 50 mMNaCl, and 1 mMMgCl2 containing 2 mM CaCl2. Diluted
recombinant calpain was added directly to the protein G–Sepharose–
bound ferlin proteins and incubated at 30 °C for 10s. and 2 min. as indi-
cated. Digestion was quenched by reconstitution into 2× SDS loading
buffer (4% SDS, 20% glycerol, 125 mM Tris, pH 7.4, and 10 mM DTT
(Sigma-Aldrich)), and samples were heated to 94 °C for 3 min.
2.6. In vitro cathepsin L cleavage
Protein bound sepharose beads were transferred into trisacetate
cleavage buffer (50 μL for each experimental condition) and split evenly
into one tube for each condition used. 10 ng/μL puriﬁed recombinant
human cathepsin L (952-CY, R&D systems) diluted in trisacetate buffer
on ice was added to ferlin-bound Protein-G beads and incubated for
the indicated time at 30 °C. Method adopted from Goulet et al., 2004
[32]. Afterwards samples were handled like described under in vitro
calpain cleavage.
2.7. Proteome proﬁler
We have used the Proteome Proﬁler Human Phospho-MAPK
(ARY002B) and the Mouse-RTK Array Kit (ARY014) from R&D systems
and followed the company's instructions.
2.8. Antibodies
Antibodies used in western blotting included N-terminal anti-
myoferlin (7D2, α-rabbit, 1:2000 abcam, ab76746, lot# GR209175-4),
C-terminal anti-myoferlin (K16, α-goat, 1:200; Santa cruz, sc-51,367,
lot# A6714), C-terminal anti-dysferlin (Hamlet-1, α-mouse, 1:5000;
Leica Microsystems, Wetzlar, Germany, NCL-Hamlet, lot# 6045527),
N-terminal anti-dysferlin (Romeo, α-rabbit, 1:1000; abcam,
ab124684), mid region anti-dysferlin, (Fer-A, α-rabbit, 1:1000; Sigma-
Aldrich, HPA021945, lot# R10883), anti-Myc (α-rabbit, 1:5000;
abcam, ab9106, lot# GR130480-24), anti-β-tubulin (1:1000; Develop-
mental Studies Hybridoma Bank, E7-c 8 M4, lot# 4/16/15), anti-
GAPDH (α-mouse, 1:10,000; Merck, Millipore, MAB374, lot#
2742734), anti-FLAG M2 (α-mouse, 1:5000, Sigma Aldrich, F3165,
lot# SLBH1191V), anti-phosphoERK1/2 (α-rabbit, 1:1000, P-p44/42
(T202/Y204) MAPK, Cell signaling, 4370P, lot#17), anti-ERK (α-rabbit,
1:1000, p44/42 MAPK ERK1/2, Cell Signalling, 4695P, lot#14), anti-
phosphoAKT (α-rabbit, 1:1000, Cell signaling, (Ser473), 9271S, lot#
9), anti-CAPNS1 (Calpain reg (P1), α-mouse, 1:500, Santa cruz, sc-
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32325, lot# E0907). For all these antibodies membranes were blocked
in 5% skim milk in PBS + 1% tween (for K16 block in 1% skim milk in
PBS-T and probe with 5% BSA in PBS-T). For anti-Calpain-2 (Large sub-
unit (M-type), α-rabbit, 1:1000, Cell signaling, 2539S, lot# 2) and
anti-Calpain-1 (1:500, α-goat, Santa cruz, sc-7531, lot# L0209) use 5%
BSA for block and antibody dilution.
2.9. PCR and primers
Polymerase chain reaction (PCR) was carried out on human cDNA
panels purchased from Clontech (Mountain View, CA; Human MTC
Panel I and Human Immune MTC Panel). Primers to myoferlin 5″
GCCTCCCTTCTGTCTGCCCCAC 3″ and 3″ GTCAGGCCCTCAAATTCTGC 5″.
GAPDH primers were supplied as part of the Clontech cDNA panel kit.
2.10. Constructs
The dysferlin cDNA construct (EGFP-FL-DYSF pcDNA3.1, National
Center for Biotechnology Information [NCBI] reference sequence
NP_003485.1) was a generous gift from Kate Bushby (Institute of
Human Genetics, International Centre for Life, Newcastle upon Tyne,
UK), and was subcloned into pIRES2-EGFP (OriGene). Myoferlin-
pCMV6 (NCBI reference sequence NM_013451.3) was purchased from
OriGene (Rockville, MD) and subcloned into pIRES2-EGFP. Exon 38a–
containing constructs (M38a, NCBI reference sequence sp|Q9NZM1-3)
were generated by PCR ampliﬁcation of exon 38a from human lung
cDNA. Exon 38a-containing products were isolated and digested with
PstI and SacI (New England Bioscience, Ipswich, MA) and inserted into
our PstI/SacI digested FL-MYOF-pIRES2 construct. All constructs were
validated by DNA sequencing.
2.11. Protein alignment and calpain cleavage prediction
Protein alignment was performed using ClustalW [33]. Calpain
cleavage prediction was performed using GPS-CCD (ccd.biocuckoo.
org; [34]).
2.12. Homology modelling
The 3D model of myoferlin C2DE was done using Modeller [35]. The
C2DE primary sequence (residues 1263–1393 of human myoferlin;
GENBANK: AAF27177.1) was aligned with the primary sequence of
myoferlin C2A, and used to compute a 3D model of the domain. The
3D model was based on coordinates deposited in the PDB database
using the NMR structure of myoferlin C2A (2DMH) as a template. Ten
representative models were calculated. The model with the lowest en-
ergy score was used for analysis.
2.13. Statistics
Statistics was performed using Prism 6 (GraphPad) using Ordinary
one-way ANOVA for analysis of proteome proﬁler arrays relative to
pIRES.
3. Results
3.1. Myoferlin cleavage products are detected in breast tumours, breast
cancer cell lines and transfected cells
Based on published reports demonstrating a doublet band for
myoferlin in cells and tissues [16,28,29], and our own data showing
the canonical myoferlin isoform (Q9NZM1) may be cleaved enzymati-
cally in transfectedHEK293 cells [27], we sought to deﬁne themolecular
determinants of myoferlin cleavage.
We detected anN-terminalmyoferlin cleavage product inmouse xe-
nograft tumours established using the human triple negative breast
cancer cell line MDA-MB-231 (Fig. 1A), conﬁrming cleaved myoferlin
is present in cancerous tissues. In cultured MO3.13 human
oligodendrocytic cells, the N-terminal cleavage product appeared only
in the presence of extracellular Ca2+ and membrane injury, whereas
in C2C12 cells, the cleavage productwas also seen in resting cells (Fig. 1A).
Western blot analyses of two human breast tumours and four
human breast cancer cell lines (BT-474, EVSA-T, MCF-7 and MDA-MB-
231 cells) conﬁrmed evidence for C-terminal fragments of ~75 kDa (de-
tected by the C-terminal antibody K-16, Fig. 1B), as well as an N-termi-
nal counter fragment of ~160 kDa (detected by 7D2, Fig. 1B). In breast
cancer cell lines, levels of the cleaved C-terminal fragment were elevat-
ed acutely (within 2 min) using a scrape assay that induces membrane
injury and acute Ca2+-ﬂux. The two human tumour samples were ag-
gressive triple negative breast cancers, with the corresponding hema-
toxylin and eosin staining representing the tumour content from each
sample (Fig. 1 C, samples #88 ~50% tumorous and #89 ~75% tumorous).
Mini-myoferlin is detected as a doublet with the dominant band detect-
ed at a slightly lower apparent molecular weight compared to anMDA-
MB-231 control. The counter fragment appears to be of similar size be-
tween tumour samples and the MDA-MB-231 control.
Transfection studies in COS-7 and HEK293 cells with myoferlin
(Q9NZM1), isoform 1, (the canonical myoferlin isoform) compared to
dysferlin 40a (isoform containing exon 40a and the calpain cleavage
site) revealed clear differences in Ca2+-triggered formation of the cleav-
age products in the different cell lines (Fig. 1D). In HEK293 cells, cleaved
fragments of myoferlin were detected in resting cells that had not been
subject to amembrane injury and Ca2+-ﬂux (Fig. 1D).Whereas, in COS-
7 cells, only low levels of the cleavage products were detected in resting
cells, with cleavage activated by scrape injury in the presence of extra-
cellular Ca2+ (Fig. 1D).
These studies highlight signiﬁcant differences between proteolytic
cleavage of myoferlin and dysferlin. Dysferlin shows strict injury- and
Ca2+-dependent cleavage by the ubiquitous calpain-1 and/or -2, with
the proteolytic cleavage site reﬁned to residues encoded by the alter-
nately spliced exon 40a [27]. These data reveal that the canonical
myoferlin isoform (Q9NZM1) myoferlin is also cleaved enzymatically,
but shows different requirements for Ca2+ in different cell lines.
3.2. Myoferlin bears two proteolytic cleavage sites.
In silico analyses of myoferlin using a calpain cleavage prediction
program (GPS-CCD, ccd.biocuckoo.org [34]) identiﬁed two high conﬁ-
dence calpain cleavage sites (Fig. 2A) that could produce C-terminal
cleavage products matching the ~75 kDa of our observed mini-
myoferlin. The ﬁrst site is encoded by exon 38 (SLLS|APPC) within the
ﬁfth C2 domain (C2DE), and is present in all myoferlin isoforms
(Fig. 2B). The second site, encoded by alternatively spliced exon 38a
(SKMA|SPAT), would be located 34 residues C-terminal to the ﬁrst
site in the C2DE domain (in exon 38) (Fig. 2B). Phylogenetic alignments
revealed that alternately splicedmyoferlin exon 38a is conserved in ver-
tebrates, from humans through to the ﬁsh class (Fig. 2C). Alignment of
myoferlin sequences to human dysferlin demonstrates the predicted
cleavage site in myoferlin exon 38a aligns with the known cleavage
site in dysferlin exon 40a (Fig. 2C). PCR analysis of a human cDNA
panel (Clontech Multiple Tissue cDNA panels I and II) revealed that
transcripts including exon 38a are aminor species (~10–15% of all tran-
scripts) in all analyzed tissues (Fig. 2D). This conservation of alternative
exons in the identical positions in dysferlin andmyoferlin argues that its
origin predates ferlin gene expansion in early chordates [2].
3.3. Molecular modelling of the cleavage sites in myoferlin
We modelled the ﬁrst putative calpain cleavage site in myoferlin
encoded by exon 38 (present in all isoforms) using the solved crystal
structure of the C2A domain of myoferlin as the homology model for
myoferlin C2DE, as it is the most similar C2 domain currently solved
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(Fig. 3A). C2 domains fold dynamically in response to binding of Ca2+
and phospholipids, therefore structural modelling of C2DE allowed us
to query whether accessibility of the cleavage motif may be regulated
by the conformational structure of the C2DE domain. For example, if a
predicted cleavage site mapped to residues of a β-strand contributing
to the hydrophobic core of the C2 domain, enzymatic cleavage may be
precluded when the domain is folded. Homology modelling indicates
the ﬁrst cleavage site (encoded by exon 38) is located in a loop between
the last two beta strands (β7 and β8) of myoferlin C2DE (red loop,
Fig. 3A). Thus, in this case, it is theoretically plausible this putative
calpain-cleavage site may be cleaved enzymatically whether or not
the C2DE domain is folded. Interestingly, alignment of residues predicted
to comprise the C2DE domain of dysferlin andmyoferlin reveal very high
amino-acid identity, except for this region encompassing the last two
beta strands and loop (Fig. 3B, β7 and β8). Importantly, the canonical
dysferlin isoform-1 (O75923) cannot be cleaved by calpains [27], consis-
tent with these non-homologous residues in myoferlin encompassing a
predicted novel calpain cleavage site not present in dysferlin.
The second putative calpain cleavage site encoded by alternatively
spliced exon 38a is immediately adjacent to the C2DE domain, in the
linker region between C2DE and C2E (Fig. 3A, dashed line, yellow repre-
sents cleavage site).
3.4. Both predicted calpain cleavage sites inmyoferlin can functionally con-
fer Ca2+-dependent, calpain-cleavage of dysferlin
To determine whether the two predicted calpain cleavage sites in
myoferlin represent bonaﬁde calpain cleavage sites, we created a series
of chimeric constructs (see Fig. 4A and B). We reciprocally substituted
residues encompassing the ﬁrst putative calpain cleavage site within
the myoferlin C2DE domain (encoded by exon 38), with the analogous
residues of the dysferlin C2DE domain (encoded by exon 40), that we
have shown experimentally is not cleaved by calpains [27]. We used
data derived from structural modelling and amino acid sequence ho-
mology to precisely substitute residues comprising the 7th and 8th β-
strands and intervening loop, that bear the putative cleavage motif
(SLLS|APPC) inmyoferlinwith the corresponding dysferlin region (con-
structs DM38 and MD40, see Fig. 4A and B). To test whether the second
putative myoferlin cleavage site encoded by alternatively-spliced
myoferlin exon 38a was functionally analogous to dysferlin exon 40a,
we created a myoferlin expression construct bearing exon 38a encoded
sequences (M38a), and, in the dysferlin backbone, we substituted
dysferlin exon 40a, with myoferlin exon 38a (DM38a). We performed
in vitro calpain cleavage assays using recombinant calpain (Fig. 5A), as
well as “in cell”cleavage assays in HEK293 cells overexpressing each
construct (Fig. 5B).
Myoferlin and dysferlin proteins were immunoprecipitated from
transfected HEK293 cell lysates with an anti-Myc antibody and pro-
tein-G-sepharose, then exposed to recombinant calpain-1 or -2
(calpain-2 not shown) (Fig. 5A, left panel). Full-length dysferlin (DFL)
that lacks exon 40a served as a negative control, as it does not encode
for a calpain cleavage site, and thus shows no detectable cleavage prod-
ucts (Fig. 5A and B left panels. Also see [27]). As expected, dysferlin
bearing exon 40a (D40a) is cleaved effectively by recombinant calpain,
releasing C-terminal mini-dysferlin (Fig. 4A, left panel, anti-Myc blot)
and the N-terminal counter fragment (Fig. 5A, left panel, Romeo blot).
Fig. 1.Myoferlin cleavage products are detected in breast tumours, breast cancer cell lines and transfected cells. (A)Western blot analysis of ﬁvemouse xenograft tumour samples derived
from MDA-MB-231 cells transplanted into nude mice, showing an N-terminal myoferlin cleavage product. (B)Western blot analysis of endogenous myoferlin in four different human
breast cancer cell lines (BT-474, EVSA-T, MCF-7 and MDA-MB-231) with (+) or without (−) scrape-injury in +Ca2+-PBS. A ~75kDa C-terminal cleavage product is detected with the
K-16 antibody recognizing a C-terminal myoferlin epitope, and a ~180 kDa counter fragment detected with 7D2 that recognizes an N-terminal myoferlin epitope. K16 works less
effectively than 7D2 with a higher background, thus 30 μg total protein is loaded on K16 gel and 10 μg total protein loaded on the 7D2 gel. (C) ~75 kDa C-terminal myoferlin
fragments (doublet bands) and an ~180 N-terminal counter fragment are also detected in triple negative human breast cancer samples (#88 and #89). H&E staining of fresh frozen
tumour sections of the same samples run on the western blot. The purple stain represents tumour tissue and the pink stain normal breast tissue (H&E staining provided by the
ABCTB). Scale bar 500 μm. (D)Western blot analysis of HEK293 and COS-7 cells transfected with full length myoferlin (MFL) or dysferlin containing the calpain cleavage site in exon
40a (D40a) with (+) or without (−) scrape-injury in +Ca2+-PBS.
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Substitution of sequences encoding either predictedmyoferlin cleavage
sites in dysferlin (DM38 or DM38a) revealed both sites are cleaved by
calpains in vitro (Fig. 5A). Similarly, both myoferlin cleavage sites are
cleaved in a Ca2+-dependent manner in transfected HEK293 cells sub-
jected to scrape injury, analogous to dysferlin exon 40a (Fig. 5B, left
panel, DM38 and DM38a).
Thus, both in vitro and ‘in cell’ cleavage assays conﬁrmed in silicopre-
dictions of myoferlin exon 38 encoded residues SLLS|APPC as a calpain
cleavage motif. Full-length myoferlin (MFL) is cleaved by calpains in
vitro (Fig. 5A, right, MFL), and is cleaved constitutively in transfected
HEK293 cells without membrane injury and Ca2+- ﬂux (Fig. 5B, right,
MFL). Conversely, substitution of the canonical myoferlin exon 38 site
with homologous dysferlin exon 40 (uncleavable) residues strongly re-
duced formation of cleavage products (Fig. 5A and B, right, MD40), con-
sistentwith previous evidencedemonstrating these dysferlin sequences
are not a favoured calpain cleavage site [27].
More complex results were obtained using myoferlin constructs to
study the second exon 38a encoded site that is homologous to the
dysferlin cleavage motif within alternative exon 40a. Surprisingly,
myoferlin bearing exon 38a (M38a), which now possesses both predict-
ed calpain cleavage sites, was not cleaved in vitro or in transfected
HEK293 (Fig. 5A and B, right panels, M38a). Interestingly, when the
canonical myoferlin exon 38 site is replaced by the homologous
‘uncleavable’ dysferlin exon 40 sequence, and exon 38a is the only po-
tential cleavage site (MD40/38a), the capacity to be cleaved by calpains
is restored, in both in vitro and ‘in cell’ cleavage assays (Fig. 5A and B,
right, MD40/38a). Thus, inclusion of exon 38a sequences in myoferlin
blocks the capacity of myoferlin protein synthesized in HEK293 cells
to be cleaved at the canonical exon 38 site ‘in cells’ or in vitro by puriﬁed
recombinant calpain.
3.5. Myoferlin cleavage is independent of calpain-1 and -2 in cells and the
cleavage modality is dictated by the C-terminus.
To establish if calpain-1 and/or -2 were responsible for enzymatic
cleavage of myoferlin, we performed targeted knock out of the calpain
small subunit 1 (CAPNS1) in HEK293 cells, an approach that renders
calpain-1 and -2 inactive and leads to the secondary reduction/ablation
of the CAPN1 and CAPN2 proteins [36]. Canonical myoferlin (MFL) was
cleaved effectively in HEK293 cells lacking CAPNS1 (Fig. 5B right
panel), whereas the cleavage of dysferlin 40a (D40a) was ablated in
the absence of CAPNS1.
To understand why myoferlin and dysferlin display different cleav-
age patterns, we sought to determine whether features intrinsic to
Fig. 2.Myoferlin bears two predicted calpain cleavage sites. (A) Calpain cleavage prediction (GPS-CCD, ccd.biocuckoo.org; [29]) ofmyoferlin resulted in two highly predicted cleavage sites
consistentwith production of a 75–80 kDa C-terminal cleavage fragment. (B) Schematic of themyoferlin protein structure showing the location of the two predicted calpain cleavage sites.
The ﬁrst predicted cleavage site (SLLS|APPC) is encoded by constitutive in exon 38, at the end of the C2DE domain and would result in a ~74 kDa mini-myoferlin fragment. The second
predicted cleavage site (SKMA|SPAT) is encoded by alternatively spliced exon 38a in the linker directly adjacent to C2DE, which would result in a slightly smaller mini-myoferlin
(~69 kDa). (C) Phylogenetic amino acid sequence alignment showing that exon 38a is evolutionary conserved down to the ﬁsh class, and that myoferlin exon 38a aligns to the same
position as exon 40a in dysferlin. (D) PCR analysis of human tissue cDNA showing myoferlin RNA is expressed throughout the different tissues tested and reveals that exon 38a is
expressed as a minor species in human tissues (~10% of total transcripts). PCR ampliﬁcation was performed for 35 and 40 cycles to control for saturation. +38a and -38a are plasmid
controls with and without exon 38a.
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Fig. 3.Molecular modelling of predicted calpain cleavage sites in myoferlin. (A) Homology modelling of the C2DE domain of myoferlin based on the closest solved crystal structure of
myoferlin C2A (2DMH, see methods) indicates the ﬁrst cleavage site (encoded by exon 38, red arrow) is located in a loop between the last two beta strands (β7 and β8) of myoferlin
C2DE (red loop). The cleavage site in exon 38a (yellow arrow) is located in the linker region (dashed line) that cannot be modelled and was drawn freely onto the model (yellow
dashed line). (B) Alignment of the C2DE sequence of dysferlin and myoferlin in relation to the β-strand (purple) shows that the region of the ﬁrst cleavage site of myoferlin has the
least homology between dysferlin and myoferlin.
Fig. 4. Chimeric constructs of myoferlin and dysferlin. (A) Graphical illustration of the design of chimeric expression constructs. Myoferlin sequence is displayed in purple and dysferlin
sequence in grey scale. The ﬁrst predicted calpain cleavage site (SLLS|APPC) site in myoferlin is coloured in red and the second cleavage site in exon 38a is highlighted in yellow
(SKMA|SPAT). The cleavage site in exon 40a in dysferlin is coloured in orange (TNTA|SPPS). (B) Amino acid sequences of the chimeric constructs. To conﬁrm the cleavage site in
myoferlin resided within the non-conserved loop between the 7th and 8th β-strand of the C2DE domain (see schematic in Fig. 3), we reciprocally substituted residues comprising the
7th and 8th β-strand and intervening linker C2DE between dysferlin and myoferlin (DM38 and MD40).
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this C-terminal region play a role in conferring constitutive or Ca2+- de-
pendent cleavage. Our phylogenetic studies establish the two C-termi-
nal C2 domains of ferlins are the most evolutionarily conserved,
implying a core function [2]. We generated another chimeric construct,
precisely substituting the C-terminal ‘mini-myoferlin’ module with the
equivalent mini-dysferlin sequences (MmDf, Fig. 6A; dashed line indi-
cates where the sequences have been swapped over). Interestingly, a
myoferlin construct with a dysferlin C-terminal domain now behaves
like dysferlin, displaying Ca2+- and injury-dependent cleavage. Ca2+-
and injury-dependent cleavage of theMmDf chimerawas also greatly at-
tenuated in CAPNS1−/− HEK293 cells, in line with its dysferlin-like
properties (Fig. 6B).
Taken together, these observations argue that Ca2+-triggered pro-
teolytic cleavage by calpain-1 or calpain-2 is conferred by the mini-
dysferlin sequences. Furthermore, these results establish that an en-
zyme other than calpain-1 and/or -2 is responsible for Ca2+- and inju-
ry-independent cleavage of myoferlin. In support of this, endogenous
myoferlin cleavage was also observed in mouse embryonic ﬁbroblasts
(MEFs) derived from either WT or CAPNS1 KO mice (Fig. 6C). With
the cleavage occurring in resting cells independent of Ca2+ and mem-
brane injury (Fig. 6C). The cathepsin family of lysosomal proteases is
also predicted to cleave myoferlin at the same amino acid sequence as
calpains are (SLLS|APPC). In an in vitro cleavage assay cathepsin L re-
leased the same-sized mini-myoferlin fragment as calpains (Fig. 6D).
3.6. Cleaved myoferlin increases ERK phosphorylation in HEK293 cells.
As myoferlin is known to play a role in growth factor receptor
recycling and secretion [15,19–22], we used proteome proﬁler arrays
to investigate the effects of our cleavable and uncleavable myoferlin
constructs on the relative phosphorylation of 65 proteins implicated in
receptor tyrosine kinase (RTK) and mitogen-activated protein kinase
(MAPK) signalling pathways (Phospho-RTK Antibody Array and
Phospho-MAPK Antibody Array from R&D Systems). We overexpressed
myoferlin full-length (MFL), myoferlin 38a (M38a), dysferlin full-length
(DFL) and vector only control (pIRES2-EGFP) in HEK293 cells. Interest-
ingly, phosphorylated ERK1 and -2 were speciﬁcally increased with
overexpression of full-length myoferlin, but not when myoferlin 38a,
dysferlin or pIRES2 vector control was overexpressed (Fig. 7A shows
the results of 13 representative proteins). We validated these results
by conventional western blot analyses using different phospho-ERK1/
2 antibodies (Cell Signaling). Three separate experiments were per-
formed formyoferlin (Fig. 7B) and two for dysferlin (Fig. 7C) in triplicate
repeats that demonstrate a two-fold increase in phospho-ERK1/2 when
myoferlin FL is transfected, relative to pIRES2 vector control (Fig. 7D). As
~30–40% cells were transfected (shown by ﬂow cytometry using the
EGFP expressed from the internal ribosome entry site in pIRES2, (data
not shown)), the upregulation in transfected cells would likely exceed
the biochemically observed average of 2-fold. This effect was speciﬁc
to ERK phosphorylation and did not alter the phosphorylation status
of AKT, a downstream target of the PI3 kinase-signalling pathway
(Fig. 7B). These data demonstrate reproducible, differential activation
of pERKwith canonical myoferlin, but not myoferlin38a, which is identi-
cal with the exception of 57 base pairs encoded by exon 38a. Although
further research is required to determine the functional relevance of
myoferlin cleavage, these data support functional specialisation con-
ferred by alternate myoferlin isoforms and linked to enzymatic
cleavage.
Fig. 5. Evaluation of predicted calpain-cleavage sites inmyoferlin. A) In vitro cleavage of dysferlin andmyoferlin constructs immunopuriﬁed from transfected HEK293 cells and incubated
with recombinant calpain-1. Protein-bound Sepharose beadswere incubated in buffer containing 2mMCaCl2 in the presence of puriﬁed0.2 A.U. of recombinant calpain-1 at 30 °C for 10 or
120 s, or in the absence of calpain (−). Proteolysiswas rapidly inhibited by reconstitution of the reaction in SDS lysis buffer and heating to 94 °C. Digested sampleswere analyzed by SDS–
PAGE andwestern blot. B) In cell cleavage of dysferlin andmyoferlin expression constructs is induced via scrape-harvesting of transfectedHEK293 cells. (+)with scrape injury in+Ca2+-
PBS; (−) without scrape injury, harvested directly into ice-cold RIPA buffer with EDTA. Dysferlin without a calpain cleavage site (DFL) is not cleaved. Dysferlin with exon 40a (D40a) is
cleaved by recombinant calpain (A) and during scrape-harvesting (B). Both predicted myoferlin cleavage sites in exon 38 and exon 38a can functionally substitute for exon 40a in in
vitro and in cell cleavage assays (DM38, DM38a). Myoferlin (MFL) is cleaved by calpain-1 in vitro (A) and is cleaved independently of scrape injury in transfected HEK293 (B). Substitution
of myoferlin exon 38 with the corresponding residues from dysferlin (encoded by exon 40; MD40) prevents cleavage, conﬁrming myoferlin exon 38 sequences contain a cleavage
motif. Paradoxically, myoferlin constructs with exon 38a (M38a) are not cleaved in vitro or in cells. Inclusion of exon 38a sequences regulates (precludes) cleavage both within exon
38a as well as at the exon 38 site.
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4. Discussion
In this study we molecularly characterize two enzymatic cleavage
sites within myoferlin in close proximity at the ﬁfth C2 domain, C2DE.
When either of themyoferlin cleavage sites are expressed in a dysferlin
expression construct, both exon 38 and exon 38a cleavage motifs can
functionally substitute for dysferlin exon 40a sequences to confer
Ca2+-dependent and calpain-dependent cleavage of dysferlin in re-
sponse to injury. Enzymatic cleavage of endogenous myoferlin
expressed in breast cancer lines, MO3.13 oligodendroglial cells and in
transfected COS-7 cells is enhanced following acute Ca2+ ﬂux induced
by membrane injury, suggesting cleavage of myoferlin is activated by
Ca2+-signalling. However, in primary mouse embryonic ﬁbroblasts,
C2C12 mouse myoblasts and transfected HEK293 cells, release of
myoferlin cleavage products occurred in resting cells.
These data suggest different signalling pathways and different en-
zymes regulate myoferlin cleavage in different cells and tissues, but
did not exclude that enzymatic cleavage of both dysferlin andmyoferlin
was linked to Ca2+-signalling and calpain activation. Calpain-1 can be
activated by intracellular Ca2+ concentrations (EC50 ~20 μM), whereas
calpain-2 has a much higher activation threshold and has an EC50
~200μMCa2+ [37]. Calpain-2 can also be activated via kinase-mediated
phosphorylation through epidermal growth factor receptor signalling in
a Ca2+-independent manner [38–40]. However, targeted knockout of
CAPNS1 in HEK293 and MEF cells demonstrated the ubiquitous
calpains, calpain-1 and -2, are not responsible for enzymatic cleavage
of myoferlin.
There are 15 members of the calpain family [41] and the lysosomal
cathepsins also share overlapping substrate speciﬁcities to calpains.
Lysosomal cathepsins are Ca2+-independent proteases that are active
at slightly acidic pH and rapidly inactivated by neutral pH [42]. The
myoferlin exon 38 motif (SLLS|APPC) registered as a likely cathepsin
substrate via in silico predictions (ExPasy), and recombinant cathepsin
L readily cleaved myoferlin in vitro to release similar cleavage products
as observed with recombinant calpain (see Fig. 6D). Cathepsins make
attractive candidates for myoferlin cleavage, as they are highly
expressed in invasive tumours [43].
Paradoxically, in transfected HEK293 cells inclusion of the second
myoferlin cleavage motif encoded by alternately spliced exon 38a
blocks enzymatic cleavage at the canonical exon 38 site, both in the ‘in
cell’ and the ‘in vitro’ cleavage using recombinant calpain. These results
suggest inclusion of exon 38a sequencesmay induce a change in tertiary
conformation, or promote a post-translational modiﬁcation or interac-
tion (preserved following immunoprecipitation), that prevents enzy-
matic cleavage. Alternately, it is plausible myoferlin is cleaved and the
released products are labile. Other proteins are known to have two dif-
ferent enzyme cleavage sites very close together, including α-spectrin
[44,45] and α-fodrin [46], whereby cleavage by caspases or calpains re-
lease similarly sized products in response to different cellular triggers.
For example, calpain cleavage ofα-fodrin can occur during platelet acti-
vation [47,48]whereas caspase cleavage ofα-fodrin is linked to apopto-
sis [49]. Inclusion of exon 38a in myoferlin may confer preferential
enzymatic cleavage by an enzyme not present in the cellular systems
of our studies.
To try to identify domains that bestow calpain/Ca2+-dependent
cleavage on dysferlin, but calpain/Ca2+-independent cleavage on
myoferlin in transfected HEK293 cells, we studied amyoferlin-dysferlin
chimera. These experiments revealed that ‘dysferlin-like’ properties are
Fig. 6.Myoferlin cleavage is independent of calpain-1 and -2. The dysferlin C-terminal domain confers calpain- and Ca2+-dependent cleavage on myoferlin. (A) Illustration of expression
constructs; Full lengthMyoferlin (MFL), Dysferlinwith exon 40a (D40a), Myoferlinwithmini-dysferlinC72 C-terminal domains (MmDf). Antibody epitopes and epitope tags are annotated for
each construct. (B)Western blot analysis ofHEK293 cells (WT and CAPNS1−/−) transfectedwithMFL,MmDf, andD40a, or anuntransfected control. In contrast to D40a, proteolytic cleavage of
MFL is insensitive to targeted knock-out of CAPNS1, and does not require scrape injury. Substitution of the myoferlin C-terminus for the dysferlin C-terminal domains confers calpain-
dependent, injury-dependent cleavage on MmDf. (C) WT and CAPNS1−/− mouse embryonic ﬁbroblasts (MEFs) showing cleavage of endogenous myoferlin detectable with the N-
terminal antibody (7D2). (D) In vitro cathepsin L cleavage of MFL transfected HEK293 cells shows the release of the same mini-myoferlin seen with the in vitro calpain-1 cleavage.
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conferred to myoferlin through substitution of the myoferlin C-termi-
nus with the dysferlin C-terminus (mini-dysferlinC72). Interestingly,
this dual-C2 domain module is highly conserved between dysferlin
and myoferlin, with 60% amino acid identity (ExPasy). The different
properties of enzymatic cleavage between dysferlin and myoferlin in
transfected HEK293 may reﬂect intrinsic differences in Ca2+- or lipid-
binding preferences of the C2E and C2F domains, and/or differences in
the cellular journey of dysferlin and myoferlin dictated by this C-termi-
nal region that exposes each protein to different enzymes. Dysferlin and
myoferlin do not have overlapping functional roles, as shown by the in-
ability of myoferlin to functionally compensate for dysferlin-deﬁciency
in dysferlin-null mice [50].
To obtain clues to the functional consequences of myoferlin cleav-
age, we performed phosphorylation proﬁling of 65 signalling proteins.
Overexpression of ‘cleavable’myoferlin (without exon 38a) consistently
resulted in increased phosphorylation of ERK1/2 (Fig. 7).MAPK/ERK sig-
nalling is implicated in cell growth, adhesion, cell survival and differen-
tiation, and its inappropriate activation has been linked to different
carcinoma types [51]. Our ongoing studieswill explore the consequence
of myoferlin over-expression on MAPK/ERK signalling pathways in a
transgenic mouse model, to better elucidate the functional conse-
quences of myoferlin cleavage and its potential relationship to growth
factor receptor signalling and the metastatic properties of cancer cells.
Enzymatic cleavage of myoferlin may explain detection of myoferlin
as a 240/170 kDa N-terminal doublet band in tumour samples and can-
cer cell lines in recent reports describing a role for myoferlin in
tumorigenesis and cancer cell metastasis [16,28–30], potentially illumi-
nating a functional adaptation of myoferlin relevant to cellular signal-
ling and oncogenesis.
5. Conclusions
• Myoferlin can be cleaved enzymatically via both calpain-dependent
and calpain-independent mechanisms to release a dual C2 domain
transmembrane-anchored module.
• Myoferlin bears two enzymatic cleavage sites; a canonical cleavage
site encoded by exon 38within the C2DE domain; and a second cleav-
age site in the linker adjacent to C2DE, encoded by alternately-spliced
exon 38a, homologous to dysferlin exon 40a.
• Differential activation of ERK signallingwith in vitro overexpression of
cleavable myoferlin, but not uncleavable myoferlin, supports func-
tional specialisation conferred by alternate myoferlin isoforms and
linked to enzymatic cleavage.
• Enzymatic cleavage of both dysferlin and myoferlin infers evolution-
ary preservation of a means to release dual C2 domain modules;
perhaps an ancestral prototype of synaptotagmin-like effectors.
Fig. 7. Overexpression of canonical full-length myoferlin (MFL) but not the uncleavable M38a, upregulates phosphorylated ERK in transfected HEK293 cells. (A) Cell lysates from
transfected HEK293 cells were incubated with Proteome Proﬁler™ Antibody Arrays (Human Phospho-MAPK and Mouse-RTK Array Kit, R&D systems). Histogram of densitometry from
duplicate spots of 13 representative proteins from the Human Phospho-MAPK Array showing elevation of phospho-ERK. No differences between MFL and M38a or empty pIRES were
observed for the remaining phosphoproteins (not shown). (B and C)Western blot experiments conﬁrm speciﬁc upregulation of pERK relative to total ERK in HEK293 cells transfected
with MFL, but not M38a, D40a or empty pIRES. Levels of pAKT were unchanged. Data show three experiments performed in triplicate. (D) Densitometric analysis of combined data from
western blots showing up-regulation of pERK in MFL expressing HEK293 cells was signiﬁcantly elevated relative to pIRES expressing cells (p= 0.0002) (one way ANOVA, Prism 6).
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5.2. Supporting	results	for	'The	enzymatic	cleavage	of	myoferlin	
releases	a	dual	C2-domain	module	linked	to	ERK	signalling'		
The	next	sections	below	show	the	results	that	were	not	part	of	my	publication,	Piper	
et	al.,	2017,	but	reveal	some	interesting	aspects	of	the	different	myoferlin	isoforms	
and	could	form	the	base	for	future	investigations.	
	
5.2.1. In	silico	analysis	of	myoferlin	gene	expression		
With	 an	 increasing	 amount	 of	 in	 publically	 available	 expression	 data,	 I	 decided	 to	
begin	this	research	by	mining	different	databases	(gtexportal,	ENSEMBL	and	NCBI)	to	
investigate	myoferlin	gene	expression	in	human	tissues.		
	 Figure	5.1,	below,	portrays	the	schematics	of	the	different	myoferlin	isoforms	
derived	from	the	GTEx	database.	Here	there	are	two	isoforms	that	appear	to	include	
the	alternately	spliced	exon	38a	as	indicated	by	the	red	arrow.		
	 Myoferlin	has	11	 transcripts	according	 to	 the	GTEx	database;	 the	Ensemble	
database	 only	 recognizes	 nine	 transcripts	 (ENST00000371501	 and	
ENST00000371502	 are	 missing,	 with	 the	 latter	 being	 an	 exon	 38a	 containing	
isoform).	 Each	 vertical	 line	 in	 Figure	 5.1	 represents	 one	 exon.	 The	 example	 is	
mammalian	breast	tissue	and	the	order	is	from	the	highest	to	the	lowest	expression	
in	 this	 particular	 tissue.	 There	 are	 two	 isoforms	 that	 appear	 to	 include	 the	
alternately	spliced	exon	38a,	indicated	by	the	red	arrow.	
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Figure	 5.1.	 Myoferlin	 isoforms	 according	 to	 the	 GTEx	 database.	 The	
transcript	 ID	 is	 shown	on	 the	 left	 (as	 ENST	numbers).	 Each	vertical	 line	
indicates	 one	 exon.	 The	 order	 is	 from	 most	 expressed	 to	 the	 lowest	
expressed	 isoform	 in	human	breast	 tissue,	 as	 an	example.	A	 red	 arrow	
indicates	the	position	of	exon	38a.	
 
When	the	different	myoferlin	isoforms	are	separately	plotted	(see	Figure	5.2	below)	
it	becomes	evident	that	the	myoferlin	isoform	most	expressed	in	a	variety	of	tissues	
is	 the	 isoform	 containing	 exon	 38a	 (ENST00000463743)	 (represented	 by	 the	 blue	
line,	Figure	5.2A	and	by	blue	boxes	 in	Figure	5.2B).	Also,	 this	 isoform	and	the	next	
two	highest	expressing	isoforms	have	been	plotted	individually	as	box	plots	in	Figure	
5.2(red	and	green	respectively).	Note	that	the	scale	for	the	blue	isoform	is	different	
(up	to	120	RPKM)	as	this	isoform	has	higher	myoferlin	gene	expression	compared	to	
the	other	isoform.	Figure	5.2C	includes	outliers	whereas	Figure	5.2A	(scale	only	to	50	
RPKM)	is	an	illustration	of	the	median	value	only.	
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Figure	 5.2:	 Myoferlin	 isoform	 expression	 according	 to	 the	 GTEx	
database.	A.	Median	of	myoferlin	expression	of	separate	isoforms.	X-axis	
shows	the	different	human	tissues	and	the	Y-axis	the	gene	expression	in	
'Reads	Per	Kilobase	Million'	(RPKM).		
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5.2.2. RNA	expression	of	exon	myoferlin	38a		
I	 conducted	 PCR	 studies	 and	 in	 silico	 analyses	 to	 investigate	whether	 exon	 38a	 is	
commonly	expressed,	 in	several	different	tissues	and	cell	 lines.	 It	became	apparent	
very	quickly	 that	myoferlin	RNA	 levels	 do	not	 correlate	with	protein	 expression	of	
myoferlin.	 Figure	 5.3,	 below,	 shows	 the	 PCR	 analysis	 of	myoferlin	 using	 exon	 38a	
specific	primers.	HEK293	cells	show	robust	myoferlin	expression	and	lots	of	exon	38a	
containing	transcript	(upper	band).		
	
	
Figure	5.3:	cDNA	analysis	of	myoferlin	exon	38a	expression	in	different	
human	breast	cancer	cell	 lines	compared	to	HEK293	cells.	The	positive	
control	 is	a	1:1	mix	of	MFL	and	M38a	vectors	and	 the	negative	control	
does	not	contain	any	template.	
	
The	breast	cancer	cell	lines	all	show	some	expression	of	the	38a	containing	transcript	
with	MCF-7	containing	the	most.	The	breast	cancer	cell	lines	also	express	myoferlin	
protein	and	show	signs	of	myoferlin	cleavage	(see	Figure	1A,	page	33,	in	Piper	et	al.,	
2017).	
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5.2.3. Discrepancy	between	myoferlin	RNA	and	protein	expression	
Comparing	 myoferlin	 RNA	 expression	 levels	 with	 protein	 expression	 in	 human	
tissues,	I	showed	that	the	RNA	level	does	not	always	correlate	with	the	protein	level.	
Figure	5.4,	below,	shows	the	RNA	and	protein	expression	of	myoferlin	in	a	variety	of	
different	 human	 tissues	 grouped	 by	 organ.	 Adipose	 tissue	 for	 example	 has	
apparently	no	myoferlin	protein	but	does	show	RNA	expression	of	almost	30	'Reads	
Per	Kilobase	Million'	(RPKM).	On	the	other	hand,	lung	shows	relatively	low	myoferlin	
RNA	expression	but	shows	high	levels	of	protein	expression.	Bladder	appears	to	be	
one	of	 the	only	 tissues	 that	 show	 correlation	between	myoferlin	RNA	and	protein	
expression.
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Figure	5.4:	Discrepancy	betw
een	m
yoferlin	RN
A	and	protein	expression.	The	expression	levels	of	m
yoferlin	
RN
A	and	protein	does	not	alw
ays	correlate	in	a	variety	of	hum
an	tissues	analysed.	RN
A	expression	is	show
n	in	
'Reads	Per	Kilobase	M
illion'	(RPKM
)	and	protein	expression	in	low
,	m
edium
	and	high.	(Graphs	taken	from
	the	
w
w
w
.proteinatlas.org	w
ebsite	w
ith	RN
A	expression	based	on	gtexportal.org).	
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5.2.4. Myoferlin	is	not	expressed	in	developing	human	skeletal	muscle	
Myoferlin	 is	 only	 expressed	 in	 primary	 myogenesis	 and	 appears	 to	 be	 lost	 from	
differentiated	 skeletal	 muscle	 in	 humans	 and	 mice.	 Dysferlin	 on	 the	 other	 hand	
shows	increased	protein	expression	with	progression	of	differentiation.	
	 To	assess	the	expression	pattern	of	myoferlin	relative	to	dysferlin	in	skeletal	
muscle	 I	 performed	 western	 blot	 analyses	 of	 a	 primary	 human	myoblast	 cell	 line	
(c1504)	 at	 different	 stages	 of	 differentiation	 (Figure	 5.5A)	 as	 well	 as	 in	 human	
skeletal	muscle	samples	of	different	ages	(Figure	5.5B).	
	
Figure	 5.5.	 Protein	 expression	 of	 dysferlin	 and	 myoferlin	 in	 human	
skeletal	muscle.	A.	Western	blot	analysis	of	differentiation	time	course	
of	 primary	human	myoblasts	 (c1504s).	 Cells	were	put	 in	 differentiation	
media	 after	 24	 hours	 in	 culture.	 Dysferlin	 protein	 expression	 increased	
with	 the	 level	 of	 maturity	 whereas	 myoferlin	 protein	 expression	
remained	 unchanged.	 Developmental	 myosin	 serves	 as	 a	 control	 for	
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differentiation	and	GAPDH	as	a	loading	control.	B.	Western	blot	analysis	
of	 human	 skeletal	 muscle	 biopsies	 of	 increasing	 ages	 from	 19-weeks	
gestation	 to	 22	 years	 of	 age.	 The	mouse	myoblast	 cell	 line	 serves	 as	 a	
positive	 control	 at	 eight	 days	 differentiation.	 Dysferlin	 expression	 was	
robustly	 detectable	 throughout	 all	 samples	 whereas	 myoferlin	 protein	
expression	can	only	be	detected	 in	 the	positive	control.	Developmental	
myosin	was	used	as	a	control	for	differentiation	and	GAPDH	as	a	loading	
control.	
	
My	 results	 showed	 that	 the	protein	expression	of	myoferlin,	 unlike	dysferlin,	 does	
not	 change	 with	 increased	 differentiation	 in	 human	 primary	 myoblasts.	
Developmental	 myosin	 protein	 expression	 served	 as	 markers	 of	 myoblast	
differentiation	and	GAPDH	serves	as	loading	control.		
	 In	 human	 skeletal	 muscle	 samples	 myoferlin	 protein	 expression	 was	 not	
detectable,	compared	to	the	positive	control	of	an	eight	days	differentiated	mouse	
myoblast	 cell	 line	 (C2C12).	 In	 contrast,	 dysferlin	 protein	 expression	 was	 robustly	
detectable	 in	 all	 skeletal	 muscle	 samples	 from	 19-week	 gestation	 to	 22-year-old	
muscle	samples.	Developmental	myosin	was	used	as	a	marker	of	muscle	maturity,	as	
it	 is	 transiently	 expressed	 during	 the	 embryonic	 and	 foetal	 development	 of	 the	
muscle,	and	disappears	from	healthy	muscle	shortly	after	birth.	GAPDH	was	used	as	
a	loading	control.	
	
5.2.5. Myoferlin	 and	 dysferlin	 show	 different	 tissue	 specific	 protein	
expression	patterns	in	mice	
Next	I	wanted	to	assess	the	expression	levels	of	myoferlin	protein	in	different	tissues	
compared	to	dysferlin	in	mice.	Figure	5.6,	below,	shows	that	myoferlin	and	dysferlin	
were	 differently	 expressed	 in	 different	 tissues.	 The	 N-terminal	myoferlin	 antibody	
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showed	a	strong	signal	 in	 lung,	pancreas	and	 in	ovaries.	Dysferlin	was	more	evenly	
expressed	throughout	the	different	tissues.	
	
Figure	 5.6:	 Myoferlin	 and	 dysferlin	 protein	 expression	 in	 different	
mouse	 tissues.	Lung,	 liver	and	ovaries	showed	robust	myoferlin	protein	
expression	with	pancreas	 showing	a	distinct	doublet	band,	which	could	
be	 the	 counter	 fragment	 to	 a	 mini-myoferlin	 cleavage	 product.	 Lung	
showed	 two	 lower	 molecular	 weight	 bands	 under	 the	 main	 myoferlin	
band	and	 liver	 showed	 two	weaker	bands	 that	were	 lower	and	did	not	
show	 the	 full-length	 myoferlin	 band.	 Ovary	 also	 exhibited	 a	 lower	
molecular	 weight	 band	 as	 well	 as	 the	 full-length	 myoferlin	 band.	
Dysferlin	was	highly	expressed	 in	heart;	had	robust	expression	 in	aorta,	
lung,	 kidney,	 pancreas	 and	 ovaries	 with	 weaker	 protein	 expression	 in	
brain	 and	 liver.	 (Note:	 achieving	 equal	 loading	 using	 tissues	 with	 very	
different	 protein	 composition	 was	 difficult.	 The	 major	 focus	 of	 this	
western	blot	was	the	comparison	of	myoferlin	and	dysferlin	expression	in	
each	tissue).	
	
5.2.6. Time-dependence	of	myoferlin	cleavage	
I	had	observed	that	detection	of	mini-myoferlin	in	cultured	cells	was	inconsistent.	In	
both	cells	 transfected	with	myoferlin	constructs,	despite	careful	harvesting	 in	cold,	
Ca2+-free	 conditions,	 sometimes	 I	 detected	 significant	 levels	 of	 the	 myoferlin	
cleavage,	and	sometimes	I	detected	very	little	or	no	evidence	for	myoferlin	cleavage.	
That	 led	 me	 to	 query	 the	 'time	 component'	 of	 my	 experiments.	 Therefore,	 I	
subsequently	 conducted	 several	 experiments	 using	 exact	 time	 points	 to	 harvest	
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transfected	 cells.	 I	 also	 compared	 cells	 transfected	 with	 myoferlin	 expression	
constructs	with	(M38a)	and	without	exon	38a	(MFL).		
	 I	 transfected	the	cells	and	replated	them	24	hours	post	 transfection	 into	as	
many	dishes	as	I	needed	for	the	experiment.	Figure	5.7A,	below,	shows	myoferlinFL	
and	myoferlin38a	protein	expression	over	72	hours	post	 replating	 (equivalent	of	96	
hours	post	transfection).		
	 It	 appears	 that	 the	 formation	 of	mini-myoferlin	 only	 occurs	 after	 a	 specific	
amount	 of	 time	 transpires;	 no	mini-myoferlin	 was	 detected	 three	 hours	 following	
replating,	 whereas	 readily	 detectable	 amounts	 of	 cleaved	 mini-myoferlin	 were	
detected	 24	 hours	 post	 replating.	 Cells	 showed	 no	 signs	 of	 ill	 health.	 Confusingly,	
myoferlin38a	 was	 not	 cleaved	 enzymatically	 at	 any	 time	 point	 in	 this	 experiment.	
Mini-myoferlin	 was	 robustly	 detectable	 using	 an	 antibody	 against	 the	 C-terminal	
Myc	tag.	The	N-terminal	myoferlin	antibody	showed	what	appears	to	be	the	counter	
fragment	 to	mini-myoferlin.	 Interestingly,	 there	 appeared	 to	 be	 some	 digested	N-
terminal	products	 in	 the	myoferlin38a	 samples.	This	 suggested	perhaps	myoferlin38a	
was	being	cleaved	enzymatically,	but	the	protein	products	generated	were	unstable.	
	 Neither	 the	C-terminal	mini-myoferlin	nor	 the	N-terminal	 counter	 fragment	
appeared	 to	 be	 generated	 in	 a	 strictly	 Ca2+-dependent	 manner.	 However,	 the	
presence	of	extracellular	Ca2+	enhanced	the	formation	of	mini-myoferlin	 in	at	 least	
two	out	of	the	three	experiments	(see	Figure	5.7B	and	C,	below).		
	 I	 attempted	 to	 further	 refine	 the	 time	period	 between	 three	 and	 24	 hours	
post	replating	when	enzymatic	cleavage	of	myoferlin	occurred.	Using	the	formation	
of	mini-myoferlin	 and	 the	N-terminal	 counter	 fragment	 as	 readout,	 I	 performed	 a	
second	experiment	using	3,	6,	9	and	24	hours	post	replating	as	my	time	points	(see	
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Figure	 5.7B,	 below).	 This	 western	 blot	 showed	 again	 that	 the	 formation	 of	 mini-
myoferlin	 only	 occurred	 after	 24	 hours	 post	 replating	 and	 not	 at	 the	 earlier	 time	
points.	In	this	case	the	N-terminal	counter	fragments	also	were	detectable	only	after	
24	hours.		
	 In	a	third	time	course	experiment	 I	assessed	how	long	mini-myoferlin	could	
exist	 in	 a	 cell.	 I	 used	 24,	 96	 and	 120	 hours	 post	 replating	 as	my	 time	 points	 and	
performed	another	western	blot	analysis.	As	expected	 the	overall	protein	 levels	of	
myoferlin	 started	 to	 disappear	 after	 96	 hours	 post	 replating	 (120	 hours	 post	
transfection)	but	 the	mini-myoferlin	 fragment	 remained	detectable	even	after	 120	
hours	post	replating.	The	counter	fragment	was	also	evident.	These	data	suggested	
that	once	cleaved,	the	two	fragments	of	myoferlin	are	reasonably	stable.	
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Figure	5.7:	Time	dependence	of	myoferlin	cleavage	in	HEK293	cells.	A.-
C.	 Cells	 were	 transfected	 24	 hours	 prior	 to	 being	 plated	 for	 the	
experiment.	 Cells	were	 harvested	 in	 the	 presence	 (+)	 or	 absence	 (-)	 of	
extracellular	Ca2+	and	scrape	injury.	A.	HEK293	cells	expressing	myoferlin	
full-length	(MFL)	or	myoferlin	38a	(M38a)	were	harvested	3,	24	or	72	hours	
post	replating.	Mini-myoferlin	is	from	24	hours	post	replating	in	both,	+	
and	 -	Ca2+	conditions	using	anti-FLAG	antibody	to	detect	 the	C-terminal	
epitope	 tag.	 At	 72	 hours	 post	 replating	 the	 mini-myoferlin	 band	
appeared	 slightly	 stronger.	Arrow	 indicates	mini-myoferlin	band	 (mMf).	
When	exon	38a	 containing	myoferlin	was	expressed,	no	mini-myoferlin	
band	 was	 detected.	 The	 N-terminal	 counter	 fragment	 was	 identified	
using	the	N-terminal	anti-myoferlin	antibody,	7D2.	MFL	shows	a	robust	N-
terminal	counter	 fragment	 from	~24	hours	onward.	M38a	also	displayed	
evidence	of	N-terminal	cleavage	products	but	they	appeared	less	stable,	
resulting	in	multiple	N-terminal	bands.	B.	Second	time	course	experiment	
of	MFL	 only.	 In	 order	 to	 narrow	 the	 'cleavage	window'	 I	 harvested	MFL	
expressing	HEK293	cells	3,	6,	9	and	24	hours	post	replating.	Only	after	24	
hours	could	a	faint	mini-myoferlin	band	be	detected	and	at	this	time	only	
in	 +	 Ca2+	 conditions.	 C.	 To	 assess	 how	 stable	mini-myoferlin	 would	 be	
once	 generated	 I	 conducted	 a	 longer	 time	 course	 experiment.	 MFL	
expressing	 HEK293	 cells	 were	 harvested	 24,	 96	 or	 120	 hours	 post	
replating.	Mini-myoferlin	was	detectable	even	120	hours	post	replating,	
even	 though	 the	 full-length	 myoferlin	 was	 no	 longer	 detectable.	 This	
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result	 suggests	 that	mini-myoferlin,	 once	made,	 is	 stable	 for	 at	 least	 a	
couple	 for	 at	 least	 days.	 The	 mini-myoferlin	 band	 appeared	 slightly	
stronger	in	the	+	Ca2+	samples	but	was	also	evident	in	the	-	Ca2+	samples.	
	
5.2.7. Effect	of	myoferlin	isoforms	on	proliferation	
I	hypothesised	that	mini-myoferlin	may	increase	the	proliferation	rate	in	the	cell.	To	
test	 this	hypothesis	 I	used	HEK293	cells	 in	an	overexpression-system.	HEK293	cells	
do	not	express	significant	levels	of	myoferlin	protein	and	thus	serve	as	a	good	model	
for	this	particular	experiment.		
	 I	 used	 the	myoferlin	 full-length	(MFL),	 the	 cleavable	myoferlin	 isoform,	 and	
used	 myoferlin	 exon	 38a	 (M38a),	 that	 cannot	 be	 cleaved,	 as	 a	 control.	 The	 empty	
pIRES2-EGFP	 vector	 served	 as	 a	 control	 for	 EGFP	 fluorescence.	 I	 performed	 a	
proliferation	 assay	 that	 I	 had	 developed	 for	 flow	 cytometric	 analyses.	 Cells	 were	
subjected	 to	 the	 lipophilic	 membrane	 dye	 DiD	 (Invitrogen)	 and	 the	 baseline	
measurement	 was	 taken	 after	 2	 hours.	 As	 the	 cells	 divided	 the	 membrane	 dye	
intensity	 halved	 and	 this	 difference	 could	 be	 measured	 at	 the	 flow	 cytometer.	
Increased	 cell	 proliferation	 would	 thus	 result	 in	 a	 greater	 decrease	 of	 DiD	
fluorescence.	 EGFP	 was	 used	 as	 a	 marker	 of	 transfection,	 and	 I	 gated	 for	 EGFP	
fluorescence	at	the	flow	cytometer	(see	Figure	5.8B,	below).		
	 Cells	were	analysed	on	day	0	(24	hours	post	transfection)	on	day	4	and	day	8	
(day	5	and	day	9	after	transfection).	Figure	5.8B	shows	the	histograms	of	pIRES,	MFL	
and	M38a	of	the	results	obtained	with	day	0	as	a	red	line,	day	4	shown	as	a	blue	line	
and	day	8	as	a	green	line	compared	to	a	blank	sample	in	grey.	
	 The	decrease	in	mean	fluorescence	intensity	relative	to	day	0	was	plotted	for,	
and	showed	no	difference	between	pIRES,	MFL	and	M38a	as	portrayed	in	Figure	5.8C,	
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below.	A	repeat	experiment	looked	at	day	0,	4,	5	and	6	showed	the	same	result	(data	
not	shown).	
	
	
Figure	5.8:	Proliferation	of	myoferlin	isoforms	in	HEK293	cells.	HEK293	
cells	 transfected	 with	 MFL,	 M38a	 or	 pIRES-EGFP	 as	 vector	 control.	 A.	
Scatter	 plots	 showing	 the	 gating	 strategy	 for	 all	 cells	 as	 well	 as	 EGFP	
positive	 cells.	 B.	 Scatter	 plots	 showing	 the	 transfection	 efficiency	 for	
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pIRES,	MFL	 and	M38a	 on	day	0.	C.	Histograms	of	 TO-PRO-3	 fluorescence	
intensity	and	the	blank,	unstained	control	(grey).	Day	0	=	red,	day	4=	blue	
and	 day	 8	 =	 green.	 D.	 Graph	 shows	 the	 percentage	 decrease	 in	mean	
fluorescence	 intensity	 (MFI)	 over	 time	 relative	 to	 day	 0.	 pIRES	 =	 open	
triangles,	MFL	=	solid	squares,	M38a=	solid	circles.	N=2	
	
From	my	experiments	I	could	conclude	that,	at	least	when	expressed	in	HEK293	cells,	
the	different	myoferlin	isoforms	do	not	alter	the	proliferation	rate	of	the	cells.	
	
5.2.8. 	No	difference	in	surface-targeting	between	myoferlinFL	and	
myoferlin38a	in	HEK293	cells	
I	also	examined	whether	both	isoforms	of	myoferlin	are	trafficked	to	the	cell	surface	
in	the	same	way.	I	used	transfected	HEK293	cells	and	an	anti-Myc	tag	antibody	that	
picked	 up	 the	 extracellular	 C-terminal	 Myc	 tag	 from	 our	 constructs.	 The	 staining	
revealed	that	there	is	no	appreciable	difference	in	the	amount	of	myoferlin	protein	
transported	to	the	cell	surface.	Figure	5.9,	below,	shows	the	flow	cytometric	analysis	
of	transfected	cells	(EGFP)	versus	cell	surface	staining	using	anti-myc	antibody	using	
AlexaFluor647	 as	 a	 secondary	 antibody.	 The	 experiment	 was	 conducted	 with	
duplicate	repeats.	
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Figure	 5.9:	 Myoferlin	 FL	 and	 38a	 surface	 staining.	 Flow	 cytometric	
analysis	 of	 the	 surface	 staining	 of	 myoferlin	 full-length	 (MFL)	 and	
myoferlin	 38a	 (M38a)	 using	 the	 construct	 Myc	 tag	 labelled	 with	
AlexaFluor647.	 This	 dot	 plot	 analysis	 shows	 all	 viable	 cells	 with	 EGFP	
staining	 on	 the	 y-axis	 and	 Myc/Alexa647	 staining	 on	 the	 x-axis.	 The	
experiment	was	done	in	duplicate	repeats	and	the	average	percentage	of	
surface	staining	is	 indicated	in	the	right	hand	corner	of	each	image.	MFL	
showed	21	%	of	surface	staining	and	M38a	20.7	%.	N	=	2.	
	
5.2.9. Inclusion	of	exon	38a	influences	sub	cellular	targeting	of	myoferlin	
To	study	the	subcellular	localisation	of	the	two	myoferlin-isoforms	(MFL	and	M38a),	I	
performed	immunohistochemistry	studies	on	HEK293	cells	expressing	each	isoform.	
Also,	I	used	the	human	breast	cancer	cell	line	MDA-MB-231	to	visualise	endogenous	
myoferlin	expression	in	the	cell.		
	 Figure	5.10A,	below,	shows	that	MFL	often	appeared	as	a	dense	perinuclear	
structure	whereas	M38a	exhibited	to	be	more	evenly	spread	out	throughout	the	cell	
(Figure	5.10B,	below)	and	less	often	aggregated	to	a	perinuclear	compartment.		
	 Dr	 Laurence	 Cantrill,	 over	 three	 different	 experiments	 counting	 several	
hundred	 cells	 each,	 helped	 me	 quantify	 these	 findings.	 The	 result	 showed	 a	
significant	 difference	 in	 the	 frequency	 with	 which	 myoferlin	 was	 targeted	 to	 the	
perinuclear	compartment	between	MFL	and	M38a.	In	over	70	%	of	cells	MFL	was	found	
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to	cluster	to	the	perinuclear	compartment	whereas	only	~38	%	of	M38a	was	found	to	
localise	 to	 this	 compartment.	 M38a	 appeared	 more	 dispersed	 throughout	 the	 cell	
than	 MFL	 (see	 Figure	 5.10B,	 below).	 The	 localisation	 of	 endogenous	 myoferlin	 in	
MDA-MB-231	cells	detected	with	the	C-terminal	myoferlin	antibody	K16	showed	an	
in-between	phenotype	with	general	signal	enrichment	around	the	nucleus	but	also	
staining	distributed	around	the	cell.	
	
	
Figure	 5.10:	 Subcellular	 localisation	 of	 myoferlin.	 Full-length	 and	 38a	
containing	 isoform	 in	HEK293	 cells	 compared	 to	 endogenous	myoferlin	
staining	 in	MDA-MB-231	cells.	A.	Anti-myc	staining	detecting	 full-length	
myoferlin	 (MFL)	 clustering	 to	 a	 peri	 nuclear	 compartment.	 B.	 Anti-myc	
staining	 detecting	 38a	 containing	 myoferlin	 (M38a)	 showing	 a	 more	
dispersed	 staining	 pattern.	 C.	 Quantification	 of	 staining	 showing	 a	
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clustering	 around	 the	 nucleus	 versus	 dispersed	 staining.	 MFL	 shows	
clustered	staining	around	the	nucleus	 in	72.4	%	of	cells	 (348	cells	 total)	
whereas	M38a	 only	 shows	 clustering	 around	 the	 nucleus	 in	 38.2	 %	 of	
cells	(241	cells	total).	Significance	has	been	established	using	a	one-way	
ANOVA.	 D.	 Endogenous	 myoferlin	 staining	 using	 the	 C-terminal	 anti-
myoferlin	 antibody	 K-16	 (red)	 in	 MDA-MB-231	 cells.	 Phalloidin488	 was	
used	to	stain	F-actin	to	outline	the	cytoskeleton	(green).	Scale	bar	10	µm.	
N	=	4.	
	
	
5.2.10. Limited	 proteolysis	 to	 probe	 different	 structural	 conformation	 of	
exon	38a		
To	analyse	the	effect	of	insertion	of	residues	encoded	by	the	alternately	spliced	exon	
38a	 on	 the	 tertiary	 structure	 of	 the	 myoferlin	 protein,	 I	 performed	 a	 limited	
proteolysis	 tryptic	 digestion	 assay	developed	by	Natalie	Woolger	 in	our	 laboratory	
(Woolger	 et	 al.,	 2017).	 This	 assay	 could	 detect	 if	 the	 inclusion	 of	 exon	 38a	 in	 the	
linker	region	following	the	C2DE	domain,	had	an	effect	on	the	stability	and	folding	of	
this	 domain.	 If	 the	 inclusion	 of	 exon	 38a	 resulted	 in	 destabilisation	 of	 the	 C2DE	
domain	 for	 instance,	 trypsin	would	be	able	 to	 access	 and	 cleave	 the	C2DE	domain,	
subsequently	resulting	in	additional	bands	being	detected	by	western	blot.	
	 Figure	5.11A	shows	 the	predicted	 trypsin	cleavage	sites	of	myoferlin.	There	
were	 two	 extra	 trypsin	 cleavage	 sites	 predicted	 in	 exon	 38a.	 Figure	 5.11B,	 below,	
shows	a	 representative	western	blot	of	 several	experiments	 that	yielded	 the	 same	
result.	 Full-length	 myoferlin	 is	 represented	 on	 the	 left	 and	 38a	 myoferlin	 on	 the	
right.	The	first	sample	of	each	was	subjected	to	saponin	only,	the	second	to	a	 low,	
1/40	trypsin	dilution,	and	the	third	to	a	higher,	1/10	trypsin	concentration.	I	probed	
two	 membranes	 with	 antibodies	 to	 detect	 the	 C-	 (using	 an	 antibody	 against	 the	
protein	tag	Myc)	and	the	N-terminus	(7D2	myoferlin	antibody)	of	myoferlin.		
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Figure	5.11:	 Trypsin	digest	of	myoferlin	 full-length	and	myoferlin	38a.	
A)	 Predicted	 trypsin	 cleavage	 sites	 using	 ExPASy	 PeptideCutter	 tool	
(Bairoch	 et	 al.,	 2005;	Wilkins	 et	 al.,	 1999).	 B)	Western	 blot	 analysis	 of	
myoferlin	 full-length	 (FL)	 and	 38a	 containing	 myoferlin	 expressed	 in	
HEK293	cells	after	digestion	with	1/40	or	1/10	trypsin	as	well	as	saponin	
only	 as	 control.	 C)	Model	 of	 C2DE	 domain	 (Dr	 Bryan	 Sutton)	 with	 the	
cleavage	sites	indicated	in	red	(constitutive)	and	yellow	(exon	38a).	N	=	2.	
	
Generally	it	appeared	that	both	isoforms	create	the	same	banding	patterns	but	the	
intensity	of	some	bands	was	different	between	the	two.	The	bands	picked	up	with	
the	C-terminal	Myc-tag	 showed	 the	 full-length	protein	 at	 ~230	 kDa	and	 there	was	
another	prominent	band	that	would	match	the	size	of	mini-myoferlin	at	~80	kDa.	A	
weakly	detectable	band	could	be	seen	at	~65	kDa	but	only	 in	 the	sample	 that	had	
been	subjected	to	the	diluted	amount	of	trypsin	(1/40).	With	increasing	amounts	of	
trypsin	the	intensity	of	the	full-length	protein	band	decreased.		
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	 The	 N-terminal	 antibody	 also	 showed	 the	 full-length	 protein	 and	 the	
reduction	 of	 protein	 when	 the	 amount	 of	 trypsin	 was	 increased.	 The	 N-terminal	
antibody	exhibited	bands	 that	 could	correspond	 to	 the	counter	 fragments	of	mini-
myoferlin	and	the	65	kDa	product	seen	with	 the	C-terminal	anti-Myc-tag	antibody.	
Interestingly,	myoferlin	38a	also	displayed	a	band	at	~80	kDa	that	matched	the	size	
of	mini-myoferlin.	In	the	calpain	cleavage	assays	I	conducted,	myoferlin	38a	did	not	
produce	 a	 mini-myoferlin	 product	 that	 I	 could	 detect	 by	 western	 blot.	 A	 more	
prominent	 band	 that	was	 generated	with	 tryptic	 digestion	 of	myoferlin	 exon	 38a,	
however,	was	the	smaller	~65	kDa	product.	This	band	was	barely	detectable	 in	the	
full-length	myoferlin	 sample	 but	was	more	 stable	 in	 exon	 38a	myoferlin;	 it	 was	 a	
doublet	band.		
	 The	full-length	myoferlin	protein	was	less	resistant	to	tryptic	digestion	when	
exon	38a	was	expressed,	 as	 the	bands	 are	 relatively	 fainter	 than	 in	 the	 full-length	
myoferlin	 isoform	 1.	 The	 N-terminal	 protein	 products	 matched	 the	 size	 of	 the	
counter	fragments	to	the	C-terminal	fragments.		
	
5.2.11. Inhibition	of	MEK	does	not	stop	myoferlin	cleavage	
Following	 on	 from	 my	 ERK	 studies	 presented	 in	 Piper	 et	 al.,	 2017	 I	 decided	 to	
investigate	 if	the	formation	of	mini-myoferlin	happens	upstream	or	downstream	of	
the	phosphorylation	of	ERK.	The	question	I	sought	to	address	was:	Does	ERK	need	to	
be	phosphorylated	in	order	for	myoferlin	to	generate	mini-myoferlin?		
	 I	 used	 the	 MEK	 inhibitor	 'PD0325901'	 to	 block	 phosphorylation	 of	 ERK.	
Transfected	HEK293	cells	were	treated	with	increasing	amounts	of	MEK	inhibitor	or	
DMSO	for	48	hours.	The	western	blot	analysis	 (see	Figure	5.12,	below)	shows	 that	
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the	 phosphorylation	 of	 ERK	 had	 been	 successfully	 blocked.	 100	 nM	MEK	 inhibitor	
strongly	reduced	the	amount	of	phosphorylated	ERK	detected	by	western	blot,	with	
1,000	 and	 10,000	 nM	 inhibitor	 seeming	 to	 block	 the	 phosphorylation	 of	 ERK	
completely.	 Total	 ERK	 remained	 unchanged	 and	 GAPDH	 was	 used	 as	 a	 loading	
control.	 Interestingly,	 the	 amount	 of	 mini-myoferlin	 formed	 remained	 unchanged	
under	the	different	treatment	conditions.		
	 Figure	 5.12,	 below,	 shows	 a	 representative	western	 blot	 result	 of	my	MEK	
inhibitor	study.	
	
	
Figure	5.12:	Western	blot	analysis	of	MEK	inhibitor	treatment	of	transfected	
HEK293	cells.	Cells	were	transfected	24	hours	before	treating	with	100,	1,000	
and	 10,000	 nM	 MEK	 inhibitor	 PD0325901	 for	 48	 hours.	 Treatment	 was	
renewed	after	24	hours.	Cells	were	harvested	 in	 the	absence	of	extracellular	
Ca2+.	Mini-myoferlin	 formation	appeared	unaltered	by	 the	 inhibition	of	MEK.	
pERK	 showed	 that	 the	 treatment	 had	worked,	 with	 decreasing	 signal	 of	 the	
pERK	 band,	 whereas	 total	 ERK	 levels	 were	 unaffected	 by	 the	 treatment.	
GAPDH	served	as	a	loading	control.	N=2.	
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 Chapter	6: Discussion	-	The	enzymatic	cleavage	of	
Myoferlin		
6.1. 	Myoferlin	cleavage	does	not	depend	on	calpains-1	and	-2	
In	the	previous	chapter	I	examined	the	enzymatic	cleavage	of	myoferlin	and	showed	
that,	unlike	the	cleavage	of	dysferlin,	myoferlin	cleavage	was	not	strictly	dependent	
on	 calpains-1	 and	 -2	 nor	 elevated	 [Ca2+]EC.	 This	 disproves	 my	 hypothesis	 that	 the	
cleavage	of	myoferlin	would	be	regulated	by	the	same	mechanisms	as	the	calpain-
dependent	cleavage	of	dysferlin.		
	 Calpains-1	and	-2	were	good	candidates	for	myoferlin	cleavage	for	a	couple	
of	reasons.	Firstly,	myoferlin	encodes	for	two	calpain	cleavage	sites	that	can	release	
a	'mini-myoferlin-sized'	C-terminal	fragment.	I	showed	that	both	cleavage	sites	were	
functional	 calpain	 cleavage	 sites	 when	 expressed	 in	 the	 dysferlin	 backbone.	
Secondly,	like	myoferlin,	calpains-1	and	-2	have	been	shown	to	play	significant	roles	
in	cancer	and	tumorigenesis:	they	are	involved	in	cell	transformation,	apoptosis	and	
cell	 survival	 as	 well	 as	 tumour	 invasion	 and	 tumour	 cell	 migration	 (Daniel	 et	 al.,	
2003;	Reichrath	et	al.,	2003;	Rios-Doria	et	al.,	2003;	Roumes,	Pires-Alves,	Gonthier-
Maurin,	Dargelos,	&	Cottin,	2010).		
	 Although	 identifying	 the	 enzyme	 that	 is	 responsible	 for	myoferlin	 cleavage	
went	 beyond	 the	 scope	 of	 my	 PhD	 project,	 I	 will	 discuss	 a	 couple	 of	 candidate	
enzymes	below.	
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6.1.1. Who	is	cleaving	myoferlin?		
6.1.1.1. Another	calpain?	
Just	 because	 it	 was	 not	 the	 ubiquitous	 calpains-1	 and	 -2	 that	 cleave	 myoferlin	 I	
cannot	exclude	all	of	 the	other	calpains	 in	 the	cleavage	of	myoferlin.	There	are	14	
calpains	 in	 the	 calpain	 family	 (calpain	1-3	and	5-15),	 as	well	 as	 two	 small	 subunits	
(CAPNS1	and	CAPNS2)	(Huang	&	Wang,	2001;	Sorimachi	&	Suzuki,	2001)	(see	Table	
6.1,	below).		
	
Table	6.1:	The	calpain	family.	Information	for	this	table	is	extracted	from	
from	Huang	and	Wang,	2001	as	well	as	from	Sorimachi	and	Suzuki,	2001	
(Huang	&	Wang,	2001;	Sorimachi	&	Suzuki,	2001).	
Calpain	protein	 Gene	name		 Other	names	 Tissue	distribution	
Calpain-1	 CAPN1	 µ-calpain	large	subunit	 Ubiquitous	
Calpain-2	 CAPN2	 m-calpain	large	subunit	 Ubiquitous	
Calpain-3	 CAPN3	 p94,	nCL-1	 Skeletal	muscle	
Calpain-5	 CAPN5	 hTRA-3,	nCL-3	 Ubiquitous	
Calpain-6	 CAPN6	 CANPX	 Placenta,	
embryonic	muscle	
Calpain-7	 CAPN7	 PalBH	 Ubiquitous	
Calpain-8	 CAPN8	 nCL-2	 Stomach	
Calpain-9	 CAPN9	 nCL-4	 Digestive	tract	
Calpain-10	 CAPN10	 -	 Ubiquitous	
Calpain-11	 CAPN11	 -	 Testis	
Calpain-12	 CAPN12	 -	 Hair	folicle	
Calpain-13	 CAPN13	 -	 Ubiquitous	
Calpain-14	 CAPN14	 -	 ND	
Calpain-15	 SOLH	 SOLH	 Ubiquitous	
CAPNS1	 CAPNS1	 Calpain	 small	 subunit,	
30K,	CAPN4	
Ubiquitous	
CAPNS2	 CAPNS2	 Calpain	small	subunit	2	 Ubiquitous	
	
It	is	known	that	calpain-2	can	be	activated	via	kinase	phosphorylation	(Glading	et	al.,	
2004;	Glading,	Chang,	 Lauffenburger,	&	Wells,	2000;	Shiraha,	Glading,	Chou,	 Jia,	&	
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Wells,	 2002),	which	might	 also	be	 the	 case	 for	 other	 calpains.	 To	date	 all	 calpains	
that	have	been	isolated	in	a	protein	form	are	primarily	Ca2+-dependent	(Khorchid	&	
Ikura,	 2002).	Given	 that	 I	 could	 show	 that	 the	 cleavage	of	myoferlin	 is	 not	 strictly	
dependent	on	Ca2+,	 I	 focussed	on	enzymes	that	do	not	require	elevated	Ca2+	 levels	
for	activation.	These	will	be	discussed	in	the	next	sections,	below.		
	
6.1.1.2. Cathepsins?	
The	 first	 family	 of	 Ca2+-independent	 enzymes	 I	will	 consider	 are	 the	 cathepsins.	 In	
humans	there	are	15	cathepsins,	which	are	mostly	cysteine	proteases	(cathepsins	B,	
C,	F,	H,	K,	L,	O,	S,	V,	W	and	X)	but	with	the	exceptions	of	cathepsin	D	and	E.	These	are	
aspartic	 proteases	 and	 cathepsins,	 A	 and	G	 being	 serine	 proteases	 (V.	 Turk	 et	 al.,	
2012).	Cysteine	cathepsins	are	mostly	lysosomal	proteases	with	optimal	activation	in	
slightly	 acidic	 pH	 conditions	 and	mostly	 unstable	 at	 neutral	 pH.	 Cathepsin	 S	 is	 an	
exception,	 and	 is	 stable	 at	 neutral	 or	 slightly	 alkaline	 pH	 (Kirschke,	Wiederanders,	
Bromme,	&	Rinne,	1989).	
	 Cysteine	 cathepsins	 are	 translated	 as	 inactive	 pro-enzymes	 and	 require	
proteolytic	cleavage	to	be	activated	when	exposed	to	the	acidic	environments	of	late	
endosomes	 and	 lysosomes	 (Gieselmann,	 Hasilik,	 &	 von	 Figura,	 1985;	Mach	 et	 al.,	
1993).	When	cathepsins	are	outside	the	lysosomes	or	in	the	extracellular	site	of	the	
cell,	 they	 can	 be	 rapidly	 and	 irreversibly	 inactivated	 at	 neutral	 pH	 (D.	 Turk	 et	 al.,	
1995).		
	 Cathepsins	have	been	linked	to	cancer	with	the	first	studies	completed	over	
30	years	ago	(Sloane,	Dunn,	&	Honn,	1981).	Sloane,	Dunn	and	Honn	investigated	the	
role	of	the	 lysosomal	cathepsin	B	 in	the	metastatic	potential	of	a	mouse	model	for	
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melanoma	(Sloane	et	al.,	1981).	Since	then	cathepsins	have	been	intensively	studied	
and	 it	 has	 become	 apparent	 from	 mouse	 models	 and	 other	 clinical	 reports	 that	
cathepsins	 play	 significant	 roles	 in	 tumour	 progression,	 tumour	 cell	 invasion	 and	
angiogenesis	(Akkari	et	al.,	2016;	Gocheva,	Chen,	Peters,	Reinheckel,	&	Joyce,	2010;	
Gocheva	et	al.,	2006;	Hazen	et	al.,	2000;	Joyce	et	al.,	2004).		
	 Cathepsins	 have	 to	 be	 considered	 as	 candidates	 for	myoferlin	 cleavage,	 as	
they	 fulfil	multiple	 criteria	 that	 fit	 the	 cleavage	pattern	of	myoferlin	 (e.g.	non-Ca2+	
dependent,	 linked	 to	 cancer	 cell	 progression	 and	 sub-cellular	 localisation).	 In	 silico	
cleavage	 prediction	 programs	 often	 show	 overlapping	 cleavage	 preferences	 for	
cathepsins	and	calpains	and	I	found	that	the	same	cleavage	sites	that	were	predicted	
for	all	cathepsins	were	also	the	ones	predicted	for	calpains.	When	I	performed	an	in	
vitro	cleavage	assay	using	cathepsin	L	the	cleavage	pattern	was	 identical	 to	that	of	
the	 calpain	 control,	 further	 supporting	 the	position	 that	 cathepsins	 are	 candidates	
for	myoferlin	cleavage.	
	
MMPs	or	ADAMs?	
The	literature	shows	mounting	evidence	that	myoferlin	is	somehow	linked	to	matrix	
metalloproteinases	 (MMPs)	 and	 ADAMs	 (a	 disintergrin	 and	 metalloproteinases)	
(Eisenberg	et	al.,	2011;	Li	et	al.,	2012;	Volakis	et	al.,	2014).	Given	that	these	enzymes	
are	also	playing	significant	roles	in	cancer	and	cell	proliferation	they	are	very	suitable	
candidates	for	myoferlin	cleavage.	
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MMPs	
Matrix	metalloproteinases	(MMPs),	also	called	matrixins,	are	a	 large	family	of	zinc-
dependent	 endopeptidases	 responsible	 for	 the	 degradation	 of	 the	 extracellular	
matrix	(EMC)	and	tissue	remodelling.	Their	targets	include	elastins,	gelatin,	collagens	
and	matrix	glycoproteins	(Verma	&	Hansch,	2007).	MMPs	are	secreted	by	a	variety	
of	 cells	 including	 osteoblasts,	 fibroblasts,	 endothelia	 cells	 and	 macrophages	
triggered	by	hormones,	growth	factors	or	cytokines	(Verma	&	Hansch,	2007).	MMPs	
are	 released	 as	 proenzymes	 and	 activated	 upon	 proteolytic	 cleavage	 of	 other	
proteases	 (e.g.	 serine	 proteases,	 plasmin	 and	 furin)	 (Verma	 &	 Hansch,	 2007).	
Members	of	 the	MMP	 family	 can	 release	 the	 cell-membrane-precursors	of	 several	
growth	 factors,	 such	 as	 the	 epidermal	 growth	 factor	 receptor	 (EGFR)	 ligands	 and	
insulin-like	 growth	 factors	 (IGFs),	 that	 promote	 cell	 proliferation	 (Nakamura	 et	 al.,	
2005).		
	 Being	involved	in	these	key	processes	of	cell	proliferation,	the	contribution	of	
MMPs	 to	 tumorigenesis	has	 long	been	a	 focus	 for	 research	and	 they	are	now	well	
canvassed	in	the	literature	(Kessenbrock,	Plaks,	&	Werb,	2010;	Page-McCaw,	Ewald,	
&	Werb,	 2007).	 It	 has	 been	 shown	 that	MMPs	 play	 an	 important	 role	 in	 tumour	
growth,	 cancer	 cell	 invasion,	 and	 metastasis	 formation	 (Gialeli,	 Theocharis,	 &	
Karamanos,	2011).	Further,	 the	over-expression	of	 several	MMPs	 (MMP-2,	 -3,	 -9,	 -
13,	-14)	has	been	linked	with	epithelial	to	mesenchymal	transition	(EMT)	(Egeblad	&	
Werb,	2002).	This	process	has	also	been	associated	with	myoferlin	over	expression	
(Volakis	et	al.,	2014).	
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ADAMs	
ADAMs	(a	disintegrin	and	metalloproteinase)	are	a	zinc-dependent	 family	of	multi-
domain	transmembrane	and	secreted	proteinases	related	to	the	MMPs.	Similarly	to	
MMPs,	 ADAMs	 play	 a	 role	 in	 releasing	 biologically	 important	 ligands	 such	 as	
epidermal	growth	factor,	tumour	necrosis	factor	α	and	transforming	growth	factor	α	
(Sahin	et	al.,	2004).		
	 Given	these	ligands	are	implicated	in	tumorigenesis	and	cancer	progression	it	
is	 not	 surprising	 that	 ADAMs	 themselves	 have	 been	 linked	 to	 cancer.	 There	 is	
emerging	evidence	to	suggest	that	ADAM-9,	ADAM-12,	ADAM-15,	and	ADAM-17	are	
causally	involved	in	tumour	formation/progression	(Duffy,	McKiernan,	O'Donovan,	&	
McGowan,	2009;	Duffy	et	al.,	2011).	Recently	myoferlin	has	been	linked	to	ADAM	12	
expression	in	HeLa	cells	(Zhou	et	al.,	2016),	thus	ADAMs	are	also	suitable	candidates	
for	myoferlin	cleavage.	
	
6.2. 	What	is	the	function	of	exon	38a?	
Myoferlin	gene	expression	does	not	correlate	with	protein	expression	 	
Interestingly,	 in	a	variety	of	human	tissues,	myoferlin	38a	seems	to	be	the	 isoform	
most	 expressed	 on	mRNA	 levels	 (according	 to	 the	 GTEx	 database).	 To	 be	 able	 to	
correlate	 the	amount	of	38a	containing	PCR	product	 to	38a	containing	protein	 the	
researcher	 would	 need	 to	 derive	 an	 isoform	 specific	 antibody	 against	 exon	 38a,	
which	the	team	did	for	dysferlin	exon	40a.	For	future	investigations	of	the	different	
myoferlin	isoforms,	the	development	of	an	exon	38a	specific	antibody	is	something	I	
would	consider	worth	investing	in.		
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Inclusion	of	exon	38a	does	not	alter	proliferation	rates	in	HEK293	cells	
In	the	proliferation	experiment	that	I	conducted	the	M38a	showed	a	tendency	to	have	
a	slightly	higher	proliferation	rate	and	this	tendency	offers	another	fruitful	target	for	
future	research.	In	the	studies	detailed	in	this	thesis	the	fact	that	I	used	transfected	
cells	 is	 always	 a	 shortcoming,	 as	 the	 over-expressed	 myoferlin	 protein	 might	 not	
behave	the	same	way	as	endogenous	myoferlin	does.	Further,	HEK293	cells	usually	
do	not	express	myoferlin	protein	and	might	therefore	deal	with	it	differently	to	cells	
that	naturally	express	myoferlin	protein.		
	 	
Future	directions	for	exon	38a	studies	
To	mitigate	these	caveats,	and	avoid	overexpression	of	exogenous	myoferlin	protein	
a	gene	edited	cell	line	using	CRISPR/Cas9	technology	would	be	preferable.	One	could	
generate	a	cell	line	that	only	expresses	myoferlin	38a	and	the	full-length	isoform.	In	
this	way	 at	 least	 the	 researcher	 could	 ensure	 that	 excess	myoferlin	 protein	 is	 not	
made.		
	
Myoferlin	protein	expression	in	proliferating	tissues		
It	is	not	unreasonable	to	surmise	that	myoferlin	might	play	a	role	in	cell	proliferation.	
In	 my	 protein	 expression	 studies	 (see	 sections	 5.2.4	 and	 5.2.5)	 I	 noticed,	 that	
myoferlin	 protein	 expression	 was	 highest	 in	 tissues	 that	 were	 not	 yet	 terminally	
differentiated.	Tissues	that	maintain	proliferative	capacity	throughout	development,	
like	 lung,	 pancreas,	 placenta	 and	 several	 cancerous	 tissues,	 showed	 the	 highest	
myoferlin	 protein	 expression.	 Dysferlin,	 on	 the	 other	 hand,	 appeared	 to	 have	 the	
opposite	 expression	 pattern	 as	 the	 protein	 levels	 increased	with	 a	 heightening	 of	
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differentiation	 in	muscle	 cells	 and	 also	 in	muscle	 tissue.	 This	 further	 supports	 the	
proposition	 that	 dysferlin	 and	myoferlin	 play	 diverse	 roles	within	 different	 tissues	
and	cells.	 It	 is	not	 surprising	 therefore	 that	 the	cleavage	of	myoferlin	 is	differently	
regulated	to	that	of	dysferlin.		
	
6.2.1. Conclusion	
In	 this	 study	 I	 have	 shown	 that	 the	 enzymatic	 cleavage	 of	myoferlin	 is	 differently	
regulated	 to	 the	 calpain-	 and	 Ca2+-dependent	 cleavage	 of	 dysferlin.	 I	 have	 also	
demonstrated	that	the	constitutive	cleavage	of	myoferlin	may	function	in	a	signaling	
cascade	 connected	 to	 the	 MAPK/ERK	 pathway.	 This	 could	 be	 a	 missing	 link	
explaining	how	myoferlin	expression	may	regulate	the	metastatic	potential	of	cancer	
cells.	 Showing	 that	 myoferlin	 cleavage	 occurs	 in	 triple	 negative	 breast	 cancer	
samples	provides	some	support	that	the	enzymatic	cleavage	of	myoferlin	could	be	a	
disease-relevant	mechanism.		
	 For	 myoferlin,	 the	 inclusion	 of	 the	 alternate	 exon	 38a	 into	 the	 canonical	
myoferlin	 isoform	 blocked	 enzymatic	 cleavage.	 These	 data	 were	 an	 interpretive	
paradox.	The	best	explanations	are:		
1) Inclusion	of	residues	encoded	by	exon	38a	induces	a	change	in	tertiary	structure,	
or	promotes	a	binding	interaction,	that	precludes	enzymatic	cleavage	at	the	exon	
38a	site,	or		
2) Myoferlin	 bearing	 exon	 38a-encoded	 residues	 is	 cleaved,	 but	 the	 protein	
products	are	unstable.		
3) Inclusion	of	exon	38a-encided	residues	results	in	the	trafficking	of	myoferlin	to	a	
compartment	where	the	enzyme	is	not	present	to	cleave	it.		
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All	explanations	imply	that	exon	38a	does	not	serve	as	an	enzymatic	cleavage	site	in	
myoferlin	but	might	 fulfil	 a	different	 function.	 I	 showed	 that	 the	 inclusion	of	 exon	
38a	alters	intracellular	targeting	of	myoferlin,	leading	to	a	more	diffuse	staining	and	
less	 perinuclear	 targeting	 of	 myoferlin.	 I	 subsequently	 demonstrated	 that	 the	
inclusion	of	exon	38a	altered	the	folding	of	the	myoferlin	protein.	
	 The	 exact	 cellular	 consequences	 of	 exon	 38a	 inclusion	 are	 yet	 to	 be	
delineated,	but	my	studies	make	it	apparent	that	this	one	little	exon,	exon	38a,	can	
significantly	change	the	behaviour	of	myoferlin.	
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6.3. Linking	the	two	parts	of	my	thesis	
When	 I	 first	 started	my	 PhD,	 investigating	 the	 cleavage	 of	 myoferlin	 was	 not	 the	
major	 aim.	 I	 intended	 to	 mirror	 the	 experiments	 our	 team	 had	 conducted	 for	
dysferlin	 and	 discover	 if	 calpains	 cleave	 myoferlin	 the	 same	 way	 they	 cleave	
dysferlin.	As	myoferlin	shares	the	largest	amount	of	sequence	homology	to	dysferlin	
(72	%	amino	acid	similarity	and	52	%	amino	acid	identity),	my	H0	hypothesis	was	that	
the	enzymatic	 cleavage	of	myoferlin	would	be	 similar	 to	 the	 cleavage	of	 dysferlin.	
But,	that	proved	not	to	be	the	case.	
	 It	is	known	that	the	cleavage	of	dysferlin	is	dependent	on	Ca2+	and	activated	
calpains	(Lek	et	al.,	2013;	Redpath	et	al.,	2014).	The	calpain	cleavage	site	of	dysferlin	
is	encoded	by	the	alternately	spliced	exon	40a,	and	the	isoform	containing	exon	40a	
is	the	only	dysferlin	isoform	that	can	be	cleaved	(Redpath	et	al.,	2014).	 	
	 When	the	team	first	saw	a	myoferlin	cleavage	product	of	~75	kDa	in	size	by	
western	blot,	I	started	searching	for	predicted	calpain	cleavage	sites.	In	silico	analysis	
of	the	myoferlin	sequences	revealed	two	predicted	calpain	cleavage	sites	that	would	
result	 in	 a	 similarly	 sized	 C-terminal	 cleavage	 product.	 The	 most	 highly	 predicted	
calpain	 cleavage	 site	 was	 encoded	 by	 an	 alternately	 spliced	 exon,	 exon	 38a.	 The	
sequence	 alignment	 to	 dysferlin40a	 demonstrated	 that	 the	 alternate	 exon	 38a	 in	
myoferlin	was	in	the	same	sequence	position	as	exon	40a	in	dysferlin.	Also,	the	fact	
that	 exon	 38a	 is	 highly	 conserved	 throughout	 the	 phyla	 suggests	 it	 has	 functional	
importance.	
	 When	 I	 started	 investigating	 the	 enzymatic	 cleavage	 of	 myoferlin,	 I	 soon	
discovered	it	was	more	complicated	than	the	calpain	cleavage	of	dysferlin	triggered	
by	 elevated	 [Ca2+]IC.	 Paradoxically,	 I	 showed	 that	 only	 the	 constitutive	 myoferlin	
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isoform	 1	 could	 be	 cleaved,	 whereas	 myoferlin	 isoforms	 containing	 residues	
encoded	by	exon	38a	could	not	be	cleaved	at	all.	
	 I	 disproved	 my	 H0-hypothesis	 but	 I	 pursued	 the	 myoferlin	 project	 to	
illuminate	how	and	why	myoferlin	is	cleaved.	This	is	how	the	minor	aim	of	this	thesis	
ripened	into	its	major	aim.	
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 Chapter	7: Material	&	Methods	
	
The	following	chapter	describes	all	experimental	procedures	and	reagents	I	used	to	
generate	the	data	presented	in	this	thesis.	
7.1. Cell	culture	
7.1.1. Cell	lines	and	culture	conditions	
All	cell	lines	used	in	this	thesis	and	their	culturing	conditions	are	listed	in	Table	7.1.	
Table	7.1:	Cell	culture	media	and	coating	for	all	cell	types	used.	
Cell	line	 Origin	 Growth	media	 Differentiation	media	 Coating	
C1504	 Human	primary	muscle	
DMEM:F12,		
10	%	Amniomax	
II,	20	%	FBS	
DMEM:F12,		
10	%	Amniomax	
II,	 2	 %	 horse	
serum	
Collagen/
matrigel	
C2C12	 Mouse	muscle	 DMEM:F12,		15	%	FBS	
DMEM:F12,		
2	%	FBS	 Collagen	
HEK293	
Human	
embryonic	
kidney	
DMEM,	10	%	
FBS	 /	
Poly-D-
Lysin	(PDL)	
COS-7	 Monkey	kidney	fibroblast-like		
DMEM:F12,		
10	%	FBS	 /	 PDL	
MO3.13	 Human	oligodendroglia	
DMEM,	10	%	
FBS	 /	 PDL	
MEF	
Mouse	
embryonic	
fibroblasts	
DMEM,	10	%	
FBS	 /	 /	
MDA-MB-231	 Human	breast	cancer	(basal)	
RPMI	1640,		
10	%	FBS	 /	 /	
MCF-7	 Human	breast	cancer	(luminal)	
RPMI	1640,		
10	%	FBS	 /	 /	
EVSA-T	 Human	breast	cancer	(luminal)	
MEM,	1xNEAA*,	
10	%	FBS	 /	 /	
BT-474	 Human	breast	cancer	(luminal)	
RPMI	1640,	10	
%	FBS	 /	 /	
All	media	was	supplemented	with	50	μg/mL	gentamicin.	*Non-Essential	Amino	Acids	
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7.2. Cell	membrane	repair	assay	
7.2.1. Two-dye	membrane	repair	assay	
7.2.1.1. Mechanical	scrape	injury	for	flow	cytometric	membrane	repair	assay	
Background	
To	 study	membrane	 repair	 from	 large	mechanical	 injuries,	 I	 used	 scrape	 injury	 to	
cause	membrane	lesions	of	>100	nm	by	cutting	off	the	cells	focal	adhesions.	As	the	
size	of	the	lesions	is	dictated	by	the	size	and	amount	of	focal	adhesions	of	the	cell,	I	
only	plated	the	cells	~45	minutes	 -	 three	hours	prior	to	the	experiment.	This	way	 I	
could	control	 for	 the	amount	of	damage	caused	by	controlling	how	much	the	cells	
have	stuck	down	onto	the	substrate.	The	amount	of	time	and	whether	or	not	to	coat	
the	 dishes	 needed	 to	 be	 assessed	 for	 each	 individual	 cell	 line,	 as	 the	 time	 to	
regenerate	 the	 focal	 adhesions	 varies	 between	 cell	 types.	 By	 doing	 this	 I	 was	
controlling	 for	 the	 amount	 of	 focal	 adhesions	 built	 and	 therefore	 the	 amount	 of	
injury	caused	by	the	scraping	procedure.		
	 I	have	developed	this	scrape	membrane	repair	assay	on	the	basis	of	Dr	Lek's	
two-dye	membrane	repair	assay	using	saponin.	For	this	assay,	cells	are	injured	in	the	
presence	of	 the	 first	membrane	 impermeable	dye	that	will	mark	all	cells	 that	have	
been	 injured.	 After	 a	 recovery	 period,	 in	 which	 the	 cells	 should	 repair	 their	
membrane	 lesions,	 the	 second	 cell	 impermeable	 dye	 is	 added	 to	 the	 sample.	 This	
dye	will	 now	 stain	 all	 cells	 that	 could	not	 repair	 their	membranes.	 The	population	
that	 is	 positive	 for	 the	 first	 dye	 but	 negative	 for	 the	 second	 dye	 is	 the	 repaired	
population	of	cells.	They	have	successfully	managed	to	exclude	the	second	dye.	The	
exact	procedure	is	described	below.	
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Experimental	procedure	 	
All	 buffers	 and	 solutions	 should	 be	 brought	 to	 RT	 prior	 to	 the	 start	 of	 the	
experiment.	All	dye-containing	solutions	should	be	kept	from	direct	light	as	much	as	
possible	(e.g.	wrap	tubes	in	aluminium	foil).	
	 Cells	were	plated	45	minutes	-	 three	hours	prior	to	the	experiment	 into	3.5	
cm	 dishes.	 Cells	 were	 washed	 with	 2x	 with	 2	mL	 PBS	 or	 HEPES	 (for	 HEK293	 Ca2+	
titration	experiment)	containing	the	amount	of	Ca2+	appropriate	for	the	experiment	
('normal'	+Ca2+	conditions	≙	900	µM).	Cells	were	then	injured	via	scraping	in	500	μL	
'scrape	solution',	which	is	PBS	or	HEPES	containing	the	first	membrane	impermeable	
dye,	TO-PRO-3	(1:2500,	TO-PRO®-3	Iodide	(ex	642/em	661)	1	mM	solution,	#T3605,	
Thermo	 Fisher/invitrogen).	 Cells	 were	 scraped	 for	 30	 seconds	 using	 a	 rubber	
policeman	 (BD).	 Following	 the	 scrape	 injury	 cells	 were	 transferred	 into	 a	 5	 mL	
polypropylene	 FACS	 tube	 and	 left	 to	 recover	 and	 reseal	 their	membranes	 for	 five	
minutes	at	RT.	Afterwards	cells	were	briefly	pelleted	at	300	g	for	one	minute.	(NOTE:	
I	have	performed	several	optimisation	experiments	with	varying	recovery	times	and	
temperatures.	For	the	cell	lines	used	in	this	thesis	five	minutes	at	RT	worked	well;	if	
studying	other	cell	lines	or	investigating	different	aspects	of	membrane	repair,	these	
conditions	may	need	re-optimising).	
	 The	 supernatant	was	 discarded	 and	 the	 pellet	 resuspended	 in	 200	 μL	 cold	
PBS	or	HEPES,	containing	the	same	Ca2+	concentration	used	for	the	scrape,	and	the	
second	 cell	 impermeable	 dye,	 propidium	 iodide	 (PI)	 (1:500,	 1	 mg/mL	 solution	 in	
water,	 (ex	 533/em	 617)	 #P3566,	 Thermo	 Fisher/invitrogen).	 PI	 will	 now	 stain	 all	
injured	cells	that	were	unable	to	repair	their	plasma	membrane	and	thus	still	allow	
the	 dye	 to	 enter	 the	 cell	 and	 stain	 the	 nucleus.	 The	 prepared	 samples	were	 then	
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transported	 to	 the	 flow	 cytometer	 on	 a	 rack	 pre-chilled	 on	 ice.	 A	 schematic	
illustration	of	the	workflow	of	the	two-dye	scrape	membrane	repair	assay	is	shown	
in	Figure	2.5.	
	
Controls	
For	 each	 experiment	 the	 appropriate	 controls	 were	 captured	 prior	 to	 sample	
acquisition.	A	blank	 sample	was	used	 to	 set	 the	gates	 for	 the	 size	of	 the	 cells	 and	
serve	as	a	negative	control	for	the	dyes.	Single	stained	controls	for	TO-PRO-3	and	PI	
were	 also	 included	 in	 every	 experiment.	 Further	 I	 also	 controlled	 for	 TO-PRO-3	
uptake	via	pinocytosis	by	including	an	undamaged,	trypsinized	control	that	has	been	
subjected	 to	TO-PRO-3	 for	 the	 same	amount	of	 time	 the	 injured	 cells	were	 left	 to	
recover	 (usually	 five	 minutes).	 This	 control	 allows	 me	 to	 set	 the	 gates	 more	
appropriately	and	analyse	the	'true'	damaged	but	repaired	population	of	cells.	
	 At	 the	 flow	 cytometer	 50,000-100,000	 cells	 were	 acquired	 (BD	 FACS	
CantoTM).	After	acquisition	of	all	 samples,	 I	analysed	the	experiment	using	FlowJo®	
software.	
	 	 	
Culturing	primary	human	myoblasts	for	membrane	repair	assay	
When	using	muscle	cells	in	this	experiment	it	is	important	that	the	myotubes	are	not	
too	big	to	fit	through	the	flow	cytometer.	We	were	using	a	primary	human	myoblast	
cell	 line	 that	we	 have	 established	 in	 our	 laboratory	 from	 an	 adult	 human	 skeletal	
muscle	 biopsy	 (c1504).	 Cells	 were	 cultured	 in	 full	 growth	 media	 and	 plated	 onto	
collagen	coated	(rat	tail	collagen	type	II)	3.5	cm	dishes	at	60	%	confluence.	Two	days	
later	the	media	was	changed	to	differentiation	media	to	initiate	myotube	formation	
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(see	Table	7.1).	Cells	were	 left	 to	differentiate	 for	 three	days.	That	allowed	for	 the	
formation	of	little	myotubes,	small	enough	to	still	fit	through	the	flow	cytometer;	if	
cells	are	too	big	the	flow	cytometer	would	be	blocked.	
	
7.2.2. Streptolysin-O	 induced	pore	 forming	 toxin	 injury	 for	 flow	cytometric	
membrane	repair	assay	
To	 generate	 a	 more	 physiological	 membrane	 injury,	 I	 have	 decided	 to	 use	
streptolysin-O	 to	 perforate	 the	 membrane.	 The	 scrape	 membrane	 repair	 assay,	
described	above,	was	adjusted	and	optimised	for	pore	forming	toxin	injury.	For	this	
assay	 cells	were	 injured	 in	 solution	 and	 not	 adhered	 in	 dishes.	 Cells	were	washed	
with	-Ca2+	PBS	and	'trypsinized'	(we	used	TripleETM	Express,	#12605-028,	Invitrogen,	
a	temperature	insensitive	version	of	trypsin).		
	
Recovery	from	trypsinisation		
TripleETM	was	quenched	with	growth	media	and	cells	were	pelleted	briefly	at	300	g	
for	one	minute	at	RT.	The	supernatant	was	discarded	and	cells	were	resuspended	in	
1	mM	Ca2+	HEPES	buffer	 (~100	µL/	500,000	cells)	and	 transferred	 into	FACS	 tubes.	
Cells	were	left	to	recover	from	the	'trypsinisation'	in	a	rack	heated	to	37°C	for	30	-	60	
minutes.	 Cells	 were	 pelleted	 and	 wash	 in	 -Ca2+	 HEPES	 buffer	 (same	 volume	 as	
before).	Aliquot	100	µL	/	~500,000	cells	for	each	condition	into	a	new	FACS	tube.		
	
Perforation	in	the	presence	of	TO-PRO-3	 	
100	µL	of	 -Ca2+	HEPES	buffer	containing	SLO	(kept	on	 ice	and	activated	with	1	mM	
DTT	prior	 to	use)	 and	1:200	TO-PRO-3	was	added	 to	 the	 samples	 (NOTE:	 the	pore	
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healing	is	instant	in	the	presence	of	Ca2+;	the	initial	injury	needs	no	Ca2+	in	order	for	
TO-PRO-3	to	stain	the	cells).	Cell	were	incubated	with	SLO	for	10	minutes	at	37°C	to	
allow	pores	to	form	and	to	perforate	the	membranes;	TO-PRO-3	should	now	label	all	
cells	that	successfully	created	membrane	pores.		
	
Repair		
Afterwards	1	mL	of	HEPES	buffer	containing	1	mM	Ca2+	was	added	to	each	sample	in	
order	for	the	cells	to	activate	their	Ca2+-dependent	membrane	repair	mechanism	to	
get	rid	of	the	pores.	The	cells	were	incubated	for	five	minutes	at	37°C.	The	reaction	
was	quenched	by	adding	1	mL	of	 cold	FBS	 (SLO	 is	 cholesterol	dependent	and	 thus	
the	cholesterol	in	FBS	will	saturate	SLO	and	quench	it).		
	
Labelling	of	cells	that	failed	to	repair		
The	 samples	were	pelleted	at	300	g	 for	one	minute	and	 resuspend	cells	 in	200	µL	
cold	HEPES	buffer	+Ca2+	containing	1:200	PI.	PI	will	now	mark	all	cells	that	could	not	
repair	 the	pores.	All	 fully	 repaired	cells	will	exclude	PI	and	will	only	be	positive	 for	
TO-PRO-3.	Place	all	samples	on	a	pre-chilled	rack	on	ice	and	read	samples	at	the	flow	
cytometer	as	described	before.	
	
7.2.3. Ca2+	 flux	 measurements	 after	 streptolysin-O	 induced	 pore	 forming	
toxin	injury		
This	 project	 has	 been	 a	 collaborative	 effort	with	 PhD	 candidate	 Reece	 Sophocleus	
from	the	University	of	Wollongong.		
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Background	
When	the	membrane	gets	injured,	Ca2+	flux	is	the	first	effect	that	can	be	measured	
before	membrane	impermeable	dyes	can	enter	the	cell	and	stain	the	nucleus.	This	is	
why	we	have	 developed	 a	 high	 throughput	 Ca2+	flux	membrane	 repair	 assay	 using	
the	'FLexStation	3	microplate	reader'	(Molecular	Devices,	Sunnyvale	California).		
	
Fura-2	as	Ca2+	indicator	 	
For	 this	 assay	we	 used	 the	 Ca2+	 dye	 Fura-2,	 AM,	 the	 acetoxymethyl	 ester	 form	of	
Fura-2,	often	used	for	non-invasive	intracellular	loading	(from	now	on	referred	to	as	
Fura-2)	 (#F1221,	 Thermo	Fisher).	 Fura-2	 is	 a	 sensitive,	 ratiometric,	 fluorescent	dye	
that	binds	 intracellular	Ca2+.	 Fura-2	 is	 excited	 at	 340	nm	and	380	nm	wavelengths	
and	 emits	 light	 at	 510	 nm	 (Grynkiewicz,	 Poenie,	 &	 Tsien,	 1985).	 The	 ratio	 of	 the	
excitation	 at	 340/380	nm	 is	 directly	 related	 to	 the	 intracellular	 Ca2+	 concentration	
([Ca2+]IC).	 Using	 the	 ratio	 of	 the	 two	 excitation-wavelengths	 helps	 extinguishing	
variables,	such	as	cell	thickness	or	variable	dye	concentration.		
	 	
Experimental	procedure	
The	 day	 before	 the	 experiment,	 HEK293	 cells	were	 plated	 onto	 PDL	 coated	 black,	
clear-bottom	96	well	plates	 (e.g.	Corning,	#	353219).	Cells	were	pre-loaded	with	5	
µM	Fura-2	and	0.02	%	pluronic	acid,	30	minutes	before	commencing	the	experiment	
(in	the	incubator	at	37°C).	The	pluronic	acid	helped	the	solubilisation	and	membrane	
crossing	of	Fura-2	(Maruyama,	Hasegawa,	Yamamoto,	&	Momose,	1989).	
	 Starting	 the	experimental	procedure,	we	 first	 collected	baseline	 readings	of	
our	cells	 for	 five	minutes.	Afterwards	 the	cells	were	 taken	out	of	 the	plate	 reader,	
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the	 loading	 buffer	 was	 removed	 and	 the	 cells	 were	 washed	 with	 200	 µL	 of	 'EC	
Calcium	Solution'	(145	mM	NaCl,	2	mM	CaCl2,	1	mM	MgCl2,	5	mM	KCl,	10	mM	HEPES	
and	 13	 mM	 glucose,	 pH	 7.4).	 After	 the	 wash,	 cells	 were	 subjected	 to	 increasing	
concentrations	 of	 SLO.	 The	 SLO	 was	 prepared	 in	 a	 separate	 96-well	 plate	 in	 EC	
Calcium	Solution	containing	DTT	(make	up	6	mL	EC	Calcium	Solution	and	add	80	µL	
of	1	M	DTT).		
	 	
Controls	
We	 also	 included	 untreated	 and	 DMSO	 treated	 controls	 (Fura-2	 is	 dissolved	 in	
DMSO)	as	well	as	an	ionomycin	control	(1.5	µM).	Ionomycin	was	used	to	empty	the	
intracellular	Ca2+	stores	(Hoth	&	Penner,	1992),	giving	us	the	'maximal	Ca2+	response'	
possible.	Manually	add	60	µL	of	assay	buffer	 (containing	SLO,	DMSO,	 ionomicin	or	
buffer	only)	 into	each	well.	After	drug	application,	 the	plate	was	put	back	 into	 the	
plate	 reader	and	the	measurement	started	straightaway.	Fura-2	 fluorescence	 (Ex	=	
340/380;	 Em=	 510)	 was	 read	 every	 minute	 for	 30	 minutes.	 The	 baseline	
measurements	were	detracted	and	the	excitation	ratio	was	analysed	using	GraphPad	
Prism.	
	
7.2.4. Laser	ablation	injury	
Background	
Laser	ablation	 injury	 is	 regarded	as	 the	 'gold	standard'	 for	membrane	 injury	 in	 the	
literature	 (Dimple	 Bansal	 et	 al.,	 2003;	 Jimenez,	Maiuri,	 Lafaurie-Janvore,	 Perez,	 &	
Piel,	2015;	Steinhardt	et	al.,	1994).	Laser	injury	allows	wounding	of	a	single	cell	in	a	
reproducible	 manner	 and	 predictable	 wound	 size,	 controlled	 by	 the	 laser.	 The	
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wounding	and	repair	of	the	can	then	be	followed	and	analysed	with	fast	time-lapse	
imaging.		
	
Experimental	procedure	
We	used	the	Zeiss	LSM	880	 inverted	 laser	scanning	confocal	microscope	 located	at	
the	 Biomedical	 Imaging	 Facility	 (BMIF)	 at	 UNSW	 to	 injure	 single	 cells	 using	 laser	
ablation.		
	 HEK293	 cells	 were	 plated	 onto	 3.5	 cm	 glass	 bottom	 dishes	 with	 a	 14	mm	
micro	well	diameter	and	No.	1.5	glass	 thickness	 (MatTek	#P35G-1.5-14-C	uncoated	
coverslip).	The	glass	micro	well	was	coated	with	PDL	prior	 to	seeding	the	cells.	For	
the	PDL-coating	add	enough	PDL	to	cover	the	entire	glass	well	and	 incubate	 in	the	
tissue	culture	hood	for	~30	minutes.	Take	PDL	off	(can	be	re-used	if	kept	sterile)	and	
wash	dishes	1x	with	PBS.	
	 Cells	were	plated	~one	hour	prior	to	the	start	of	the	experiment	to	achieve	
better	 morphological	 consistency	 between	 cells.	 Cells	 were	 plated	 only	 onto	 the	
glass	 well	 in	 the	 middle	 of	 the	 dish	 and	 not	 onto	 the	 whole	 dish	 (less	 cells	 are	
needed	this	way).	Cell	were	washed	with	+Ca2+	PBS	and	then	loaded	with	2	µM	FM1-
43	(a	fluorescent	cell-impermeant	membrane	dye,	#T35356,	Thermo	Fisher)	in	+Ca2+	
PBS	and	incubated	for	30	minutes	at	37°C.		
	 Cells	 were	 damaged	 with	 a	 2-photon	 laser	 with	 850	 nm	wavelengths.	 The	
damaged	area	and	 length	of	damage	was	optimised	so	 that	cells	would	be	 injured	
but	did	not	suffer	too	larger	injuries	to	recover.	For	HEK293	cells	the	initial	damage	
area	was	~0.31	µm2	(4x4	pixel)	and	cells	were	damaged	for	10.5	ms	(65.5	µsec	'pixel	
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dwell'	for	4x4	=	16	pixels	=	10.5	ms).	Different	cell	lines	might	require	different	laser	
settings	to	achieve	the	same	injury.		
	
Measuring	and	analysing	membrane	damage	and	repair	
The	 increase	 in	mean	 fluorescence	 intensity	 (MFI)	was	 analysed	 over	 at	 least	 two	
minutes	using	Fiji	(Schindelin	et	al.,	2012).	The	regions	of	interest	(ROIs)	were	set	to	
25x25	 pixel;	 this	 is	 a	 relatively	 large	 ROI,	 chosen	 to	 allow	 for	 laser	 induced	
membrane	movement	and	blebbing,	without	loosing	the	main	area	of	interest.		
	 The	MFI	 of	 the	 initial	 injury	 site,	 as	 well	 as	 the	 inside	 of	 the	 cell	 and	 the	
opposite	membrane	were	measured	and	the	data	transferred	 into	GraphPad	Prism	
for	analysis.		
	
7.3. Transfections,	western	blotting	and	immunohistochemistry	
7.3.1. Transfections	
For	all	transfections	cells	were	plated	the	day	before	at	~50	to	75	%	of	the	desired	
confluence	 on	 the	 day	 of	 transfection	 (initial	 seeding	 confluence	 depends	 on	 the	
growth	rate	of	the	cell	 line	used).	Alternately	cells	can	be	plated	 in	the	morning	of	
the	 transfection	 day	 at	 the	 desired	 density	 and	 transfected	 at	 night;	 this	way	 it	 is	
easier	to	achieve	the	correct	confluence.	All	reagents	should	be	at	RT	at	time	of	use	
(except	for	the	cell	media	which	will	be	at	37°C).	
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CaPO4	(HEK293	cells)	
For	the	calcium	phosphate	transfection,	cells	should	be	about	65	%	confluent	in	a	10	
cm	dish	with	7	mL	full	growth	media.	Place	14	µg	DNA	(2	µg/mL	media)	into	a	2	mL	
eppendorf	tube.	Carefully	add	0.35	mL	0.25	M	CaCl2	dropwise	to	the	DNA.	Mix	gently	
3x	by	pipetting	up	and	down.	Then	add	0.35	mL	2x	BES;	be	very	careful	and	slowly	
add	BES	dropwise	to	the	transfection	mixture.	NOTE:	Precipitate	is	going	to	form	as	
soon	as	BES	 is	added	to	 the	solution.	 Incubate	 the	 transfection	mixture	 for	~10-15	
minutes	at	RT	and	then	add	0.7	mL	dropwise	onto	your	dish	of	cells.	Swirl	briefly	and	
gently	and	place	 in	the	 incubator	at	37˚C	at	5	%	CO2.	Preferably	change	the	media	
after	eight	hours	of	incubation	to	avoid	toxicity.	NOTE:	For	experiments	that	involve	
+/-	Ca2+	conditions	this	transfection	is	not	ideal	as	the	precipitate	contains	Ca2+.	Use	
PEI	transfection	instead.	
	
PEI	transfection	(HEK293	cells)	
For	 polyethylenimine	 (PEI,	 Polysciences)	 transfections	 cells	 should	 be	 ~80	 %	
confluent.	 The	 reagents	 used	 for	 PEI	 transfection	 are	 summarized	 in	 Table	 7.2	 for	
different	 dish-sizes.	 For	 a	 transfection	 in	 a	 3.5	 cm	 dish	 use	 8.3	 µL	 PEI,	 add	 20	 µL	
sodium	chloride	(NaCl)	and	mix	by	vortexing	briefly.	Add	3	µg	DNA	and	gently	mix	by	
flicking	the	tube.	Spin	down	briefly	and	incubate	for	15	minutes	at	RT.	Add	dropwise	
to	 the	 dish	 of	 cells	 containing	 2	mL	 full	 growth	media.	 Replace	media	 after	 eight	
hours	 if	 possible	 to	 avoid	 toxicity,	 or	 transfect	 at	 night	 and	 replace	media	 in	 the	
morning	 to	 reduce	 toxicity	 (we	 have	 not	 observed	 significant	 amounts	 of	 toxicity	
from	PEI	transfections	over	night).	
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Table	7.2:	PEI	transfection	ratios	for	different	dish	sizes	
Dish/Plate	 Surface	Area	 Medium	 PEI	 NaCl	 DNA	
24	well	 2	cm2	 0.5	mL	 2.1	µL	 50	µL	 1	µg	
35	mm/6	well	 10	cm2	 2	mL	 8.3	µL	 20	µL	 3	µg	
60	mm	 20	cm2	 3	mL	 12.5	µL	 300	µL	 6	µg	
100	mm	 60	cm2	 7	mL	 29.1	µL	 700	µL	 14	µg	
	
	
GeneJuice®	(C2C12	cells)	
The	mouse	muscle	cell	 line,	C2C12,	was	 transfected	using	GeneJuice®.	Cells	 should	
be	at	~70	%	confluence	at	transfection.	For	a	3.5	cm	dish	use	100	µL	Opti-MEM	and	
add	7.5	µL	GeneJuice®.	Vortex	briefly	and	incubate	for	five	minutes	at	RT.	Add	2.5	μg	
DNA	and	mix	gently	by	pipetting	up	and	down	3x.	Incubate	for	10	minutes	at	RT	and	
add	dropwise	to	your	dish.	Incubate	over	night.		
	
Table	7.3:	GeneJuice®	transfection	ratios	for	different	dish	sizes	
Dish/Plate	 Surface	Area	 Medium	 GeneJuice®	 Opti-MEM	 DNA	
24	well	 2	cm2	 0.5	mL	 1.5	µL	 20	µL	 0.5	µg	
35	mm/6	well	 10	cm2	 2	mL	 7.5	µL	 100	µL	 2.5	µg	
60	mm	 20	cm2	 3	mL	 15	µL	 200	µL	 5	µg	
	
	
Lipofectamin®	LTX	(COS-7	cells)	
COS-7	 cells	 were	 transfected	 using	 Lipofectamin®	 LTX.	 Cells	 should	 be	 ~70	 %	
confluent	at	the	time	of	transfection.	Change	media	to	antibiotic	free	media	at	least	
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one	 hour	 prior	 to	 transfection	 to	 allow	 for	 calibration	 of	 the	media	 (two	 hours	 is	
better).	For	this	transfection	two	separate	transfection	mixtures	are	prepared.		
1) 3	 μg	 DNA	 +	 200	 μL	 Opti-MEM	 +	 4μL	 PLUS	 reagent	 and	 incubate	 for	 five	
minutes.	
2) 6	μL	Lipofectamin®	LTX	+	200	μL	Opti-MEM,	vortex	briefly	and	 incubate	 for	
five	minutes.	
Mix	 the	 two	 solutions	 together,	 pipette	 up	 and	 down	 3x	 and	 incubate	 for	 ~30	
minutes	at	RT.	Add	dropwise	to	the	cells	and	incubate	during	the	day.	Change	media	
to	full	growth	media	at	night	(over	night	transfection	works	as	well).		
	
Lipofectamine®	3000		
For	transfection	efficiency	of	almost	100	%	in	HEK293	cells	use	Lipofectamine®	3000.	
It	is	much	more	expensive	than	CaPO4	or	PEI	but	if	maximum	transfection	efficiency	
is	desired	this	might	be	necessary.	For	this	method,	change	to	antibiotic	free	media	
at	least	one	hour	prior	to	transfection.	Two	mixtures	are	prepared	separately	for	this	
transfection	method.	For	a	3.5	cm	dish	use:	
1) 4	μL	Lipofectamine®	3000	+	125	μL	Opti-MEM,	vortex	briefly	
2) 2.5	μg	DNA	+	125	μL	OptiMEM	+	5	μL	P3000,	mix	by	gently	pipetting	up	and	
down	3x.	
Mix	both	solutions	together	and	incubate	for	five	minutes	at	RT.	Then	add	dropwise	
to	 antibiotic-	 and	 serum-free	 media	 (replace	 with	 full	 growth	 media	 after	 four	
hours).	
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7.4. Western	blotting	
7.4.1. Harvesting	cells	for	western	blot	analysis	
Undamaged	+/-	Ca2+	
To	harvest	cells	without	damaging	the	membrane	by	scraping,	cells	are	lysed	directly	
from	the	plate.	For	this	cells	are	washed	in	cold	PBS	-Ca2+	followed	by	a	30	seconds	
wash	 with	 10	 mM	 EDTA.	 After	 removing	 the	 EDTA	 a	 final	 PBS	 -Ca2+	 wash	 is	
performed.	The	volume	depends	on	the	size	of	 the	culture	dish.	E.g.	a	3.5	cm	dish	
would	 be	 washed	 with	 2	 mL	 PBS	 and	 EDTA.	 For	 undamaged	 plus	 Ca2+	 harvest	
conditions	 cells	 are	 washed	 twice	 in	 cold	 PBS	 +Ca2+	 followed	 by	 45	 minutes.	
incubation	with	RIPA	buffer	 substituted	with	 1	mM	Ca2+	 and	no	 EDTA.	Afterwards	
the	sample	is	treated	like	the	undamaged	–Ca2+	samples.	After	this	step	all	samples	
are	 treated	 the	 same.	 RIPA	 buffer	 containing	 freshly	 added	 protease	 inhibitors	
(1:500)	 is	added	to	solubilize	the	cells	and	the	dish	 is	 incubated	on	 ice	on	a	rocker	
shaker	for	>45	minutes.		
	 The	 supernatant	 gets	 transferred	 into	 a	 1.5	 mL	 eppendorf	 tube	 and	
centrifuged	 at	 20,000	 g	 at	 4°C	 for	 15	 minutes	 in	 order	 to	 pellet	 the	 insoluble	
components	of	the	cells.	The	supernatant	is	transferred	into	a	fresh	tube	leaving	~10	
μL	 behind.	 2x5	μL	 are	 taken	out	 to	 perform	a	BCA	 assay	 (Thermo	 Fisher,	 PierceTM	
BCA	Protein	Assay	Kit,	#23225)	to	determine	the	protein	concentration	if	necessary.	
After	adding	sample	buffer	and	DTT	the	sample	 is	heat	 inactivated	at	94°C	for	four	
minutes	and	stored	at	-80°C	or	used	immediately.	
	
	
	
	 246	
Scrape	injury	+/-	Ca2+	
When	the	cells	were	supposed	to	be	injured	cells	were	washed	twice	in	either	+	or	-
Ca2+	PBS	 (-Ca2+	has	a	10	mM	EDTA	wash	 for	30	seconds	between	 the	PBS	washes)	
and	than	scraped	in	+/-	Ca2+	PBS	using	a	rubber	policeman.	The	volume	is	dependent	
on	the	size	of	the	dish,	but	for	a	3.5	cm	dish	500	μL	PBS	is	used.	The	scraped	cells	are	
transferred	into	a	1.5	mL	eppendorf	tube	and	pelleted	at	3,000	g	for	three	minutes	
at	4°C.	The	supernatant	is	discarded	and	the	pellet	re-suspended	in	RIPA	-Ca2+	(~150	
μL	 for	 a	 confluent	 3.5	 cm	 dish).	 Further	 sample	 preparation	 is	 described	 under	
“undamaged	without	Ca2+”.	
	
Enhanced	scrape	injury	with	saponin	
To	 increase	 the	 amount	 of	 calpain	 activation	 and	 subsequent	 calpain	 cleavage	 of	
dysferlin	we	have	modified	the	scrape	injury	by	adding	0.001	%	saponin	to	the	+Ca2+	
PBS	 scrape	 solution.	 Wash	 your	 cells	 twice	 with	 PBS	 +Ca2+,	 then	 add	 the	 scrape	
solution	containing	saponin	and	scrape	for	30	seconds	after	that	proceed	as	normal.	
	
Scrape	injury	with	calpeptin	treatment	
Cells	are	grown	to	~70	-	80	%	confluence.	Cells	are	pre-treated	with	calpeptin	(30	-	
100	µM)	three	hours	and	again	30	minutes.	prior	to	the	scrape	harvest.	For	the	initial	
treatment	half	 the	media	 is	 taken	off	 and	 collected	 into	a	 tube;	2x	 the	amount	of	
calpeptin	 is	 added	 to	 the	 collected	media	 and	 then	added	back	onto	 the	dish	 you	
want	to	treat.	For	the	second	treatment	the	whole	media	is	removed	and	replaced	
with	new	media	that	contains	the	correct	amount	of	calpeptin	(if	the	media	doesn't	
get	changed	there	will	be	too	much	DMSO	in	the	media).	 Ideally	the	media	for	the	
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second	treatment	will	be	pre-conditioned	in	the	incubator	to	acquire	the	correct	pH	
and	 temperature.	 For	 the	 harvest	 cells	 get	 washed	 2x	 with	 PBS	 +Ca2+	 and	 then	
scraped	for	30	sec.	in	PBS	+Ca2+	containing	calpeptin.	After	that	proceed	as	normal.	
	
7.4.1.1. Western	blot	from	tissue	sections	
To	 prepare	 cut	 tissues	 for	 western	 blot,	 cut	 at	 least	 10	 sections	 ~10	 μm2	 on	 the	
cryostat	set	to	~-30°C.	Transfer	cut	sections	into	1.5	mL	eppendorf	tubes	pre-chilled	
on	dry	 ice.	 Lyse	 sections	 in	~10	μL/section	 (as	 a	 starting	point)	 in	 lysis	buffer	 (125	
mM	 tris	 pH	 8.8	 and	 4	 %	 SDS)	 with	 freshly	 added	 protease	 inhibitor	 cocktail	 and	
phosphatase	 inhibitor	 cocktail	 (Sigma).	 NOTE:	 SDS	will	 crash	 out	 of	 solution	when	
cold.	 Keep	 buffer	 at	 RT	 but	 leave	 tubes	 on	 ice	 (wet	 ice).	 Sonicate	 samples	 till	
dissolved	(~10	bursts).	Perform	BCA	assay	on	2	x	5	μL	from	this	sample	to	determine	
the	protein	concentration.	Add	4	x	loading	buffer	(250	mM	tris	pH	6.8,	8	%	SDS,	40	%	
glycerol)	and	DTT	(100	mM	final)	heat	samples	at	94˚C	for	five	minutes.	Briefly	spin	
to	get	rid	of	condensation	and	store	at	-80˚C	or	use	straight	away.	
	
7.4.2. SDS-PAGE	western	blot	analysis	
In	order	to	separate	proteins	by	their	molecular	weight	protein	samples	were	loaded	
on	 a	 western	 blot	 gel	 (mostly	 Invitrogen	 Bis-Tris	 4-12	 %	 BOLT	 gels).	 The	 samples	
were	 run	 in	 MOPS	 buffer	 and	 500	 μL	 of	 antioxidant	 was	 added	 into	 the	 inner	
chamber.	The	samples	were	run	at	165	V	for	one	hour	(or	till	the	dye	front	reaches	
the	 bottom	 of	 the	 gel).	 Afterwards	 the	 proteins	 were	 blotted	 onto	 a	 PVDF	
membrane	that	has	been	activated	with	methanol	for	one	minute.	Block	membranes	
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for	30	minutes	with	 the	appropriate	block	 (mostly	PBS-T	with	5	%	 skim	milk)	on	a	
rocker-shaker	at	RT.	Probe	with	1˚	antibody	over	night	at	4˚C	or	for	two	hours	at	RT.	
Wash	membranes	3x10	minutes	with	PBS-T	(or	TBS-T	if	used	for	antibody).	Incubate	
with	2˚	HRP-conjugated	antibody	for	two	hours	at	RT.	Wash	3x10	minutes	with	PBS-T	
(or	 TBS-T	 if	 used	 for	 antibody).	 Incubate	 membrane	 with	 ECL	 solution	 for	 ~two	
minutes	and	develop	film	in	the	dark	room.	
	 The	antibodies	and	conditions	used	for	western	blot	are	summarised	in	Table	
7.4.
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Table	7.4:	Antibodies	used	for	w
estern	blot	in	this	study	
Antibody	
against	
Antibody/clone	
nam
e	
Epitope	
Species	
Dilution	
Block	
Com
pany	
Product	
num
ber	
M
yoferlin	
7D2	
N
-term
.		
aa300-400	
α-rabbit	
1:5,000	
PBS-T/5	%
	Skim
	m
ilk	
abcam
	
ab76746	
M
yoferlin	
K-16	
C-term
.	
aa1550-1600	
α-goat	
1:200	
Block	in	PBS-T/1	%
	
Skim
	m
ilk	and	probe	
w
ith	PBS-T/5	%
	BSA	
Santa	Cruz	
sc-51367	
Dysferlin	
Ham
let-1	
aa1999-2016	
α-m
ouse	
1:5,000	
PBS-T/5	%
	Skim
	m
ilk	
N
ovocastra	
N
CL-Ham
let	
Dysferlin	
Rom
eo	
aa123-142	
α-rabbit	
1:1,000	
PBS-T/5	%
	Skim
	m
ilk	
abcam
	
ab124684	
Dysferlin	
FerA	
aa644-783	
α-rabbit	
1:1,000	
PBS-T/5	%
	Skim
	m
ilk	
Sigm
a-Aldrich	
HPA021945	
Calpain-1	
	
/	
α-goat	
1:300	
PBS-T/5	%
	BSA	
Santa	Cruz	
sc-7531	
Calpain-2	
Calpain-2,	Large	
subunit	(M
-type)	
/	
α-rabbit	
1:1,000	
PBS-T/5	%
	BSA	
Cell	Signaling	
2539S	
	
Calpain-S1	
CAPN
S1,		
Calpain	reg	(P-1)	
/	
α-m
ouse	
1:500	
PBS-T/5	%
	BSA	
Santa	Cruz	
sc-32325	
ERK	
ERK	p44/42	
M
APK	(Erk1/2)	
/	
α-rabbit	
1:2,000	
PBS-T/5	%
	Skim
	m
ilk	
Cell	Signaling	
4695P	
pERK	
P-p44/42	M
APK	
(T202/Y204)	
/	
α-rabbit	
1:2,000	
PBS-T/5	%
	Skim
	m
ilk	
Cell	Signaling	
4370P	
pAKT	
Phospho-Akt	
(Ser473)	
/	
α-rabbit	
1:2,000	
PBS-T/5	%
	Skim
	m
ilk	
Cell	Signaling	
9271S	
β-Tubulin	
E7-C	8M
4	
/	
α-rabbit	
1:2,000	
PBS-T/5	%
	Skim
	m
ilk	
Hybridom
a	bank	
	
GAPDH	
/	
/	
α-m
ouse	
1:10,000	
PBS-T/5	%
	Skim
	m
ilk	
M
illipore	
M
AB374	
cM
yc	
/	
EQ
KLISEEDL	
α-rabbit	
1:5,000	
PBS-T/5	%
	Skim
	m
ilk	
abcam
	
ab9106	
FLAG	
FLAG	M
2	
DYKDDDDK	
α-m
ouse	
1:5,000	
PBS-T/5	%
	Skim
	m
ilk	
Cell	Signaling	
AB	2315513	
HRP-conjugated	2°	antibodies	w
ere	used	1:2,000	(GE	Healthcare	Lifescience)
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7.5. Immunoprecipitation	and	in	vitro	calpain	and	cathepsin	cleavage	
7.5.1. Immunoprecipitation	
Myoferlin-,	 dysferlin-	 and	 the	 chimeric	 expression	 constructs	 with	 a	 C-terminal	
epitope	tag	were	transfected	into	HEK293	cells	in	10	cm	culture	dishes	using	CaPO4	
transfection	(7.3.1).	24	hours	post	transfection	the	cells	were	harvested	by	lysis	in	4	
mL	RIPA	buffer	with	1:500	protease	 inhibitor	cocktail.	Cell	 lysates	were	transferred	
into	a	15	mL	tube	and	50	μL	of	Protein-G-Sepharose	beads	(GE	Healthcare,	prepared	
in	 RIPA	 buffer)	 added	 to	 pre-clear	 the	 lysates	 by	 constant	 inversion	 at	 4°C	 for	 2	
hours.		
	 The	insoluble	cell	material	and	the	sepharose	beads	were	pelleted	at	15,000	
g	 for	15	minutes	at	4°C.	The	supernatant	was	 transferred	 into	a	new	15	mL	 falcon	
tube	 and	 1	 μg	 of	 primary	 antibody	 (rabbit	 α-myc)	 was	 added.	 The	 lysates	 plus	
primary	antibody	were	incubated	overnight	at	4°C	with	constant	 inversion	allowing	
the	primary	antibody	to	bind	to	the	tag	of	the	expressed	proteins.		
	 The	 next	 morning,	 150	 μL	 of	 Protein-G-Sepharose	 beads	 prepared	 in	 RIPA	
buffer	 (pre-washed	 three	 times	 with	 RIPA	 buffer	 plus	 1:500	 protease	 inhibitor	
cocktail)	were	added	 to	each	 tube	and	 incubated	 for	2	hours	at	4°C	with	 constant	
inversion.	Protein-G	beads	were	then	pelleted	at	4500	g	for	30	seconds	and	washed	
three	times	in	5	mL	of	pre-chilled	Ca2+-free	HEPES	cleavage	buffer	(20	mM	HEPES;	50	
mM	NaCl;	2	mM	CaCl2;	1	mM	MgCl2;	Sigma	Aldrich;	pH	7.5).		
	 For	the	cathepsin	L	cleavage	beads	were	washed	in	50	mM	trisacetate	buffer	
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+	5	mM	DTT	at	a	slightly	acidic	pH	of	5.62	(Felbor	et	al.,	2000).	Beads	were	then	used	
for	the	calpain	or	cathepsin	cleavage	assay.	
	
7.5.2. In	vitro	Calpain-1	and	-2	cleavage	
Protein	 bound	 sepharose	 beads	 were	 transferred	 into	 calcium-containing	 HEPES	
cleavage	 buffer	 (50	 μL	 for	 each	 experimental	 condition)	 and	 split	 evenly	 into	 one	
tube	 for	 each	 condition	 used.	 Purified	 calpain-1	 or	 calpain-2	 (Calpain-1	 porcine	
erythrocytes,	 #208712	 (3.84	 U/μL)	 and	 recombinant	 rat	 Calpain-2	 #208718	 (1	
U/µL),both	from	Merck	milipore,	Calbiochem)	was	diluted	to	the	desired	number	of	
active	units	per	μL	 in	Ca2+-containing	HEPES	cleavage	buffer	on	 ice.	Diluted	calpain	
was	 then	 added	 to	 the	 tube	 containing	 the	 ferlin-bound	 protein-G	 beads	 and	 the	
tubes	incubated	for	the	indicated	time	OR	indicated	calcium	concentration	at	30°C	to	
allow	calpain	cleavage	 to	occur.	To	quench	cleavage	at	 the	desired	 time	point	and	
remove	bound	protein	from	the	beads,	40	μL	of	4x	SDS-lysis	buffer	and	10	μL	of	2	M	
DTT	was	added	and	tubes	heated	to	94°C	for	three	minutes.	The	cleavage	reaction	
was	then	stored	at	-80°C	for	subsequent	western	blot.		
	
7.5.3. In	vitro	Cathepsin	L	cleavage	
Protein	bound	sepharose	beads	were	transferred	into	trisacetate	cleavage	buffer	(50	
μL	for	each	experimental	condition)	and	split	evenly	into	one	tube	for	each	condition	
used.	Purified	cathepsin	L	 (rhCathepsin-L	R&D	systems,	#952-CY)	was	diluted	to	10	
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ng/μL	concentration	in	trisacetate	buffer	on	ice.	Diluted	cathepsin	L	was	then	added	
to	the	tube	containing	the	ferlin-bound	Protein-G	beads	and	the	tubes	incubated	for	
the	indicated	time	at	30°C	to	allow	cathepsin	L	cleavage	to	occur.	Rest	like	described	
before	under	in	vitro	calpain	cleavage.		
	
7.6. Cell	proliferation	assay	
To	 assess	 potential	 differences	 in	 proliferation	 rate	 between	 myoferlin	 FL	 and	
myoferlin	 38a	we	 adapted	 a	 fluorescence	 dye	 proliferation	 protocol.	 HEK293	 cells	
were	 transfected	 with	 either	 myoferlin	 FL	 or	 38a	 and	 pIRES	 empty	 as	 a	 negative	
control	using	PEI.	We	used	the	far	red	fluorescent	dye	DiD	vibrant	(Invitrogen)	(DiD:	
1,1'--dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine,4-chlorobenzenesulfonate	
salt).	 106	 cells	 were	 harvested	 by	 trypsinisation,	 quenched	 and	 pelleted	 for	 three	
minutes	 at	 300	 g	 at	 room	 temperature.	 The	 pellet	 was	 resuspended	 in	 1	 mL	 full	
growth	media	with	5	μL	DiD	in	a	15	mL	falcon	tube.	The	cells	were	then	incubated	at	
37°C	in	a	heat	block	protected	from	light.	Cells	were	mixed	occasionally	(~2	x	during	
incubation)	by	flicking	the	tube.	After	20	minutes	the	dye	was	diluted	with	5	mL	full	
growth	 media.	 Cells	 are	 pelleted	 at	 300	 g	 for	 three	 minutes	 and	 resuspended	 in	
enough	 growth	 media	 to	 plate	 as	 many	 dishes	 as	 needed.	 To	 achieve	 ~50	 %	
confluence	plate	3x	6	cm	dishes.		
	 Cells	were	 then	sub-cultured	 for	 several	days	 (up	 to	10	days	cells	were	still	
transfected).	About	three	hours	after	the	cells	have	been	plated	the	first	time	point	
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is	 analysed	 at	 the	 flow	 cytometer.	 Cells	 are	 trypsinized	 and	 pelleted	 as	 described	
before	using	4	mL	round	bottom	FACS	tubes.	The	cell	pellets	are	resuspended	in	PBS	
+Ca2+.	For	the	first	reading	it	is	important	to	bring	the	adequate	controls:	unstained,	
EGFP	only	and	DiD	only	controls.	At	the	flow	cytometer	all	the	gates	are	set	up	and	
the	compensation	control	set	up.	For	the	first	reading	after	three	hour	(we	call	t0)	all	
cells	 should	 be	 uniformly	 stained	 for	 DiD.	 Over	 the	 next	 cell	 divisions	 the	 dye	
fluorescence	will	half	with	every	cell	division.	
	
7.7. Limited	proteolysis	-	Trypsin	digest	
Background	
This	technique	has	been	developed	and	optimised	by	my	colleague	Natalie	Woolger.	
In	 my	 studies	 I	 have	 utilised	 this	 technique	 to	 analyse	 potential	 conformational	
changes	to	the	myoferlin	protein	caused	by	insertion	of	exon	38a.		
	 Trypsin	 is	 a	 serine	 protease	 that	 is	 secreted	 by	 the	 pancreas	 and	 aids	 the	
digestion	 of	 food	 proteins	 (Brown,	 Freedman,	 &	 Troll,	 1973;	 Sprang	 et	 al.,	 1987).	
Trypsin	 cleaves	 target	 proteins	 at	 the	 C-terminal	 side	 of	 every	 arginine	 or	 lysine	
residue	 if	accessible,	generating	easily	digestible	protein	peptides.	 In	 this	assay	we	
are	using	saponin	to	perforate	the	membrane	and	allow	trypsin	to	enter	the	inside	of	
the	cell.	
	 Myoferlin	 has	 >1400	 predicted	 trypsin	 cleavage	 sites.	 If	 they	 were	 all	
accessible	 myoferlin	 would	 be	 cut	 up	 into	 over	 thousand	 little	 pieces.	 But	 the	
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conformation	of	a	protein	or	the	way	a	protein	is	embedded	into	the	membrane	can	
hinder	 trypsin	 from	accessing	 the	 cleavage	 sites.	We	have	 harnessed	 this	 trade	 of	
trypsin	 to	 our	 advantage.	 We	 subjected	 cells	 expressing	 myoferlin	 to	 increasing	
amounts	of	 trypsin	 and	 ran	 the	 samples	on	 a	western	blot.	 Probing	with	different	
myoferlin	 antibodies	 to	 analyse	 the	 generation	 of	 different	 C-and	 N-terminal	
myoferlin	fragments.	
	 Our	 hypothesis	 was	 that	 the	 inclusion	 of	 exon	 38a	 in	 the	 linker	 region	
between	 the	 C2DE	 and	 C2E	 domain	might	 render	myoferlin	 the	 C2DE	 domain	more	
accessible	for	trypsin	cleavage.	
	
Experimental	procedure	
HEK293	cells	were	plated	onto	10	cm	dishes	and	transfected	the	next	day.	24	hours	
post	transfection	cells	were	washed	2x	with	-Ca2+	PBS,	followed	by	a	wash	with	-Ca2+	
PBS	+	10	mM	EDTA	to	chelate	all	Ca2+.	Finally	cells	are	washed	once	more	with	-Ca2+	
PBS.	Afterwards	cells	are	scrape	harvested	in	1.5	mL	-Ca2+/+Mg2+	PBS.		
	 The	cells	were	 transferred	 into	a	15	mL	 falcon	 tube,	pre-chilled	on	 ice,	and	
pelleted	 for	 two	 minutes	 at	 300	 g.	 The	 cell	 pellet	 was	 resuspended	 in	 500	 µL	 -
Ca2+/+Mg2+	PBS	and	the	sample	divided	into	5	x	100	µL	aliquots.	The	samples	were	
then	 subjected	 to	 tryptic	 digestion	 using	 either	 saponin	 only	 (0.0001	 %	 final)	 or	
increasing	concentrations	of	trypsin	minus	EDTA	(Life	Technologies	15050057):	1/10,	
1/20,	 1/40	 and	 1/80	 (equivalent	 of	 250,	 125,	 62.5	 or	 31.5	 mg/ml	 trypsin)	 in	 -
Ca2+/+Mg2+	PBS	containing	0.005	%	saponin	(0.0001	%	final).		
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	 The	digest	solution	was	prepared	in	1.5	mL	eppendorf	tubes	placed	in	a	rack	
on	 ice.	 The	 samples	 were	 then	 pipetted	 into	 the	 digestion	 solution	 using	 a	 multi	
channel	pipette	and	mixed	2s	by	pipetting	up	and	down.	Samples	were	digested	for	
one	minute	at	RT	and	the	reaction	quenched	by	adding	200	µL	-Ca2+/+Mg2+	PBS	+	1	%	
FBS.	Samples	were	pelleted	at	300	g	for	three	minutes	followed	by	a	wash	with	cold	
PBS	-Ca2+.	The	pellets	were	then	solubilised	in	RIPA	buffer	on	a	spinning	wheel	at	4°C	
for	30	minutes.	Afterwards	the	insoluble	debris	was	spun	down	at	1300	rpm	for	15	
minutes	 at	 4°C	 and	 ~130	 µL	 of	 the	 supernatant	 was	 transferred	 into	 a	 new	
eppendorf	 tube.	 Add	 2x	 lysis	 buffer	 and	 20	 mM	 DTT	 to	 each	 sample	 and	 heat	
inactivated	 at	 94°C	 for	 three	minutes.	 The	 protein	 concentration	 was	 determined	
using	BCA	assay	and	~20	µg	of	protein	was	 loaded	onto	a	4-12	%	Bis-Tris	western	
blot	gel.	The	membranes	were	probed	with	different	antibodies	against	myoferlin	or	
the	 epitope	 tags	 and	 the	 banding	 pattern	 analysed	 and	 compared	 between	
myoferlinFL	and	myoferlin38a.	
	
7.8. Molecular	biology	techniques	
7.8.1. Polymerase	chain	reaction	and	cloning	
Preparing	for	a	PCR	
Prepare	samples	on	 ice	and	expose	all	 tubes,	pipettes	and	pipette	 tips	used	 to	UV	
light	for	~20	min	prior	to	commencing	PCR	preparations.	For	your	PCR	mix	add	1	µL	
forward	primer	and	1	µL	reverse	primer,	15	µL	buffer	D	and	11	µL	DEPEC	water.	Last	
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add	0.2	µL	taq	polymerase	(invitrogen,	#100021276)	and	1	µL	of	your	DNA	sample	(if	
the	 DNA	 is	 not	 very	 concentrated	 add	 2	 µL).	Mix	 by	 flicking	 the	 tube	 and	 briefly	
spinning	 it	down.	PCR	was	carried	out	 in	an	 'Applied	Bioscience	Thermocycler'	PCR	
machine.	
For	the	myoferlin	exon	38a	screening	PCR	I	have	optimised	the	PCR	conditions	to	be	
as	followed:		
94°C	4	min	
___________	
94°C	30	sec	
58°C	30	sec	
72°C	45	sec	
72°C	7	min	
___________	35x	
4°C	∞	
	
	
These	conditions	work	well	for	PCR	products	of	~300	bp	in	size.	For	the	screening	of	
our	PZ	mice	we	optimised	the	PCR	conditions	to	be	as	followed:		
	
	
94°C	5	min	
___________	
94°C	30	sec	
61°C	30	sec	
72°C	45	sec	
72°C	10	min	
___________	38x	
4°C	∞	
	
The	human	tissue	cDNA	panel	
For	the	screening	of	several	human	tissues	for	the	presence	of	absence	of	myoferlin	
exon	38a	we	purchased	a	cDNA	panel	from	Clontech	(Human	MTC	Panel	1,	Immune	
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Panel	and	Gut	Panel).	
Primers	
Primers	were	designed	using	Primer	3.0	and	purchased	from	Sigma	Aldrich.	Table	7.5	
shows	a	list	of	all	the	primers	used	in	this	thesis.	
Table	7.5:	Primers	used	in	this	study	
mCAPN1	F		 ATCTCTACCAGGCCCATGTG	
mCAPN1	R	 GCGTTTCATAATCCTGGCCC	
mCAPN2	F	 AACCGGATCGCTACCATGG	
mCAPN2	R	 ATCTCCCTTGAACTGTACTTACC	
mCAPNS1	F	 AGACCATCCCAGCCCATATG	
mCAPNS1	R	 AGACCATCCCAGCCCATATG	
F_GAPDH_AK	 GAGTCAACGGATTTGGTCGT	
R_GAPDH_AK		 TGGACTCCACGACGTACTCA		
hGAPDH	F	 GAGTCAACGGATTTGGTCGT	
hGAPDH	R	 TGGACTCCACGACGTACTCA	
F_hCAPNS1_gDNA		 	GCTTCAGATTCCTCCCAGGT	
R_hCAPNS1_gDNA		 CCCGGCCTAATTCATGTACC		
Myoferlin	primers	 	
R	exon2	Myof	(Dr	Redpath)	 CCCAGTATCTTGCCCTTTTTC	(sequencing	primer)	
5FMyo_PstI	 CACCCAAACTTCTCTGGCAC	
5FMyo_'Pst2'	(no	Pst2	site)	 GCCTCCCTTCTGTCTGCCCCAC	
Myo38_R	 GAAGCCAGTAATGGTTTGGTGTC	
Myof38a_F	 GGCTTCTCCAGCGACAGTGCAT	
Myof38a_R	 ATGCACTGTCGCTGGAGAAGCC	
3RMyof_40	start	 GTCAGGCCCTCAAATTCTGC	
3RMyof_40	end	 CCTCGGTACAACTTGAACGT	
3RMyo_Sac1	 TCATCCCGGGTAAAGGTGTC	
Myof_46_F	 GCCAACAAAATCCTGCACCA	
'Myof_48_R'	(actually	49)	 TTCATTGCCAGGAATCCAGC	
hMYOF_3_F	 CATGAACCCCAAGCTGGAC	(sequencing	primer)	
	
7.8.2. Making	DNA	from	ear	clips	
In	order	to	genotype	mice	 it	 is	common	practice	to	extract	DNA	from	the	ear	clips	
that	you	get	when	marking	the	animals.		
		
	
258	
	 Collect	frozen	ear	clips	in	1.5	mL	eppendorf	tubes	and	add	200	μL	STE	buffer	
(100	mM	Tris	pH	8.5,	5	nM	EDTA,	0.2	%	SDS,	100	mM	NaCL)	to	your	clips.	Add	4	μL	
20	mg/mL	Protinase	K	to	digest	contaminating	proteins.	Incubate	the	digest	for	one	
hour	at	55°C.	Afterwards	the	Proteinase	K	gets	 inactivated	at	70°C	for	five	minutes	
and	the	reaction	stopped	by	putting	the	samples	on	ice.	Spin	samples	at	maximum	
speed	 for	10	minutes	and	 take	100	µL	of	 the	 supernatant	 leaving	 the	 rest	behind.	
From	here	the	DNA	can	be	precipitated	using	ethanol.	
	 	
EtOH	precipitation	
Use	1	volume	of	your	DNA	mix	obtained	before	and	add	0.1	volume	of	2	M	NaOAC	
and	2	volumes	of	100	%	EtOH.	Spin	the	mixture	at	maximum	speed	for	20	minutes	at	
4°C.	Remove	the	supernatant	and	wash	with	70	%	ethanol.	Spin	again	at	max.	speed	
for	 10	minutes	 at	 4°C	 and	 remove	 the	 supernatant.	 Air-dry	 the	 pellet	 (sticky	 tape	
tube	upside-down	onto	 shelf	works	well).	Dissolve	 the	dry	pellet	 in	DEPEC	 treated	
water	(~30	µL).	Take	1	µL	for	PCR.	
	
RNA	extraction	and	making	of	cDNA	
For	 'simple'	 RNA	 extractions	 from	 cells	 I	 have	 used	 the	 RNeasy®	 Mini	 Kit	 from	
QIAGEN	(#74104)	and	followed	the	instructions.	
	 To	make	 cDNA	 from	 RNA	 use	 1	 μg	 RNA	 and	make	 up	 to	 8	 μL	with	 DEPEC	
water.	Then	add	2	μL	pdN(6)	 random	primers	and	2	μL	Oligo(DT)s	primers	 (one	or	
the	other	would	be	sufficient	but	this	way	we	can	be	sure	we	are	not	running	out).	
		
	
259	
The	total	mix	is	now	12	µL.	Heat	mix	at	65°C	for	five	minutes.	and	chill	on	ice	for	two	
minutes	afterwards.	In	the	meantime	make	a	master	mix.	
	 Master	mix:	4	μL	5x	First	Strand	buffer,	2	μL	DTT,	1μL	dNTPs	(10	mM),	1	μL	
SSIII.	Then	add	8	μL	of	the	master	mix	to	12	μL	RNA	mix	and	run	cDNA	program	on	
PCR	machine.	
	
Making	gDNA	
Genomic	DNA	 (gDNA)	was	used	 to	check	 for	CRISPR	editing	events	 in	 the	genomic	
DNA.	I	either	used	the	'Genomic	DNA	Purification'	kit	from	SIGMA	Aldrich	(#G1N70)	
or	extracted	gDNA	using	a	freeze/thaw	method.		
	 Freeze/thaw	 method:	 For	 this	 add	 50	 μL	 TE	 buffer	 to	 your	 cell	 pellet	 and	
thaw/freeze	it	2x	on	dry	ice	and	in	your	hand.	Heat	inactivate	samples	at	94°C	for	10	
minutes	and	take	2	μL	to	conduct	subsequent	PCR	analyses.	
	
7.8.3. Generation	of	myoferlin	expression	constructs	
Table	 7.6	 summarises	 all	 constructs	 used	 in	 this	 study.	 The	 table	 indicates	 which	
constructs	I	made	(*)	and	which	ones	Samuel	Ross	(**),	our	research	assistant	made.		
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Table	7.6:	Protein	expression	constructs	used	in	this	study.	
Name	 Construct		 Vector	 Species	
MFL	 Myoferlin	full	length	 EGFP-pIRES	 Human	
M38a	*	 Myoferlin	plus	exon	38a	 EGFP-pIRES	 Human	
MD40/38a	*	 Myoferlin-Dysferlin	exon	40	
and	myoferlin	exon	38a	
EGFP-pIRES	 Human	
MD40	*	 Myoferlin-Dysferlin	exon	40	 EGFP-pIRES	 Human	
MmDf	**	 Myoferlin	with	miniDysferlin	 pcDNA3	(no	EGFP)	 Human	
DM38/mMf	**	 Dysferlin	with	miniMyoferlin	
and	myoferlin's	constitutive	
cleavage	site	
pcDNA3	(no	EGFP)	 Human	
DM38	*	 Dysferlin	with	myoferlin's	
constitutive	cleavage	site	
pcDNA3	(no	EGFP)	 Human	
DM38a	*	 Dysferlin	with	myoferlin's	
exon	38a	
pcDNA3	(no	EGFP)	 Human	
D40a	 Dysferlin	with	exon	40a	 EGFP-pIRES/pcDNA3	
(no	EGFP)	
Human	
DFL	 Dysferlin	full	length	 EGFP-pIRES/pcDNA3	
(no	EGFP)	
Human	
*	Constructs	that	I	have	made	for	this	project.	**	Constructs	made	with	the	help	of	
Samuel	Ross.	
	
	
7.8.3.1. Cloning	strategies	
Myoferlin38a	(M38a)	
This	construct	is	the	myoferlin	isoform	1	with	exon	38a	cloned	into	it.	Exon	38a	was	
amplified	from	human	lung	using	primer	PstI	and	SacI.	The	band	was	excised	and	the	
DNA	 purified	 using	 the	 PureLinkTM	 Quick	 Gel	 Extraction	 &	 PCR	 Purification	 Kit	
(#K220001,	 Qiagen).	 The	 DNA	was	 then	 sequenced	 and	 sub-cloned	 into	myoferlin	
EGFP-pIRES	using	PstI	and	SacI.	
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MyoferlinD40/38a	(MD40/38a)	
Here	we	ablated	the	constitutive	myoferlin	cleavage	site	in	exon	38.	We	substituted	
63	bases	that	include	the	first	predicted	calpain	cleavage	site	with	exon	40	sequence	
from	dysferlin	 that	we	 know	 cannot	 be	 cleaved	 in	 dysferlin.	We	excised	 the	piece	
containing	exon	38	 from	myoferlin38a	using	PstI	 and	SacI.	Dysferlin40a	was	digested	
with	 ClaI,	 excising	 the	 fragment	 that	 contains	 exon40.	 This	 piece	 was	 then	 sub-
cloned	into	myoferlin38a	to	generate	myoferlinD40/38a.	
	 ClaI	digest:	7	μL	DNA,	1	μL	ClaI,	5	μL	cutsmart	and	36	μL	DEPEC.	Incubate	for	
two	hours	or	over	night	at	37°C.	To	avoid	the	cut	ends	of	the	plasmids	from	sticking	
back	 together	 treat	 your	 sample	 with	 shrimp	 alkaline	 phosphatase	 (SAP)	 to	
dephosphorylate	the	ends.	For	that	add	1	μL	SAP	for	1h	at	37°C	and	heat	inactivate	
at	 65°C.	 Load	 25	 μL	 on	 a	 PCR	 gel	 and	 check	 for	 a	 57	 bp	 shift	 with/without	 38a	
(207/276bp).	
	
MyoferlinD40	
This	 construct	 was	 made	 as	 a	 negative	 control.	 The	 canonical	 cleavage	 site	 of	
myoferlin	was	substituted	with	dysferlin	exon	40	as	described	above.	This	construct	
does	not	encode	 for	any	calpain	 cleavage	 sites.	We	used	 the	myoferlinFL	 construct	
and	 digested	 it	 using	 PstI	 and	 SacI	 and	 inserted	 the	 ClaI	 dysferlin-fragment	
containing	exon	40.	
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DysferlinM38	
This	construct	has	the	canonical	myoferlin	cleavage	site	encoded	by	exon	38	inserted	
into	the	dysferlin	backbone.	For	this	construct	we	have	ordered	a	piece	of	DNA	that	
contained	the	myoferlin	38	sequence	as	we	could	not	derive	a	cloning	strategy	that	
would	have	allowed	sub-cloning	 it	 from	the	other	constructs.	We	ordered	the	DNA	
fragments	needed	fro	Blue	Heron	 in	a	shuttle	vector	and	cut	out	the	piece	needed	
using	 SacI	 and	 PstI.	 We	 digested	 dysferlin	 with	 ClaI	 and	 inserted	 the	 myoferlin	
sequence.	
	
DysferlinM38a	
Once	the	DysferlinM38	construct	was	sequenced	I	used	it	to	generate	the	DysferlinM38a	
construct.		
	
7.8.4. Ligation	
To	calculate	 the	correct	 ratio	of	 insert	 to	vector	 for	 ligations	 I	have	generally	used	
this	formula:		
	 (100ng	vector	x	kb	insert)/	(kb	vector	x	2/1)	=	ng	insert	
For	 all	 ligations	 we	 have	 either	 used	 a	 quick	 or	 a	 normal/conventional	 ligation	
protocol.	 For	quick	 ligations	we	used	 the	Quick	 ligationTM	 kit	 from	NEW	ENGLAND	
Bio	Labs.	An	example	of	a	20	µL	ligation	might	be:	3	μg	vector	plus	0.3	μg	insert	plus	
10	μL	2x	quick	ligase	buffer.	Add	5	μL	DEPEC	H2O	and	1	μL	Quick	ligase.	Ligate	at	RT	
for	five	to	10	minutes.		
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	 For	a	conventional	ligation	of	15	µL	volume,	use	1.5	μL	10x	buffer,	0.5	μL	T4	
ligase,	1	μL	ATPs	,	3	μL	vector	and	9	μL	insert.	Ligate	at	16°C	over	night.	
	
7.8.5. Transformation	
The	finished	constructs	were	then	transformed	into	chemically	competent	E.coli	cells	
(OneShot®	 TOP10	 Chemically	 competent	 cells,	 #C404003,	 Invitrogen).	 During	
transformation	work	on	a	clean	bench	near	the	flame	to	keep	samples	as	sterile	as	
possible.	Place	2	µL	of	your	DNA	insert	into	a	pre-chilled,	sterile	5	mL	round	bottom	
tube	on	ice	(near	the	flame).		
	 Thaw	chemically	competent	cells	on	ice	and	add	25	μL	(half	of	one	vial)	to	the	
2	μL	of	your	insert	(near	the	flame).	Incubate	for	30	minutes	on	ice.	Heat-shock	cells	
at	42°C	for	30	and	then	add	275	μL	S.O.C.media	(Super	Optimal	broth	with	Catabolic	
repression).	Leave	on	ice	for	two	minutes	and	then	place	into	a	shaker-incubator	set	
to	 37°C.	 Incubate	 for	 one	 hour;	 this	 will	 give	 the	 bacteria	 enough	 time	 to	 start	
expressing	the	antibiotic	resistance-genes.	After	one	hour	plate	~1/2	the	amount	of	
grown	 bacteria	 onto	 antibiotic	 agar	 plates	 (100	 mg/mL	 ampicillin	 or	 50	 mg/mL	
kanamycin)	using	a	sterile	glass	pipette	 formed	 into	a	 triangle	at	 the	end	to	streak	
out	the	bacteria.		
	
Making	LB	broth	and	agar	plates	 	
To	make	1	L	of	LB	broth	or	agar	plates	weigh	10	g	Tryptone	(BD	#21705),	10	g	NaCl	
and	5	g	Yeast	(BD	#211929).	For	agar	plates	add	15g	Agar	(BD	#214010)	into	a	sterile	
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2	L	SCHOTT	bottle.	Autoclave	and	add	antibiotics	when	the	solution	has	cooled	to	<	
65°C.	Poor	agar	 into	10	cm	plastic	dishes	near	 the	 flame	(~15	mL	per	dish)	and	 let	
cool	for	several	hours.	Afterwards	store	in	the	cold	room	in	a	sealed	plastic	bag.	
	
7.8.6. Mini-	and	Maxi-preps	
After	 the	 transformed	colonies	have	grown,	pick	single	colonies	and	perform	mini-
preps	to	generate	clean	cDNA	to	send	for	sequencing	(or	to	use	for	transfections	if	
no	 large	 amount	 of	 DNA	 is	 required).	 When	 picking	 colonies,	 circle	 and	 number	
them,	then	pick	the	colony	and	streak	it	out	onto	a	new	agar	plate	in	a	straight	line	
with	the	according	number.	Afterwards	place	the	tip	into	2	mL	of	LB	to	grow	bacteria	
for	mini-preps.	This	way,	after	the	sequencing	has	been	confirmed	the	correct	clone	
can	be	grown	for	midi-	or	maxi-preps	straightaway.	
	 For	 mini-preps	 I	 was	 using	 the	 Viogene,	 "Mini	 PLUSTM	 "	 Plasmid	 DNA	
Extraction	System	#GF2002	(250	preps).		
	 The	 clean	 DNA	 is	 then	 sent	 for	 Sanger	 sequencing	 with	 1	 µL	 sequencing	
primer,	 2	µL	DNA	and	9	µL	DEPEC	water.	 The	obtained	 sequence	 can	be	 analysed	
using	SEQUENCHER®	DNA	analysis	software.	
	 Once	the	sequence	 is	confirmed,	 the	DNA	can	be	expanded	by	growing	the	
correct	 clone	 up	 to	 maxi-size	 and	 the	 cDNA	 extracted	 using	 QIAGEN,	 HiSpeed	
Plasmid	 Maxi	 Kit	 #12662.	 Bacteria	 are	 grown	 in	 LB	 broth	 (see	 above)	 containing	
antibiotics.	I	recommend	to	grow	a	2	mL	'starter'	during	the	day/	or	over	night	first	
and	then	inoculate	the	larger	amount	of	LB	needed	for	maxi-preps	
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7.8.7. Gel	extraction	
All	 PCR	products	were	 excised	 and	purified	 using	 the	 Invitrogen,	 PureLinkTM	Quick	
Gel	Extraction	&	PCR	Purification	Combo	Kit,	#K220001	or	the	GENOMED,	JET	quick	
Gel	Extraction	Spin	Kit	#42025.	
	
7.9. CRISPR/Cas9	technology		
CRISPR	stands	fro	Clustered	regularly	interspaced	short	palindromic	repeats	and	Cas	
9	 for	CRISPR	associated	protein	9.	This	 technology	has	 revolutionised	 the	scientific	
world	in	the	last	couple	of	years.	The	CRISPR/Cas	technology	is	now	widely	used	for	
gene	 editing.	 In	 this	 study	 I	 am	 using	 CRISPR/Cas9	 technology	 in	 order	 to	 create	
knock	out	cell	lines.	Non-homologous	end	joining	(NHEJ)	is	the	most	efficient	way	to	
generate	a	complete	genomic	knock	out	of	your	gene	of	interest.	
	
7.9.1. Designing	CRISPR	oligos	
To	design	CRISPR	oligos	the	genomic	DNA	(gDNA)	sequence	of	the	gene	of	interest	is	
needed.	This	can	be	found	on	the	UCSC	genome	browser	(genome.ucsc.edu).	Copy	
and	 paste	 ~100	 nucleotides	 around	 the	 area	 that	 you	want	 to	 knock	 out	 into	 the	
CRISPR	design	tool	on	CRISPR.mit.edu	developed	by	Zhang	Lab,	MIT	2015	(genome-
engineering.org).	 Pick	 the	 oligos	 that	 target	 the	 appropriate	 region	 and	 have	 the	
least	off	target	effects.	To	minimise	off	target	effects	you	can	use	a	double	nickase	
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approach.	Here	 I	have	used	the	double	strand	break	Cas9	rather	than	the	mutated	
single	strand	break	nickase	approach.		
	 After	 you	have	picked	 the	CRISPR	oligos	 you	 can	 insert	 them	 into	a	CRISPR	
design	 template	 also	 provided	 by	 CRISPR.mit.edu.	 The	 oligos	 should	 be	 20	
nucleotides	long	followed	by	a	three	nucleotide	PAM	sequence:	NGG.	Cas9	nuclease	
cuts	three	nucleotides	upstream	of	the	PAM	site.	Order	the	complete	oligos	from	IDT	
or	SIGMA.	
	
7.9.2. Cloning	the	CRISPR/Cas9	vector	with	your	target	sequence	
In	 this	study	 I	have	used	the	pSp	Cas9	 (BB)-2A-Puro	 (PX459)	vector	 (~9200bp)	 that	
encodes	 for	 the	 Cas9	 enzyme	 as	well	 as	 puromycin	 and	 ampicillin	 resistance.	 The	
vector	was	digested	with	BbS1	(GAAGC(N)2')	for	two	hours	at	37°C	followed	by	heat	
inactivation	 for	 20	minutes	 at	 65°C.	 As	 a	 control	 for	 successful	 digestion	 a	 ~5	 µL	
sample	was	run	out	on	a	1	%	agarose	gel	for	one	hour	at	100	V.	The	oligonucleotide	
CRISPR	 guides	 were	 resuspended	 in	 DEPEC	 H2O	 to	 a	 10	 µM	working	 stock.	 Equal	
amounts	of	complementary	guides	were	annealed	at	94°C	for	three	to	five	minutes	
and	then	allowed	to	cool	down	slowly	at	RT.	The	double-stranded	guides	were	then	
ligated	 into	 the	 PX459	 digested	 vector	 using	 the	 quick	 ligase	 protocol	 described	
before.	From	here	we	transformed	the	DNA	and	extracted	cDNA	that	we	send	off	for	
sequencing	 (described	 before).	 The	 cDNA	 containing	 the	 vector	 with	 successfully	
inserted	guides	was	then	transfected	into	the	cells.	
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7.9.3. CRISPR	workflow	
I	have	described	the	workflow	of	the	generation	of	CRISPR	knock-out	cell	 lines	 in	a	
figure	 in	 the	 result	 section	 of	modifiers	 of	membrane	 repair.	 To	 have	 a	 complete	
protocol	 for	 the	 CRISPR	 gene	 editing	 technique	 we	 have	 been	 using	 in	 the	 lab	 I	
would	like	to	restate	the	workflow	in	the	following	section.	
	
Transfection	
Cells	 were	 plated	 into	 3.5	 cm	 dishes	 the	 day	 before	 transfection.	 At	 ~70	 %	
confluence	 cells	 were	 transfected	 with	 the	 pSpCas9(BB)-2A-Puro	 (px459)	 vector	
containing	our	CRISPR	guides.		
	
Puromycin	selection	
~24	 hours	 post	 transfection	 cells	were	 split	 into	 2	 x	 10	 cm	 dishes.	 24	 hours	 after	
splitting,	 the	 cells	 were	 put	 into	 selection	media	 containing	 puromycin.	 The	 exact	
puromycin	 concentration	 has	 been	 established	 for	 each	 cell	 line	 individually	 (2.5	
µg/mL	for	HEK293	cells,	5	µg/mL	for	C2C12	cells	and	7.5	µg/mL	for	COS-7	cells).	After	
two	 days	 in	 selection	 (>90	 %	 of	 cells	 would	 have	 died	 by	 then)	 the	 media	 was	
replaced	with	normal	growth	media.		
	
Growing	and	picking	single	colonies	
Dependent	 on	 the	 cell	 line	 it	 takes	 ~3-10	 days	 to	 be	 able	 to	 see	 single	 colonies	
growing.	When	the	colonies	are	big	enough	to	be	picked	and	not	touching	any	other	
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colonies	 they	were	picked	of	 the	plate	with	a	200	µL	pipette	using	sterile	 tips.	For	
this	the	dishes	were	placed	under	a	dissection	microscope.	The	tissue	culture	room	
was	made	as	sterile	as	possible	as	the	scope	did	not	fit	into	the	tissue	culture	hood.	
~30	colonies	were	picked	and	transferred	into	96-well	plated	containing	~200	µL	of	
growth	media.		
	
Clone	analysis	
The	 single	 clones	were	 then	grown	and	 transferred	 into	bigger	dishes	as	 required.	
The	rest	of	the	colonies	from	the	dish	(or	from	a	separate	dish)	were	pulled	together	
to	 extract	 gDNA	 from.	 The	 polyclonal	 gDNA	was	 used	 to	 analyse	 if	 the	 locus	 had	
been	 successfully	 targeted	 by	 our	 CRISPR	 guides.	 For	 that	we	would	 perform	 PCR	
analysis	 looking	 for	 a	 'smeary'	 band	 as	well	 as	 send	 the	 PCR	 amplicon	 for	 Sanger	
sequencing	 looking	 for	 'messy'	 reads.	 Once	 we	 have	 established	 that	 the	 correct	
locus	was	targeted	the	single	clones	were	harvested	when	at	least	3	x	3.5	cm	dishes	
were	almost	confluent.	One	dish	was	harvested	for	gDNA,	one	for	western	blot	and	
at	least	one	was	frozen.	The	western	blot	analysis	turned	out	to	be	a	very	useful	tool	
to	access	the	subsequent	loss	of	protein	caused	by	CRISPR-targeting	the	gene.		
	 From	 the	western	 blot,	 three	 clones	 that	 showed	 no	 protein	 expression	 of	
the	 targeted	gene	were	selected.	These	 three	clones	were	 then	PCR	amplified	and	
the	amplicon	cloned	 into	pTOPO	2.1	 to	establish	what	exact	genetic	 changes	have	
occurred	 on	 each	 allele.	 At	 least	 12	 clones	 were	 send	 off	 for	 Sanger	 sequencing.	
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Once	 we	 have	 established	 that	 all	 four	 alleles	 were	 targeted	 the	 cell	 lines	 were	
expanded	and	achieved	for	future	use.	
	
7.10. Haemotoxylin	and	Eosin	(H&E)	staining	
Background	
This	 simple	 two-dye	histological	 staining	protocol	 has	 truly	 stood	 the	 test	 of	 time,	
having	 first	 been	 described	 in	 1867	 by	 Dr	 Eduard	 Schwarz	 (Schwarz,	 1876).	 H&E	
staining	 is	 still	 counted	 as	 one	 of	 the	 gold	 standard	 histological	 staining	 protocols	
today;	H&E	 staining	 is	widely	 used	 in	pathology	 to	 visualise	 sub-structures	of	 cells	
and	tissues	(reviewed	in	Chan,	2014	(J.	K.	Chan,	2014)).	
	 Haemotoxylin	 generally	 stains	 basophilic	 structures	 like	 the	 rough	
endoplasmic	 reticulum,	 the	 ribosomes	 and	 the	 nucleus	 resulting	 in	 a	 blue/purple	
stain.	Eosin	is	an	acidic	dye	that	stains	'eosinophilic'	structures	that	include	the	cell	
membrane,	most	organelles	and	the	extracellular	matrix,	in	a	pink	colour	(reviewed	
in	Chan,	2014	(J.	K.	Chan,	2014)).	
	
Experimental	procedure	
Transverse	8	µm	sections	were	cut	from	the	following	frozen	tissue	samples	(mouse	
skeletal	muscles	in	our	case)	and	harvested	onto	a	glass	slide.	On	the	slides,	sections	
were	 fixed	 with	 10	 %	 neutral	 buffered	 formalin	 for	 10	 minutes	 and	 washed	 four	
times	 in	 distilled	 water	 (dH2O).	 After	 that	 slides	 were	 placed	 in	 glass	 chamber	
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containing	 haemotoxylin	 (Unripened	 Harris	 Haemotoxylin	 (Prositech),	 oxidising	
agent	 (ripener),	 40	mL/L	 glacial	 acetic	 acid)	 for	 four	minutes,	 followed	by	 another	
wash	 in	dH2O	(four	 times).	Afterwards	samples	were	dipped	 in	LiCO3	(2.5	g	 lithium	
carbonate	and	100	mL	distilled	water)	for	10	seconds,	and	rinsed	again	in	dH2O.	Next	
sections	 were	 placed	 into	 the	 eosin	 solution	 (500	 mg	 aqueous	 eosin	 Y,	 50	 mg	
phloxine,	75	mL	distilled	water,	370	mL	100	%	ethanol,	2mL	glacial	 acetic	acid)	for	
five	 seconds	 followed	by	a	100	%	ethanol	 fixation	 (dip	 samples	 in	 twice).	Carefully	
dry	glass	slides	by	wiping	with	a	tissue	and	then	coverslips	were	mounted	onto	the	
samples	 on	 the	 glass	 slide	 using	 xylene-based	 ultramount.	 Samples	were	 analysed	
and	images	taken	using	an	Aperio	ScanScope	CS	with	20x	magnification.	
	
7.11. Buffers	used	in	this	thesis		
I	 have	 listed	 some	 of	 the	 buffers	 used	 in	 the	main	 text.	 Here	 I	 would	 like	 to	 list	
buffers	used	in	a	practical	table	format.	
	
	 	 		Table	7.7:	Buffers	used	in	this	thesis	
MOPS	buffer	1	L	
209.2	g	MOPS	(50	mM)	(SIGMA,	M3183-1KG)	
121.2	g	Tris	Base	(50	mM)	
20	g	SDS	(0.1	%)	(Biosciences,	#DG093)	
6	g	EDTA	(1	mM)	
Transfer	buffer	
0.25	mM	Tris	
192	mM	glycerol	
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0.075	%	SDS	
15	%	methanol,	added	freshly	
LB	broth/agar	1	L	
10	g	Tryptone	(BD	#21705)	
10	g	NaCl	
5	g	Yeast	(BD	#211929)	
/+	15	g	Agar	(BD	#214010)	
4	x	Loading	buffer	
250	mM	Tris	pH	6.8	
8	%	SDS	
40	%	Glycerol	
+bromophenol	blue	
4	x	Lysis	buffer	
250	mM	Tris	pH	6.8	
8	%	SDS	
RIPA	buffer	
50mM	Tris	pH	7.5	
0.5	%	D.O.C.	
1	%	Np40	
0.1	%	SDS	
150mM	NaCl	
10mM	EDTA	
Stripping	buffer	(WB)	
62.5	mM	Tris-HCL	pH	6.8	
2	%	SDS	
435	μL/50	mL	β-Mercaptoethanol		
(30	min	@	55°C)	
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 Chapter	9: Appendix		
9.1. Sequence	analysis	of	CRISPR	targeted	HEK293	calpain	knock-out	
cell	lines	
9.1.1. HEK293	CAPN1-/-	
Wild	type	sequence		
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCCGGCAG
GATGTCGGAGGAGATCATCACGCCGGTGTACTGCACTGGGGTGTCAGCCCAAGTGCAGAAGC
AGCGGGCCAGGGAGCTGGGCCTGGGCCGCCATGAGAATGCCATCAAGTACCTGGGCCAGGAT
TATGAGCAGCTGCG 
 
Clone	#4	
Allele	1	
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCCGGCAG
GATGTCGGAGGAGATAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTAT
CTGTGCACTGGGGTGTCAGCCCAAGTGCAGAAGCAGCGGGCCAGGGAGCTGGGCCTGGGCCG
CCATGAGAATGCCATCAAGTACCTGGGCCAGGATTATGAGCAGCTGCG 
52	bp	insertion	
	
Allele	2	
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCCGGCAG
GATGTCGGAGGAGATCATCACGCCGGTGTACTGGCACTGGGGTGTCAGCCCAAGTGCAGAAG
CAGCGGGCCAGGGAGCTGGGCCTGGGCCGCCATGAGAATGCCATCAAGTACCTGGGCCAGGA
TTATGAGCAGCTGCG 
1	bp	insertion	
	
Allele	3	
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCCGGCAG
ATGTGACACTGGGGTGTCAGCCCAAGTGCAGAAGCAGCGGGCCAGGGAGCTGGGCCTGGGCC
GCCATGAGAATGCCATCAAGTACCTGGGCCAGGATTATGAGCAGCTGCG	
27	bp	deletion		
	
Allele	4	
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCCGGCAG
GATGTCGGAGGAGATCATCACGCCGGTGTACTGCTTACCGTAACTTGAAAGTATTTCGATTT
CTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGGCACTGGGGTGTCAGCCCAAGTG
CAGAAGCAGCGGGCCAGGGAGCTGGGCCTGGGCCGCCATGAGAATGCCATCAAGTACCTGGG
CCAGGATTATGAGCAGCTGCG	
69	bp	insertion 
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Clone	#14	
Allele	1	
CAGGAGCCCAGGTTATAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCC
GGCAGGATGTCGGAGGAGATCATCACGCCACTGGGGTGTCAGCCCAAGTGCAGAAGC
AGCGGGCCAGGGAGCTGGGCCTGGGCCGCCATGAGAATGCCATCAAGTACCTGGGCC
AGGATTATGAGCAGCTGCG 
10bp	deletion		
 
Allele	2	
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCC
GGCAGGATGTCGGAGGAGATCATCACGCCGGTGTACTGGCACTGGGGTGTCAGCCCA
AGTGCAGAAGCAGCGGGCCAGGGAGCTGGGCCTGGGCCGCCATGAGAATGCCATCAA
GTACCTGGGCCAGGATTATGAGCAGCTGCG 
1	bp	insertion 
 
Allele	3	
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCC
GGCAGGATGTCGGAGGAGATCATCACGCCGGTGTACTGGGGTGTCAGCCCAAGTGCA
GAAGCAGCGGGCCAGGGAGCTGGGCCTGGGCCGCCATGAGAATGCCATCAAGTACCT
GGGCCAGGATTATGAGCAGCTGCG 
5	bp	deletion 
 
Allele	4	
CAGGAGCCCAGGTTCTAGTCTTGGGAAGGCCTGGGTTCTGAGCAGGCCCATCTGTCC
GGCAGGATGTCGGAGGAGATCATCACGCCGGCACTGGGGTGTCAGCCCAAGTGCAGA
AGCAGCGGGCCAGGGAGCTGGGCCTGGGCCGCCATGAGAATGCCATCAAGTACCTGG
GCCAGGATTATGAGCAGCTGC 
7	bp	deletion 
	
9.1.2. HEK293	CAPN2-/-	
Wild	type	sequence 
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTGCCTGGAGGCCGGGACG
CTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTTG
GG 
	
Clone	#7	
Allele	1	
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTTGCCTGGAGGCCGGGAC
GCTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTT
GGG	
1bp	insertion 
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Allele	2	
CATCAAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGCGCTCTTCCAGGAC
CCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTTGGG 
16bp	deletion	
 
Allele	3	
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGACTGGAGGCCGGGACGCTCT
TCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTTGGG 
4b	deletion 
 
 
Clone	#26	
REPEATIDLY	found	only	1bp	insertion	even	in	a	total	gDNA	screen	
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTTGCCTGGAGGCCGGGAC
GCTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTT
GGG 
 
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTTGCCTGGAGGCCGGGAC
GCTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTT
GGG 
 
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTTGCCTGGAGGCCGGGAC
GCTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTT
GGG 
 
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTTGCCTGGAGGCCGGGAC
GCTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTT
GGG 
 
AAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGAGAGGGCCATC
AAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTTGCCTGGAGGCCGGGAC
GCTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTT
GGG 
 
9.1.3. HEK293	CAPNS1-/-	
Wild	type	reference	
ATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGGGGAGGCGGG
GGCCTGGGTGGGGGCCTGGGAAATGTGCTTGGAGGCCTGATCAGCGGGGCCGGGGGC
GGCGGCGGCGGCGGCGGCGGCGGCGGCGGTGGTGGAGGCGGCGGTGGCGGTGGAACG
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GCCATGCGCATCCTAGGCGGAGTCATCAGCGCCATCAG 
	
Clone	#10	
Allele	1	
ATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGT
GGTGGAGGCGGCGGTGGCGGTGGAACGGCCATGCGGCATCCTAGGCGGAGTCATCAG
CGCCATCAG 
87	bp	deletion and	1	bp	insertion 
 
Allele	2	
ATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCAGCGGCGGGGGAGGCGGG
GGCCTGGGTGGGGGCCTGGGAAATGTGCTTGGAGGCCTGATCAGCGGGGCCGGGGGC
GGCGGCGGCGGCGGCGGCGGCGGCGGCGGTGGTGGAGGCGGCGGTGGCGGTGGAACG
GCCATGCGGCATCCTAGGCGGAGTCATCAGCGCCATCAG 
1	bp	insertion	
 
Allele	3 
ATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGC
GGTGGTGGAGGCGGCGGTGGCGGTGGAACGGCCATGCGGCATCCTAGGCGGAGTCAT
CAGCGCCATCAG 
84	bp	deletion	and	1	bp	insertion 
 
Allele	4	
ATGTTCCTGGTTAACTTGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGCGGTGGTGGA
GGCGGCGGTGGCGGTGGAACGGCCATGCGGCATCCTAGGCGGAGTCATCAGCGCCAT
CAG 
93	bp	deletion	and	1	bp	insertion 
 
 
Clone	#13	
Allele	1	
ATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGCGGTGGTGGA
GGCGGCGGTGGCGGTGGAACGGCCATGCGGCATCCTAGGCGGAGTCATCAGCGCCAT
CAG 
93	bp	deletion	and	1	bp	insertion 
 
Allele	2 
ATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGCGGTGGTGGA
GGCGGCGGTGGCGGGAGTCATCAGCGCCATCAG 
119	bp	deletion	
Allele	3 
ATGTTCCTGGTTAACTCGTTCTTGAAGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGT
GGTGGAGGCGGCGGTGGCGGGAGTCATCAGCGCCATCAG 
113	bp	deletion	
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9.1.4. C2C12	CRISPR	knock-out	cell	lines	
• CAPNS1-/-	(clone	#2)	
• CAPN1-/-	(clones	need	screening)	
• CAPN2-/-	(clone	#3,	#5)	
• DYSF-/-	(clone	#4,	#8,	#11)	
• CAPN3-/-	(clones	need	screening)	
• MG53-/-	(several	clones,	generated	by	Dr	Frances	Lemckert)	
 
 
 
 
9.2. Ethics		
See	next	pages.	
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%
CMRI"/"CHW"Animal"Ethics"Committee" "
%
Application%for%Approval%of%a%Project%Involving%Animals%
All"questions"must"be"answered"
Project"number":"
%
%%%%%%%%%%%%If%this%is%a%renewal,%please%provide%the%current%project%number%otherwise%leave%blank%
Brief"title"of"project":" Calpain%vs.%Dysferlin%@%The%hierarchy%of%muscle%membrane%repair%
" %
Project"summary":"
Word%limited%to%
approx%250%words%%
Membrane%resealing%after%injury%is%necessary%for%cell%survival,%with%particular%importance%
to%mechanically%active%skeletal%muscle.%Dysferlin%is%a%key%mediator%of%acute%muscle%
membrane%repair%and%dysferlin%gene%mutations%cause%a%late@onset%skeletal%muscular%
dystrophy%proposed%to%be%due%to%defective%membrane%repair.%After%membrane%injury,%
dysferlin%is%cleaved%by%the%calcium@dependent%protease%calpain%in%the%region%coded%by%
alternatively%spliced%exon40a.%This%yields%a%C@terminal%mini@dysferlin%that%we%believe%is%
the%form%of%dysferlin%mediating%acute%membrane%resealing.%%
%%
This%study%aims%to%dissect%the%role%of%calpain%and%dysferlin%exon40a%in%membrane%repair%
and%muscular%dystrophy.%%
%%
We%are%generating%a%skeletal%muscle%KO%of%the%regulatory%‘calpain%small%subunit%1’%
(CapnS1Sk.Mus@/@)%common%to%the%ubiquitous%calpain@1%and%calpain@2.%This%should%
prevent%all%activity%of%the%ubiquitous%calpain%proteins%in%muscle%tissue,%and%thus%prevent%
cleavage%of%dysferlin.%%
%%
Additionally,%using%CRISPR/Cas9%gene@editing,%we%are%altering%the%normal%splicing%of%
dysferlin%exon40a%to%create%2%mouse%lines:%%
Dysf40a@/@%%@where%exon40a%is%knocked@out%so%that%no%dysferlin%isoform%can%be%cleaved.%%
Dysf40aCON%–%where%exon40a%is%fused%to%the%constitutive%exon40%and%all%dysferlin%
isoforms%can%theoretically%be%cleaved%to%mini@dysferlin.%
%%
We%will%study%the%importance%of%dysferlin%cleavage%to%the%membrane%repair%pathway,%and%
the%relative%importance%of%membrane%repair%to%the%development%of%muscular%dystrophy.%%
%
In"which"facility"will"your"project"be"conducted":" %CMRI%%%%%%%%%%%%%% %CHW%
Is"this"project"a"full"study"(FS)"or"a"pilot"study"(PS):" %FS%%%%%%%%%%%%%%%%%%%% %PS%
Chief"Investigator":" Associate%Professor%Sandra%Cooper%
Position":" Group%leader%
Department":"" Institute%for%Neuroscience%and%Muscle%Research%(INMR)%
Organisation":" The%Children's%Hospital%at%Westmead%
Email"address:" Sandra.Cooper@sydney.edu.au%
Proposed"commencement"date":" %%%March%2016%
Proposed"duration"of"project":" %%%3%years%
%
DECLARATION":"As"Chief"Investigator"for"the"proposed"research"project""""""""""""""I"declare:"P"
%
1) I%have%made%myself%fully%aware%of%the%provisions%of%the%NSW%Legislation%and%the%Australian%code%of%practice%for%the%care%
and%use%of%animals%for%scientific%purposes,%8th%Edition%2013%(the%Code).%
2) I%have%designed%the%project%with%the%requirements%to%reduce,%refine%and%whenever%possible%replace%animal%usage.%%
3) The%experiments%and%procedures%described%in%this%application%are%required%to%gain%worthwhile%new%information%and/or%
understanding%and%do%not%constitute%unnecessary%repetition%of%work%previously%conducted%either%by%myself%or%other%
research%groups.%%%
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%
4) I%have%listed%all%investigators,%supervisors%and%team%members%of%the%project.%I%shall%assure%that%they%are%familiar%with%
the%code%and%have%experience%and%qualifications%appropriate%to%their%roles%in%the%project.%
5) I%shall%ensure%accurate%animal%records%are%maintained%and%shall%promptly%provide%annual%reports%detailing%progress%
with%the%project%and%animal%usage%compared%with%permitted%animal%usage.%%%
6) Any%non@compliance%with%the%Code%or%events%adverse%to%the%welfare%of%an%animal%in%this%project%will%be%immediately%
reported%to%the%animal%facility%manager.%%
7) I%have%provided%information%pertaining%to%animal%requirements%and%resources%for%this%project%to%the%appropriate%animal%
facility%manager.%
8) I%accept%responsibility%for%the%whole%project%including%all%procedures,%supervision%of%all%investigators%and%animal%welfare%
including%any%requirements%that%may%be%made%by%the%AEC.%
9) No%work%with%animals%will%commence%without%written%AEC%approval.%
%
Chief%Investigator%Signature% %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% %
Date% %
%
% %
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%
SECTION"1"
PROJECT"ADMINISTRATION""
A)""Staff"member"responsible"for"
supervision"of"project":" Associate%Professor%Sandra%Cooper%
B)""Postal"address"for"
correspondence":"
INMR,%Kid's%Research%Institute,%
Children's%Hospital%at%Westmead,%
Locked%Bag%4001,%Westmead,%2145%
C)""Telephone"
Work:%
Mobile:%
9845%1456%
0408275305%
D)"Email"address":" Sandra.Cooper@sydney.edu.au%
E)"Emergency"contact"(name"&"
phone)"in"case"of"an"emergency"
related"to"animal"welfare"
Dr%Frances%Lemckert,%0425207922%
%
F)" Name" Procedures""
Responsible"for"
Experience""
in"procedures"
Chief"Investigator" Sandra%Cooper% Project%design/planning% >15%years%
Supervisor" Sandra%Cooper% Project%design/planning% >15%years%
Team"Members" Frances%Lemckert% Perform%ALL%procedures%outlined%in%
this%application%including%injections%
(intramuscular,%intraperitoneal%and%
tail%vein%injections),%monitoring%of%
mice,%euthanasia,%tissue%collection%and%
analysis,%genotyping,%monitoring,%
handling%mice%and%blood%collection,%
perform%downhill%run%experiments%
26%years%
% Ann@Katrin%Piper% Perform%most%procedures%outlined%in%
this%application%with%training%and%
supervision%if%needed.%
~1%year,%all%relevant%
training%has%been%
completed%
% Peter%Houweling% Assist%with%experimental%designs;%
handling%mice%for%training%purposes%
(mouse%treadmill%experiments)%
9%years%large%(sheep%and%
cattle)%and%5%years%small%
(mouse)%animal%model.%
% % % %
% % % %
% % % %
G)"
i)""""Have"you"ever"had"an"Animal"Research"Authority"cancelled?%
If%yes,%please%provide%details%of%the%date%on%which%the%authority%was%cancelled%and%the%
reason%for%cancellation:%%
%
%
%
Yes%% No%
ii)"""Has"an"application"to"another"AEC"been"submitted"for"substantially"the"same"project?" Yes%% No%
iii)""Has"an"application"to"another"AEC"been"refused"for"substantially"the"same"project?" Yes%% No%
iiii)"Is"the"work"supported"by"a"research"grant?" Yes%% No%
v)"""Name"of"funding"agency"/"organisation"" NHMRC%(APP1103618)%&%The%Jain%Foundation%
H)"
i)""Does"this"application"involve"the"use"of"gene"technology"and/or"genetically"modified" Yes%% No%
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%
organisms?"
!
It!is!the!responsibility!of!the!chief!investigator!to!obtain!approval!by!the!IBC,!and!OGTR!if!
appropriate,!for!the!use!of!gene!technology!and!genetically!modified!organisms.!!No!project!
should!proceed!until!approval!for!Animal!Ethics!and!Biosafety!have!been!obtained.!
ii)""Has"IBC"approval"been"obtained"and"OGTR"been"notified""""""""""
(for"exempt"dealings)?"
!
Yes%% No%
iii)""Has"IBC"and"OGTR"approval"been"obtained"(for"nonPexempt"dealings)?"
!
If%yes,%please%provide%the%reference%number%of%IBC/OGTR%certification:%NL14.05,%NL15.03%
%
If%no,%please%notify%the%AEC%Secretary%(by%email%at%acec@cmri.usyd.edu.au)%of%the%reference!
number%of%certification%when%the%approval%has%been%granted%by%the%IBC/OGTR.!
Yes%% No%
iv)""What"category"of"genetic"technology"and"dealings"does"this"project"fall"under?"
NLRD%@%PC2%(Schedule%3,%Part%2,%2.1a%AND%Schedule%3%Part%1.1%a)%%
% %
5"|"P a g e "
%
SECTION"2"
ANIMAL"NUMBERS"
A)"
If"renewing"a"previously"approved"project,"please"provide"the"total"number"of"animals"used"since"the"first"or"
initial"approval%
Species" Strain" Numbers"
N/A% % %
% % %
% % %
% % %
% % %
%
If%you%do%not%have%the%number%of%animals%recorded%since%the%first%approval,%please%provide%the%date%from%
which%numbers%have%been%recorded.%%%%Date:%%
%
%
%
B)"
Specify"the"number"and"species"of"animals"required"for"the"duration"of"the"approved"project."Include"only"
those"animals"of"the"right"genotype"required"for"experimental"purposes"only."Please"refer"to"Appendix"1"and"2"
for"classification"of"“purpose”"and"“procedure”.""(Link"to"Appendix"1"&"2)"
%
Species" Strain" Sex"
"
Age/weight" Number""of"animals"
required""
Purpose" Procedure"
Mouse% C57BL/6%WT% M/F% adult% 88% 4% 3%
Mouse% C57BL/6%Dysf@/@% M/F% adult% 88% 4% 3%
Mouse% C57BL%/CapnS1Sk.Mus%@/@% M/F% adult% 39% 4% 3%
Mouse% C57BL/6%Dysf40a@/@% M/F% adult% 39% 4% 3%
Mouse% C57BL/6%Dysf40aCON% M/F% adult% 39% 4% 3%
Mouse% C57BL/6%WT% M/F% day%0@4% 48% 4% 3%
Mouse% C57BL/6%Dysf@/@% M/F% day%0@4% 48% 4% 3%
Mouse% C57BL%/CapnS1Sk.Mus%@/@% M/F% day%0@4% 24% 4% 3%
Mouse% C57BL/6%Dysf40a@/@% M/F% day%0@4% 24% 4% 3%
Mouse% C57BL/6%Dysf40aCON% M/F% day%0@4% 24% 4% 3%
%
Grand"total"of"animals"required":" 461%
Describe"any"adverse"characteristics"of"the"required"strains"that"may"impact"on"the"welfare"or"supply"of"animals:"
"
The%CapnS1Sk.Mus@/@%is%a%new%mouse%line%currently%being%generated%under%GMO%protocol%K340.%%We%expect%this%
mouse%to%develop%a%skeletal%muscular%dystrophy%similar%to%the%dysferlin%null%mouse,%but%consider%it%likely%that%the%
disease%onset%may%be%earlier,%and%more%severe%than%that%for%the%dysferlin%null%line.%However,%we%do%not%expect%
this%to%be%life@limiting,%nor%to%adversely%affect%the%breeding%performance%of%these%mice,%as%it%has%been%reported%
that%cardiac@specific%knockout%of%CapnS1%gave%minimal%phenotype%until%the%mice%were%physiologically%stressed.%
%
Dysf40a@/@%and%Dysf40aCON%are%also%new%mouse%lines%currently%being%generated%using%CRISPR/Cas9%technology%
under%protocol%K337.%%The%phenotypes%of%these%lines%are%difficult%to%predict%at%this%stage%but%we%do%not%expect%a%
severe%adverse%effect%on%the%mice%as%global%knockout%of%dysferlin%does%not%lead%to%severe%dystrophic%pathology.%
%
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%
As%part%of%this%proposal,%we%will%carefully%monitor%these%mice%and%harvest%muscle%tissue%at%different%ages,%
comparing%this%to%both%WT%mice%and%to%Dysf@/@%mice.%%This%will%alert%us%to%the%onset%of%muscle%disease,%and%to%the%
extent%of%this%disease%in%comparison%to%the%dysferlin@null%mice.%
%
If%mice%are%significantly%adversely%affected%by%any%developing%muscular%dystrophy%or%unexpected%phenotype,%we%
will%assess%the%degree%of%impact%on%the%animals%and%report%back%to%this%ACEC. 
%
In%consultation%with%Kim%Hewitt,%CHW%Transgenic%Facility%Manager,%we%will%develop%strategies%to%minimize%
adverse%impact%on%the%welfare%of%the%mice,%including%changes%to%our%experimental%plans%where%appropriate,%as%
well%as%husbandry%practices.%%%
%
%
C)"
Provide"an"estimate"of"the"number"of"animals"in"the"breeding"colonies"required"to"produce"the"experimental"
animals"requested"in"Section"6a"
%
Species" Strain" Sex"
"
Age/weight" Number"of"
animals"
required""
Purpose"
(1"or"2)"
Procedure""
Mouse% C57BL/6%WT% F/M% Adult% 20% 1% 1%
Mouse% C57BL/6%Dysf@/@% F/M% Adult% 20% 1% 1%
Mouse% C57BL/6%CapnS1Sk.Mus%@/@% F/M% Adult% 28% 1% 1%
Mouse% C57BL/6%Dysf40a@/@% F/M% Adult% 28% 1% 1%
Mouse% C57BL/6%Dysf40aCON% F/M% Adult% 28% 1% 1%
Grand"total"of"animals"required":" 124%
%
D)""Justification:"
Please%justify%the%animal%numbers%required.%%This%can%be%done%by%describing%how%the%experimental%design%
accounts%for%the%number%of%animals%requested%and/or%a%flow%chart%can%be%appended%as%a%separate%document.%
%
Under%the%ideal%scenario,%we%will%be%able%to%perform%experiments%on%all%5%genotypes%we%are%studying%at%the%same%
time,%in%a%5@way%comparison%between:%
1.%C57BL/6%WT%%
2.%Dysf@/@%%%(Bla/J)%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%(1.%and%2.%are%our%two%control%lines%for%all%experiments)%%
3.%CapnS1Sk.Mus@/@%%
4.%Dysf40a@/@%%
5.%Dysf40aCON%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%(3.%4.%&%5.%are%our%three%novel%experimental%lines)%%%
%
However,%this%requires%a%not%just%good%planning%but%also%a%great%deal%of%good%luck%as%far%as%breeding%and%supply%of%
experimental%animals%is%concerned,%and%it%is%far%more%likely%that%we%will%be%performing%our%experiments%in%2%
groups:%%
• Group%one%will%involve%a%3@way%comparison%of%WT,%Dysf@/@%and%CapnS1Sk.Mus@/@,%%
• Group%two%will%involve%a%four@way%comparison%between%WT,%Dysf@/@,%Dysf40a@/@%and%Dysf40aCON%lines.%
%
If%we%are%fortunate%enough%to%perform%the%5@way%comparison%for%any%of%our%experiments,%this%will%halve%the%
number%of%C57BL/6%WT%and%Dysf@/@%control%animals%needed.%%Given%the%logistical%challenge%of%breeding%mice%from%
5%different%genotypes%at%the%same%time%we%have%to%be%prepared%for%the%less%ideal%scenario%of%splitting%the%
experimental%cohort%into%two%groups.%%In%this%case%we%would%need%twice%as%many%control%animals%as%for%the%single%
cohort,%and%have%used%these%numbers%for%all%our%experimental%calculations.%
"
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%
1) To"study"the"onset"and"progression"of"a"muscular"dystrophy"in"different"mouse"models""
(CapnS1Sk.MusP/P,"Dysf40aP/P%and"Dysf40aCON)""
We%want%to%study%the%newly%generated%CapnS1Sk.Mus@/@,%Dysf40a@/@%and%Dysf40aCON%mouse%models%and%
observe%disease%progression%without%experimental%interference.%%Four%time%points%(t1@4)%will%be%carefully%
selected%after%the%monitoring%period%of%the%newly%generated%mice%has%been%completed%to%minimize%the%
impact%on%the%mice;%we%expect%our%time%points%to%be%distributed%between%weaning%age%and%18%months,%
but%will%be%prepared%to%shorten%the%study%period%if%required.%
At%time%point%t3%(~6%months%of%age)%we%will%compare%mice%that%were%housed%with%or%without%a%training%
wheel%to%assess%if%spontaneous%exercise%and%increased%activity%influences%disease%progression%and%muscle%
morphology.%Thus%at%time%point%t3%we%will%have%twice%as%many%animals%as%in%time%points%t1,%t2%and%t4.%
"
Age:%from%weaning%to%18%months%%
Explain"number"of"mice"needed:%3%mice/genotype,%4%time%points%(t1@4),%t3%wheel%and%no%wheel%%
t1=%~2%months%%@%%3%mice%
t2=%~4%months%%@%%3%mice%
t3=%~6%months%%@%%6%mice%(wheel%vs.%no%wheel)%
t4=%12@%18%months%%@%3%mice%
"
Group"1"
WT""""""""""""""""""""""""""15"
DysfP/P"""""""""""""""""""""15"
CapnS1Sk.MusP/P"""""""15"
Group"2"
WT""""""""""""""""""""""""""15"
DysfP/P"""""""""""""""""""""15"
Dysf40aP/P""""""""""""""15"
Dysf40aCON""""""""""""15"
"
Total"number"of"mice:%%%%105""%
%
2) Characterization"of"membrane"repair"defects"in"calpain"vs"dysferlin"mouse"models:%
%
a. Isolation"of"foot"muscle"fibres"(FDB"fibres)""
"""""""Age:"adult%mice%(8%weeks%and%older)"
"""""""Explain"number"of"mice"needed:%no%additional%mice%will%be%needed.%%
"""""""Mice%can%be%used%at%the%2@month%time%point%from%the%aging%protocol%above%(1).%%
%%%%%%%3%mice%for%each%genotype,%performed%in%two%groups%as%above%(3x7%=%21),%each%individual%mouse%
%%%%%%%will%give%us%enough%isolated%fibres%to%perform%1@2%experiments.%%
%%%%%%%We%will%perform%different%membrane%damage%assays%on%the%isolated%fibres%(e.g.%pore@forming%%
%%%%%%%toxin%and%laser%injury).%
%
Total"number"of"mice:%no%additional%mice%needed%
%
%
b. Isolation"of"primary"myoblasts"
Age:%day%0@4"
Explain"number"of"mice"needed:%3%litters%x%~8%pups/litter%%
"
Group"1"
WT"""""""""""""""""""""""""24"
DysfP/P""""""""""""""""""""24"
CapnS1Sk.MusP/P""""""24"
Group"2"
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%
WT"""""""""""""""""""""""""24"
DysfP/P""""""""""""""""""""24"
Dysf40aP/P"""""""""""""24"
Dysf40aCON"""""""""""24"
"
Total"number"of"mice:"""168"pups"
%
Generally,%4@8%pups%pooled%will%generate%enough%cells%to%perform%one%experiment%after%cells%have%been%
isolated,%depending%on%age.%Derived%primary%myoblast%will%have%to%be%sorted%for%the%muscle%cell%marker%
NCAM%to%ensure%the%purity%of%our%cell%culture%and%remove%fibroblast%contamination%(this%is%unavoidable%
for%cells%derived%from%fresh%tissue).%Mouse%muscle%cells%do%not%freeze%and%thaw%very%well.%Therefore,%only%
freshly%derived%cells%will%be%used%for%experiments.%"
%
We%derive%primary%myoblast%cultures%from%all%mouse%lines,%and%perform%our%suite%of%membrane%repair%
assays%on%differentiated%myotubes%using%scrape%injury,%pore%forming%toxin%injury,%ballistic%or%laser%injury%
to%create%different%types%of%membrane%injury.%
%
3)""""Downhill"run"–"eccentric"contraction""
This%assay%is%used%to%induce%physiological%muscle%damage%to%specific%muscles%of%the%mouse,%enabling%us%to%
study%both%the%degree%of%damage,%and%the%physiological%repair%process%in!vivo.%%
%
"
Figure!1:!Schematic!the!two!scenarios!of!potential!experimental!groups.!%
"
Age:%adult%(8%weeks%and%older)%%
Explain"number"of"mice"needed:%6%adult%mice/genotype;%2%time%points%(~day%1%and%~day%7%post@exercise)%
(6x2%=%12%adult%mice).%Repeat%experiment%for%reproducibility%(12x2%=%24)%
PrePexperimental"trial%of%downhill%run%duration%and%degree%of%incline%plus%administration%and%detection%
of%Evan’s%Blue%Dye%–%10%mice%per%genotype%–%controls%only%(10x2%=%20)%
Trial"cohort"
""""""""""""""WT"""""""""""""""""""""""""10"
"""""""""""""DysfP/P"""""""""""""""""""""10"
Group"1"
WT"""""""""""""""""""""""""24%
DysfP/P""""""""""""""""""""24"
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%
CapnS1Sk.MusP/P""""""24"
Group"2"
WT"""""""""""""""""""""""""24"
DysfP/P""""""""""""""""""""24"
Dysf40aP/P"""""""""""""24"
Dysf40aCON"""""""""""24"
"
Total"number"of"mice:""""188%%
%
%
%
E)""Justify"the"use"of"animals"in"this"project:"
The!answer!to!this!question!must!be!in!enough!detail!to!satisfy!State!and!NH&MRC!regulations.!
%
We%are%studying%the%molecular%pathway%of%muscle%membrane%repair,%and%its%importance%to%the%development%of%
muscular%dystrophy.%In%the%specific%case%of%dysferlinopathy,%we%know%that%the%skeletal%muscular%dystrophy%is%not%
restricted%to%muscle%cells,%but%is%characterised%by%a%strong%inflammatory%infiltrate%in%the%muscle,%demonstrating%
involvement%of%the%immune%system%in%the%disease%course.%
Thus%we%cannot%model%the%disease%in%isolated%muscle%cells%alone,%but%need%the%full%interplay%of%muscle%tissue%with%
other%tissues%of%the%mouse%to%allow%proper%expression%of%the%disease%course%and%allow%us%to%understand%fully%the%
effects%our%genetic%%changes%have%made%to%the%course%of%disease.%
We%will%be%performing%physiological%exercise%challenges%to%our%mice%and%measuring%both%induced%membrane%
damage%as%well%as%physiological%recovery%of%tissue%over%time.%%Whilst%immediate%repair%of%the%breach%in%a%muscle%
membrane%may%involve%only%the%cells%directly%affected,%longer%term%repair%involves%activation%of%satellite%cells%
(muscle%stem%cells)%that%fuse%in%to%the%muscle%fibres%to%replace%irreparably%damaged%regions%of%the%fibre,%and%
infiltration%by%immune%cells%such%as%macrophages%that%clean%up%the%cellular%debris%and%create%space%for%the%new%
fibre%to%be%made.%%None%of%the%current%cell%culture%techniques%allow%us%to%accurately%model%these%in%vivo%
processes%that%involve%many%cell%types,%time%and%space.%%
%
"
F)""Have"alternative"techniques"been"investigated?""
What%alternatives%have%been%considered%and%why%have%they%been%rejected%
as%unsuitable?%
"
Yes% % No% %
We%have%performed%a%wealth%of%prior%in%vitro%studies%that%have%informed%our%current%understanding%of%calpain%
and%dysferlin%in%the%membrane%repair%pathway.%
In%vitro%cell%studies%have%provided%us%new%information%about%the%role%of%calpain%in%cleavage%of%dysferlin%for%acute%
membrane%repair,%and%the%existence%of%the%calpain@cleavage%motif%within%the%alternatively%spliced%exon40a%of%
dysferlin.%%%
We%have%performed%flow%cytometry%studies%which%showed%us%that%external%application%of%calpain%is%beneficial%to%
acute%membrane%resealing.%These%studies%have%led%us%to%the%point%at%which%we%need%to%move%into%animal%studies%
to%dissect%the%role%of%calpain%and%dysferlin%in%muscle%membrane%repair%and%to%decipher%the%importance%of%
membrane%repair%defects%to%the%development%of%muscular%dystrophy.%
%
%
G)""Does"the"project"involve"the"reuse"of"any"animals"that"have"been"the"
subject"of"previous"research?"
If%YES,%what%has%previously%been%done%to%these%animals?%(Include%project%
name%and%number)%See!Animal!Research!Act!Section!25!(B);!Code!of!Practice!Clause!
2.2.16%
%
Yes% % No% %
 
%
%
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%
H)""Can"tissues"be"shared"with"other"researchers"at"the"conclusion"of"the"
experiment?"
%
Yes% % No% %
%
% %
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SECTION"3"
ANIMAL"WELFARE"
A)""Source"of"animals%–%where%obtained%% %In@house%%%%% ARC%%%%% %Other%(please%specify)%
%
%
%
%
B)""Location%–%where%will%animals%be%housed% %CMRI%%%%% CHW%%%%%%
%%
C)""Location%–%where%will%the%research%take%place"(Compelling!justification!is!required!to!take!animals!outside!of!
the!animal!facility!that!house!the!animals)%
We%will%perform%many%of%our%studies%within%the%CHW%Transgenic%facility,%and%in%the%INMR%research%laboratory%on%
level%3%of%the%Kid's%Research%Institute.%%
%
Mice%that%are%used%for%primary%cell%culture%or%muscle%fibre%isolation%will%be%taken%to%the%research%laboratory%on%
level%3%of%the%KRI%so%tissues%can%be%harvested%and%processed%in%a%sterile%fashion%immediately%after%sacrifice%of%the%
mice.%%%
%
The%downhill%run%experiment%requires%access%to%a%mouse%treadmill,%and%we%have%been%offered%the%loan%of%this%
piece%of%equipment%from%our%collaborators%at%the%Murdoch%Children's%Research%Institute%(MCRI)%in%Melbourne.%%%
The%intention%is%that%we%will%arrange%our%experiments%for%a%time%during%which%the%treadmill%is%available%for%use,%
and%we%will%relocate%the%treadmill%to%the%CHW%Transgenic%Facility%(after%appropriate%fumigation).%%%
If%it%the%availability%of%mice%for%these%experiments%does%not%fit%with%availability%of%the%treadmill,%it%is%possible%we%
will%need%to%transport%mice%to%MCRI%and%travel%there%to%perform%the%experiments.%%If%this%appears%likely,%we%will%
return%to%the%ACEC%to%seek%permission%for%this%to%occur.%
%
%
D)""Housing%–%cage%type/s%%
Static%micro@isolator%cage %
%
Click%here%to%select%cage%type %
%
%
E)""Stocking"densities%–%minimum%and%maximum%number%of%animals%per%cage%%
%Standard%%%%%% %Other%(please%provide%further%information)%
 
%
%
%
F)""Is"a"special"diet"required?""Yes% %No% %
If%yes,%please%provide%dietary%information%%
%
% "
G)""Anaesthesia"and"Analgesia" "
Monitoring%during%recovery%% Yes%% No%
%
%
%
% Name"of"agent:" Route"of"administration:" Dose:""
1." Isofluorane% Inhalation% 3@5%%in%oxygen%at%0.8@1L/min%
for%induction,%reducing%to%1@
3%%for%maintenance.%
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2."
%
% % %
3." % % %
4." % % %
5." % % %
H)""What"actions"will"be"taken"to"minimise"pain"or"distress:%
%
@%Mice%will%be%group@caged%wherever%possible%to%allow%appropriate%socialisation%up%until%the%point%of%use.%%
@%All%manipulations%will%be%carried%out%by%trained%personnel.%%
@%Mice%are%kept%in%a%quiet%and%warm%environment%during%and%after%the%procedure%to%assist%recovery%and%reduce%
stress%to%the%animals.%
%
 
I)""Surgery%
Are%there%any%surgical%procedures%involved%in%this%project%% %Yes%% %No%
Will%monitoring%be%conducted% Yes%% No%
If%this%project%does%involve%surgery,%please%describe%pre%and%post@op%care%and%management,%experience%of%
personnel,%sterile%techniques,%sites%(specific%details%about%the%surgical%procedures%should%be%included%in%the%
procedures%table%on%page%8)%
%
%
%
 
J)""Blood"collection"
Is%blood%collection%required%% %Yes%% %No%
Will%monitoring%be%conducted%% Yes%% No%
"
" Site" Frequency" Volume"
1." Tail%vein% 4%x%% max.%200uL/%time%point%
2." Cardiac%puncture% 1%x%% ~1mL%
3." % % %
4." % % %
%
"
K)""Injections"
Are%injections%required% %Yes%% %No%
Will%monitoring%be%conducted%% %Yes%% %No%
% Name"of"reagent:" Route"of"administration:" Dose:" Frequency:"
1." Evans%Blue%Dye%(EBD)% intraperitoneal%(IP)% %50%uL/10g%body%
weight%of%a%0.5%%
solution%%
single%dose%
2." % % % %
3." % % % %
4." % % % %
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%
5."
%
% % % %
%
L)""Please"describe"the"methods"of"handling"and"restraint"
For%simple%handling,%adult%mice%will%be%grasped%by%the%base%of%the%tail.%This%will%be%used%when%moving%mice%
between%the%cage%and%treadmill%for%the%downhill%run%experiments.%
%
For%other%procedures%requiring%restraint%such%as%detailed%examinations%or%intraperitonal%injections,%mice%will%be%
grasped%by%the%scruff%of%the%neck%and%secured%at%the%base%of%the%tail.%%
%
For%isofluorane%anaesthesia,%mice%are%handled%by%tail%to%remove%them%from%the%cage%and%placed%into%the%
anaesthetic%chamber.%%After%a%sufficient%plane%of%anaethesia%is%reached,%mice%are%removed%from%the%anaesthetic%
chamber%by%tail%and%placed%onto%a%plastic%board%where%their%limbs%are%taped%down%to%provide%ready%access%to%the%
chest%and%abdomen.%%A%face%mask%delivering%a%constant%supply%of%anaesthetic%is%fitted%to%the%mouse%once%it%is%
placed%on%the%board,%ensuring%the%mouse%remains%adequately%anaesthetised%throughout%the%following%procedure.%
%
%
"
M)""Longest"or"maximum"duration"
animals"will"be"kept"in"this"study"
18%months%(ageing%mice)%
"
N)""Are"the"animals"euthanased%at"the"end"of"the"experiment?% Yes% % No% %
If%yes,%how%are%they%euthanased?%Where%and%who%will%carry%out%this%procedure?%
%
Mice%will%be%euthananized%using%the%most%appropriate%method%from%the%below%previously%approved%methods%list:%
1.% CO2%asphyxia%–%for%up%to%10%minutes%
2.% Cervical%dislocation%
3.% Anaesthetic%overdose%
4.% Decapitation%–%0@4%days%old%
%
Adult%mice%being%used%for%tissue%harvest%will%be%culled%in%the%INMR%research%laboratory,%and%cervical%dislocation%
will%most%commmonly%be%used%as%it%can%be%performed%in%any%location%and%does%not%require%access%to%specific%
equipment.%%%
Newborn%mice%being%used%for%tissue%harvest%will%also%be%culled%in%the%INMR%research%laboratory%and%decapitation%
will%be%the%method%used.%
Our%downhill%run%mice%will%receive%a%terminal%cardiac%puncture%under%isofluorane%anaesthesia,%and%if%the%degree%
of%exsanguination%is%not%sufficient%to%ensure%death%of%the%mice,%they%will%be%immediately%culled%by%cervical%
dislocation%whilst%still%under%anaesthesia.%
All%personnel%included%in%the%protocol%have%or%will%be%trained%in%the%methods%to%be%used%for%the%protocol.%Only%
people%nominated%on%this%protocol%will%be%performing%the%procedure%as%required.%Facility%staff%can%perform%the%
procedure%in%the%event%that%the%research%group%is%unable%carry%it%out.%
%
%
"
O)""Detail"the"criteria"that"determines"the"end"point"of"the"experiment%
Note*!Animal!Facility!Staff!will!euthanise!an!animal!that!has!reached!an!endUpoint!if!the!researcher!can!not!be!
contacted!within!a!reasonable!time!frame.!
!
The%end%point%of%our%experiments%have%been%pre@determined%based%on%expected%outcomes%(for%example,%aging%to%
specific%ages)%but%will%be%modified%if%any%unexpected%detrimental%impact%is%demonstrated%by%the%animals.%
For%many%of%our%experiments,%mice%will%be%culled%and%tissues%harvested%post@cull,%and%we%are%not%performing%any%
interventions%that%may%adversely%affect%our%mice.%Thus%the%end@point%of%the%experiment%will%be%the%time%at%which%
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%
the%mouse%is%culled.%
%
For%our%downhill%run%experiment,%we%propose%one%group%of%mice%will%be%culled%approximately%24%hours%post@run%
for%assessment%of%muscle%damage%via%Evans%Blue%Dye%uptake%into%the%muscle,%and%serum%CK%measurements.%
For%the%second%group%of%mice%undergoing%the%downhill%run%protocol,%there%will%be%no%Evan's%blue%Dye%injection,%
and%mice%will%be%culled%at%around%7%days%post@exercise%to%assess%longer@term%muscle%repair.%
If%any%of%our%experimental%cohorts%show%any%serious%adverse%impact%following%the%downhill%run,%we%will%closely%
monitor%the%mice,%and%will%bring%forward%the%end@point%of%the%experiment%if%necessary%to%alleviate%adverse%
welfare%impacts.%
%
%
"
P)""Does"the"project"involve"any"of"the"following"which"could"be"dangerous"to"animals"or"humans?"
Pathogenic%organisms:%
Biological%toxins:%
Radiation%/%radioactive%agents:%
Known%carcinogens:%
%
Yes%% No%
Yes%% No%
Yes%% No%
Yes%% No%
If"yes"to"any"of"the"above,"please"complete"the"following:"
Dose%level%or%titer%:%
%
%
Route%of%administration%:% %
Have%appropriate%approvals%
been%obtained?%
%
Yes%% No%
How%will%the%impact%to%the%
animals%be%assessed?% %
"
Q)""Please"list"any"monitoring"form/s"(as"indicated"in"section"4)"that"you"will"be"using"during"this"work.""
Include%a%copy%of%each%form%with%this%application%–%eg.%score%sheet,%anaesthetic%/%surgical%report.%%
"
1.%% Monitoring%form%@%aged%
mice%
2.%% Downhill%run%experimental%
checklist%
3.%% %
4.% % 5.% % 6.% %
7.% % 8.% % 9.% %
"
" "
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% Table#of#Procedures#
Procedure#
Short#D
escription#
Is#there#pain#or#
distress#involved#
w
ith#the#
procedure?#
Y/N
%
Category#of#invasiveness%
%(Link%to%Categories%table%2%
appendix%III)%
H
ow
#w
ill#the#im
pact#to#the#
anim
al#be#m
inim
ised?#
(3)%Blood%collection%%%
The%tail%is%w
arm
ed%by%gently%holding%
betw
een%palm
%and%fingers%to%dilate%
the%tail%vein%or%placed%under%a%heat%
lam
p.%For%disinfection%the%area%of%
injection%is%sw
apped%w
ith%alcohol.%A%
fine%lancet%w
ill%be%used%to%incise%the%
skin%over%the%vein.%The%blood%w
ill%be%
collected%by%applying%a%
m
icroheam
atocrit%tube%directly%to%
the%site.%%
Y%
C)%M
inor%stress%/%pain%%
The%procedure%w
ill%be%carried%out%
by%trained%personnel%w
ith%
experience%in%the%procedure%to%
m
inim
ise%the%duration%of%handling%
and%to%ensure%the%procedure%is%
carried%out%in%an%efficient%
m
anner.%Volum
es%taken%during%
venous%blood%collection%w
ill%be%
the%sm
allest%required%to%analyse%
CK%levels,%and%w
ill%not%exceed%
m
axim
um
%volum
e%for%w
eight%
recom
m
ended%by%the%N
HRM
C%(as%
outlined%in%“G
uidelines%to%
prom
ote%the%w
ellbeing%of%anim
als%
used%for%scientific%purposes”%–%
Factsheet%C),%to%m
inim
ize%the%
effects%of%blood%loss%on%m
ouse%
health.%%
(3)%Dow
nhill%run2%eccentric%
excersise%
Dow
nhill%running%is%used%to%generate%
eccentric%contractions%in%vivo.%M
ice%
w
ill%be%put%on%the%treadm
ill%and%
perform
%a%dow
nhill%run%protocol%
after%acclim
atisation%to%the%treadm
ill%
and%consecutive%flat2running%sessions%
of%increasng%duration%and%speed%for%
a%period%of%up%to%7%days.%
%Y%
C)%M
inor%stress%/%pain
%
M
ice%w
ill%be%w
ell%acclim
atized%to%
the%treadm
ill%prior%perform
ing%
experim
ents%to%m
inim
ize%stress%
and%anxiety.%M
ice%w
ill%be%
m
onitored%throughout%the%
experim
ent%and%if%any%signs%of%
distress%are%detected%the%
experim
ent%w
ill%be%stopped%and%
the%m
ice%w
ill%be%returned%to%their%
cages%to%recover.%The%m
ice%w
ill%be%
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%
given%treats%after%the%
experim
ents%in%form
%of%sunflow
er%
seeds%to%rew
ard%them
.%
%
%
(3)%Evans%blue%dye%adm
inistration%
M
ice%participating%in%the%dow
nhill%
run%protocol%w
ill%be%injected%
intraperitoneally%%
(i.p.)%w
ith%sterile%0.5%
%Evans%Blue%dye%
in%phosphate2buffered%saline%as%
described%previously%(Rooney%et%al,%
2006.%J.%Cell%Biol.)%
%%Y%
%
C)%M
inor%stress%/%pain%%
Intraperitoneal%injection%w
ill%be%
undertaken%by%personnel%
experienced%this%procedure.%%
M
ice%w
ill%be%m
onitored%follow
ing%
injection%to%ensure%there%are%no%
adverse%effects%(see%dow
nhill%run%
checklist).%
%
(2)%Inhalant%anaesthesia%%
M
ice%are%placed%into%the%anaesthetic%
cham
ber%and%exposed%to%a%constant%
flow
%of%isofluorane.%%After%a%sufficient%
plane%of%anaethesia%is%reached,%m
ice%
are%rem
oved%from
%the%anaesthetic%
cham
ber%by%tail%and%placed%onto%a%
plastic%board%w
here%their%lim
bs%are%
taped%dow
n%to%provide%ready%access%
to%the%chest%and%abdom
en.%%A%face%
m
ask%delivering%a%constant%supply%of%
anaesthetic%%is%fitted%to%the%m
ouse%
once%it%is%placed%on%the%board,%
ensuring%the%m
ouse%rem
ains%
adequately%anaesthetised%
throughout%the%follow
ing%procedure.%%
Y%
B)%Little%or%no%discom
fort%%
M
ice%only%handled%w
hen%ready%to%
perform
%procedure,%m
ice%placed%
into%anaesthetic%cham
ber%and%
im
m
ediately%exposed%to%the%%
anaesthetic%agent%to%m
inim
ise%
tim
e%taken%for%m
ouse%to%becom
e%
unconscious.%Anaesthesia%of%m
ice%
w
ill%only%be%perform
ed%at%the%
tim
e%of%tissue%harvest%(aged%m
ice%
and%after%dow
nhill%run)%to%allow
%
for%cardiac%puncture%2%it%is%non2
recovery/term
inal%anaesthesia%
(2)%Cardiac%puncture%2%end%point%
blood%collection%
Blood%draw
n%directly%from
%left%
ventricle%of%m
ouse%heart%w
ith%needle%
and%syringe%w
hile%m
ouse%under%
anaesthetic%to%m
axim
ise%volum
e%of%
blood%collected%
N
%
B)%Little%or%no%discom
fort%%
M
ouse%under%anaesthetic%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
17#|#P
a
g
e
#
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
n
%
%%%%%
%
%%%%%
%
%%%%%
%
%%%%%
%
Select%category%from
%drop%dow
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SECTION#4#
EXPERIMENTAL#PLAN#
A)#
Scientific#Description:#
Please%try%not%to%exceed%two%pages%
%
If%this%application%is%for%the%renewal%of%a%current%project,%please%highlight%any%new%additions%(procedures,%
objectives,%techniques%etc.,%in%bold#face#type)%
%
%The$AEC$must,$by$regulation,$include$two$categories$of$lay$members$who$do$not$have$a$scientific$or$veterinary$
background.$$A$description$that$is$accessible$to$all$members$of$the$Committee$will$expedite$the$assessment$of$
your$application.$
%
Mutations%in%dysferlin%cause%muscular%dystrophy.%%Lack%of%dysferlin%causes%a%membrane%repair%defect%in%isolated%
myofibres.%%Proposed%that%defective%membrane%repair%underpins%dysferlinopathy%–%skeletal%muscular%dystrophy.%
Calpain%has%previously%been%shown%to%be%essential%for%acute%membrane%resealing%there%are%2%ubiquitous%calpains%
and%it%has%not%been%determined%which%of%these%is%responsible%
We%have%shown%calpain%cleaves%dysferlin%in%response%to%calcium%influx%associated%with%membrane%breach.%%MiniG
dysferlinC72%module%released%and%we%believe%this%plays%specialized%role%in%acute%membrane%resealing.%%Thus%
calpain%is%the%“enabler”%of%dysferlin’s%membrane%repair%capacity%and%acts%upstream%in%the%membrane%repair%
cascade.%
The%region%of%dysferlin%that%carries%the%calpain%cleavage%motif%is%coded%by%the%alternatively%spliced%exon40a.%%
Levels%of%exon40aGcontaining%isoforms%are%very%low%in%skeletal%muscle%and%heart,%the%major%tissues%
demonstrating%a%phenotype%with%dysferlin%mutations/dysferlinopathy.%%these%are%also%the%mechanically%active,%
dynamic%tissues%that%have%been%shown%to%suffer%membrane%injury/microtears/permeability%with%everyday%use%SO%
we%may%expect%levels%of%exon40a%to%be%higher%if%this%provides%dysferlin%the%capacity%for%cleavage%and%thus%to%
function%in%membrane%repair.%
%
We%will%confirm%skeletal%muscle%deficiency%of%calpainG1%and%calpainG2%in%CapnS1Sk.MusG/G%mice%
through%Western%blot%analysis%of%skeletal%muscles%(see%below),%heart,%lung,%liver,%kidney,%brain.%
We%will%perform%detailed%muscle%phenotyping%of%CapnS1Sk.MusG/G%mice.%We%will%compare%
C57BL/6%WT,%DysfG/G%and%CapnS1Sk.MusG/G%mice%at%2,%6%and%12%months%of%
age,%with%n=6%animals%per%genotype%at%each%timeGpoint.%We%will%study%quadriceps,%extensor%
digitorum%longus,%tibilais%anterior,%gastrocnemius%and%diaphragm,%and%assess:%a)%Muscle%
histopathology%as%published%in.%We%will%measure%i)%Serum%creatine%kinase%levels,%ii)%
Number%of%central/internal%nuclei%and%expression%of%regeneration%markers%cardiac%actin%and%
neonatal%myosin,%iii)%Evidence%for%fibrotic%deposition%through%hematoxylin%and%eosin%staining,%
and%immunolabelling%for%collagen,%iv)%Confirm%normal%immunohistochemistry%and%Western%
blot%for%members%of%the%dystrophinGassociated%protein%complex.%b)%ExerciseGinduced%muscle%
damage.%We%will%assess%serum%creatine%kinase%and%evidence%for%muscle%damage%following%
downhill%running%(as%performed%by%AI%North%in%(34)),%via%histological%assessment%of%centralised%
nuclei%and%fibre%degeneration/regeneration,%fours%days%after%the%downhill%run%eccentric%injury.%
1) We%derive%primary%myoblast%cultures%from%all%lines,%and%perform%our%suite%of%membrane%repair%
assays%on%differentiated%myotubes%isolated%myofibres%(FDB%=%flexor%digitorus%brevis%foot%muscle).%
%
B)#
Experimental#Approach#&#Technique#
Sequence%of%events%(related%specifically%to%animal%experimentation):%
Use$dot$points$and/or$append$a$flow$chart$as$a$separate$document$
%
%
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1) Disease#progression#–#aging#experiment:#
 
To#study#the#onset#and#progression#of#a#muscular#dystrophy#in#different#mouse#models##
(CapnS1Sk.MusR/R,#Dysf40aR/R#and#Dysf40aCON)##
#
- Mice%will%be%housed%in%small%groups%(3%per%cage)%and%allowed%to%age%out%to%a%maximum%12%–%18%
months%to%observe%the%onset%and%progression%of%skeletal%muscular%dystrophy.%Mice%will%be%
monitored%at%least%monthly%(following%the%initial%12%week%monitoring%period)%to%check%for%signs%of%
skeletal%muscle%weakness%or%any%other%adverse%phenotype,%and%will%be%culled%at%4%different%timeG
points%to%allow%histological%and%biochemical%analysis%of%dystrophic%features%in%the%muscle.%
%
Voluntary#exercise#–#wheel#running#
- The%sixGmonth%cohort%will%include%one%cage%of%3%mice%of%each%genotype%that%is%caged%conventionally,%
and%a%second%cage%of%3%mice%in%which%a%running%wheel%is%provided%to%allow%mice%to%exercise%at%their%
free%will%to%see%if%voluntary%exercise%alters%the%onset%and%progression%of%dystrophy.%%
%
Analysis#of#muscle#damage#markers#from#blood#R#Creatine#kinase#measurement#
- At%the%indicated%timeGpoints%(see%figure%3)%mice%will%be%anaesthetized%and%a%terminal%cardiac%bleed%
will%be%performed%to%collect%large%amounts%of%blood%for%analysis.%This%is%a%nonGrecoverable%procedure%
and%if%the%mice%do%not%die%under%anesthetic%due%to%exsanguination,%they%will%immediately%be%
sacrificed%by%cervical%dislocation.%
#
Histopathology#
- Cryostat%sections%will%be%cut%from%each%of%the%muscles%samples.%#
- One% crossGsection% will% be% stained% with% Haematoxylin% and% Eosin% (H% &% E)% as% described% previously%
(Rooney% et% al,% 2006.% J.% Cell% Biol.).% The% percentage% of% cells% with% central% and% internalised% nuclei% (a%
marker%of%the%regeneration%typical%of%dystrophic%muscle)%within%the%entire%muscle%crossGsection%will%
be%determined%by%assessing%200%contiguous%fibres.%%
- The% degree% of% mononuclear% infiltrate% and% extracellular% fibrosis/fat% deposition% (also% increased% in%
dystrophic%muscle%tissue)%will%also%be%graded%on%each%H%&%EGstained%crossGsection.%
- Other%crossGsection%will%be%analysed%for%other%proteins%(e.g.%MG53,%dysferlin,%calpain,%IgG,%IgM,%LDH%
and%other%proteins%of%interest).%
%
Biochemical#analysis#of#skeletal#muscle#and#other#tissues#
- To% assess% potential% increase/decrease% of% protein% expression% and% to% confirm% genotypes% we% will%
perform%Western%blot%analysis%of%all%harvested%tissues.%
%
See%figure%2%for%a%schematic%representation%of%the%experimental%procedures.%%
%
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%%
Figure$2:$Schematic$of$mouse$age$study!
%
Cardiac#puncture#–#endpoint#bleed##
To%collect%a%large%amount%of%blood%for%analysis,%mice%will%be%anaesthetised%and%cardiac%puncture%
performed.%This%is%a%nonGrecoverable%procedure%and%the%mice%will%be%euthanised%via%exsanguination%
with%cervical%dislocation%used%as%well%if%required.%
#
#
2) Downhill#runR#eccentric#exercise:#
 
 
$$$$$$$$$$$$$$$$$$$Figure$3:$Schematic$of$downhill$run$protocol$–$eccentric$exercise!
 
Acclimatising#mice#to#treadmill#
Prior% to%the%downhill% run%experiment,%mice%will%be% familiarised%with%the%treadmill% to%reduce%stress%and%
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anxiety% associated% with% the% final% exercise% protocol.% Initially% mice% will% be% placed% in% the% treadmill% and%
allowed%time%for%exploration%without%the%treadmill%operating.%Mice%will%be%returned%to%cages%and%given%a%
treat% in% form% of% sunflower% seeds.% After% this,% mice% will% be% placed% on% the% treadmill,% and% the% treadmill%
started%slowly%with%no%incline%so%the%mice%have%a%gradual%introduction%and%become%familiarised%with%the%
process.%%Over%the%next%week%the%mice%will%be%exposed%to%the%treadmill%with%gradually%increasing%speed%
so%they%receive%sufficient%training%to%be%able%to%undertake%to%final%downhill%run%protocol.%%After%sufficient%
acclimatisation%has%been%reached%mice%can%commence%experiments.%%
#
CK#measurements#–#muscle#damage#marker#
The%appearance%of%creatine%kinase%(CK)%in%blood%has%been%generally%considered%to%be%an%indirect%marker%
of%muscle%damage.%Blood%will%be%taken%from%the%mice%via%the%tail%vein%before%and%after%exercise%to%assess%
the%release%of%muscle%damage%markers%like%creatine%kinase%(potentially%also%IgG,%IgM%and%LDH)%into%the%
blood% stream.% Elevated% blood% CK% indicates% that% muscle% cells% have% been% broken% down% and% therefore%
provide%a%good%readout%for%muscle%damage.%
%
Evans#Blue#dye#injection#
30%minutes%prior%to%exercise,%one%group%of%mice%will%be%injected%i.p.%with%sterile%0.5%%Evans%Blue%dye%in%
phosphateGbuffered%saline%as%described%previously%(Rooney%et%al,%2006.%J.%Cell%Biol.)#
#
Downhill#run#
- Mice%will%be%run%on%a%downhill%incline.%%
- 30%minutes%prior%to%exercise%Evans%Blue%dye%injection%
- For% downhill% run,% the% speed% will% gradually% be% increased,% with% electrical% stimulus% if% necessary% to%
encourage%continuous%running.%%
- 30%minutes% following%exercise,% creatine%kinase% (CK)% levels%will%be%measured% in%all%mice%via% tail% vein%
sampling.%The%blood%volume%taken%for%CK%analysis%will%be%limited%according%to%weight%of%the%mouse%–%
to%a%maximum%volume%of%200μL,%and%the%CK%level%will%be%assayed.%
%
Tissue#collection/storage#
At% 2% timeGpoints% after% the% downhill% run% (~1% &% 7% days)% mice% will% be% euthanased% by% cardiac% puncture% and%
skeletal%muscles%tissues/other%tissues%of%interest%harvested%for%analysis.%%
%
Tissues%of%interest%include,%but%are%not%limited%to:%
%
Skeletal#muscle#
1.%%%%Extensor%digitorum%longus%(EDL%–anterior%lower%limb)%
2.%%%%Tibialis%Anterior%(anterior%lower%limb)%%
3.%%%%Soleus%(anterior%lower%limb)%
4.%%%%Gastrocnemius%(posterior%lower%limb)%
5.%%%%Quadriceps%(anterior%upper%limb)%
6.%%%%Diaphragm%
%
Other#tissues#of#interest#
7.%%%%Heart%
8.%%%%Lung%
9.%%%%Liver%
10.%%Kidney%
11.%%Brain%%
%
Histopathological%analyses%will%be%performed%as%described%above.%
%
C)#
What#new#information#and/or#understanding#is#to#be#sought#from#this#project?#
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#
We%are%aiming%to%better%describe%the%interGlinked%roles%for%dysferlin%and%calpain%in%membrane%repair.%This%project%
will%help%us%to%understand%the%role%of%calpain%and%dysferlin,%and%particularly%the%role%of%dysferlin%exon%40a%in%
muscular%dystrophy.%Primary%muscle%cells%and%myofibres%of%all%primary%mouse%models%(WT,%DysfG/G,%CapnS1Sk.MusG/G,%
Dysf40aG/G%and%Dysf40aCON%)%will%give%us%the%tool%to%study%membrane%repair%after%different%types%of%injury%(e.g.%
mechanical%injury%and%perforation%by%pores).%This%study%could%greatly%contribute%to%the%understanding%of%dysferlin%
muscular%dystrophy%and%whether%defective%membrane%repair%underpins%the%development%of%muscular%dystrophy.%%
The%comparison%of%aging%mice%with%and%without%voluntary%exercise%may%also%help%ascertain%whether%exercise%is%
likely%to%be%of%therapeutic%benefit%for%patients%with%dysferlinopathy.%
%
D)#
If#the#project#repeats#previously#reported#experiments,##please#provide#the#reasons#for#the#experiments#to#be#
repeated#
#
The%hereGdescribed%experiments%have%been%previously%reported%in%dysferlin%null%mice.%%
In%our%study%the%dysferlin%null%mice%serve%as%a%control%group%for%dysferlin%muscular%dystrophy.%%
We%want%to%compare%our%newly%generated%mouse%model%(CapnS1Sk.MusG/G)%to%the%dysferlin%null%mouse%to%assess%
what%has%a%greater%effect%on%muscle%damage%and%pathology%–%dysferlin%or%calpain.%This%has%not%been%reported.%
Further%we%want%to%dissect%out%the%role%of%dysferlin%exon40a%in%muscular%dystrophy%and%membrane%repair.%%We%
will%compare%the%mice%that%have%no%exon%40a%(Dysf40aG/G)%to%the%mice%that%only%have%the%dysferlin%isoform%
(Dysf40aCON)%to%the%dysferlin%null%mice%as%our%control%group%,and%again%no%studies%of%this%sort%have%ever%been%
reported.%
%
%
%
Comments:#
%
%
%
%
Supporting#documentation#(other#than#monitoring#forms#eg.#Literature,#approval#of#collaborative#projects#by#
other#AEC’s):#
 
1.%
2.%
3.%
 
%
%
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%
PLEASE#SUBMIT:#
%
An%electronic%copy%of%the%completed%application%to%the%AEC%by%email%to%acec@cmri.org.au%%%%
%
AND%
%
One%unstapled%signed%copy%of%the%application%(including%supporting%documentation%as%appropriate)%to%the%AEC%c/oG%
Ms%Jane%Seaman,%AEC%Secretary,%CMRI%
%
Please#note#that#applications#from#both#CMRI#&#CHW#must#be#endorsed#and#signed#by#the#Manager#of#the#
relevant#animal#facility#before#submission#to#AEC.#
%
%
For#CHW#Investigators#only:#
#
• Please%provide%a%letter%outlining%how%your%proposal%fits%within%your%overall%research.%This%will%assist%in%the%
review%of%resource%allocation%and%space%availability%by%the%Manager%of%the%CHW%Transgenic%Facility.%
%
%
PLEASE#ENSURE#ALL#QUESTIONS#ARE#ANSWERED.##IF#A#QUESTION#IS#NOT#RELEVANT,#PLEASE#WRITE#
N/A#
%
%
%
%
%
% %
%
%
Signature%(Chief%Investigator)% % Date%
%
%
%
%
% %
%
%
Endorsed%by%animal%facility%manager%%
(delete%as%appropriate)%%
%
BioResources%Veterinary%Manager%/%
%CHW%Transgenic%Facility%Manager%
% Date%
%
%
%
%
%
%
%
%
%
%
% %
Document%Approved%%%%%%8.8.2013% % Version%1%
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Appendix#1#R#Purpose#of#the#project:#
#
(Link#to#Animal#Numbers)#
#
Please%enter%the%most%appropriate%numerical%code%(1%–%10)%from%those%listed%below%to%describe%the%
primary%purpose%of%the%project.%
%
1.# Stockbreeding#
% %
Breeding%protocols%to%produce%new%teaching%or%research%stock.%Only%include%the%animals%
used%to%produce%progeny,%NOT%the%progeny%themselves.%
% %
2.# Stock#maintenance%
% %
Holding%protocols%for%animals%maintained%for%use%in%other%protocols.%
%
Example:%Fistulated%ruminants%which%are%maintained%under%a%holding%protocol,%for%use%in%
other%short%term%feeding%trial%protocols.%
% %
3.# Education%
% %
Protocols%carried%out%for%the%achievement%of%educational%objectives.%The%purpose%of%the%
protocol%is%not%to%acquire%new%knowledge,%rather%to%pass%on%established%knowledge%to%
others.%This%would%include%interactive%or%demonstration%classes%in%methods%of%animal%
husbandry,%management,%examination%and%treatment%.%
%
Example:%Animals%held%by%veterinary%schools%to%teach%examination%procedures%such%as%
pregnancy%diagnosis;%sheep%used%in%shearing%demonstration%classes%for%students;%dogs%
used%to%teach%animal%care%to%TAFE%students.%
% %
4.# Research:#human#or#animal#biology%
% %
Research%protocols%which%aim%to%increase%the%basic%understanding%of%the%structure,%
function%and%behaviour%of%animals,%including%humans,%and%processes%involved%in%
physiology,%biochemistry%and%pathology.%
% %
5.# Research:#human#or#animal#health#and#welfare%
% %
Research%protocols%which%aim%to%produce%improvements%in%the%health%and%welfare%of%
animals,%including%humans.%
% %
6.# Research:#animal#management#or#production%
% %
Research%protocols%which%aim%to%produce%improvements%in%domestic%or%captive%animal%
management%or%production.%
% %
7.# Research:#environmental#study%
% %
Research%protocols%which%aim%to%increase%the%understanding%of%animals’%environment%and%
its%role%in%it,%or%aim%to%manage%wild%or%feral%populations.%These%will%include%studies%to%
determine%population%levels%and%diversity%and%may%involve%techniques%such%as%
observation,%radio%tracking%or%capture%and%release.%
% %
8.# Production#of#biological#products%
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% %
Using%animals%to%produce%products%other%than%milk,%meat,%eggs,%leather,%fur,%etc.%
%
Example:%use%of%a%sheep%flock%to%donate%blood%to%produce%microbiological%media;%
production%of%commercial%antiGserum.%Do%not%include%animals%which%come%under%code%10%
(below).%
% %
9.# Diagnostic#procedure%
% %
Using%animals%directly%as%part%of%a%diagnostic%process.%
%
Example:%inoculating%day%old%chicks%with%Newcastle%Disease%virus%to%determine%virulence.%
% %
10.# Regulatory#product#testing%
% %
Protocols%for%the%testing%of%products%required%by%regulatory%authorities,%such%as%the%
Australian%Pesticides%and%Veterinary%Medicines%Authority%(APVMA).%If%the%product%testing%
is%not%a%regulatory%requirement,%eg.%as%part%of%a%quality%assurance%system,%those%animals%
should%be%included%in%the%appropriate%category%selected%from%1%–%9%below.%
%
Example:%preGregistration%efficacy%or%toxicity%testing%of%drugs%and%vaccines.%
% %
%
% %
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Appendix#2#–#Type#of#Procedure#
#
Enter%the%highest%appropriate%numerical%code%(1%–%8)%from%those%listed%below%to%describe%the%type%of%
procedures%carried%out%on%the%animals%in%the%project%(see%also%multiple%types%of%procedure).%
%
1.% Observation#Involving#Minor#Interference%
Examples# . observational%study%only%
. breeding,%or%reproductive%study%with%no%detriment%to%the%animal%
. genetic%study%with%no%detriment%to%the%animal%
. feeding%trial,%such%as%Digestible%Energy%determination%of%feed%in%a%balanced%diet%
. behavioural%study%with%minor%environmental%manipulation%
# %
2.# Animal#Unconscious#Without#Recovery%
Examples# . no%experimentation%on%living%animals%(animals%killed%painlessly%for%biochemical%
analysis,%in%vitro%cell,%tissue%or%organ%studies)%
. experiments%under%anaesthesia,%without%recovery%(animals%are%fully%anaesthetised%for%
the%duration%of%the%experiment%and%are%killed%upon%conclusion%of%the%procedure)%
# %
3.# Minor#Conscious#Intervention%
Examples# . injections,%blood%sampling%
. minor%dietary%or%environmental%deprivation%or%manipulation,%such%as%feeding%nutrientG
deficient%diets%for%short%periods%
# #
4.# Minor#Surgery#Without#Recovery#%
Examples# . biopsies%
. cannulations%
# #
5.# Major#Surgery#With#Recovery#%
Examples# . orthopaedic%surgery%
. abdominal%or%thoracic%surgery%
. transplant%surgery%
# #
6.# Minor#Physiological#Challenge%
Examples# . minor%infection,%minor%or%moderate%genetic%modification,%early%oncogenesis%
. arthritis%studies%with%pain%alleviation%
. prolonged%deficient%diets,%induction%of%metabolic%disease%
. residue%testing%
. polyclonal%antibody%production%
. antiserum%production%
# #
7.# Major#Physiological#Challenge%
Examples# . major%infection,%major%genetic%modification,%oncogenesis%without%pain%alleviation%
. arthritis%studies%with%no%pain%alleviation,%uncontrolled%metabolic%disease%
. isolation%or%environmental%deprivation%for%extended%periods%
. monoclonal%antibody%raising%in%mice%
# #
8.# Death#as#an#Endpoint%
27#|#P a g e #
%
This%category%only%applies%in%those%rare%cases%where%the%death%of%the%animal%is%a%planned%
part%of%the%procedures.%
Examples# . lethality%testing%
It%does%not%include:%death%by%natural%causes;%animals%which%are%euthanased%on%completion%
of%the%project;%animals%which%are%killed%if%something%goes%wrong;%animals%killed%for%
dissection;%accidental%deaths%
% %
9.# Production#of#genetically#modified#animals%
This%category%is%intended%to%allow%for%the%variety%of%procedures%which%occur%during%the%
production%of%genetically%modified%animals.%%It%includes%all%animals%used%in%GM%production%
other%than%the%final%progeny%which%are%used%in%a%different%category%of%procedure.%
Examples% . Initial%breeding%animals%for%GM%production%
. Animals%culled%as%part%of%the%GM%production%process%
#
Multiple#types#of#procedures#
%
Some%protocols%will%include%animals%which%are%subject%to%different%types%of%procedures.%This%may%occur,%
for%example,%where%a%group%of%animals%are%given%an%injection%of%saline%(procedure%#3)%and%a%test%group%are%
given%a%substance%which%has%a%more%severe%procedure%(say%#6%or%#7).%In%this%case,%the%animal%numbers%
should%be%allocated%to%the%different%procedures%accordingly.%
%
% %
28#|#P a g e #
%
Appendix#3#R#Categories#of#Invasiveness#in#Animal#Experiments#
#
(Link#to#Table#of#Procedures)#
#
A% Experiments#on#cell#and#tissue#samples#
Examples# 1.%%Tissue%cultures%
2.%%Tissues%obtained%at%necropsy%
3.%%The%use%of%eggs,%protozoa%or%other%singleGcell%organisms%
# %
B# Experiments#causing#little#or#no#discernible#discomfort#or#stress#
Examples# 1.%%Animals%being%maintained%in%production%management%systems%including%timed%matings%
2.%%ShortGterm%restraint%of%animals%for%observation%or%examination%
3.%%Blood%sampling%under%anaesthesia%
4.%%NonGtoxic%injections%by%intravenous,%subcutaneous,%intramuscular,%intraperitoneal,%or%
oral%route,%but%not%intrathoracic%or%intracardiac%
5.%%Acute%nonGsurvival%studies%where%animals%are%anaesthetised%and%do%not%regain%
consciousness%
6.%%Euthanasia%by%approved%methods%%
7.%%Transient%periods%of%food%and/or%water%deprivation,%not%exceeding%normal%duration%of%
abstinence%
# %
C# Experiments#causing#minor#stress#or#pain#of#short#duration#
Examples# Note:%%Procedures%should%not%cause%significant%changes%in%the%animal’s%appearance,%
physiological%parameters%–%i.e.%respiratory,%cardiac%rate,%faecal%or%urinary%output,%or%in%
social%responses,%during%or%after%procedures.%
%
1.%%Minor%surgeries%or%procedures%under%anaesthesia,%such%as%cannulation,%catheterisation%
of%blood%vessel%,%biopsy%
2.%%Tail%nicking%for%blood%collection%while%animal%properly%restrained%
3.%%Short%periods%of%restraint%beyond%that%for%simple%observation%or%examination%
4.%%Short%periods%of%food%and/or%water%deprivation%that%exceeds%periods%of%natural%
abstinence%%
5.%%Behavioural%experiments%on%conscious%animals%with%shortGterm%restraint%
6.%%Euthanasia%by%rapid%decapitation%on%properly%restrained,%conscious%animals%
# #
D# Experiments#causing#moderate#to#higher#level#of#distress#or#discomfort#
Examples# Note:%%Procedures%should%not%cause%prolonged%or%severe%clinical%distress%as%may%be%
exhibited%by%a%wide%range%of%clinical%signs,%such%as%abnormal%behavioural%patterns%or%
attitudes,%the%absence%of%grooming,%dehydration,%abnormal%vocalization,%prolonged%
anorexia,%circulatory%collapse,%extreme%lethargy%or%disinclination%to%move,%and%clinical%
signs%of%severe%or%advanced%local%or%systemic%infection.%
%
1.%%Major%surgical%procedures%conducted%under%general%anaesthesia,%with%subsequent%
recovery%
2.%Prolonged%periods%of%physical%restraint%
3.%Induction%of%behavioural%stress%%–%maternal%deprivation,%aggression%
4.%Procedures%which%cause%severe,%persistent%or%irreversible%disruption%or%sensorimotor%
organisation%
5.%The%use%of%Freund’s%Complete%Adjuvant%
6.%The%exposure%of%an%animal%to%noxious%stimuli%from%which%escape%is%impossible%
# #
E# Procedures#inflicting#severe#pain#at#or#above#the#tolerance#level#of#unanaesthetised#
conscious#animals###
% Note:%%Procedures%will%not%be%approved%unless%there%is%extremely%compelling%evidence%that%
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%
the%data%is%critically%important%to%improvement%of%human%or%animal%health%and%the%use%of%
animals%is%irreplacable.%
%
1.%%Noxious%stimuli%or%agents%with%unknown%severe%effects%
2.%%Highly%invasive%manipulations%
3.%%Exposure%to%drugs%or%chemicals%at%levels%that%may%markedly%impair%physiological%
systems%%
4.%%Behavioural%studies%having%unknown%degree%of%distress%
5.%%Use%of%muscle%relaxants%or%paralytic%drugs%without%anaesthetics%
6.%%Induction%of%burns%or%trauma%on%unanaesthetised%animals%
7.%%Any%procedure%causing%severe%pain%unrelieved%by%analgesia%
8.%%Any%experiment%where%death%is%expected%as%an%endpoint%in%some%or%all%animals%
%
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